


**CUMULATIVE
SUPPLEMENT 10
OCTOBER 2017**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2017

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**Cumulative Supplement 10
October 2017**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**CUMULATIVE SUPPLEMENT 10
October 2017**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

JAI PHARMA LTD
(JAI PHARMA LTD)

TG UNITED LABS LLC
(TG UNITED LABS)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

MYLAN LABORATORIES LTD
(MYLAN LABS LTD)

CHARTWELL RX SCIENCES LLC
(CHARTWELL RX)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-

counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a

particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS	18130	18391	18711	19012	
LISTED SINGLE	2646	2688	2708	2721	
SOURCE	(14.6%)	(14.6%)	(14.5%)	(14.3%)	
MULTISOURCE	15484	15703	16003	16291	
	(85.4%)	(85.4%)	(85.5%)	(85.7%)	
THERAPEUTICALLY	15335	15581	15882	16180	
EQUIVALENT	(84.7%)	(84.7%)	(84.9%)	(85.1%)	
NOT THERAPEUTICALLY	129	122	121	111	
EQUIVALENT	(0.7%)	(0.7%)	(0.6%)	(0.6%)	
EXCEPTIONS ¹	73	73	73	73	
	(0.4%)	(0.4%)	(0.4%)	(0.4%)	
NEW MOLECULAR	7	14	17	14	
ENTITIES APPROVED					
NUMBER OF	1051	1053	1050	1054	
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code

for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	AUROBINDO PHARMA LTD	EQ 600MG BASE;300MG	A206151	001	Mar 28, 2017	Mar NEWA
AB	CIPLA LTD	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Mar NEWA
AB	LUPIN LTD	EQ 600MG BASE;300MG	A204990	001	Mar 28, 2017	Mar NEWA

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS
TYMLOS

+	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017	Apr NEWA
---	-------------------	------------------------	---------	-----	--------------	----------

ABEMACICLIB

TABLET;ORAL

VERZENIO

+	ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017	Sep NEWA
+		100MG	N208716	002	Sep 28, 2017	Sep NEWA
+		150MG	N208716	003	Sep 28, 2017	Sep NEWA
+		200MG	N208716	004	Sep 28, 2017	Sep NEWA

ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

+	JANSSEN BIOTECH	500MG	N202379	002	Apr 14, 2017	May NEWA
---	-----------------	-------	---------	-----	--------------	----------

>A> ACALABRUTINIB

>A> CAPSULE;ORAL

>A> CALQUENCE

>A>	+	ACERTA PHARMA BV	100MG	N210259	001	Oct 31, 2017	Oct NEWA
-----	---	------------------	-------	---------	-----	--------------	----------

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB	ZYDUS PHARMS USA INC	333MG	A205995	001	May 26, 2017	May NEWA
----	----------------------	-------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

ACETAMINOPHEN

AP	CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan CAHN
----	----------------	---------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA	TEDOR PHARMA INC	300MG;50MG	A207635	001	Jun 05, 2017	May NEWA
----	------------------	------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB	TEDOR PHARMA INC	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Jul NEWA
----	------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Apr CTNA
AA	MALLINCKRODT INC	325MG;50MG;40MG	A087804	001	Jan 24, 1985	Mar CAHN
@	NOVAST LABS LTD	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Sep CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	ALLIED PHARMA INC	120MG/5ML;12MG/5ML	A086366	001		Jul CAHN
---	-------------------	--------------------	---------	-----	--	----------

SUSPENSION;ORAL

CAPITAL AND CODEINE

@	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001		Aug DISC
---	--------------------	--------------------	---------	-----	--	----------

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	ANDA REPOSITORY	300MG;60MG	A089673	001	Feb 10, 1988	Sep CAHN
---	-----------------	------------	---------	-----	--------------	----------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ABHAI LLC	300MG; 5MG	A209036	001	Jun 21, 2017	Jun	NEWA
AA		300MG; 7.5MG	A209036	002	Jun 21, 2017	Jun	NEWA
AA		300MG; 10MG	A209036	003	Jun 21, 2017	Jun	NEWA
AA		325MG; 5MG	A209037	001	Jun 21, 2017	Jun	NEWA
AA		325MG; 7.5MG	A209037	002	Jun 21, 2017	Jun	NEWA
AA		325MG; 10MG	A209037	003	Jun 21, 2017	Jun	NEWA
AA	AMNEAL PHARMS NY	300MG; 5MG	A206869	001	Jun 23, 2017	Jun	NEWA
AA	LANNETT HOLDINGS INC	300MG; 5MG	A207171	001	Jun 20, 2017	Jun	NEWA
AA		300MG; 7.5MG	A207171	002	Jun 20, 2017	Jun	NEWA
AA		300MG; 10MG	A207171	003	Jun 20, 2017	Jun	NEWA
AA		325MG; 5MG	A207172	001	Jun 22, 2017	Jun	NEWA
AA		325MG; 7.5MG	A207172	002	Jun 22, 2017	Jun	NEWA
AA		325MG; 10MG	A207172	003	Jun 22, 2017	Jun	NEWA
AA	MALLINCKRODT INC	300MG; 5MG	A206718	001	Mar 31, 2017	Mar	NEWA
AA		300MG; 7.5MG	A206718	002	Mar 31, 2017	Mar	NEWA
AA		300MG; 10MG	A206718	003	Mar 31, 2017	Mar	NEWA
AA	! MIKART	300MG; 7.5MG	A040658	002	Mar 24, 2006	May	CHRS
AA		300MG; 7.5MG	A040658	002	Mar 24, 2006	Apr	CMS1
AA	!	300MG; 10MG	A040658	003	Jun 23, 2004	May	CHRS
AA		300MG; 10MG	A040658	003	Jun 23, 2004	Apr	CMS1
AA	UPSHER-SMITH LABS	325MG; 5MG	A206484	001	Mar 24, 2017	Jun	CAHN
AA		325MG; 5MG	A206484	001	Mar 24, 2017	Mar	NEWA
AA		325MG; 7.5MG	A206484	002	Mar 24, 2017	Jun	CAHN
AA		325MG; 7.5MG	A206484	002	Mar 24, 2017	Mar	NEWA
AA		325MG; 10MG	A206484	003	Mar 24, 2017	Jun	CAHN
AA		325MG; 10MG	A206484	003	Mar 24, 2017	Mar	NEWA
>A> AA	WES PHARMA INC	325MG; 5MG	A210211	001	Oct 30, 2017	Oct	NEWA
>A> AA		325MG; 7.5MG	A210211	002	Oct 30, 2017	Oct	NEWA
>A> AA		325MG; 10MG	A210211	003	Oct 30, 2017	Oct	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	AMNEAL PHARMS	325MG; 5MG	A040777	001	Nov 27, 2007	May	CAHN
AA	ASCENT PHARMS INC	325MG; 2.5MG	A207419	001	Mar 22, 2017	Mar	NEWA
AA		325MG; 5MG	A207419	002	Mar 22, 2017	Mar	NEWA
AA		325MG; 7.5MG	A207419	003	Mar 22, 2017	Mar	NEWA
AA		325MG; 10MG	A207419	004	Mar 22, 2017	Mar	NEWA
AA	LANNETT HOLDINGS INC	325MG; 5MG	A207333	001	Sep 25, 2017	Sep	NEWA
AA		325MG; 10MG	A207333	002	Sep 25, 2017	Sep	NEWA
AA	NOVEL LABS INC	325MG; 2.5MG	A204407	001	Feb 24, 2017	Feb	NEWA
AA		325MG; 5MG	A204407	002	Feb 24, 2017	Feb	NEWA
AA		325MG; 7.5MG	A204407	003	Feb 24, 2017	Feb	NEWA
AA		325MG; 10MG	A204407	004	Feb 24, 2017	Feb	NEWA
	PERCOCET						
AA	! VINTAGE PHARMS LLC	325MG; 7.5MG	A040330	003	Nov 23, 2001	Jan	CMS1
AA	!	325MG; 10MG	A040330	004	Nov 23, 2001	Jan	CMS1

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

+	@ MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014	Aug	DISC
---	--------------------	--------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	APOGEE PHARMA	325MG; 37.5MG	A202076	001	Mar 30, 2012	Sep	CAHN
AB	AUROBINDO PHARMA LTD	325MG; 37.5MG	A207152	001	Mar 22, 2017	Mar	NEWA
>A>	@ CSPC OUYI PHARM CO	325MG; 37.5MG	A076914	001	Jul 26, 2006	Oct	CAHN
AB	MACLEODS PHARMS LTD	325MG; 37.5MG	A206885	001	May 02, 2017	Apr	NEWA
>D>	@ WATSON LABS	325MG; 37.5MG	A076914	001	Jul 26, 2006	Oct	CAHN

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB	SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988	Jul	CMS1
----	----------------------	-------	---------	-----	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION
ACETAZOLAMIDE SODIUM

AP PAR STERILE PRODUCTS EQ 500MG BASE/VIAL A205358 001 Jun 20, 2017 Jun NEWA

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT ICU MEDICAL INC 250MG/100ML N017656 001 Feb CAHN

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

>D> ! BAUSCH AND LOMB 2%;0.79% A040063 001 Feb 25, 1994 Oct DISC
>A> @ 2%;0.79% A040063 001 Feb 25, 1994 Oct DISC

ACETOHEXAMIDE

TABLET;ORAL
ACETOHEXAMIDE

@ WATSON LABS TEVA 250MG A071893 001 Nov 25, 1987 May CAHN
@ 500MG A071894 001 Nov 25, 1987 May CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS
ACETYLCYSTEINE

>A> AP SAGENT PHARMS 6GM/30ML (200MG/ML) A091684 001 Oct 31, 2017 Oct NEWA

ACITRETIN

CAPSULE;ORAL
ACITRETIN

>D> AB MYLAN PHARMS INC 17.5MG A203707 001 Sep 10, 2015 Oct DISC
>A> @ 17.5MG A203707 001 Sep 10, 2015 Oct DISC
>D> AB 22.5MG A203707 002 Sep 10, 2015 Oct DISC
>A> @ 22.5MG A203707 002 Sep 10, 2015 Oct DISC

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL
SEMPREX-D

+! AUXILIUM PHARMS LLC 8MG;60MG N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

CAPSULE;ORAL
ACYCLOVIR

>D> AB APOTEX INC 200MG A075677 001 Sep 28, 2005 Oct CHRS
>A> AB ! 200MG A075677 001 Sep 28, 2005 Oct CHRS
AB BOSCOGEN 200MG A075090 001 Jan 26, 1999 May CAHN
AB CARLSBAD TECHNOLOGY 200MG A206261 001 Aug 16, 2017 Aug NEWA
@ CHARTWELL MOLECULES 200MG A074872 001 Apr 22, 1997 Jan CAHN
@ MYLAN 200MG A074727 001 Apr 22, 1997 Jun DISC
ZOVIRAX
>D> AB +! MYLAN PHARMS INC 200MG N018828 001 Jan 25, 1985 Oct CHRS
>A> AB + 200MG N018828 001 Jan 25, 1985 Oct CHRS

OINTMENT;TOPICAL
ACYCLOVIR

>A> AB G AND W LABS INC 5% A205591 001 Nov 13, 2017 Oct NEWA
AB GLENMARK PHARMS LTD 5% A205510 001 Jul 31, 2017 Jul NEWA
AB TOLMAR 5% A206437 001 Jul 31, 2017 Jul NEWA

SUSPENSION;ORAL
ZOVIRAX

AB +! MYLAN PHARMS INC 200MG/5ML N019909 001 Dec 22, 1989 Jan CAHN

TABLET;BUCCAL
SITAVIG

+! EPI HLTH 50MG N203791 001 Apr 12, 2013 Jun CAHN

TABLET;ORAL
ACYCLOVIR

@ CHARTWELL MOLECULES 400MG A074834 001 Apr 24, 1997 Jan CAHN
@ 800MG A074834 002 Apr 24, 1997 Jan CAHN
AB HERITAGE PHARMS INC 400MG A074891 001 Oct 31, 1997 Apr CMFD
AB 800MG A074891 002 Oct 31, 1997 Apr CMFD
AB MYLAN PHARMS INC 400MG A075211 001 Sep 28, 1998 Mar CAHN
AB 800MG A075211 002 Sep 28, 1998 Mar CAHN

TABLET; ORAL

	ZOVIRAX						
AB	+	MYLAN PHARMS INC	400MG	N020089	001	Apr 30, 1991	Jan CAHN
AB	+	!	800MG	N020089	002	Apr 30, 1991	Jan CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

		ACYCLOVIR SODIUM					
		@ ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar CAHN
		@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar CAHN
AP	!	HIKMA PHARMS	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Mar CTEC
AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Mar NEWA
AP			EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Mar NEWA
AP		ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	May NEWA
AP			EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	May NEWA

ADENOSINE

INJECTABLE; INJECTION

		ADENOSINE					
AP		WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan CAHN
AP			3MG/ML	A076500	001	Jun 16, 2004	Jan CAHN
		@	3MG/ML	A076501	001	Jun 16, 2004	Jan CAHN

SOLUTION; IV (INFUSION)

		ADENOSINE					
>A>	AP	AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Oct NEWA
>A>	AP		90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Oct NEWA

ALBENDAZOLE

TABLET; ORAL

		ALBENZA					
		+	IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996
						Jun	CAHN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

		PROVENTIL-HFA					
BX	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May CAHN
		SOLUTION; INHALATION					
		ALBUTEROL SULFATE					
>A>	AN	AUROBINDO PHARMA LTD	EQ 0.083% BASE	A206224	001	Oct 17, 2017	Oct NEWA
	AN	SUN PHARMA GLOBAL	EQ 0.083% BASE	A207857	001	Jul 21, 2017	Jul NEWA

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

		ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE					
AN		WATSON LABS TEVA	EQ 0.083% BASE; 0.017%	A077063	001	Dec 31, 2007	Feb CAHN

ALENDRONATE SODIUM

SOLUTION; ORAL

		FOSAMAX					
	+	@ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Sep CRLD

TABLET; ORAL

		ALENDRONATE SODIUM					
		@ UPSHER-SMITH LABS	EQ 5MG BASE	A075871	001	Apr 22, 2009	Jun CAHN
		@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Jun CAHN
		@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Jun CAHN
		@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Jun CAHN
		@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Jun CAHN

ALLOPURINOL

TABLET; ORAL

		ALLOPURINOL					
>A>	AB	ZYDUS PHARMS USA INC	100MG	A210117	001	Oct 12, 2017	Oct NEWA
>A>	AB		300MG	A210117	002	Oct 12, 2017	Oct NEWA
		ZYLOPRIM					
	AB	+	CASPER PHARMA LLC	100MG	N016084	001	Jul CAHN
	AB	+	!	300MG	N016084	002	Jul CAHN

ALLOPURINOL; LESINURADTABLET; ORAL
DUZALLO

+	ARDEA BIOSCIENCES	200MG; 200MG	N209203	001	Aug 18, 2017	Aug NEWA
+	!	300MG; 200MG	N209203	002	Aug 18, 2017	Aug NEWA
+	IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017	Sep CAHN
+	!	300MG; 200MG	N209203	002	Aug 18, 2017	Sep CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 0.5MG BASE	A206647	001	Dec 22, 2016	May CAHN
AB		EQ 1MG BASE	A206647	002	Dec 22, 2016	May CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	May CAHN
---	------------	---	---------	-----	--------------	----------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	May CAHN
---	------------	--	---------	-----	--------------	----------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993	Apr CAHN
AB		0.5MG	A074342	002	Oct 31, 1993	Apr CAHN
AB		1MG	A074342	003	Oct 31, 1993	Apr CAHN
AB		2MG	A074342	004	Oct 31, 1993	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan CAHN
AB		1MG	A090871	002	Jun 07, 2011	Jan CAHN
AB		2MG	A090871	003	Jun 07, 2011	Jan CAHN
AB		3MG	A090871	004	Jun 07, 2011	Jan CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A078561	001	Mar 16, 2010	Sep CAHN
AB		0.5MG	A078561	002	Mar 16, 2010	Sep CAHN
AB		1MG	A078561	003	Mar 16, 2010	Sep CAHN
AB		2MG	A078561	004	Mar 16, 2010	Sep CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

	@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	May CAHN
	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	May CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	May CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	May CAHN
AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	May CAHN
	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	May CAHN

SUPPOSITORY; URETHRAL

MUSE

+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar CAHN
+	!	0.25MG	N020700	002	Nov 19, 1996	Mar CAHN
+	!	0.5MG	N020700	003	Nov 19, 1996	Mar CAHN
+	!	1MG	N020700	004	Nov 19, 1996	Mar CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	100MG	A208966	001	Jun 21, 2017	Jun NEWA
AB		HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017	May NEWA
AB		LANNETT HOLDINGS INC	100MG	A209221	001	Jun 15, 2017	May NEWA
AB		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	May NEWA
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

+	ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug NEWA
+	!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug NEWA

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr CAHN
AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995	May CAHN
		SYMMETREL					
+	@	ENDO PHARMS	50MG/5ML	N016023	002		Jan CRLD

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB		NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan NEWA
AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	May NEWA
AB	!	USL PHARMA	100MG	A076186	001	Dec 16, 2002	Jun CAHN

AMCINONIDE

CREAM;TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.025%	N018116	001		Jun CRLD
+	@		0.1%	N018116	002		Jun CRLD

LOTION;TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.1%	N019729	001	Jun 13, 1988	Jun CRLD
---	---	----------	------	---------	-----	--------------	----------

OINTMENT;TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.1%	N018498	001		Jun CRLD
---	---	----------	------	---------	-----	--	----------

AMIFOSTINE

INJECTABLE;INJECTION

AMIFOSTINE

AP		MYLAN LABS LTD	500MG/VIAL	A204363	001	Jul 17, 2017	Jul NEWA
AP		SUN PHARMA GLOBAL	500MG/VIAL	A077126	001	Mar 14, 2008	Apr CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB		WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Jul CAHN
----	--	------------------	-----	---------	-----	--------------	----------

AMINO ACIDS

INJECTABLE;INJECTION

AMINOSYN 10%

		ICU MEDICAL INC	10% (10GM/100ML)	N017673	003		Feb CAHN
--	--	-----------------	------------------	---------	-----	--	----------

AMINOSYN 10% (PH6)

		ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb CAHN
--	--	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN 3.5%

		ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004		Feb CAHN
--	--	-----------------	--------------------	---------	-----	--	----------

AMINOSYN 5%

		ICU MEDICAL INC	5% (5GM/100ML)	N017673	001		Feb CAHN
--	--	-----------------	----------------	---------	-----	--	----------

AMINOSYN 7%

		ICU MEDICAL INC	7% (7GM/100ML)	N017673	002		Feb CAHN
--	--	-----------------	----------------	---------	-----	--	----------

AMINOSYN 7% (PH6)

		ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985	Feb CAHN
--	--	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN 8.5%

		ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004		Feb CAHN
--	--	-----------------	--------------------	---------	-----	--	----------

AMINOSYN 8.5% (PH6)

		ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985	Feb CAHN
--	--	-----------------	--------------------	---------	-----	--------------	----------

AMINOSYN II 10%

		ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986	Feb CAHN
--	--	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 10% IN PLASTIC CONTAINER

		ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991	Feb CAHN
--	--	-----------------	------------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

AMINOSYN II 15% IN PLASTIC CONTAINER

ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991	Feb CAHN
AMINOSYN II 3.5%					
@ ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986	Feb CAHN
AMINOSYN II 5%					
@ ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986	Feb CAHN
AMINOSYN II 7%					
ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986	Feb CAHN
AMINOSYN II 8.5%					
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986	Feb CAHN
AMINOSYN-HBC 7%					
ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985	Feb CAHN
AMINOSYN-HF 8%					
ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Jun CAHN
AMINOSYN-PF 10%					
ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986	Feb CAHN
AMINOSYN-PF 7%					
ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985	Feb CAHN
AMINOSYN-RF 5.2%					
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001		Apr CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

@ ICU MEDICAL INC	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789	005		Feb CAHN
-------------------	---	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	004	Apr 03, 1986	Apr CAHN
-----------------	--	---------	-----	--------------	----------

AMINOSYN II 7% W/ ELECTROLYTES

@ ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	006	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986	Apr CAHN
-----------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M

@ ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL

GLEOLAN

+! NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017	Jun NEWA
---------	------------	---------	-----	--------------	----------

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

>A> AP	AUROBINDO PHARMA LTD	50MG/ML	A204550	001	Oct 25, 2017	Oct NEWA
--------	----------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	Jan CAHN
	@ MYLAN	200MG	A075188	001	Feb 24, 1999	Mar DISC
AB	SANDOZ	200MG	A075315	001	Dec 23, 1998	Mar CHRS
AB	TARO PHARM	100MG	A075424	002	Dec 18, 2002	Mar CAHN
AB		200MG	A075424	001	Mar 30, 2001	Mar CAHN
		300MG	A076362	002	Dec 02, 2003	Mar CAHN
AB		400MG	A076362	001	Nov 29, 2002	Mar CAHN
	PACERONE					
AB	UPSHER-SMITH LABS	100MG	A075135	002	Apr 12, 2005	Jun CAHN
AB		200MG	A075135	001	Apr 30, 1998	Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	10MG	A210086	001	Oct 06, 2017	Sep NEWA
AB		25MG	A210086	002	Oct 06, 2017	Sep NEWA
AB		50MG	A210086	003	Oct 06, 2017	Sep NEWA
AB		75MG	A210086	004	Oct 06, 2017	Sep NEWA
AB		100MG	A210086	005	Oct 06, 2017	Sep NEWA
AB		150MG	A210086	006	Oct 06, 2017	Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	@ ANDA REPOSITORY	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Sep CAHN
	@	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Sep CAHN
	@ WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988	May CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar CAHN
	@	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	May DISC
AB		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar CAHN
	@	EQ 5MG BASE	A078224	002	Feb 27, 2008	May DISC
AB		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar CAHN
	@	EQ 10MG BASE	A078224	003	Feb 27, 2008	May DISC
	@ SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Sep DISC
	@	EQ 5MG BASE	A204900	002	Jul 23, 2015	Sep DISC
	@	EQ 10MG BASE	A204900	003	Jul 23, 2015	Sep DISC
AB	UPSHER-SMITH LABS	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Jun CAHN
AB		EQ 5MG BASE	A077759	002	Jul 09, 2007	Jun CAHN
AB		EQ 10MG BASE	A077759	003	Jul 09, 2007	Jun CAHN
AB	VIVIMED GLOBAL	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Aug CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Aug CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Aug CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;20MG	A207073	001	Jul 17, 2017	Jul NEWA
AB		EQ 5MG BASE;40MG	A207073	002	Jul 17, 2017	Jul NEWA
AB		EQ 10MG BASE;20MG	A207073	003	Jul 17, 2017	Jul NEWA
AB		EQ 10MG BASE;40MG	A207073	004	Jul 17, 2017	Jul NEWA
AB	ALKEM LABS LTD	EQ 5MG BASE;20MG	A209042	001	Aug 14, 2017	Jul NEWA
AB		EQ 5MG BASE;40MG	A209042	002	Aug 14, 2017	Jul NEWA
AB		EQ 10MG BASE;20MG	A209042	003	Aug 14, 2017	Jul NEWA
AB		EQ 10MG BASE;40MG	A209042	004	Aug 14, 2017	Jul NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;20MG	A206906	001	May 15, 2017	May NEWA
AB		EQ 5MG BASE;40MG	A206906	002	May 15, 2017	May NEWA
AB		EQ 10MG BASE;20MG	A206906	003	May 15, 2017	May NEWA
AB		EQ 10MG BASE;40MG	A206906	004	May 15, 2017	May NEWA
AB	GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Jun NEWA
AB		EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Jun NEWA
AB		EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Jun NEWA
AB		EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Jun NEWA
AB	JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017	May NEWA
AB		EQ 5MG BASE;40MG	A207450	002	May 15, 2017	May NEWA
AB		EQ 10MG BASE;20MG	A207450	003	May 15, 2017	May NEWA
AB		EQ 10MG BASE;40MG	A207450	004	May 15, 2017	May NEWA
>A> AB	MICRO LABS	EQ 5MG BASE;20MG	A207435	001	Nov 02, 2017	Oct NEWA

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>A>	AB	EQ 5MG BASE;40MG	A207435	002	Nov 02, 2017	Oct NEWA
>A>	AB	EQ 10MG BASE;20MG	A207435	003	Nov 02, 2017	Oct NEWA
>A>	AB	EQ 10MG BASE;40MG	A207435	004	Nov 02, 2017	Oct NEWA
	AB	TORRENT PHARMS LTD EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Apr CAHN
	AB	EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Apr CAHN
	AB	EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Apr CAHN
	AB	EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Apr CAHN
	AB	ZYDUS PHARMS USA INC EQ 5MG BASE;20MG	A207771	001	Sep 22, 2017	Sep NEWA
	AB	EQ 5MG BASE;40MG	A207771	002	Sep 22, 2017	Sep NEWA
	AB	EQ 10MG BASE;20MG	A207771	003	Sep 22, 2017	Sep NEWA
	AB	EQ 10MG BASE;40MG	A207771	004	Sep 22, 2017	Sep NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	GEN HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	May CAHN
----	----------	------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

LOTION;TOPICAL

LAC-HYDRIN

	+ @ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan CRLD
--	-------------	-------------	---------	-----	--------------	----------

AMOXAPINE

TABLET;ORAL

AMOXAPINE

	@ UPSHER-SMITH LABS	25MG	A072943	001	Jun 28, 1991	Jun CAHN
	@	50MG	A072944	001	Jun 28, 1991	Jun CAHN
	@	100MG	A072878	001	Jun 28, 1991	Jun CAHN
	@	150MG	A072879	001	Jun 28, 1991	Jun CAHN
	@ WATSON PHARMS TEVA	25MG	A072418	001	May 11, 1989	Feb CAHN
	@	50MG	A072419	001	May 11, 1989	Feb CAHN
	@	100MG	A072420	001	May 11, 1989	Feb CAHN
	@	150MG	A072421	001	May 11, 1989	Feb CAHN

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXIL

	+ @ DR REDDYS LABS INC	200MG/5ML	N050760	001	Apr 15, 1999	Sep CRLD
	@	200MG/5ML	N050760	001	Apr 15, 1999	Feb DISC
	+ @	400MG/5ML	N050760	002	Apr 15, 1999	Sep CRLD
	@	400MG/5ML	N050760	002	Apr 15, 1999	Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

	TEVA	125MG	A064013	002	Sep 11, 1995	Feb CTEC
!		250MG	A064013	001	Dec 22, 1992	Feb CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AUGMENTIN '200'

	+ @ DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb DISC
	AUGMENTIN '400'					
	+ @ DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb DISC
	AUGMENTIN ES-600					
	+ @ DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB	!	SANDOZ	250MG;EQ	125MG	BASE		A065189	001	Aug 23, 2005	Feb	CHRS
>D>	AB			875MG;EQ	125MG	BASE		A065063	001	Mar 14, 2002	Oct	CHRS
>A>	AB	!		875MG;EQ	125MG	BASE		A065063	001	Mar 14, 2002	Oct	CHRS
	AB	!	SANDOZ INC	500MG;EQ	125MG	BASE		A065117	001	Nov 27, 2002	Feb	CHRS
			AUGMENTIN '875'									
>D>	AB	+	DR REDDYS LABS INC	875MG;EQ	125MG	BASE		N050720	001	Feb 13, 1996	Oct	CHRS
>A>	AB	+		875MG;EQ	125MG	BASE		N050720	001	Feb 13, 1996	Oct	CHRS

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Feb CTEC
!		400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Feb CTEC
		AUGMENTIN '200'				
	+ @ DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Feb DISC

TABLET, CHEWABLE;ORAL
AUGMENTIN '400'

+ @ DR REDDYS LABS INC 400MG;EQ 57MG BASE N050726 002 May 31, 1996 Feb DISC

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL
ADZENYS ER

+! NEOS THERAPS INC EQ 1.25MG BASE/ML N204325 001 Sep 15, 2017 Sep NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
MYDAYIS

+ SHIRE DEV LLC 3.125MG;3.125MG;3.125MG;3.125MG N022063 001 Jun 20, 2017 Jun NEWA
+ 6.25MG;6.25MG;6.25MG;6.25MG N022063 002 Jun 20, 2017 Jun NEWA
+ 9.375MG;9.375MG;9.375MG;9.375MG N022063 003 Jun 20, 2017 Jun NEWA
+ 12.5MG;12.5MG;12.5MG;12.5MG N022063 004 Jun 20, 2017 Jun NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ALVOGEN MALTA	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017	Jul NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017	Jul NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017	Jul NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017	Jul NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017	Jul NEWA
AB		5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017	Jul NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017	Jul NEWA
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002	May CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002	May CAHN
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May CAHN
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002	May CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002	May CAHN
>A> AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Oct NEWA
>A> AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Oct NEWA
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Oct NEWA
>A> AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Oct NEWA
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Oct NEWA
>A> AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Oct NEWA
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Oct NEWA

AMPICILLIN SODIUM

INJECTABLE;INJECTION
AMPICILLIN SODIUM

>A>	@ HANFORD GC	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Oct CMS1
>A> AP		EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Oct CMS1
>A> AP		EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Oct CMS1
>A>	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Oct CMS1
>A>	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Oct CMS1
>A> AP		EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Oct CMS1
>A>	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Oct CMS1
	@ WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986	Jan CAHN
	@	EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986	Jan CAHN
	@	EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986	Jan CAHN
	@	EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986	Jan CAHN
	@	EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986	Jan CAHN
	@	EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986	Jan CAHN
	PENBRITIN-S					
+ @	WYETH AYERST	EQ 125MG BASE/VIAL	N050072	001		Jun CRLD
+ @		EQ 250MG BASE/VIAL	N050072	002		Jun CRLD
+ @		EQ 500MG BASE/VIAL	N050072	003		Jun CRLD
+ @		EQ 1GM BASE/VIAL	N050072	004		Jun CRLD
+ @		EQ 2GM BASE/VIAL	N050072	005		Jun CRLD
+ @		EQ 4GM BASE/VIAL	N050072	006		Jun CRLD

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION
AMPICILLIN AND SULBACTAM

AP	ANTIBIOTICE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201406	001	Dec 07, 2015	Jul CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201406	002	Dec 07, 2015	Jul CAHN
AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan CAHN

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL A065076 001 Mar 19, 2002 Jan CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	May DISC
AB		EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Mar CAHN
	@	EQ 0.5MG BASE	A077613	001	Jun 27, 2006	May DISC
	@	EQ 1MG BASE	A076811	002	Apr 18, 2005	May DISC
AB		EQ 1MG BASE	A076811	002	Apr 18, 2005	Mar CAHN
	@	EQ 1MG BASE	A077613	002	Jun 27, 2006	May DISC
AB	TORRENT PHARMS LTD	EQ 0.5MG BASE	A209151	001	Jun 30, 2017	Jun NEWA
AB		EQ 1MG BASE	A209151	002	Jun 30, 2017	Jun NEWA
	@ UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Jun CAHN
	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Jun CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

	@ SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011	Sep DISC
	@ WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010	May CAHN
	ARIMIDEX					
AB	+! ASTRAZENECA PHARMS	1MG	N020541	001	Dec 27, 1995	May CAHN

APREPITANT

CAPSULE; ORAL

APREPITANT

>A>	AB	GLENMARK PHARMS LTD	40MG	A207777	001	Oct 12, 2017	Oct NEWA
>A>	AB		80MG	A207777	002	Oct 12, 2017	Oct NEWA
>A>	AB		125MG	A207777	003	Oct 12, 2017	Oct NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

	+! HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016	Feb NEWA
AP	+! NOVARTIS PHARMS CORP	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Jun CAHN

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570	001	May 22, 2017	May NEWA
AP	+! SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May CFTG

ARIPIPRAZOLE

TABLET; ORAL

ARIPIPRAZOLE

AB	ORCHID HLTHCARE	2MG	A202683	001	May 23, 2017	May NEWA
AB		5MG	A202683	002	May 23, 2017	May NEWA
AB		10MG	A202683	003	May 23, 2017	May NEWA
AB		15MG	A202683	004	May 23, 2017	May NEWA
AB		20MG	A202683	005	May 23, 2017	May NEWA
AB		30MG	A202683	006	May 23, 2017	May NEWA
AB	SANTOS BIOTECH	2MG	A091279	001	Jan 09, 2017	May CAHN
AB		5MG	A091279	002	Jan 09, 2017	May CAHN
AB		10MG	A091279	003	Jan 09, 2017	May CAHN
AB		15MG	A091279	004	Jan 09, 2017	May CAHN
AB		20MG	A091279	005	Jan 09, 2017	May CAHN
AB		30MG	A091279	006	Jan 09, 2017	May CAHN

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

+	ALKERMES INC	1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017	Jun NEWA
---	--------------	----------------------------	---------	-----	--------------	----------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

	NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017	Sep NEWA
AB		200MG	A202768	005	Sep 28, 2017	Sep NEWA

ARSENIC TRIOXIDEINJECTABLE; INJECTION
TRISENOX

>A>	+	CEPHALON	2MG/ML	N021248	002	Oct 13, 2017	Oct NEWA
-----	---	----------	--------	---------	-----	--------------	----------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATEINJECTABLE; INJECTION
SEPTOCAINE

AP	+	DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Jun CFTG
----	---	---------	---	---------	-----	--------------	----------

AP		HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Jun NEWA
----	--	--------------	--	---------	-----	--------------	----------

AP		HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Jun NEWA
----	--	--------------	--	---------	-----	--------------	----------

>A> ASCORBIC ACID

>A> SOLUTION; IV (INFUSION)

>A> ASCOR

>A>	+	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017	Oct NEWA
-----	---	--------	--------------------------	---------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN KINJECTABLE; IV (INFUSION)
INFUVITE PEDIATRIC

+	SANDOZ INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	001	Feb 21, 2001	May CAHN
---	------------	--	---------	-----	--------------	----------

+	SANDOZ INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021646	001	Jan 29, 2004	May CAHN
---	------------	--	---------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN EINJECTABLE; INJECTION
M.V.I.-12 (WITHOUT VITAMIN K)

+	@ HOSPIRA	20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML	N008809	006	Sep 09, 2004	Aug DISC
---	-----------	--	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINETABLET; ORAL
FIORINAL

+	@ ALLERGAN SALES LLC	325MG; 50MG; 40MG	N017534	003	Apr 16, 1986	Jan CRLD
---	----------------------	-------------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOLTABLET; ORAL
CARISOPRODOL AND ASPIRIN

AB		NOVAST LABS LTD	325MG; 200MG	A040832	001	Jan 07, 2010	Sep CAHN
----	--	-----------------	--------------	---------	-----	--------------	----------

ASPIRIN; DIPYRIDAMOLECAPSULE, EXTENDED RELEASE; ORAL
ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	25MG; 200MG	A206392	001	Mar 08, 2016	May CAHN
AB		IMPAX LABS INC	25MG; 200MG	A206964	001	Jan 18, 2017	Jan NEWA
AB		PAR PHARM INC	25MG; 200MG	A207944	001	Jan 18, 2017	Jan NEWA
AB		SANDOZ INC	25MG; 200MG	A206739	001	Jan 18, 2017	Jan NEWA
AB		ZYDUS PHARMS USA INC	25MG; 200MG	A206753	001	Aug 29, 2017	Aug NEWA

ASPIRIN; MEPROBAMATETABLET; ORAL
EQUAGESIC

>D>		@ CARACO	325MG; 200MG	N011702	003	Dec 29, 1983	Oct CAHN
>A>		@ SUN PHARM INDUSTRIES	325MG; 200MG	N011702	003	Dec 29, 1983	Oct CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	UNIQUE PHARM LABS	25MG	A077443	001	Sep 13, 2006	Aug CAHN
AB		50MG	A077443	002	Sep 13, 2006	Aug CAHN
AB		100MG	A077443	003	Sep 13, 2006	Aug CAHN
	@ WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991	May CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB	APOTEX INC	10MG	A078983	001	May 30, 2017	May NEWA	
AB		18MG	A078983	002	May 30, 2017	May NEWA	
AB		25MG	A078983	003	May 30, 2017	May NEWA	
AB		40MG	A078983	004	May 30, 2017	May NEWA	
AB		60MG	A078983	005	May 30, 2017	May NEWA	
AB		80MG	A078983	006	May 30, 2017	May NEWA	
AB		100MG	A078983	007	May 30, 2017	May NEWA	
AB	AUROBINDO PHARMA LTD	10MG	A079016	001	May 30, 2017	May NEWA	
AB		18MG	A079016	002	May 30, 2017	May NEWA	
AB		25MG	A079016	003	May 30, 2017	May NEWA	
AB		40MG	A079016	004	May 30, 2017	May NEWA	
AB		60MG	A079016	005	May 30, 2017	May NEWA	
AB		80MG	A079016	006	May 30, 2017	May NEWA	
AB		100MG	A079016	007	May 30, 2017	May NEWA	
AB	GLENMARK PHARMS LTD	10MG	A079019	001	May 30, 2017	May NEWA	
AB		18MG	A079019	002	May 30, 2017	May NEWA	
AB		25MG	A079019	003	May 30, 2017	May NEWA	
AB		40MG	A079019	004	May 30, 2017	May NEWA	
AB		60MG	A079019	005	May 30, 2017	May NEWA	
AB		80MG	A079019	006	May 30, 2017	May NEWA	
AB		100MG	A079019	007	May 30, 2017	May NEWA	
AB	TEVA PHARMS USA	10MG	A079022	001	May 30, 2017	May NEWA	
AB		18MG	A079022	002	May 30, 2017	May NEWA	
AB		25MG	A079022	003	May 30, 2017	May NEWA	
AB		40MG	A079022	004	May 30, 2017	May NEWA	
AB		60MG	A079022	005	May 30, 2017	May NEWA	
AB		80MG	A079022	006	May 30, 2017	May NEWA	
AB		100MG	A079022	007	May 30, 2017	May NEWA	
STRATTERA							
AB	+	LILLY	10MG	N021411	002	Nov 26, 2002	May CFTG
AB	+		18MG	N021411	003	Nov 26, 2002	May CFTG
AB	+		25MG	N021411	004	Nov 26, 2002	May CFTG
AB	+		40MG	N021411	005	Nov 26, 2002	May CFTG
AB	+		60MG	N021411	006	Nov 26, 2002	May CFTG
AB	+		80MG	N021411	007	Feb 14, 2005	May CFTG
AB	+		100MG	N021411	008	Feb 14, 2005	May CFTG

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	TEVA PHARMS USA	EQ 10MG BASE	A205300	001	Mar 27, 2017	Mar NEWA
AB		EQ 20MG BASE	A205300	002	Mar 27, 2017	Mar NEWA
AB		EQ 40MG BASE	A205300	003	Mar 27, 2017	Mar NEWA
AB		EQ 80MG BASE	A205300	004	Mar 27, 2017	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr NEWA
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr NEWA
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr NEWA
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr NEWA

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

>A>	AB	APOTEX INC	750MG/5ML	A209750	001	Oct 11, 2017	Oct NEWA
	AB	PADDOCK LLC	750MG/5ML	A207833	001	Apr 28, 2017	Apr NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION						
ATRACURIUM BESYLATE						
AP	MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Jun NEWA
	@ WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998	Feb CAHN
ATRACURIUM BESYLATE PRESERVATIVE FREE						
AP	MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Mar NEWA
TRACRIUM						
+	@ HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985	Apr CMS1
TRACRIUM PRESERVATIVE FREE						
+	@ HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983	Apr CMS1

ATROPINE SULFATE

SOLUTION;INTRAVENOUS							
ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE							
+	!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Aug NEWA
+	!		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Aug NEWA
SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL							
ATROPINE SULFATE ANSYR PLASTIC SYRINGE							
+	!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug CDFR
+	!		0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug CDFR
+	!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL						
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE						
AA	ANI PHARMS INC	0.025MG; 2.5MG	A086727	001		Jun CMFD

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)						
AVYCAZ						
+!	CEREXA	EQ 0.5GM BASE; 2GM/VIAL	N206494	001	Feb 25, 2015	May CAHN

AZACITIDINE

POWDER;IV (INFUSION), SUBCUTANEOUS							
AZACITIDINE							
AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar	CTEC
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar	CDFR
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar	CDFR
AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	Jun	NEWA
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar	CDFR
VIDAZA							
AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar	CDFR

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION					
IMURAN					
+	@ CASPER PHARMA LLC	EQ 100MG BASE/VIAL	N017391	001	Jul CAHN

AZELASTINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	AZELASTINE HYDROCHLORIDE						
AT	SANDOZ INC	0.05%	A202305	001	May 31, 2012	Feb	CAHN
	OPTIVAR						
AT	+! MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Mar	CAHN
	SPRAY, METERED;NASAL						
	ASTELIN						
AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar	CAHN
	ASTEPRO						
	@ MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar	CAHN
AB	+!	EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar	CAHN
	AZELASTINE HYDROCHLORIDE						
AB	ALKEM LABS LTD	EQ 0.125MG BASE/SPRAY	A208156	001	Aug 18, 2017	Aug	NEWA
AB	AMNEAL PHARMS LLC	EQ 0.125MG BASE/SPRAY	A204660	001	Aug 28, 2017	Aug	NEWA
AB	BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb	CAHN
AB	UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Jun	CAHN
AB		EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar	NEWA
AB	WEST-WARD PHARMS INT	EQ 0.1876MG BASE/SPRAY	A207243	001	Sep 22, 2017	Sep	NEWA
AB	ZYDUS PHARMS USA INC	EQ 0.125MG BASE/SPRAY	A091409	001	Aug 14, 2017	Jul	NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	APOTEX INC	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Apr NEWA
	DYMISTA					
AB	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Apr CFTG
	+	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Mar CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Aug CTEC
AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Aug CTEC

INJECTABLE;INJECTION

AZITHROMYCIN

>A>	@ CSPC OUYI PHARM CO	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Oct CAHN
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan NEWA
>D>	@ PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Oct CAHN

TABLET;ORAL

AZITHROMYCIN

	@ MYLAN	EQ 250MG BASE	A065365	001	May 30, 2007	Jun DISC
	@	EQ 500MG BASE	A065366	001	May 30, 2007	May DISC
	ZITHROMAX					
AB	+ PFIZER	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr CRLD
AB	+	EQ 500MG BASE	N050784	001	May 24, 2002	Apr CRLD

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

>A>	AP	AKORN	50,000 UNITS/VIAL	A206719	001	Oct 20, 2017	Oct NEWA
-----	----	-------	-------------------	---------	-----	--------------	----------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

CORTISPORIN

	+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984	Feb CAHN
--	---	----------------	--	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOSPORIN

AT	+	CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Apr CMFD
----	---	-------------------	--	---------	-----	--	----------

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar CAHN
AP		0.5MG/ML	A091193	002	May 03, 2016	Mar CAHN
AP		2MG/ML	A091193	003	May 03, 2016	Mar CAHN

GABLOFEN

	+	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012	Mar CRLD
AP		PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Apr CAHN
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Apr CAHN
	+		1MG/ML	N022462	004	Jun 22, 2012	Apr CAHN
AP			2MG/ML	N022462	003	Nov 19, 2010	Apr CAHN

TABLET;ORAL

BACLOFEN

	@ MYLAN	10MG	A077181	001	Jul 29, 2005	May DISC
AB	OXFORD PHARMS	10MG	A077088	002	Oct 31, 2007	Apr CMS1
AB	USL PHARMA	10MG	A074584	001	Aug 19, 1996	Jun CAHN
AB		20MG	A074584	002	Aug 19, 1996	Jun CAHN

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB	WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Jul CTEC
BX		750MG	A077806	001	Dec 28, 2007	Apr CTEC

BARIUM SULFATEFOR SUSPENSION; ORAL
E-Z-HD

+! BRACCO 98% (334GM/BOTTLE)

N208036 001 Jan 11, 2016 Apr CPOT

E-Z-PAQUE

+! BRACCO 96% (169GM/BOTTLE)

N208036 002 Apr 07, 2017 Apr NEWA

SUSPENSION; ORAL

LIQUID E-Z-PAQUE

+! BRACCO 60% (213GM/355ML)

N208143 003 Mar 01, 2017 Mar NEWA

TAGITOL V

+! BRACCO 40% (8GM/20ML)

N208143 005 Aug 04, 2017 Aug NEWA

VARIBAR NECTAR

+! BRACCO 40% (96GM/240ML)

N208143 004 Jul 07, 2017 Jul NEWA

BECLOMETHASONE DIPROPIONATEAEROSOL, METERED; INHALATION
QVAR REDHALER

+ NORTON WATERFORD 0.04MG/INH

N207921 001 Aug 03, 2017 Aug NEWA

+! 0.08MG/INH

N207921 002 Aug 03, 2017 Aug NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB AMNEAL PHARMS 5MG

A076820 001 Feb 03, 2006 Apr CAHN

AB 10MG

A076820 002 Feb 03, 2006 Apr CAHN

AB 20MG

A076820 003 Feb 03, 2006 Apr CAHN

AB 40MG

A076820 004 Feb 03, 2006 Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

LOTENSIN HCT

+ @ US PHARMS HOLDINGS I 5MG; 6.25MG

N020033 001 May 19, 1992 May DISC

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

AB + KING PHARMS LLC 5MG; 40MG

N018647 001 May 25, 1983 Mar CAHN

AB +! 5MG; 80MG

N018647 002 May 25, 1983 Mar CAHN

BENZNIDAZOLE

TABLET; ORAL

BENZNIDAZOLE

+ CHEMO RESEARCH SL 12.5MG

N209570 001 Aug 29, 2017 Aug NEWA

+! 100MG

N209570 002 Aug 29, 2017 Aug NEWA

BENZONATATE

CAPSULE; ORAL

TESSALON

AA + PFIZER 100MG

N011210 001 Apr CRLD

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB TOLMAR 5%; EQ 1% BASE

A204087 001 Jun 27, 2017 Jun NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA ANDA REPOSITORY 50MG

A040578 001 Apr 17, 2006 Sep CAHN

@ EPIC PHARMA LLC 50MG

A040714 001 Oct 29, 2007 May CAHN

AA TWI PHARMS INC 50MG

A040578 001 Apr 17, 2006 Mar CAHN

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

@ ANDA REPOSITORY 1MG

A081264 001 Jan 23, 1992 Sep CAHN

@ 2MG

A081265 001 Jan 23, 1992 Sep CAHN

AA EPIC PHARMA LLC 0.5MG

A072264 001 Feb 27, 1989 May CAHN

AA 1MG

A072265 001 Feb 27, 1989 May CAHN

AA 2MG

A072266 001 Feb 27, 1989 May CAHN

OXFORD PHARMS 0.5MG

A040706 002 Feb 14, 2008 May CMS1

TABLET;ORAL

BENZTROPINE MESYLATE

		1MG	A040706	003	Feb 14, 2008	May CMS1
AA	!	UPSHER-SMITH LABS 0.5MG	A040103	001	Dec 12, 1996	Feb CAHN
AA	!	1MG	A040103	002	Dec 12, 1996	Feb CAHN
AA	!	2MG	A040103	003	Dec 12, 1996	Feb CAHN
AA	!	USL PHARMA 0.5MG	A040103	001	Dec 12, 1996	Jun CAHN
AA	!	1MG	A040103	002	Dec 12, 1996	Jun CAHN
AA	!	2MG	A040103	003	Dec 12, 1996	Jun CAHN

BETAINE HYDROCHLORIDEFOR SOLUTION;ORAL
CYSTADANE

+	!	ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996	Jul CAHN
---	---	---------------	--------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	!	FOUGERA PHARMS INC EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan CAHN
	@	TARO EQ 0.05% BASE	A074272	001	Sep 30, 1994	Apr CAHN
		DIPROSONE				
+	@	SCHERING EQ 0.05% BASE	N017781	001		Jan CRLD

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	!	FOUGERA PHARMS INC EQ 0.05% BASE	N019141	001	Sep 04, 1984	Aug CAHN
AB			TARO EQ 0.05% BASE	A074271	001	Sep 15, 1994	Apr CAHN

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

>A>	AB		TELIGENT PHARMA INC EQ 0.05% BASE	A206118	001	Nov 09, 2017	Oct NEWA
-----	----	--	-----------------------------------	---------	-----	--------------	----------

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB		PERRIGO UK FINCO 0.12%	A078337	001	Nov 26, 2012	Apr CAHN
AB		RICONPHARMA LLC 0.12%	A207144	001	May 24, 2017	May NEWA
AB		TARO PHARM 0.12%	A208204	001	May 24, 2017	May NEWA

LUXIQ

AB	+	!	MYLAN PHARMS INC 0.12%	N020934	001	Feb 28, 1999	Jan CAHN
----	---	---	------------------------	---------	-----	--------------	----------

CREAM;TOPICAL

BETAMETHASONE VALERATE

AB	+	!	FOUGERA PHARMS INC EQ 0.1% BASE	N018861	001	Aug 31, 1983	Aug CAHN
----	---	---	---------------------------------	---------	-----	--------------	----------

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB	+	!	FOUGERA PHARMS INC EQ 0.1% BASE	N018866	001	Aug 31, 1983	Aug CAHN
----	---	---	---------------------------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

BETAMETHASONE VALERATE

AB	+	!	FOUGERA PHARMS INC EQ 0.1% BASE	N018865	001	Aug 31, 1983	Aug CAHN
----	---	---	---------------------------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		MEDIMETRIKS PHARMS EQ 0.5% BASE	A075630	001	Apr 12, 2001	Sep CAHN
AT		TELIGENT EQ 0.5% BASE	A075630	001	Apr 12, 2001	Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA		ECI PHARMS LLC 5MG	A040725	001	Oct 26, 2007	Sep CAHN
AA		10MG	A040726	001	Oct 26, 2007	Sep CAHN
AA		25MG	A040727	001	Oct 26, 2007	Sep CAHN
AA		50MG	A040728	001	Oct 26, 2007	Sep CAHN
	@	IMPAX LABS 5MG	A040721	001	Nov 01, 2006	Jan CMS1
	@	10MG	A040721	002	Nov 01, 2006	Jan CMS1
	@	25MG	A040721	003	Nov 01, 2016	Jan CMS1
AA		LANNETT HOLDINGS INC 5MG	A040677	002	Mar 27, 2008	May CMS1
AA		10MG	A040677	003	Mar 27, 2008	May CMS1
AA		25MG	A040677	004	Mar 27, 2008	May CMS1
AA		UPSHER-SMITH LABS 5MG	A040633	001	Jun 01, 2005	Jun CAHN
AA		10MG	A040634	001	Jun 01, 2005	Jun CAHN
AA		25MG	A040635	001	Jun 01, 2005	Jun CAHN
AA		50MG	A040636	001	Jun 01, 2005	Jun CAHN

BETRIXABANCAPSULE;ORAL
BEVYXXA

+	PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017	Jun NEWA
+	!	80MG	N208383	002	Jun 23, 2017	Jun NEWA

BICALUTAMIDETABLET;ORAL
BICALUTAMIDE

AB	SANTOS BIOTECH	50MG	A091011	001	Jun 10, 2015	May CAHN	
AB	WATSON LABS TEVA	50MG	A078634	001	Aug 28, 2009	May CAHN	
CASODEX							
AB	+	! ASTRAZENECA PHARMS	50MG	N020498	001	Oct 04, 1995	May CAHN

BIMATOPROSTSOLUTION/DROPS;OPHTHALMIC
BIMATOPROST

AT	SANDOZ INC	0.03%	A202565	001	May 05, 2015	Mar CAHN
----	------------	-------	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDETABLET, CHEWABLE, TABLET, CAPSULE;ORAL
HELIDAC

+	@ CASPER PHARMA LLC	262.4MG,N/A,N/A,N/A,250MG,N/A,N/A, N/A,500MG	N050719	001	Aug 15, 1996	Jul CAHN
---	---------------------	---	---------	-----	--------------	----------

BISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATE

	@ ANDA REPOSITORY	5MG	A075474	001	Oct 25, 2002	Sep CAHN
	@	10MG	A075474	002	Oct 25, 2002	Sep CAHN
AB	ORIT LABS LLC	5MG	A204891	001	Jan 11, 2017	Jan NEWA
AB		10MG	A204891	002	Jan 11, 2017	Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDETABLET;ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ WATSON LABS TEVA	2.5MG;6.25MG	A075469	001	Sep 25, 2000	May CAHN	
	@	5MG;6.25MG	A075469	002	Sep 25, 2000	May CAHN	
	@	10MG;6.25MG	A075469	003	Sep 25, 2000	May CAHN	
ZIAC							
AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Jan CAHN
AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Jan CAHN
AB	+	!	10MG;6.25MG	N020186	002	Mar 26, 1993	Jan CAHN

BIVALIRUDININJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP	APOTEX INC	250MG/VIAL	A204876	001	Jul 06, 2017	Jun NEWA
AP	DR REDDYS LABS LTD	250MG/VIAL	A201577	001	May 26, 2017	May NEWA

BOSENTANTABLET, FOR SUSPENSION;ORAL
TRACLEER

+	!	ACTELION PHARMS	32MG	N209279	001	Sep 05, 2017	Sep NEWA
---	---	-----------------	------	---------	-----	--------------	----------

BOSUTINIB MONOHYDRATETABLET;ORAL
BOSULIF

>A>	+	PF PRISM CV	EQ 400MG BASE	N203341	003	Oct 27, 2017	Oct NEWA
-----	---	-------------	---------------	---------	-----	--------------	----------

BRETYLIUM TOSYLATEINJECTABLE;INJECTION
BRETYLIUM TOSYLATE

@	WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan CAHN
---	----------------------	---------	---------	-----	--------------	----------

BREXPIPIRAZOLETABLET;ORAL
REXULTI

+	!	OTSUKA PHARM CO LTD	2MG	N205422	004	Jul 10, 2015	Aug CHRS
+			4MG	N205422	006	Jul 10, 2015	Aug CHRS

BRIGATINIBTABLET; ORAL
ALUNBRIG

	+	ARIAD	30MG	N208772	001	Apr 28, 2017	Apr NEWA
	+	!	90MG	N208772	002	Apr 28, 2017	Apr NEWA
>A>	+		180MG	N208772	003	Oct 02, 2017	Oct NEWA

BRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AT		SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb CAHN
AT			0.2%	A078075	001	Jan 30, 2008	Mar CAHN
		QOLIANA					
AT		SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar CAHN

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

AT1		AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar CAHN
AT1	!	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb CHRS
AT2	!	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar CHRS

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

	@	UPSHER-SMITH LABS	4MG	A083215	001		Jun CAHN
--	---	-------------------	-----	---------	-----	--	----------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		TARO PHARM	2MG/5ML; 10MG/5ML; 30MG/5ML	A205112	001	Feb 27, 2017	Feb NEWA
----	--	------------	-----------------------------	---------	-----	--------------	----------

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB		AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Jul NEWA
AB		APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Mar NEWA
AB		SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Sep NEWA
AB		ZYDUS PHARMS USA INC	3MG	A206134	001	May 04, 2017	Apr NEWA

SUSPENSION; INHALATION

BUDESONIDE

>A>	AN		CIPLA LTD	0.25MG/2ML	A205710	001	Nov 16, 2017	Oct NEWA
>A>	AN			0.5MG/2ML	A205710	002	Nov 16, 2017	Oct NEWA
>A>	AN			1MG/2ML	A205710	003	Nov 16, 2017	Oct NEWA

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	!	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar CAHN
AP		WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan CAHN

BUMEX

	+	@	VALIDUS PHARMS	0.25MG/ML	N018226	001	Feb 28, 1983	Jun CAHN
--	---	---	----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

BUMETANIDE

>A>	AB		AMNEAL PHARMS CO	0.5MG	A209724	001	Oct 18, 2017	Oct NEWA
>A>	AB			1MG	A209724	002	Oct 18, 2017	Oct NEWA
>A>	AB			2MG	A209724	003	Oct 18, 2017	Oct NEWA

BUMEX

AB	+		VALIDUS PHARMS	0.5MG	N018225	002	Feb 28, 1983	Jun CAHN
AB	+			1MG	N018225	001	Feb 28, 1983	Jun CAHN
AB	+			2MG	N018225	003	Jun 14, 1985	Jun CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		BAXTER HLTHCARE CORP	0.75%	A207266	001	Jul 25, 2016	Aug CAHN
----	--	----------------------	-------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CAHN

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar NEWA
AB		EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	May CAHN
AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	May CAHN
	ZUBSOLV					
+	OREXO US INC	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan CHRS
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan CHRS

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Sep NEWA
AB		100MG	A207389	002	Sep 18, 2017	Sep NEWA

WELLBUTRIN

+	@ GLAXOSMITHKLINE	50MG	N018644	001	Dec 30, 1985	Sep CRLD
+	@	75MG	N018644	002	Dec 30, 1985	Sep CRLD
+	@	100MG	N018644	003	Dec 30, 1985	Sep CRLD

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3	ANBISON LAB CO LTD	150MG	A207224	001	Jun 30, 2017	Jun NEWA
AB3		300MG	A207224	002	Jun 30, 2017	Jun NEWA
AB3	JUBILANT GENERICS	150MG	A207459	001	Jun 30, 2017	Jun NEWA
AB3		300MG	A207459	002	Jun 30, 2017	Jun NEWA
AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar NEWA
AB3		300MG	A090693	002	Apr 06, 2017	Mar NEWA
AB3	SCIEGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar NEWA
AB3		300MG	A207479	002	Apr 12, 2017	Mar NEWA
AB3	SINOTHERAPEUTICS INC	150MG	A208652	001	Aug 21, 2017	Aug NEWA
AB3		300MG	A208652	002	Aug 21, 2017	Aug NEWA
AB2	TECH ORGANIZED	150MG	A206122	001	Aug 17, 2016	Sep CAHN
>A>	AB3	TWI PHARMS INC	A210081	001	Nov 03, 2017	Oct NEWA
>A>	AB3	300MG	A210081	002	Nov 03, 2017	Oct NEWA

FORFIVO XL

+	!	ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan CAHN
---	---	---------	-------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	May NEWA
AB		7.5MG	A208829	002	May 24, 2017	May NEWA
AB		10MG	A208829	003	May 24, 2017	May NEWA
AB		15MG	A208829	004	May 24, 2017	May NEWA
AB		30MG	A208829	005	May 24, 2017	May NEWA
	@ MYLAN	5MG	A075467	001	Feb 28, 2002	Jun DISC
	@	10MG	A075467	003	Feb 28, 2002	Jun DISC
	@	15MG	A075467	004	Feb 28, 2002	Jun DISC
AB	STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr CAHN
AB		7.5MG	A202330	005	Feb 17, 2017	Sep NEWA
AB		10MG	A202330	002	Aug 25, 2014	Apr CAHN
AB		15MG	A202330	003	Aug 25, 2014	Apr CAHN
AB		30MG	A202330	004	Aug 25, 2014	Apr CAHN

BUSULFAN

INJECTABLE; INJECTION						
BUSULFAN						
AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar NEWA
AP	SANDOZ INC	6MG/ML	A205106	001	Jul 07, 2017	Jun NEWA

BUTABARBITAL SODIUM

TABLET; ORAL						
BUTISOL SODIUM						
	@ MYLAN SPECIALITY LP	15MG	N000793	002		Mar CAHN
	+!	30MG	N000793	004		Mar CAHN
	@	50MG	N000793	003		Mar CAHN
	@	100MG	N000793	005		Mar CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION						
BUTORPHANOL TARTRATE						
	@ BAXTER HLTHCARE CORP	2MG/ML	A075697	001	Oct 23, 2001	Aug CAHN
BUTORPHANOL TARTRATE PRESERVATIVE FREE						
	@ BAXTER HLTHCARE CORP	1MG/ML	A075695	001	Oct 23, 2001	Aug CAHN
	@	2MG/ML	A075695	002	Oct 23, 2001	Aug CAHN
AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan CAHN

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL						
SORILUX						
	+! MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan CAHN
OINTMENT; TOPICAL						
CALCIPOTRIENE						
	! GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	May CAHN

CALCITONIN SALMON

SPRAY, METERED; NASAL						
CALCITONIN-SALMON						
AB	! APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr CHRS
	MIACALCIN					
	+ @ MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr DISC

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL						
FORTICAL						
	@ UPSHER-SMITH LABS	200 IU/SPRAY	N021406	001	Aug 12, 2005	Jun CAHN

CALCITRIOL

CAPSULE; ORAL						
CALCITRIOL						
AB	AMNEAL PHARMS	0.25MCG	A203289	002	Jun 14, 2017	May NEWA
AB		0.5MCG	A203289	001	Jun 14, 2017	May NEWA
INJECTABLE; INJECTION						
CALCIJEX						
	+ @ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	May CRLD
	+ @	0.002MG/ML	N018874	002	Sep 25, 1986	May CRLD
CALCITRIOL						
	! AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	May CHRS

CALCIUM ACETATE

CAPSULE; ORAL						
CALCIUM ACETATE						
AB	CHARTWELL RX	667MG	A091312	001	Jun 01, 2012	Mar CAHN
TABLET; ORAL						
CALCIUM ACETATE						
AB	! PADDOCK LLC	667MG	A091561	001	Apr 13, 2011	Apr CHRS
	ELIPHOS					
AB	CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr CHRS

CALCIUM CHLORIDE

INJECTABLE;INJECTION
CALCIUM CHLORIDE 10%

AP	LUITPOLD PHARMS INC	100MG/ML	A209088	001	Jul 27, 2017	Jul NEWA
	CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER					
AP	+! HOSPIRA	100MG/ML	N021117	001	Jan 28, 2000	Jul CFTG

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;86 0MG/100ML	N018254	001		Aug DISC
-----------	---	---------	-----	--	----------

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;86 0MG/100ML	N020000	001	Apr 17, 1992	Aug CTEC
---------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;30MG/100ML;60 0MG/100ML;310MG/100ML	N017608	001		Feb CAHN
----	-----------------	---	---------	-----	--	----------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6 00MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988	Feb CAHN
-------------------	--	---------	-----	--------------	----------

@	20MG/100ML;5GM/100ML;179MG/100ML;6 00MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988	Feb CAHN
---	--	---------	-----	--------------	----------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6 00MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988	Feb CAHN
-------------------	--	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;6 00MG/100ML;310MG/100ML	N019685	002	Oct 17, 1988	Feb CAHN
----	-----------------	--	---------	-----	--------------	----------

AP		20MG/100ML;5GM/100ML;328MG/100ML;6 00MG/100ML;310MG/100ML	N019685	008	Oct 17, 1988	Feb CAHN
----	--	--	---------	-----	--------------	----------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6 00MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988	Feb CAHN
-------------------	--	---------	-----	--------------	----------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;6 00MG/100ML;310MG/100ML	N019685	004	Oct 17, 1988	Feb CAHN
----	-----------------	--	---------	-----	--------------	----------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6 00MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988	Feb CAHN
-------------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	33MG/100ML;30MG/100ML;860MG/100ML	N018251	001		Feb CAHN
----	-----------------	-----------------------------------	---------	-----	--	----------

SOLUTION;IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	33MG/100ML;30MG/100ML;860MG/100ML	N017635	001		Feb CAHN
----	-----------------	-----------------------------------	---------	-----	--	----------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N017641	001		Feb CAHN
----	-----------------	---	---------	-----	--	----------

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+! ICU MEDICAL INC	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N019416	001	Jan 17, 1986	Feb CAHN
----	--------------------	---	---------	-----	--------------	----------

CALCIUM GLUCONATE

SOLUTION;IV (INFUSION)

CALCIUM GLUCONATE

+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	Jun NEWA
+!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	Jun NEWA
+!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	Jun NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

AB	ALEMBIC PHARMS LTD	32MG	A209119	001	Jun 20, 2017	Jun NEWA
AB	ZYDUS PHARMS USA INC	4MG	A091390	001	Aug 23, 2017	Aug NEWA
AB		8MG	A091390	002	Aug 23, 2017	Aug NEWA
AB		16MG	A091390	003	Aug 23, 2017	Aug NEWA
AB		32MG	A091390	004	Aug 23, 2017	Aug NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MYLAN PHARMS INC	16MG;12.5MG	A090704	001	Dec 04, 2012	May CAHN
AB		32MG;12.5MG	A090704	002	Dec 04, 2012	May CAHN
AB		32MG;25MG	A090704	003	Dec 04, 2012	May CAHN

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Feb NEWA
AB		500MG	A204741	002	Feb 28, 2017	Feb NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

	@ BOSCOGEN	12.5MG	A074677	004	May 30, 1997	May CAHN
	@	25MG	A074677	002	May 30, 1997	May CAHN
	@	50MG	A074677	001	May 30, 1997	May CAHN
	@	100MG	A074677	003	May 30, 1997	May CAHN
AB	MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996	Mar CAHN
AB		25MG	A074434	002	Feb 13, 1996	Mar CAHN
AB		50MG	A074434	003	Feb 13, 1996	Mar CAHN
AB	!	100MG	A074434	004	Feb 13, 1996	Mar CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

EQUETRO

+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004	Jun CAHN
+		200MG	N021710	002	Dec 10, 2004	Jun CAHN
+	!	300MG	N021710	003	Dec 10, 2004	Jun CAHN

SOLUTION; IV (INFUSION)

CARNEXIV

+	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan CAHN
---	---------------------	----------------------	---------	-----	--------------	----------

SUSPENSION; ORAL

TERIL

AB	TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004	Mar CAHN
----	------------	-----------	---------	-----	--------------	----------

CARBIDOPA

TABLET; ORAL

CARBIDOPA

>A> AB	NOVEL LABS INC	25MG	A204763	001	Oct 20, 2017	Oct NEWA
--------	----------------	------	---------	-----	--------------	----------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

	IDT AUSTRALIA LTD	10MG;100MG	A073587	002	Jun 29, 1995	Jul CMS1
		25MG;250MG	A073587	003	Jun 29, 1995	Jul CMS1

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

@	WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004	May CAHN
@		150MG/VIAL	A076162	002	Oct 14, 2004	May CAHN
@		450MG/VIAL	A076162	003	Oct 14, 2004	May CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan NEWA
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan NEWA
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan NEWA
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan NEWA

INJECTABLE;IV (INFUSION)
CARBOPLATIN

AP		150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan NEWA
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan NEWA
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan NEWA
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Apr NEWA
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Apr NEWA
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Apr NEWA
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Apr NEWA

CARISOPRODOL

CAPSULE;ORAL
SOMA

	@ MYLAN SPECIALITY LP	250MG	N011792	003		Mar CAHN
	TABLET;ORAL					
	CARISOPRODOL					
	@ EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000	May CAHN
AA	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Apr CMFD
AB	NOSTRUM LABS INC	250MG	A207237	001	May 11, 2017	Apr NEWA
	@ SUN PHARM INDS LTD	350MG	A040755	001	Feb 27, 2007	Sep DISC
	SOMA					
AB	+! MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007	Mar CAHN
AA	+	350MG	N011792	001		Mar CAHN

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

AT	! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May CHRS
AT		1%	A075476	001	Jan 03, 2000	Mar CAHN
	OCUPRESS					
	+ @ NOVARTIS	1%	N019972	001	May 23, 1990	May DISC

CARVEDILOL

TABLET;ORAL
CARVEDILOL

	@ PLIVA HRVATSKA DOO	3.125MG	A078240	001	Oct 30, 2007	Jul DISC
	@	6.25MG	A078240	002	Oct 30, 2007	Jul DISC
	@	12.5MG	A078240	003	Oct 30, 2007	Jul DISC
	@	25MG	A078240	004	Oct 30, 2007	Jul DISC

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL
CARVEDILOL PHOSPHATE

>A>	AB	SUN PHARM INDUSTRIES	10MG	A090132	001	Oct 25, 2017	Oct NEWA
>A>	AB		20MG	A090132	002	Oct 25, 2017	Oct NEWA
>A>	AB		40MG	A090132	003	Oct 25, 2017	Oct NEWA
>A>	AB		80MG	A090132	004	Oct 25, 2017	Oct NEWA
	COREG CR						
>D>	+	SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	Oct CFTG
>A>	AB	+	10MG	N022012	001	Oct 20, 2006	Oct CFTG
>D>	+		20MG	N022012	002	Oct 20, 2006	Oct CFTG
>A>	AB	+	20MG	N022012	002	Oct 20, 2006	Oct CFTG
>D>	+		40MG	N022012	003	Oct 20, 2006	Oct CFTG
>A>	AB	+	40MG	N022012	003	Oct 20, 2006	Oct CFTG
>D>	+		80MG	N022012	004	Oct 20, 2006	Oct CFTG
>A>	AB	+	80MG	N022012	004	Oct 20, 2006	Oct CFTG

CASPOFUNGIN ACETATE

POWDER;IV (INFUSION)
CANCIDAS

AP	+! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar CDFR
AP	+!	70MG/VIAL	N021227	002	Jan 26, 2001	Mar CDFR
	CASPOFUNGIN ACETATE					
AP	GLAND PHARMA LTD	50MG/VIAL	A207092	001	Sep 29, 2017	Sep NEWA
AP		70MG/VIAL	A207092	002	Sep 29, 2017	Sep NEWA
AP	MYLAN LABS LTD	50MG/VIAL	A207650	001	Sep 29, 2017	Sep NEWA
AP		70MG/VIAL	A207650	002	Sep 29, 2017	Sep NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATECAPSULE;ORAL
CEFADROXIL

AB	CSPC OUYI PHARM CO	EQ 500MG BASE	A205072	001	Jul 28, 2017	Jul NEWA
----	--------------------	---------------	---------	-----	--------------	----------

CEFAZOLIN SODIUMINJECTABLE;INJECTION
CEFAZOLIN SODIUM

>D>	AP	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014	Oct CHRS
>A>	!		EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014	Oct CHRS
>D>	AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Oct DISC
>A>	@		EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Oct DISC
>D>	AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Oct DISC
>A>	@		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Oct DISC
>D>	AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Oct DISC
>A>	@		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Oct DISC
>D>	AP	!	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Oct DISC
>A>	@		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Oct DISC

CEFDINIRCAPSULE;ORAL
OMNICEF

+	@	ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan CRLD
FOR SUSPENSION;ORAL							
OMNICEF							
+	@	ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan CRLD
+	@		250MG/5ML	N050749	002	Jul 29, 2004	Jan CRLD

CEFIXIMEFOR SUSPENSION;ORAL
CEFIXIME

AB	BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan NEWA
AB		200MG/5ML	A206938	002	Feb 06, 2017	Jan NEWA
AB		500MG/5ML	A206939	001	Feb 06, 2017	Jan NEWA
SUPRAX						
AB	+! LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan CFTG

CEFOTAXIME SODIUMINJECTABLE;INJECTION
CLAFORAN

@	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987	Aug DISC
@		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987	Aug DISC

CEFOTETAN DISODIUMINJECTABLE;INJECTION
CEFOTAN

AP	+	TELIGENT	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Apr CAHN
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Apr CAHN
	@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Apr CAHN
CEFOTAN IN PLASTIC CONTAINER							
	@	TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr CAHN
	@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr CAHN

CEFOXITIN SODIUMINJECTABLE;INJECTION
CEFOXITIN

>D>	AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	Oct DISC
>A>	@		EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	Oct DISC
>D>	AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	Oct DISC
>A>	@		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	Oct DISC
>D>	AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	Oct DISC
>A>	@		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	Oct DISC
AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan CAHN
AP			EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan CAHN
AP			EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan CAHN
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
+	@	MERCK	EQ 20MG BASE/ML	N050581	003	Sep 20, 1984	Sep CRLD
+	@		EQ 40MG BASE/ML	N050581	004	Sep 20, 1984	Sep CRLD
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
+	@	MERCK	EQ 20MG BASE/ML	N050581	002	Sep 20, 1984	Sep CRLD
+	@		EQ 40MG BASE/ML	N050581	001	Sep 20, 1984	Sep CRLD

CEFPROZILTABLET;ORAL
CEFPROZIL

AB	AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan CAHN
AB		500MG	A065340	002	May 24, 2007	Jan CAHN

CEFTAZIDIMEINJECTABLE;INJECTION
FORTAZ

AP	+	TELIGENT	500MG/VIAL	N050578	001	Jul 19, 1985	Apr CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr CAHN

CEFTAZIDIME SODIUMINJECTABLE;INJECTION
FORTAZ IN PLASTIC CONTAINER

	@	TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	May CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May CAHN

CEFTRIAXONE SODIUMINJECTABLE;INJECTION
CEFTRIAXONE

>D>	AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Oct DISC
>A>		@	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Oct DISC
		CEFTRIAXONE SODIUM					
	AP	HIKMA FARMACEUTICA	EQ 10GM BASE/VIAL	A090701	001	Oct 04, 2017	Sep NEWA
	AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan NEWA
		ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
	+	@ HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
	+	@	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
	+	@	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD

CEFUROXIME AXETILTABLET;ORAL
CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
AB		EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
AB		EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN

CEFUROXIME SODIUMINJECTABLE;INJECTION
CEFUROXIME SODIUM

AP	ACS DOBFAR SPA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Sep CAHN	
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Sep CAHN	
		ZINACEF					
AP	+	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May CAHN
		ZINACEF IN PLASTIC CONTAINER					
	@	TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN
		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
		CEFUROXIME SODIUM					
AB	ACS DOBFAR SPA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Sep CAHN	
		ZINACEF					
AB	+	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May CAHN

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar NEWA
AB		100MG	A207061	002	Apr 04, 2017	Mar NEWA
AB		200MG	A207061	003	Apr 04, 2017	Mar NEWA
AB		400MG	A207061	004	Apr 04, 2017	Mar NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan CAHN
AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan CAHN
	FOR SUSPENSION;ORAL					
	CEPHALEXIN					
AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336	001	Jul 25, 2007	Aug CMFD
AB		EQ 250MG BASE/5ML	A065336	002	Jul 25, 2007	Aug CMFD

CEPHAPIRIN SODIUMINJECTABLE;INJECTION
CEPHAPIRIN SODIUM

	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan CAHN
	@	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan CAHN
	@	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan CAHN
	@	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan CAHN

CETIRIZINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
ZERVIAE

>A>	+	!	EYEVANCE PHARMS	EQ 0.24% BASE	N208694	001	May 30, 2017	Oct CAHN
>D>	+	!	NICOX OPHTHALMICS	EQ 0.24% BASE	N208694	001	May 30, 2017	Oct CAHN
	+	!		EQ 0.24% BASE	N208694	001	May 30, 2017	May NEWA

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	ALLIED PHARMA INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr CAHN
----	-------------------	---------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB	RISING PHARMS INC	30MG	A203775	001	Jun 04, 2014	May CAHN
----	-------------------	------	---------	-----	--------------	----------

CHENODIOL

TABLET;ORAL

CHENIX

	+	@	LEADIANT BIOSCI INC	250MG	N018513	002	Jul 28, 1983	Feb CAHN
--	---	---	---------------------	-------	---------	-----	--------------	----------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLOROMYCETIN

	+	@	PARKEDALE	EQ 1GM BASE/VIAL	N050155	001		Mar CRLD
--	---	---	-----------	------------------	---------	-----	--	----------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

	@	UPSHER-SMITH LABS	5MG	A084678	001		Jun CAHN
	@		5MG	A084919	001		Aug CAHN
	@		10MG	A084041	001		Jun CAHN
	@		10MG	A084920	001		Aug CAHN
	@		25MG	A084679	002		Jun CAHN
	@		25MG	A084823	001		Aug CAHN
	@	USL PHARMA	10MG	A084623	001		Apr DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIOGARD

AT	COLGATE PALMOLIVE CO	0.12%	A073695	001	Jan 14, 1994	May CAHN
----	----------------------	-------	---------	-----	--------------	----------

CHLOROPROCAINE HYDROCHLORIDE

SOLUTION;INTRATHECAL

CLOROTEKAL

	+	SINTETICA SA	50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017	Sep NEWA
--	---	--------------	--------------------	---------	-----	--------------	----------

CHLOROQUINE PHOSPHATE

TABLET;ORAL

ARALEN

	+	@	SANOFI AVENTIS US	EQ 300MG BASE	N006002	001		Sep DISC
			CHLOROQUINE PHOSPHATE					
AA	!	NATCO PHARMA LTD	EQ 300MG BASE	A090612	001	Jan 21, 2011	Sep CHRS	

CHLOROTHIAZIDE

TABLET; ORAL
CHLOROTHIAZIDE

! MYLAN 250MG A084217 002 Sep CMS1

CHLORPHENESIN CARBAMATE

TABLET; ORAL
MAOLATE

@ PAMLAB LLC 400MG N014217 002 Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA ACELLA PHARMS LLC 4MG/5ML; 5MG/5ML A206891 001 Jun 09, 2017 May NEWA
@ TRIS PHARMA INC 4MG/5ML; 5MG/5ML A206438 001 Jan 27, 2015 Sep DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA BIO-PHARM INC 4MG/5ML; 5MG/5ML; 60MG/5ML A206660 001 May 15, 2017 May NEWA
@ TRIS PHARMA INC 4MG/5ML; 5MG/5ML; 60MG/5ML A203838 001 Nov 26, 2014 Sep DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

USL PHARMA 10MG A083386 001 Jun CAHN
10MG A083386 001 May CTEC
! 25MG A084112 001 Jun CAHN
! 25MG A084112 001 May CHRS
50MG A084113 001 Jun CAHN
50MG A084113 001 May CTEC
! 100MG A084114 001 Jun CAHN
! 100MG A084114 001 May CHRS
200MG A084115 001 Jun CAHN
200MG A084115 001 May CTEC

THORAZINE

@ GLAXOSMITHKLINE 10MG N009149 002 May CRLD
@ 25MG N009149 007 May CRLD
@ 50MG N009149 013 May CRLD
@ 100MG N009149 018 May CRLD
@ 200MG N009149 020 May CRLD

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC 250MG A087353 001 Jan CAHN
@ WATSON LABS TEVA 250MG A088826 001 Sep 26, 1984 May CAHN
GLUCAMIDE
AB ANI PHARMS INC 250MG A088641 001 Oct 11, 1984 Jul CMFD

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB RICONPHARMA LLC 25MG A206904 001 Mar 30, 2017 Mar NEWA
AB 50MG A206904 002 Mar 30, 2017 Mar NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

AB ZYDUS PHARMS USA INC EQ 4GM RESIN/SCOOPFUL A202902 001 Apr 25, 2017 Aug CTNA
AB EQ 4GM RESIN/SCOOPFUL A202902 001 Apr 25, 2017 Apr NEWA

PREVALITE

AB UPSHER-SMITH LABS EQ 4GM RESIN/PACKET A073263 001 Feb 22, 1996 Jun CAHN
AB EQ 4GM RESIN/SCOOPFUL A073263 002 Oct 30, 1997 Jun CAHN

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

UNIV TX MD ANDERSON 4-100mCi/ML A205690 001 Oct 29, 2015 Jul CPOT

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

AB	ALEMBIC PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A208705	001	May 12, 2017	May NEWA
AB		EQ 135MG FENOFIBRIC ACID	A208705	002	May 12, 2017	May NEWA

CICLESONIDEAEROSOL, METERED;INHALATION
ALVESCO

+	!	ASTRAZENECA PHARMS	0.08MG/INH	N021658	002	Jan 10, 2008	Jul CAHN
+	!		0.16MG/INH	N021658	003	Jan 10, 2008	Jul CAHN

AEROSOL, METERED;NASAL
ZETONNA

+	!	ASTRAZENECA PHARMS	0.037MG/INH	N202129	001	Jan 20, 2012	Jul CAHN
---	---	--------------------	-------------	---------	-----	--------------	----------

SPRAY, METERED;NASAL
OMNARIS

+	!	ASTRAZENECA PHARMS	0.05MG/INH	N022004	001	Oct 20, 2006	Jul CAHN
---	---	--------------------	------------	---------	-----	--------------	----------

CICLOPIROXCREAM;TOPICAL
CICLOPIROX

AB	PERRIGO NEW YORK	0.77%	A077364	001	Mar 03, 2006	Apr CAHN
----	------------------	-------	---------	-----	--------------	----------

GEL;TOPICAL
CICLOPIROX

AB	+	!	CNTY LINE PHARMS	0.77%	N020519	001	Jul 21, 1997	Sep CTNA
----	---	---	------------------	-------	---------	-----	--------------	----------

SHAMPOO;TOPICAL
CICLOPIROX

AT	PERRIGO CO	1%	A078594	001	Feb 16, 2010	Apr CAHN
----	------------	----	---------	-----	--------------	----------

CILOSTAZOLTABLET;ORAL
CILOSTAZOL

AB	CHARTWELL RX	50MG	A077722	001	Sep 24, 2012	Sep CAHN
AB		100MG	A077831	001	Sep 24, 2012	Sep CAHN
	@ EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005	May CAHN
	@	100MG	A077022	001	Nov 23, 2004	May CAHN
	@ MYLAN	50MG	A077323	002	Apr 20, 2006	May DISC
	@	100MG	A077323	001	Apr 20, 2006	May DISC
	@ MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Mar DISC
	@	100MG	A077019	002	Nov 23, 2004	Mar DISC
	@ PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007	Mar DISC
	@	100MG	A077898	002	Oct 29, 2007	Mar DISC
	PLETAL					
+	@ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan CRLD
+	@	100MG	N020863	002	Jan 15, 1999	Jan CRLD

CIMETIDINETABLET;ORAL
CIMETIDINE

@	CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan CAHN
@		300MG	A074281	002	May 17, 1994	Jan CAHN
@		400MG	A074281	003	May 17, 1994	Jan CAHN
@		800MG	A074329	001	May 17, 1994	Jan CAHN
@	SANDOZ INC	200MG	A074250	001	Jun 29, 1995	Mar CAHN
@		300MG	A074250	002	Jun 29, 1995	Mar CAHN
@		400MG	A074250	003	Jun 29, 1995	Mar CAHN
@		800MG	A074250	004	Jun 29, 1995	Mar CAHN
@	UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Jun CAHN
@		300MG	A074506	002	Jan 24, 1996	Jun CAHN
@		400MG	A074506	003	Jan 24, 1996	Jun CAHN
@		800MG	A074506	004	Jan 24, 1996	Jun CAHN

CIMETIDINE HYDROCHLORIDESOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

AA	PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	May CAHN
----	-------------	-------------------	---------	-----	--------------	----------

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPRO

+ @ BAYER HLTHCARE 400MG/40ML (10MG/ML)

N019847 001 Dec 26, 1990 Feb DISC

+ @ 200MG/20ML (10MG/ML)

N019847 002 Dec 26, 1990 Feb DISC

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @ BAYER HLTHCARE 200MG/100ML

N019857 001 Dec 26, 1990 Feb DISC

+ @ 400MG/200ML

N019857 002 Dec 26, 1990 Feb DISC

CIPROFLOXACIN

AP ! BAXTER HLTHCARE CORP 200MG/20ML (10MG/ML)

A078062 001 Apr 29, 2008 Aug CAHN

AP ! 400MG/40ML (10MG/ML)

A078062 002 Apr 29, 2008 Aug CAHN

AP ! CLARIS 200MG/20ML (10MG/ML)

A078062 001 Apr 29, 2008 Feb CHRS

AP ! 400MG/40ML (10MG/ML)

A078062 002 Apr 29, 2008 Feb CHRS

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP BAXTER HLTHCARE CORP 200MG/100ML

A078024 001 Mar 18, 2008 Aug CAHN

AP 400MG/200ML

A078024 002 Mar 18, 2008 Aug CAHN

AP ! HOSPIRA 200MG/100ML

A077753 001 Mar 18, 2008 Feb CHRS

AP ! 400MG/200ML

A077753 002 Mar 18, 2008 Feb CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

>D> AT AMRING PHARMS EQ 0.3% BASE

A078598 001 Jan 16, 2008 Oct DISC

>A> @ EQ 0.3% BASE

A078598 001 Jan 16, 2008 Oct DISC

AT EQ 0.3% BASE

A078598 001 Jan 16, 2008 Mar CAHN

AT TELIGENT EQ 0.3% BASE

A076754 001 Jun 09, 2004 Apr CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ MYLAN EQ 250MG BASE

A075685 002 Jun 09, 2004 Aug DISC

@ EQ 500MG BASE

A075685 003 Jun 09, 2004 Aug DISC

@ EQ 750MG BASE

A075685 001 Jun 09, 2004 Aug DISC

AB TARO PHARM EQ 100MG BASE

A076912 001 Feb 18, 2005 Mar CAHN

AB EQ 250MG BASE

A076912 002 Oct 06, 2004 Mar CAHN

AB EQ 500MG BASE

A076912 003 Oct 06, 2004 Mar CAHN

AB EQ 750MG BASE

A076912 004 Oct 06, 2004 Mar CAHN

AB UNIQUE PHARM LABS EQ 250MG BASE

A076639 001 Sep 10, 2004 Aug CAHN

AB EQ 500MG BASE

A076639 002 Sep 10, 2004 Aug CAHN

AB EQ 750MG BASE

A076639 003 Sep 10, 2004 Aug CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP ACCORD HLTHCARE EQ 2MG BASE/ML

A205873 001 Jun 16, 2017 Jun NEWA

AP JIANGSU HENGRUI MED EQ 2MG BASE/ML

A209334 001 Aug 30, 2017 Aug NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP ACCORD HLTHCARE EQ 2MG BASE/ML

A205872 001 Jun 16, 2017 Jun NEWA

AP EQ 10MG BASE/ML

A205872 002 Jun 16, 2017 Jun NEWA

AP JIANGSU HENGRUI MED EQ 2MG BASE/ML

A204960 001 Jan 27, 2017 Jan NEWA

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP GLAND PHARMA LTD 1MG/ML

A207323 001 Mar 17, 2017 Mar NEWA

AP + HQ SPCLT PHARMA 1MG/ML

N018057 004 Nov 08, 1988 Mar CRLD

PLATINOL

+ @ HQ SPCLT PHARMA 10MG/VIAL

N018057 001 Mar CRLD

+ @ 50MG/VIAL

N018057 002 Mar CRLD

PLATINOL-AQ

+ @ HQ SPCLT PHARMA 0.5MG/ML

N018057 003 Jul 18, 1984 Mar CRLD

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

@ MYLAN PHARMS INC EQ 10MG BASE

A077668 001 Feb 28, 2007 Mar DISC

@ EQ 20MG BASE

A077668 002 Feb 28, 2007 Mar DISC

@ EQ 40MG BASE

A077668 003 Feb 28, 2007 Mar DISC

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA AUROBINDO PHARMA LTD EQ 10MG BASE/5ML

A077812 001 Aug 28, 2006 Jan CAHN

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

@ EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004	May CAHN
@	EQ 20MG BASE	A077036	002	Oct 28, 2004	May CAHN
@	EQ 40MG BASE	A077036	003	Oct 28, 2004	May CAHN
@ MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005	Jun DISC
@	EQ 20MG BASE	A077039	002	Feb 03, 2005	Jun DISC
@	EQ 40MG BASE	A077039	003	Feb 03, 2005	Jun DISC
@ MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	May DISC
@	EQ 20MG BASE	A077037	002	Nov 05, 2004	May DISC
@	EQ 40MG BASE	A077037	003	Nov 05, 2004	May DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+! FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACK	N202535	001	Jul 16, 2012	Mar CAHN
	ET				

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

@ MYLAN	250MG	A065195	001	Mar 11, 2005	May DISC
@	500MG	A065195	002	Mar 11, 2005	May DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

@ SANDOZ	2.68MG	A073459	001	Oct 31, 1993	Feb DISC
! TEVA	2.68MG	A073283	001	Jan 31, 1992	Feb CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 150MG BASE	A065194	001	Mar 22, 2004	May CAHN
AB		EQ 300MG BASE	A065194	002	Mar 22, 2004	May CAHN
AB	LANNETT	EQ 75MG BASE	A065243	002	Aug 12, 2005	Aug CMS1
	@ MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	May DISC
	@	EQ 150MG BASE	A091225	002	May 31, 2011	May DISC
	@	EQ 300MG BASE	A091225	003	May 31, 2011	May DISC
	CLINDAMYCIN HYDROCHLORIDE					
AB	LANNETT	EQ 150MG BASE	A065243	003	Aug 12, 2005	Aug CMS1

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	INVAGEN PHARMS	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Apr NEWA
AA	ORIT LABS LLC	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Jun CAHN
AA	PADDOCK LLC	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Apr CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

EVOCLIN

AT	+! MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan CAHN
----	---------------------	----	---------	-----	--------------	----------

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

AP	MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Sep NEWA
AP		EQ 150MG BASE/ML	A204749	001	Oct 10, 2017	Sep NEWA
AP	SAGENT PHARMS	EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Apr CAHN
AP	WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN
	CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE CORP	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jul CAHN
AP		EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jul CAHN
AP		EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jul CAHN
AP	CELERITY PHARMS	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jun NEWA
AP		EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jun NEWA
AP		EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jun NEWA

SOLUTION;IV (INFUSION)

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	May CAHN
+!	EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	May CAHN
+!	EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	May CAHN

SOLUTION;IV (INFUSION)

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

		BASE/ML)							
+	!	CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG	N208083	001	Apr 20, 2017	Apr	NEWA	
			BASE/ML)						
+	!		EQ 600MG BASE/50ML (EQ 12MG	N208083	002	Apr 20, 2017	Apr	NEWA	
			BASE/ML)						
+	!		EQ 900MG BASE/50ML (EQ 18MG	N208083	003	Apr 20, 2017	Apr	NEWA	
			BASE/ML)						
		SOLUTION;TOPICAL							
		CLINDAMYCIN PHOSPHATE							
AT		FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan	CAHN	
		@ NOVAST LABS LTD	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep	CAHN	
		SWAB;TOPICAL							
		CLINDETS							
AT		PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Apr	CAHN	

CLOBAZAM

SUSPENSION;ORAL

ONFI

+	!	LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan	CAHN	
		TABLET;ORAL							
		ONFI							
		@ LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan	CAHN	
+			10MG	N202067	002	Oct 21, 2011	Jan	CAHN	
+	!		20MG	N202067	003	Oct 21, 2011	Jan	CAHN	

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017	Jul	NEWA	
		OLUX							
AB1	+	!	MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan	CAHN
			OLUX E						
AB2	+	!	MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan	CAHN
		CREAM;TOPICAL							
		CLOBETASOL PROPIONATE							
AB1		FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan	CAHN	
AB1		MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	May	CMFD	
		@	0.05%	A075338	001	Feb 09, 2001	Jan	CAHN	
AB1		TARO	0.05%	A074249	001	Jul 08, 1996	Apr	CAHN	
		CLOBETASOL PROPIONATE (EMOLLIENT)							
		@ NOVAST LABS LTD	0.05%	A075733	001	Aug 22, 2001	Sep	CAHN	
AB2		TELLIGENT PHARMA INC	0.05%	A209411	001	Aug 21, 2017	Aug	NEWA	
		GEL;TOPICAL							
		CLOBETASOL PROPIONATE							
AB		PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr	CAHN	
AB		TARO	0.05%	A075279	001	May 28, 1999	Apr	CAHN	
AB		TELLIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb	NEWA	
		LOTION;TOPICAL							
		CLOBETASOL PROPIONATE							
AB		LUPIN LTD	0.05%	A209147	001	Sep 22, 2017	Sep	NEWA	
		OINTMENT;TOPICAL							
		CLOBETASOL PROPIONATE							
AB		GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar	NEWA	
AB		TARO	0.05%	A074248	001	Jul 12, 1996	Apr	CAHN	
>A> AB		ZYDUS PHARMS USA INC	0.05%	A210199	001	Oct 27, 2017	Oct	NEWA	
		TEMOVATE							
+		@ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CRLD	
		SHAMPOO;TOPICAL							
		CLOBETASOL PROPIONATE							
>A> AB		HI-TECH PHARMACAL	0.05%	A209871	001	Oct 27, 2017	Oct	NEWA	
		SOLUTION;TOPICAL							
		CLOBETASOL PROPIONATE							
>A> AT		MACLEODS PHARMS LTD	0.05%	A209361	001	Oct 25, 2017	Oct	NEWA	
AT		TARO	0.05%	A075224	001	Nov 16, 1998	Apr	CAHN	
		SPRAY;TOPICAL							
		CLOBETASOL PROPIONATE							
AT		AKORN	0.05%	A207218	001	Apr 28, 2017	Apr	NEWA	
AT		ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb	NEWA	

CLOFARABINE

INJECTABLE;IV (INFUSION)

CLOFARABINE

AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr NEWA	
>A>	AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017	Oct NEWA
>A>	AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017	Oct NEWA
>A>	AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017	Oct NEWA
CLOLAR							
AP	+!	GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr CFTG

CLOFAZIMINE

CAPSULE;ORAL

LAMPRENE

	+ @	NOVARTIS	50MG	N019500	002	Dec 15, 1986	Aug DISC
--	-----	----------	------	---------	-----	--------------	----------

CLOFIBRATE

CAPSULE;ORAL

CLOFIBRATE

	@	USL PHARMA	500MG	A070531	001	Jun 16, 1986	Jun CAHN
--	---	------------	-------	---------	-----	--------------	----------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb CMFD
AB		50MG	A074953	002	Jun 25, 1997	Feb CMFD
AB		75MG	A074953	003	Jun 25, 1997	Feb CMFD

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

	@	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar DISC
	@		1MG	A074940	002	Oct 30, 1997	Mar DISC
	@		2MG	A074940	003	Oct 30, 1997	Mar DISC
AB	PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb CAHN	
AB		1MG	A077856	002	Jun 28, 2006	Feb CAHN	
AB		2MG	A077856	003	Jun 28, 2006	Feb CAHN	

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

		CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Jul CMS1
			0.2MG	A071785	003	Apr 05, 1988	Jul CMS1
	@		0.3MG	A071785	001	Apr 05, 1988	Feb CAHN
AB	PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb CAHN	
AB		0.2MG	A077901	002	Mar 09, 2007	Feb CAHN	
AB		0.3MG	A077901	003	Mar 09, 2007	Feb CAHN	

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Apr CAHN	
AB1		0.1MG	A203320	001	May 15, 2015	Apr CAHN	
	@	0.2MG	A202792	002	May 15, 2015	Apr CAHN	
	@	0.2MG	A203320	002	May 15, 2015	Apr CAHN	
>A>	AB1	LUPIN LTD	0.1MG	A209285	001	Oct 23, 2017	Oct NEWA

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ACME LABS	EQ 75MG BASE	A078004	001	May 17, 2012	Jul CAHN
AB	ALLIED PHARMA INC	EQ 75MG BASE	A078004	001	May 17, 2012	Mar CAHN
AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

	AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017	Aug CMS1
		7.5MG	A072112	003	Aug 11, 2017	Aug CMS1

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

>D>	AB	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Oct DISC
>A>	@		3.75MG	A076911	001	Sep 29, 2004	Oct DISC
>D>	AB		7.5MG	A076911	002	Sep 29, 2004	Oct DISC

TABLET;ORAL									
CLORAZEPATE DIPOTASSIUM									
>A>	@	7.5MG	A076911	002	Sep 29, 2004	Oct	DISC		
>D>	AB	15MG	A076911	003	Sep 29, 2004	Oct	DISC		
>A>	@	15MG	A076911	003	Sep 29, 2004	Oct	DISC		
AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000	Mar	CAHN		
AB		7.5MG	A075731	002	Apr 27, 2000	Mar	CAHN		
AB		15MG	A075731	001	Apr 27, 2000	Mar	CAHN		
<u>CLOTTRIMAZOLE</u>									
SOLUTION;TOPICAL									
CLOTTRIMAZOLE									
AT	! TARO	1%	A074580	001	Jul 29, 1996	Apr	CAHN		
	LOTTRIMIN								
	+ @ SCHERING PLOUGH	1%	N017613	001		Jul	CRLD		
<u>CLOZAPINE</u>									
SUSPENSION;ORAL									
VERSACLOZ									
	+! TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013	Sep	CAHN		
TABLET;ORAL									
CLOZAPINE									
AB	MAYNE PHARMA	50MG	A203807	003	Aug 22, 2017	Aug	NEWA		
AB		200MG	A203807	004	Aug 22, 2017	Aug	NEWA		
>A>	AB	SUN PHARM INDS INC	A075713	004	Nov 07, 2017	Oct	NEWA		
<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE									
	@ PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988	May	CAHN		
<u>CODEINE SULFATE</u>									
SOLUTION;ORAL									
CODEINE SULFATE									
	@ WEST-WARD PHARMS INT	30MG/5ML	N202245	001	Jun 30, 2011	Jan	CAHN		
TABLET;ORAL									
CODEINE SULFATE									
AB	+ WEST-WARD PHARMS INT	15MG	N022402	001	Jul 16, 2009	Jan	CAHN		
AB	+	30MG	N022402	002	Jul 16, 2009	Jan	CAHN		
AB	+!	60MG	N022402	003	Jul 16, 2009	Jan	CAHN		
<u>COPANLISIB DIHYDROCHLORIDE</u>									
POWDER;IV (INFUSION)									
ALIQOPA									
	+! BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017	Sep	NEWA		
<u>CORTICOTROPIN</u>									
INJECTABLE;INJECTION									
PURIFIED CORTROPHIN GEL									
	@ ANI PHARMS INC	40 UNITS/ML	N008975	001		May	CAHN		
	@	80 UNITS/ML	N008975	002		May	CAHN		
<u>CORTICOTROPIN-ZINC HYDROXIDE</u>									
INJECTABLE;INJECTION									
CORTROPHIN-ZINC									
	@ ANI PHARMS INC	40 UNITS/ML	N009854	001		May	CAHN		
<u>COSYNTROPIN</u>									
SOLUTION;INTRAVENOUS									
COSYNTROPIN									
	@ SANDOZ INC	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008	May	CAHN		
<u>CROMOLYN SODIUM</u>									
CONCENTRATE;ORAL									
CROMOLYN SODIUM									
>A>	AA	AILEX PHARMS LLC	A209264	001	Oct 16, 2017	Oct	NEWA		
>D>	AA	PACK PHARMS LLC	A202583	001	Oct 27, 2011	Oct	CAHN		
>A>	AA	RISING PHARMS INC	A202583	001	Oct 27, 2011	Oct	CAHN		
GASTROCROM									
AA	+! MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN		

		SOLUTION; INHALATION					
		CROMOLYN SODIUM					
>A>	AN	AILEX PHARMS LLC	10MG/ML	A209453	001	Oct 16, 2017	Oct NEWA
		@ BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Jul DISC
	AN		10MG/ML	A075585	001	Dec 21, 2000	Feb CAHN
		INTAL					
		+ @ KING PHARMS LLC	10MG/ML	N018596	001	May 28, 1982	Sep CRLD
		@	10MG/ML	N018596	001	May 28, 1982	May CAHN
		SOLUTION/DROPS; OPHTHALMIC					
>D>		CROLOM					
>D>	AT	BAUSCH AND LOMB	4%	A074443	001	Jan 30, 1995	Oct DISC
>A>		@	4%	A074443	001	Jan 30, 1995	Oct DISC

CYANOCOBALAMIN

		INJECTABLE; INJECTION					
		CYANOCOBALAMIN					
AP		MYLAN LABS LTD	1MG/ML	A204829	001	Jun 05, 2017	May NEWA
		DODEX					
		@ ACCORD HLTHCARE	1MG/ML	A083022	001		Jun CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

		TABLET; ORAL					
		CYCLOBENZAPRINE HYDROCHLORIDE					
AB		JUBILANT CADISTA	7.5MG	A077563	003	Aug 25, 2017	Aug NEWA
AB		OXFORD PHARMS	5MG	A077209	002	Feb 03, 2006	May CMS1
AB		PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb CAHN
AB			10MG	A077797	002	Feb 28, 2007	Feb CAHN
AB		RUBICON RES PVT LTD	5MG	A208170	001	May 31, 2017	May NEWA
AB			7.5MG	A208170	002	May 31, 2017	May NEWA
AB			10MG	A208170	003	May 31, 2017	May NEWA
		@ UPSHER-SMITH LABS	5MG	A072854	002	Feb 03, 2006	Jun CAHN
		@	10MG	A072854	001	Nov 19, 1991	Jun CAHN

CYCLOPHOSPHAMIDE

		CAPSULE; ORAL					
		CYCLOPHOSPHAMIDE					
		+ WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan CAHN
		+!	50MG	N203856	002	Sep 16, 2013	Jan CAHN
		INJECTABLE; INJECTION					
		CYTOXAN (LYOPHILIZED)					
		+ @ BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb CRLD
		+ @	1GM/VIAL	N012142	004	Aug 30, 1982	Feb CRLD
		+ @	2GM/VIAL	N012142	005	Aug 30, 1982	Feb CRLD

CYPROHEPTADINE HYDROCHLORIDE

		SYRUP; ORAL					
		CYPROHEPTADINE HYDROCHLORIDE					
AA		BIO-PHARM INC	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
AA		SILARX PHARMS INC	2MG/5ML	A203191	001	Jul 13, 2017	Jul NEWA
		PERIACTIN					
		+ @ MERCK	2MG/5ML	N013220	002		Jan CRLD
		TABLET; ORAL					
		CYPROHEPTADINE HYDROCHLORIDE					
AA		AILEX PHARMS LLC	4MG	A207555	001	Jan 31, 2017	Sep CAHN
AA		APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan NEWA
AA		IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb CAHN
AA		SANTOS BIOTECH	4MG	A040644	001	May 30, 2006	May CAHN
AA		ZYDUS PHARMS USA INC	4MG	A208938	001	May 19, 2017	May NEWA

CYSTEAMINE BITARTRATE

		CAPSULE, DELAYED RELEASE; ORAL					
		PROCYSBI					
		+ HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar CAHN
		+!	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar CAHN

CYSTEAMINE HYDROCHLORIDE

		SOLUTION/DROPS; OPHTHALMIC					
		CYSTARAN					
		+! LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb CAHN

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

AP	MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar CAHN
>A> AP	SAGENT PHARMS	20MG/ML	A206190	001	Nov 09, 2017	Oct NEWA
	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar CTEC
!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar CHRS
!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar CHRS
!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar CHRS
	CYTOSAR-U					
@	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar DISC
@		500MG/VIAL	A075206	002	Dec 30, 1998	Mar DISC
@		1GM/VIAL	A075206	004	Dec 30, 1998	Mar DISC
@		2GM/VIAL	A075206	003	Dec 30, 1998	Mar DISC

CYTARABINE; DAUNORUBICIN

POWDER; INTRAVENOUS
VYXEOS

+	CELATOR PHARMS	100MG; 44MG	N209401	001	Aug 03, 2017	Aug NEWA
---	----------------	-------------	---------	-----	--------------	----------

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE

AP	!	FRESENIUS KABI USA	200MG/VIAL	A075371	002	Aug 27, 1999	Feb CHRS
		DTIC-DOME					
+	@	BAYER HLTHCARE	100MG/VIAL	N017575	001		Apr DISC
+	@		200MG/VIAL	N017575	002		Apr DISC

DACTINOMYCIN

INJECTABLE; INJECTION
DACTINOMYCIN

>A> AP	MYLAN LABS LTD	0.5MG/VIAL	A203385	001	Nov 09, 2017	Oct NEWA
--------	----------------	------------	---------	-----	--------------	----------

DALBAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)
DALVANCE

+	ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Aug CAHN
---	--------------------	--------------------	---------	-----	--------------	----------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL
AMPYRA

AB	+	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan CFTG
		DALFAMPRIDINE					
AB		ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan NEWA
AB		AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan NEWA

DANTROLENE SODIUM

INJECTABLE; INJECTION
DANTROLENE SODIUM

AP	HIKMA PHARMS	20MG/VIAL	A204762	001	Jun 19, 2017	Jun NEWA
----	--------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
XIGDUO XR

+	ASTRAZENECA AB	EQ 2.5MG BASE; 1GM	N205649	005	Jul 28, 2017	Jul NEWA
---	----------------	--------------------	---------	-----	--------------	----------

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL
QTERN

+	ASTRAZENECA AB	EQ 10MG BASE; EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb NEWA
---	----------------	---------------------------	---------	-----	--------------	----------

DAPSONE

GEL; TOPICAL
ACZONE

>D>	+	ALLERGAN	5%	N021794	001	Jul 07, 2005	Oct CFTG
>A> AB	+		5%	N021794	001	Jul 07, 2005	Oct CFTG
>A>		DAPSONE					
>A> AB		TARO	5%	A209506	001	Oct 16, 2017	Oct NEWA

TABLET; ORAL

DAPSONE

AB	ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017	Mar	NEWA
AB		100MG	A204380	002	Mar 23, 2017	Mar	NEWA
>A>	NOVITIUM PHARMA	25MG	A206505	001	Dec 01, 2016	Oct	CAHN
>A>		100MG	A206505	002	Dec 01, 2016	Oct	CAHN
>D>	PAR PHARM INC	25MG	A206505	001	Dec 01, 2016	Oct	CAHN
>D>		100MG	A206505	002	Dec 01, 2016	Oct	CAHN
AB	VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Sep	CAHN
AB		100MG	A204074	002	May 10, 2016	Sep	CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

	+! SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017	Sep	NEWA
	POWDER; IV (INFUSION)						
	DAPTOMYCIN						
>A>	+! XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017	Oct	NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN

AB	MACLEODS PHARMS LTD	EQ 7.5MG BASE	A207302	001	Jul 28, 2017	Jul	NEWA
AB		EQ 15MG BASE	A207302	002	Jul 28, 2017	Jul	NEWA

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

AP	ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb	NEWA
AP	CHEMI SPA	50MG/VIAL	A206033	001	Sep 22, 2017	Sep	NEWA
AP	PHARMASCIENCE INC	50MG/VIAL	A204607	001	May 31, 2017	May	NEWA

DEFERASIROX

GRANULE; ORAL

JADENU SPRINKLE

+	NOVARTIS PHARMS CORP	90MG	N207968	001	May 18, 2017	May	NEWA
+		180MG	N207968	002	May 18, 2017	May	NEWA
+!		360MG	N207968	003	May 18, 2017	May	NEWA

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP	GLAND PHARMA LTD	500MG/VIAL	A207384	001	Sep 29, 2017	Sep	NEWA
AP		2GM/VIAL	A207384	002	Sep 29, 2017	Sep	NEWA

DEFLAZACORT

SUSPENSION; ORAL

EMFLAZA

+!	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb	NEWA
+!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CAHN

TABLET; ORAL

EMFLAZA

+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb	NEWA
+		18MG	N208684	002	Feb 09, 2017	Feb	NEWA
+		30MG	N208684	003	Feb 09, 2017	Feb	NEWA
+!		36MG	N208684	004	Feb 09, 2017	Feb	NEWA
+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr	CAHN
+		18MG	N208684	002	Feb 09, 2017	Apr	CAHN
+		30MG	N208684	003	Feb 09, 2017	Apr	CAHN
+!		36MG	N208684	004	Feb 09, 2017	Apr	CAHN

DELAFLOXACIN MEGLUMINE

POWDER; IV (INFUSION)

BAXDELA

+!	MELINTA THERAPS INC	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Jun	NEWA
----	---------------------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL

BAXDELA

+!	MELINTA THERAPS INC	EQ 450MG BASE	N208610	001	Jun 19, 2017	Jun	NEWA
----	---------------------	---------------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Feb CAHN
AB		25MG	A205153	002	Oct 28, 2016	Feb CAHN
AB		50MG	A205153	003	Oct 28, 2016	Feb CAHN
AB		75MG	A205153	004	Oct 28, 2016	Feb CAHN
AB		100MG	A205153	005	Oct 28, 2016	Feb CAHN
AB		150MG	A205153	006	Oct 28, 2016	Feb CAHN

DESMETHYL PIROXICAM

CAPSULE; ORAL

PIROXICAM

>D>	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Oct CMS1
		10MG	A073536	002	Jan 23, 2008	Mar CMS1

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

	@ HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000	Jul DISC
AP	SAGENT PHARMS	0.004MG/ML	A204695	001	Aug 22, 2017	Aug NEWA
AP		0.004MG/ML	A204751	001	Aug 22, 2017	Aug NEWA
	@ TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Jul DISC

SPRAY, METERED; NASAL

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB	ZYDUS PHARMS USA INC	0.01MG/SPRAY	A091345	001	Oct 03, 2017	Sep NEWA
	NOCTIVA					
>A>	+ AVADEL SPECLT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Oct CAHN
>A>	+!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Oct CAHN
>D>	+ SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Oct CAHN
	+!	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Mar NEWA
>D>	+!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Oct CAHN
	+!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Mar NEWA
	STIMATE					
	@ FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994	Jun CAHN
	STIMATE (NEEDS NO REFRIGERATION)					
	+! FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Jun CAHN
	TABLET; ORAL					
	DESMOPRESSIN ACETATE					
AB	HERITAGE PHARMA	0.1MG	A207880	001	May 26, 2017	May NEWA
AB		0.1MG	A207880	001	May 26, 2017	May CAHN
AB		0.2MG	A207880	002	May 26, 2017	May NEWA
AB		0.2MG	A207880	002	May 26, 2017	May CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	ACCORD HLTHCARE	0.15MG,N/A;0.02MG,0.01MG	A209170	001	Jun 05, 2017	May NEWA
AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG	A206853	001	Mar 22, 2017	Mar NEWA
	KALLIGA					
AB	AUROBINDO PHARMA LTD	0.15MG;0.03MG	A207081	001	May 17, 2017	May NEWA

DESONIDE

CREAM; TOPICAL

DESONIDE

AB	GLENMARK PHARMS	0.05%	A209729	001	Jul 24, 2017	Jul NEWA
----	-----------------	-------	---------	-----	--------------	----------

LOTION; TOPICAL

DESONIDE

AB	GLENMARK PHARMS	0.05%	A209494	001	Sep 26, 2017	Sep NEWA
AB	TELIGENT PHARMA INC	0.05%	A207855	001	Sep 28, 2017	Sep NEWA

OINTMENT; TOPICAL

DESONIDE

AB	GLENMARK PHARMS LTD	0.05%	A209996	001	Sep 15, 2017	Sep NEWA
AB	HI-TECH PHARMACAL	0.05%	A208836	001	Mar 27, 2017	Mar NEWA

DESOXIMETASONE

CREAM; TOPICAL							
TOPICORT							
AB	! TARO	0.05%	A 073210	001	Nov 30, 1990	Apr	CAHN
AB	!	0.25%	A 073193	001	Nov 30, 1990	Apr	CAHN
	+ @	0.25%	N 017856	001		May	CAHN
TOPICORT LP							
	+ @ TARO	0.05%	N 018309	001		May	CAHN
GEL; TOPICAL							
DESOXIMETASONE							
AB	RISING PHARMS INC	0.05%	A 204675	001	Aug 12, 2016	May	CAHN
TOPICORT							
AB	! TARO	0.05%	A 074904	001	Jul 14, 1998	Apr	CAHN
	+ @	0.05%	N 018586	001	Mar 29, 1982	May	CAHN
	+ @ TARO PHARMS NORTH	0.05%	N 018586	001	Mar 29, 1982	Jan	CRLD
OINTMENT; TOPICAL							
DESOXIMETASONE							
AB	RISING PHARMS INC	0.25%	A 204272	001	Nov 30, 2016	May	CAHN
AB	ZYDUS PHARMS USA INC	0.25%	A 205206	001	Sep 19, 2017	Sep	NEWA
TOPICORT							
AB	+! TARO	0.05%	N 018594	001	Jan 17, 1985	May	CAHN
AB	!	0.25%	A 074286	001	Jun 07, 1996	Apr	CAHN
	+ @	0.25%	N 018763	001	Sep 30, 1983	May	CAHN
SPRAY; TOPICAL							
DESOXIMETASONE							
AT	PERRIGO ISRAEL	0.25%	A 206441	001	Jan 20, 2017	Jan	NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL							
DESVENLAFAXINE SUCCINATE							
AB	ACTAVIS LABS FL	EQ 25MG BASE	A 204065	001	Jul 29, 2016	May	CAHN
AB		EQ 50MG BASE	A 204065	002	Jul 29, 2016	May	CAHN
AB		EQ 100MG BASE	A 204065	003	Jul 29, 2016	May	CAHN
AB	WEST-WARD PHARMS INT	EQ 25MG BASE	A 204082	002	Aug 28, 2017	Aug	NEWA
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A 204020	001	Oct 11, 2017	Sep	NEWA
AB		EQ 100MG BASE	A 204020	002	Oct 11, 2017	Sep	NEWA

DEUTETRABENAZINE

TABLET; ORAL							
AUSTEDO							
	+ TEVA BRANDED PHARM	6MG	N 208082	001	Apr 03, 2017	Apr	NEWA
	+	9MG	N 208082	002	Apr 03, 2017	Apr	NEWA
	+!	12MG	N 208082	003	Apr 03, 2017	Apr	NEWA

DEXAMETHASONE

TABLET; ORAL							
DEXAMETHASONE							
AB	LARKEN LABS INC	1.5MG	A 201270	001	Jul 17, 2017	Jul	NEWA
BP	PAR PHARM	6MG	A 088481	001	Nov 28, 1983	May	CHRS
	@ UPSHER SMITH	0.75MG	A 087534	001		Jun	CAHN
	@	1.5MG	A 087533	001		Jun	CAHN
BP	XSPIRE PHARMA	1.5MG	A 088237	001	Apr 28, 1983	Aug	CAHN
BP		1.5MG	A 088237	001	Apr 28, 1983	Jul	CAHN
HEXADROL							
>A>	@ ASPEN GLOBAL INC	0.5MG	N 012675	004		Oct	CAHN
>A>	@	0.75MG	N 012675	007		Oct	CAHN
>A>	@	1.5MG	N 012675	009		Oct	CAHN
>A>	@	4MG	N 012675	010		Oct	CAHN
>D>	@ ORGANON USA INC	0.5MG	N 012675	004		Oct	CAHN
>D>	@	0.75MG	N 012675	007		Oct	CAHN
>D>	@	1.5MG	N 012675	009		Oct	CAHN
>D>	@	4MG	N 012675	010		Oct	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION							
DEXAMETHASONE SODIUM PHOSPHATE							
AP	WEST-WARD PHARMS INT	EQ 4MG PHOSPHATE/ML	A 084282	001		Aug	CMFD
SOLUTION/DROPS; OPHTHALMIC, OTIC							
DEXAMETHASONE SODIUM PHOSPHATE							
AT	! SANDOZ INC	EQ 0.1% PHOSPHATE	A 088771	001	Jan 16, 1985	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OPHTHALMIC
MAXITROL

AT	SANDOZ INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062341	001	May 22, 1984	Feb CAHN
----	------------	--	---------	-----	--------------	----------

DEXLANSOPRAZOLECAPSULE, DELAYED RELEASE;ORAL
DEXILANT

AB	+! TAKEDA PHARMS USA	60MG	N022287	002	Jan 30, 2009	Apr CFTG
----	----------------------	------	---------	-----	--------------	----------

AB	PAR PHARM INC	60MG	A202294	001	Apr 19, 2017	Apr NEWA
----	---------------	------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB

+ @	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Aug DISC
-----	-------------------	------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Mar CAHN
----	-----------------	---	---------	-----	--------------	----------

AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Sep NEWA
----	---------------------	---	---------	-----	--------------	----------

AP	LUITPOLD PHARMS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May CAHN
----	---------------------	---	---------	-----	--------------	----------

AP	PHARMAFORCE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May NEWA
----	-------------	---	---------	-----	--------------	----------

AP	WEST-WARD PHARMS INT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Apr NEWA
----	----------------------	---	---------	-----	--------------	----------

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	IMPAX LABS INC	25MG	A203614	001	Jul 05, 2017	Jun NEWA
----	----------------	------	---------	-----	--------------	----------

AB		35MG	A203614	002	Jul 05, 2017	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB	TEVA PHARMS USA	25MG	A202731	001	Jul 05, 2017	Jun NEWA
----	-----------------	------	---------	-----	--------------	----------

AB		35MG	A202731	004	Jul 05, 2017	Jun NEWA
----	--	------	---------	-----	--------------	----------

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	LANNETT	2.5MG	A209468	001	Sep 25, 2017	Sep NEWA
----	---------	-------	---------	-----	--------------	----------

AB		5MG	A209468	002	Sep 25, 2017	Sep NEWA
----	--	-----	---------	-----	--------------	----------

AB		10MG	A209468	003	Sep 25, 2017	Sep NEWA
----	--	------	---------	-----	--------------	----------

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE

AB	+ IMPAX LABS INC	5MG	N017078	001		Aug CAHN
----	------------------	-----	---------	-----	--	----------

AB	+	10MG	N017078	002		Aug CAHN
----	---	------	---------	-----	--	----------

AB	+!	15MG	N017078	003		Aug CAHN
----	----	------	---------	-----	--	----------

DEXTROAMPHETAMINE SULFATE

AB	NESHER PHARMS	5MG	A209111	001	Jun 27, 2017	Jun NEWA
----	---------------	-----	---------	-----	--------------	----------

AB		10MG	A209111	002	Jun 27, 2017	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB		15MG	A209111	003	Jun 27, 2017	Jun NEWA
----	--	------	---------	-----	--------------	----------

>A>	AB	VINTAGE PHARMS	5MG	A205673	001	Oct 31, 2017	Oct NEWA
-----	----	----------------	-----	---------	-----	--------------	----------

>A>	AB		10MG	A205673	002	Oct 31, 2017	Oct NEWA
-----	----	--	------	---------	-----	--------------	----------

>A>	AB		15MG	A205673	003	Oct 31, 2017	Oct NEWA
-----	----	--	------	---------	-----	--------------	----------

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

@ EPIC PHARMA LLC

@

		5MG	A090652	001	Mar 07, 2014	May CAHN
--	--	-----	---------	-----	--------------	----------

		10MG	A090652	002	Mar 07, 2014	May CAHN
--	--	------	---------	-----	--------------	----------

>A>	AA	SUNRISE PHARM INC	5MG	A210059	001	Oct 18, 2017	Oct NEWA
-----	----	-------------------	-----	---------	-----	--------------	----------

>A>	AA		10MG	A210059	002	Oct 18, 2017	Oct NEWA
-----	----	--	------	---------	-----	--------------	----------

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB	ACTAVIS ELIZABETH	20MG;10MG	A202934	001	Oct 10, 2017	Sep NEWA
----	-------------------	-----------	---------	-----	--------------	----------

NUEDEXTA

AB	+! AVANIR PHARMS	20MG;10MG	N021879	001	Oct 29, 2010	Sep CFTG
----	------------------	-----------	---------	-----	--------------	----------

DEXTROSE

INJECTABLE;INJECTION					
DEXTROSE 10% IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	10GM/100ML	N018080 001	Feb CAHN
DEXTROSE 20% IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	20GM/100ML	N018564 001	Mar 23, 1982 Feb CAHN
DEXTROSE 30% IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	30GM/100ML	N019345 001	Jan 26, 1985 Feb CAHN
DEXTROSE 40% IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	40GM/100ML	N018562 001	Mar 23, 1982 May CAHN
DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	50MG/ML	N016367 002	Feb CAHN
DEXTROSE 50% IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	50GM/100ML	N018563 001	Mar 23, 1982 Feb CAHN
	@		50GM/100ML	N019894 001	Dec 26, 1989 Jun CAHN
DEXTROSE 70% IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	70GM/100ML	N018561 001	Mar 23, 1982 Apr CAHN
AP	+!		70GM/100ML	N019893 001	Dec 26, 1989 Feb CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER					
		ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;2	N017610 001	Feb CAHN
			34MG/100ML		

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION					
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER					
		ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;1	N019513 001	May 08, 1986 Feb CAHN
			5MG/100ML;260MG/100ML;25MG/100ML		

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;22	N019844 001	Jun 10, 1993 Aug DISC
			0MG/100ML;140MG/100ML		

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION					
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER					
		ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;22	N017609 001	Feb CAHN
			2MG/100ML;526MG/100ML;502MG/100ML		

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION					
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634 004	Sep CRLD
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
AP	+	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634 001	Sep CRLD
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER					
AP	+	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634 003	Sep CRLD
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
AP	+	BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634 002	Sep CRLD
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
		ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371 001	Apr CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371 003	Apr CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
		ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371 002	Apr CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;	N019870 001	Jun 10, 1993 Aug DISC
			280MG/100ML;91MG/100ML		

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Feb	CAHN
		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	001	Jan 17, 1986	Jun	CAHN
		5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	006	Mar 28, 1988	Jun	CAHN
	POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	005	Mar 28, 1988	Feb	CAHN
AP		5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009	Jul 05, 1983	Feb	CAHN
	POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988	Apr	CAHN
AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24, 1988	Apr	CAHN
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988	Jun	CAHN
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	006	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24, 1988	Apr	CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Feb	CAHN
		5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988	Jun	CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	010	Jul 05, 1983	Feb	CAHN
AP		5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	007	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	005	Mar 24, 1988	Apr	CAHN
AP		5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24, 1988	Apr	CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986	Jun	CAHN
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983	Feb	CAHN
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986	Jun	CAHN
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	002		Feb	CAHN
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	007	Mar 24, 1988	Apr	CAHN
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	004	Jul 05, 1983	Feb	CAHN
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988	Jun	CAHN
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	003		Feb	CAHN
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	009	Mar 24, 1988	Apr	CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	005	Mar 28, 1988	Feb	CAHN
		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	007	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988	Jun	CAHN
		5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988	Jun	CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	008	Mar 28, 1988	Feb	CAHN
AP		5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	004	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	001	Mar 24, 1988	Apr	CAHN
AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	003	Mar 24, 1988	Apr	CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	B BRAUN	10GM/100ML; 900MG/100ML	N019631	015	Feb 24, 1988	Aug	CTEC
	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
+	ICU MEDICAL INC	5GM/100ML; 225MG/100ML	N017606	001		Feb	CAHN

INJECTABLE; INJECTION

	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001	Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001	Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	+! ICU MEDICAL INC	5GM/100ML;900MG/100ML	N017585	001	Aug CRLD
AP		5GM/100ML;900MG/100ML	N017585	001	Feb CAHN

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

+	@	LIEBEL-FLARSHEIM	66%; 10%	N019292	001	Sep 29, 1989	Aug DISC
		RENOGRAFIN-76					
+	!	BRACCO	66%; 10%	N010040	001		Aug CTEC

DIAZEPAM

TABLET; ORAL

DIAZEPAM

@	UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Jun CAHN
@		5MG	A070303	001	Dec 20, 1985	Jun CAHN
@		10MG	A070304	001	Dec 20, 1985	Jun CAHN
@	VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb CAHN
@		5MG	A070463	001	Feb 25, 1986	Feb CAHN
@		10MG	A070464	001	Feb 25, 1986	Feb CAHN

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

+	!	STRONGBRIDGE US	50MG	N011366	002	Aug 07, 2015	Aug CRLD
---	---	-----------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

@	WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998	May CAHN
---	------------------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT		ANDA REPOSITORY	1.5%	A202393	001	Nov 24, 2014	Sep CAHN
AT	!	APOTEX INC	1.5%	A202027	001	May 27, 2014	Jul CHRS
AT		RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017	Jul NEWA
AT		TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Mar CAHN

PENNSAID

>D>	AT	+	!	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014	Oct CTEC
>A>		+	!		2%	N204623	001	Jan 16, 2014	Oct CTEC
	AT	+	!		2%	N204623	001	Jan 16, 2014	May CFTG

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT		SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb CAHN
----	--	------------	------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

@	ALLIED PHARMA INC	50MG	A074986	001	Feb 26, 1999	Apr CAHN
@		75MG	A074986	002	Feb 26, 1999	Apr CAHN
AB	UNIQUE PHARM LABS	25MG	A090066	001	Dec 01, 2010	Aug CAHN
AB		50MG	A090066	002	Dec 01, 2010	Aug CAHN
AB		75MG	A077863	003	Jun 08, 2007	Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

	@	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Apr DISC
AB	!	DEXCEL LTD	100MG	A076201	001	Nov 06, 2002	Apr CHRS
		VOLTAREN-XR					
	+	@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Jul CRLD

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB		EAGLE PHARMS	50MG; 0.2MG	A200540	001	Mar 14, 2014	Jan CAHN
AB			75MG; 0.2MG	A200540	002	Mar 14, 2014	Jan CAHN
AB		EXELA HOLDINGS	50MG; 0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB			75MG; 0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION					
DICYCLOMINE HYDROCHLORIDE					
AP	LUITPOLD PHARMS INC	10MG/ML	A208353	001	Feb 17, 2017 Feb NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL					
DIDANOSINE					
	@ MYLAN PHARMS INC	125MG	A090788	001	Apr 08, 2010 May DISC
	@	200MG	A090788	002	Apr 08, 2010 May DISC
	@	250MG	A090788	003	Apr 08, 2010 May DISC
	@	400MG	A090788	004	Apr 08, 2010 May DISC
FOR SOLUTION; ORAL					
DIDANOSINE					
	@ AUROBINDO PHARMA	10MG/ML	A078112	001	Mar 08, 2007 Jul DISC
VIDEX					
+!	BRISTOL-MYERS SQUIBB	10MG/ML	N020156	001	Oct 09, 1991 Jul CTEC
TABLET, FOR SUSPENSION; ORAL					
DIDANOSINE					
	@ AUROBINDO	100MG	A077275	001	Aug 14, 2012 Jul DISC
	@	150MG	A077275	002	Aug 14, 2012 Jul DISC
	@	200MG	A077275	003	Aug 14, 2012 Jul DISC

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL					
NATAZIA					
+!	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A	N022252	001	May 06, 2010 Apr CTEC

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL					
DIETHYLPROPION HYDROCHLORIDE					
	@ EPIC PHARMA LLC	25MG	A040828	001	Nov 05, 2008 May CAHN

DIFLORASONE DIACETATE

CREAM; TOPICAL					
PSORCON					
+ @	TARO PHARMS NORTH	0.05%	N020205	001	Nov 20, 1992 Sep CRLD
OINTMENT; TOPICAL					
DIFLORASONE DIACETATE					
AB	RICONPHARMA LLC	0.05%	A207440	001	Feb 27, 2017 Feb NEWA
AB	! TARO	0.05%	A075331	001	May 14, 1999 Apr CAHN
PSORCON					
+ @	PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985 Mar CRLD

DIFLUNISAL

TABLET; ORAL					
DIFLUNISAL					
	@ ALLIED PHARMA INC	250MG	A073562	001	Nov 27, 1992 Jul CAHN
	@	500MG	A073563	001	Nov 27, 1992 Jul CAHN
AB	ZYDUS PHARMS USA INC	500MG	A203547	001	Jun 16, 2017 Jun NEWA

DIGOXIN

ELIXIR; ORAL					
DIGOXIN					
+!	WEST-WARD PHARMS INT	0.05MG/ML	N021648	001	Aug 26, 2004 Jan CAHN
INJECTABLE; INJECTION					
DIGOXIN					
AP	SANDOZ INC	0.25MG/ML	A040481	001	Aug 21, 2003 Mar CAHN
AP	WEST-WARD PHARMS INT	0.25MG/ML	A083391	001	Jul CAHN
LANOXIN					
AP	+! COVIS PHARMA BV	0.25MG/ML	N009330	002	May CAHN
LANOXIN PEDIATRIC					
+!	COVIS PHARMA BV	0.1MG/ML	N009330	004	May CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

AP	HIKMA PHARMS	1MG/ML	A206621	001	Sep 15, 2017	Sep NEWA
AP	WEST-WARD PHARMS INT	1MG/ML	A040453	001	Jun 09, 2003	Jan CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB3	SUN PHARM INDS LTD	120MG	A203023	001	Jun 08, 2017	May NEWA
AB3		180MG	A203023	002	Jun 08, 2017	May NEWA
AB3		240MG	A203023	003	Jun 08, 2017	May NEWA
AB3		300MG	A203023	004	Jun 08, 2017	May NEWA
AB3		360MG	A203023	005	Jun 08, 2017	May NEWA
AB3	ZYDUS PHARMS USA INC	120MG	A206534	001	Aug 08, 2017	Jul NEWA
AB4		120MG	A206641	001	Aug 11, 2017	Jul NEWA
AB3		180MG	A206534	002	Aug 08, 2017	Jul NEWA
AB4		180MG	A206641	002	Aug 11, 2017	Jul NEWA
AB3		240MG	A206534	003	Aug 08, 2017	Jul NEWA
AB4		240MG	A206641	003	Aug 11, 2017	Jul NEWA
AB3		300MG	A206534	004	Aug 08, 2017	Jul NEWA
AB4		300MG	A206641	004	Aug 11, 2017	Jul NEWA
AB3		360MG	A206534	005	Aug 08, 2017	Jul NEWA
AB4		360MG	A206641	005	Aug 11, 2017	Jul NEWA
AB4		420MG	A206641	006	Aug 11, 2017	Jul NEWA

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

AP	! ATHENEX INC	5MG/ML	A074617	001	Feb 28, 1996	Mar CAHN
AP	WEST-WARD PHARMS INT	5MG/ML	A078538	001	Dec 17, 2008	Jan CAHN

TABLET;ORAL
DILTIAZEM HYDROCHLORIDE

@	CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992	Feb CAHN
@		60MG	A074093	002	Nov 05, 1992	Feb CAHN
@		90MG	A074093	003	Nov 05, 1992	Feb CAHN
@		120MG	A074093	004	Nov 05, 1992	Feb CAHN

DIMENHYDRINATE

INJECTABLE;INJECTION
DIMENHYDRINATE

@	WATSON LABS TEVA	50MG/ML	A080615	001		May CAHN
---	------------------	---------	---------	-----	--	----------

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982	May CAHN
---	-------------	------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE						
@	WATSON LABS TEVA	10MG/ML	A080873	001		May CAHN
@		50MG/ML	A080873	002		May CAHN
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE						
@	WATSON LABS TEVA	50MG/ML	A080873	003		May CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION
DIPYRIDAMOLE

AP	! ATHENEX INC	5MG/ML	A074939	001	Apr 13, 1998	Mar CAHN
----	---------------	--------	---------	-----	--------------	----------

TABLET;ORAL

DIPYRIDAMOLE						
	IDT AUSTRALIA LTD	50MG	A086944	001	Feb 25, 1992	Aug CMS1
		75MG	A086944	003	Feb 25, 1992	Aug CMS1

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL
DISOPYRAMIDE PHOSPHATE

AB	MAYNE PHARMA	EQ 150MG BASE	A070173	002	May 31, 1985	Sep CMS1
----	--------------	---------------	---------	-----	--------------	----------

DISULFIRAMTABLET; ORAL
DISULFIRAM

AB	CHARTWELL MOLECULES	250MG	A091563	001	Dec 31, 2012	Jan CAHN
AB		500MG	A091563	002	Dec 31, 2012	Jan CAHN
	@ WATSON LABS TEVA	500MG	A086890	001		May CAHN

DIVALPROEX SODIUMTABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

AB	PRINCETON INC	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009	Feb CAHN
AB		EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009	Feb CAHN
AB		EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009	Feb CAHN
AB	UPSHER-SMITH LABS	EQ 125MG VALPROIC ACID	A078182	001	Jul 29, 2008	Jun CAHN
AB		EQ 250MG VALPROIC ACID	A078182	002	Jul 29, 2008	Jun CAHN
AB		EQ 500MG VALPROIC ACID	A078182	003	Jul 29, 2008	Jun CAHN

DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOBUTREX

+	@ LILLY	EQ 12.5MG BASE/ML	N017820	002		Aug CRLD
---	---------	-------------------	---------	-----	--	----------

DOCETAXELINJECTABLE; INJECTION
DOCEFREZ

+	@ SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011	Aug DISC
+	@	80MG/VIAL	N022534	002	May 03, 2011	Aug DISC

DOCETAXEL

AP	ACTAVIS LLC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Feb CAHN
AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Feb CAHN
		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Feb CAHN
AP	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017	Jan NEWA
AP		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017	Jan NEWA
		200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017	Jan NEWA
	+	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016	Aug DISC
	+	160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017	Jan NEWA
AP	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Aug NEWA
AP		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Aug NEWA
AP		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Aug NEWA
AP	JIANGSU HENGRUI MED	20MG/ML (20MG/ML)	A207252	001	Aug 09, 2017	Jul NEWA
	!	40MG/ML	A203170	001	Feb 15, 2017	Jan NEWA
AP		80MG/4ML (20MG/ML)	A207252	002	Aug 09, 2017	Jul NEWA
AP		160MG/8ML (20MG/ML)	A207252	003	Aug 09, 2017	Jul NEWA
	@ PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan DISC
	@	80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan DISC
	@	130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan DISC
	@	200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan DISC

DOFETILIDECAPSULE; ORAL
DOFETILIDE

AB	MAYNE PHARMA INC	0.125MG	A207058	001	Jun 06, 2016	Feb CAHN
AB		0.25MG	A207058	002	Jun 06, 2016	Feb CAHN
AB		0.5MG	A207058	003	Jun 06, 2016	Feb CAHN

>D> DOLASETRON MESYLATE>D> INJECTABLE; INJECTION
>D> ANZEMET

>D>	+	!	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Oct DISC
>A>	+	@		12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Oct DISC
>D>	+	!		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Oct DISC
>A>	+	@		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Oct DISC

>D> TABLET; ORAL
>D> ANZEMET

>D>	+		US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Oct DISC
>A>	+	@		50MG	N020623	001	Sep 11, 1997	Oct DISC
>D>	+	!		100MG	N020623	002	Sep 11, 1997	Oct DISC
>A>	+	@		100MG	N020623	002	Sep 11, 1997	Oct DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	5MG	A078662	001	May 31, 2011	Jun CAHN
AB		10MG	A078662	002	May 31, 2011	Jun CAHN
AB	ALLIED PHARMA INC	5MG	A078662	001	May 31, 2011	Mar CAHN
AB		10MG	A078662	002	May 31, 2011	Mar CAHN
AB	CADILA PHARMS LTD	5MG	A204609	001	Sep 19, 2017	Sep NEWA
AB		10MG	A204609	002	Sep 19, 2017	Sep NEWA
AB	VIVIMED GLOBAL	5MG	A090551	001	May 31, 2011	Aug CAHN
AB		10MG	A090551	002	May 31, 2011	Aug CAHN
AB	ZHEJIANG HISUN PHARM	23MG	A202410	001	Mar 24, 2017	Mar NEWA
AB	ZYDUS PHARMS USA INC	23MG	A203162	001	Aug 31, 2017	Aug NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB	AMNEAL PHARMS	10MG; 14MG	A208328	001	Jan 27, 2017	Jan NEWA
AB		10MG; 28MG	A208328	002	Jan 27, 2017	Jan NEWA
	NAMZARIC					
AB	+ FOREST LABS LLC	10MG; 14MG	N206439	001	Dec 23, 2014	Jan CFTG
AB	+!	10MG; 28MG	N206439	002	Dec 23, 2014	Jan CFTG

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

@ TELIGENT	40MG/ML	N018656	001	Jun 28, 1983	May CAHN
------------	---------	---------	-----	--------------	----------

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

+ @ SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010	Sep DISC
+ @	500MG/VIAL	N022106	001	Oct 12, 2007	Sep DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar CAHN
AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb CAHN
AT	ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013	Sep CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	SANDOZ INC	EQ 2% BASE; EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar CAHN
AT	ZAMBON SPA	EQ 2% BASE; EQ 0.5% BASE	A091180	001	Dec 04, 2013	Sep CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar CAHN
----	-------------	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	ZYDUS PHARMS USA INC	EQ 1MG BASE	A208719	001	Jul 07, 2017	Jun NEWA
AB		EQ 2MG BASE	A208719	002	Jul 07, 2017	Jun NEWA
AB		EQ 4MG BASE	A208719	003	Jul 07, 2017	Jun NEWA
AB		EQ 8MG BASE	A208719	004	Jul 07, 2017	Jun NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB	AMNEAL PHARMS CO	EQ 10MG BASE	A207482	001	Jun 28, 2017	Jun NEWA
AB		EQ 25MG BASE	A207482	002	Jun 28, 2017	Jun NEWA
AB		EQ 50MG BASE	A207482	003	Jun 28, 2017	Jun NEWA
AB		EQ 75MG BASE	A207482	004	Jun 28, 2017	Jun NEWA
AB		EQ 100MG BASE	A207482	005	Jun 28, 2017	Jun NEWA
	@ WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991	May CAHN

CREAM; TOPICAL
ZONALON

+	!	MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan CAHN
---	---	------------------	----	---------	-----	--------------	----------

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

AP		AMNEAL PHARMS CO	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	May NEWA
AP			4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	May NEWA
AP			4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	May NEWA

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP		AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb NEWA
AP			50MG/VIAL	A208888	002	Feb 17, 2017	Feb NEWA
AP		GLAND PHARMA LTD	2MG/ML	A209825	001	Aug 11, 2017	Jul NEWA

INJECTABLE, LIPOSOMAL; INJECTION
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017	May NEWA
AB			50MG/25ML (2MG/ML)	A208657	002	May 15, 2017	May NEWA

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

AB		ALEMBIC PHARMS LTD	EQ 75MG BASE	A209165	001	Jul 28, 2017	Jul NEWA
AB			EQ 100MG BASE	A209165	002	Jul 28, 2017	Jul NEWA
AB		MAYNE PHARMA INC	EQ 50MG BASE	A209396	001	Sep 29, 2017	Sep NEWA
AB			EQ 75MG BASE	A209396	002	Sep 29, 2017	Sep NEWA
AB			EQ 100MG BASE	A209396	003	Sep 29, 2017	Sep NEWA

TABLET; ORAL
DOXYCYCLINE

AB		ZYDUS PHARMS USA INC	EQ 50MG BASE	A209582	001	Sep 28, 2017	Sep NEWA
AB			EQ 75MG BASE	A209582	002	Sep 28, 2017	Sep NEWA
AB			EQ 100MG BASE	A209582	003	Sep 28, 2017	Sep NEWA
AB			EQ 150MG BASE	A209582	004	Sep 28, 2017	Sep NEWA

DOXYCYCLINE HYCLATECAPSULE, DELAYED RELEASE; ORAL
DOXYCYCLINE HYCLATE

@	MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005	Jul DISC
@		EQ 100MG BASE	A065281	002	Dec 21, 2005	Jul DISC

INJECTABLE; INJECTION
DOXYCYCLINE

AP		ZYDUS PHARMS USA INC	EQ 100MG BASE/VIAL	A207757	001	Sep 28, 2017	Sep NEWA
AP			EQ 200MG BASE/VIAL	A207757	002	Sep 28, 2017	Sep NEWA

VIBRAMYCIN

+	@	PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan CRLD
+	@		EQ 200MG BASE/VIAL	N050442	001		Jan CRLD

TABLET; ORAL
ACTICLATE

AB	+	AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jun CFTG
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jun CFTG

DOXYCYCLINE HYCLATE

AB		AMNEAL PHARMS CO	EQ 75MG BASE	A209372	001	Oct 06, 2017	Sep NEWA
AB			EQ 150MG BASE	A209372	002	Oct 06, 2017	Sep NEWA
		CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Mar CMFD
		@	EQ 50MG BASE	A062269	003		Jan CAHN
AB			EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan CAHN
		@	EPIC PHARMA LLC	A065182	001	May 13, 2005	May CAHN
AB		LUPIN LTD	EQ 75MG BASE	A208818	001	Sep 27, 2017	Sep NEWA
AB			EQ 150MG BASE	A208818	002	Sep 27, 2017	Sep NEWA
AB		MAYNE PHARMA INC	EQ 75MG BASE	A208765	001	Jun 14, 2017	May NEWA
AB			EQ 150MG BASE	A208765	002	Jun 14, 2017	May NEWA
AB		NOVEL LABS INC	EQ 100MG BASE	A207558	001	Sep 06, 2017	Aug NEWA
>A> AB		ZYDUS PHARMS USA INC	EQ 100MG BASE	A207773	001	Oct 30, 2017	Oct NEWA

DRONABINOLSOLUTION;ORAL
SYNDROS

+! INSYS DEV CO INC 5MG/ML

N205525 001 Mar 23, 2017 Mar NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB PII 3MG;0.02MG

A203291 001 Jul 18, 2017 Jul NEWA

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB MACLEODS PHARMS LTD EQ 20MG BASE
 AB EQ 30MG BASE
 AB EQ 60MG BASE
 AB PRINSTON INC EQ 20MG BASE
 AB EQ 30MG BASE
 AB EQ 60MG BASE
 AB ZYDUS HLTHCARE EQ 20MG BASE
 AB EQ 30MG BASE
 AB EQ 60MG BASE

A204815 001 Mar 23, 2017 Mar NEWA
 A204815 002 Mar 23, 2017 Mar NEWA
 A204815 003 Mar 23, 2017 Mar NEWA
 A206653 001 May 18, 2017 May NEWA
 A206653 002 May 18, 2017 May NEWA
 A206653 003 May 18, 2017 May NEWA
 A090739 001 Jan 08, 2014 Apr CAHN
 A090739 002 Jan 08, 2014 Apr CAHN
 A090739 003 Jan 08, 2014 Apr CAHN

DUTASTERIDECAPSULE;ORAL
DUTASTERIDE

AB AMNEAL PHARMS 0.5MG
 >A> AB HAUPT PHARMA 0.5MG
 AB MARKSANS PHARMA 0.5MG
 AB ZYDUS PHARMS USA INC 0.5MG

A203118 001 Nov 20, 2015 May CAHN
 A207935 001 Oct 13, 2017 Oct NEWA
 A204376 001 Apr 07, 2017 Mar NEWA
 A204373 001 Oct 04, 2017 Sep NEWA

DYPHYLLINETABLET;ORAL
LUFYLLIN

@ MYLAN SPECIALITY LP 200MG
 @ 400MG

A084566 001 Mar CAHN
 A084566 002 Mar CAHN

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICAL
ECOZA

+! CHEMO RESEARCH SL 1%

N205175 001 Oct 24, 2013 May CAHN

CREAM;TOPICAL
SPECTAZOLE

AB + ALVOGEN MALTA 1%
 + @ 1%

N018751 001 Dec 23, 1982 Sep CMFD
 N018751 001 Dec 23, 1982 Mar CMS1

EDARAVONESOLUTION;IV (INFUSION)
RADICAVA

+! MITSUBISHI TANABE 30MG/100ML (0.3MG/ML)

N209176 001 May 05, 2017 May NEWA

EDROPHONIUM CHLORIDEINJECTABLE;INJECTION
TENSILON

+ @ TELIGENT 10MG/ML

N007959 001 Apr CAHN

TENSILON PRESERVATIVE FREE

+ @ TELIGENT 10MG/ML

N007959 002 Apr CAHN

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB AJANTA PHARMA LTD EQ 20MG BASE
 AB EQ 40MG BASE
 AB MYLAN PHARMS INC EQ 20MG BASE
 AB EQ 40MG BASE
 AB TEVA PHARMS USA EQ 20MG BASE
 AB EQ 40MG BASE
 AB ZYDUS PHARMS USA INC EQ 20MG BASE
 AB EQ 40MG BASE

A205186 001 Aug 29, 2017 Aug NEWA
 A205186 002 Aug 29, 2017 Aug NEWA
 A205152 001 Aug 11, 2017 Jul NEWA
 A205152 002 Aug 11, 2017 Jul NEWA
 A202040 001 Jun 27, 2017 Jun NEWA
 A202040 002 Jun 27, 2017 Jun NEWA
 A206409 001 Jun 16, 2017 Jun NEWA
 A206409 002 Jun 16, 2017 Jun NEWA

TABLET; ORAL							
RELPAK							
AB	+	PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jun CFTG
AB	+	!	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jun CFTG
<u>ELVITEGRAVIR</u>							
TABLET; ORAL							
VITEKTA							
	+	@ GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014	May DISC
	+	@	150MG	N203093	002	Sep 24, 2014	May DISC
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>							
TABLET; ORAL							
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE							
AB		TEVA PHARMS USA	200MG; 300MG	A090894	001	Jun 08, 2017	May NEWA
TRUVADA							
AB	+	! GILEAD	200MG; 300MG	N021752	001	Aug 02, 2004	May CFTG
<u>ENALAPRIL MALEATE</u>							
SOLUTION; ORAL							
EPANED							
	+	! SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016	Jul CRLD
<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>							
TABLET; ORAL							
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE							
	@	UPSHER-SMITH LABS	5MG; 12.5MG	A076116	001	Sep 19, 2001	Jun CAHN
	@		10MG; 25MG	A076116	002	Sep 19, 2001	Jun CAHN
<u>ENALAPRILAT</u>							
INJECTABLE; INJECTION							
ENALAPRILAT							
AP	!	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar CAHN
VASOTEC							
	+	@ BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988	Mar CRLD
<u>ENASIDENIB MESYLATE</u>							
TABLET; ORAL							
IDHIFA							
	+	CELGENE CORP	EQ 50MG BASE	N209606	001	Aug 01, 2017	Aug NEWA
	+	!	EQ 100MG BASE	N209606	002	Aug 01, 2017	Aug NEWA
<u>ENTACAPONE</u>							
TABLET; ORAL							
ENTACAPONE							
AB		AJANTA PHARMA LTD	200MG	A205792	001	Aug 31, 2017	Aug NEWA
AB		MACLEODS PHARMS LTD	200MG	A207210	001	Jun 05, 2017	May NEWA
	@	MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	May DISC
<u>ENTECAVIR</u>							
TABLET; ORAL							
ENTECAVIR							
AB		ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Aug NEWA
AB			1MG	A205824	002	Aug 25, 2017	Aug NEWA
AB		PRINSTON INC	0.5MG	A208782	001	Oct 10, 2017	Sep NEWA
AB			1MG	A208782	002	Oct 10, 2017	Sep NEWA
AB		SANDOZ INC	0.5MG	A206672	001	May 11, 2017	May NEWA
AB			1MG	A206672	002	May 11, 2017	May NEWA
AB		ZYDUS PHARMS USA INC	0.5MG	A206745	001	Jun 23, 2017	Jun NEWA
AB			1MG	A206745	002	Jun 23, 2017	Jun NEWA
<u>EPHEDRINE SULFATE</u>							
SOLUTION; INTRAVENOUS							
AKOVAZ							
AP	+	! FLAMEL IRELAND LTD	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Mar CTEC
EPHEDRINE SULFATE							
AP		AKORN INC	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Mar NEWA
AP		SANDOZ INC	50MG/ML (50MG/ML)	A209784	001	Aug 23, 2017	Aug NEWA
SOLUTION; IV (INFUSION)							
CORPHEDRA							
		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A204055	001	May 05, 2017	Apr NEWA
AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar CAHN

EPINEPHRINEINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

BX	+	IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Jun CAHN
BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Jun CAHN
		TWINJECT 0.15					
		@ IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Jun CAHN
		TWINJECT 0.3					
		@ IMPAX LABS INC	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Jun CAHN
		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
		ADRENALIN					
	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CDFR
	+		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Aug CDFR
		SYMJEPI					
	+	ADAMIS PHARMS CORP	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDEINJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@	BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb CAHN
@		0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb CAHN
@	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar CAHN
@		0.01MG/ML;2%	A080406	002		Mar CAHN

EPLERENONETABLET;ORAL
EPLERENONE

AB		ACCORD HLTHCARE	25MG	A206922	001	Jul 13, 2017	Jul NEWA
AB			50MG	A206922	002	Jul 13, 2017	Jul NEWA
AB		MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan NEWA
AB			50MG	A203896	002	Feb 02, 2017	Jan NEWA

EPTIFIBATIDEINJECTABLE;INJECTION
EPTIFIBATIDE

>A>	AP	ACCORD HLTHCARE	2MG/ML	A205557	001	Nov 06, 2017	Oct NEWA
>A>	AP		75MG/100ML	A205557	002	Nov 06, 2017	Oct NEWA
	AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr NEWA
	AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr NEWA
	AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	May CAHN
	AP		75MG/100ML	A205581	002	Dec 08, 2016	May CAHN

ERGOLOID MESYLATESTABLET;ORAL
ERGOLOID MESYLATES

!	SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991	May CHRS
	HYDERGINE					
+	@ NOVARTIS	1MG	N017993	001		May DISC

ERYTHROMYCINGEL;TOPICAL
E-GLADES

	@	MYLAN PHARMS INC	2%	A065009	001	Mar 18, 2002	Jan CAHN
		ERYGEL					
AT	+	MYLAN PHARMS INC	2%	N050617	001	Oct 21, 1987	Jan CAHN
		ERYTHROMYCIN					
AT		PERRIGO CO	2%	A063211	001	Jan 29, 1993	Apr CAHN
AT		TELIGENT PHARMA INC	2%	A208154	001	Jul 19, 2017	Jul NEWA

OINTMENT;TOPICAL

>D>		AKNE-MYCIN					
>D>	+	DOW PHARM	2%	N050584	001	Jan 10, 1985	Oct DISC
>A>	+	@	2%	N050584	001	Jan 10, 1985	Oct DISC

SOLUTION;TOPICAL

A/T/S

		@ TARO	2%	A062405	001	Nov 18, 1982	Apr CAHN
		ERYTHRA-DERM					
>D>		@ PADDOCK LLC	2%	A062687	001	Feb 05, 1988	Oct CAHN
>A>		@ SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Oct CAHN
		ERYTHROMYCIN					
		@ FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Aug DISC
AT	!	PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Aug CHRS
		SWAB;TOPICAL					
		ERYCETTE					
	+	@ JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985	Sep CRLD
		ERYTHROMYCIN					
		@ MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996	Jan CAHN
AT	!	PERRIGO CO	2%	A064126	001	Jul 03, 1996	Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

>D>	AB	+	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	001		Oct CTEC
>A>		+		EQ 200MG BASE/5ML	N050207	001		Oct CTEC
			ERYPED					
>D>	AB	+	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Oct CTEC
>A>		+		EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Oct CTEC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

		@ BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062759	001	May 20, 1988	Jul DISC
--	--	--------	-------------------------------------	---------	-----	--------------	----------

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

	AB		AMNEAL PHARMS	EQ 5MG BASE	A205619	001	May 17, 2017	May NEWA
	AB			EQ 10MG BASE	A205619	002	May 17, 2017	May NEWA
	AB			EQ 20MG BASE	A205619	003	May 17, 2017	May NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB		ALKEM LABS LTD	EQ 20MG BASE	A208333	001	Oct 20, 2017	Oct NEWA
>A>	AB			EQ 40MG BASE	A208333	002	Oct 20, 2017	Oct NEWA
	AB		KREMERS URBAN PHARMS	EQ 20MG BASE	A205563	001	Sep 01, 2017	Aug NEWA
	AB			EQ 40MG BASE	A205563	002	Sep 01, 2017	Aug NEWA

FOR SUSPENSION, DELAYED RELEASE;ORAL

NEXIUM

	+	ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	May CRLD
--	---	--------------------	---------------------	---------	-----	--------------	----------

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

	AP	!	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May CHRS
	AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Aug CHRS
	AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May CHRS
	AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb NEWA
	AP		MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	May NEWA
	AP			EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	May NEWA
			NEXIUM IV					
	+	@	ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May DISC
AP	+	!		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Aug CMFD
	+	@		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May DISC

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADERM

	+	@	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986	May DISC
	+	@		0.1MG/24HR	N019081	003	Sep 10, 1986	May DISC
			VIVELLE					
		@	NOVARTIS	0.05MG/24HR	N020323	002	Oct 28, 1994	May DISC
		@		0.1MG/24HR	N020323	004	Oct 28, 1994	May DISC

GEL, METERED;TRANSDERMAL							
ELESTRIN							
+	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Mar	CAHN
SPRAY;TRANSDERMAL							
EVAMIST							
+	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May	CAHN
TABLET;VAGINAL							
ESTRADIOL							
AB	TEVA PHARMS USA	10MCG	A206388	001	Jul 21, 2017	Jul	NEWA
<u>ESTRADIOL ACETATE</u>							
TABLET;ORAL							
FEMTRACE							
+	@ APIL	0.45MG	N021633	001	Aug 20, 2004	Jun	DISC
+	@	0.9MG	N021633	002	Aug 20, 2004	Jun	DISC
+	@	1.8MG	N021633	003	Aug 20, 2004	Jun	DISC
<u>ESTRADIOL VALERATE</u>							
INJECTABLE;INJECTION							
ESTRADIOL VALERATE							
@	SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr	CAHN
@		20MG/ML	A040628	002	Oct 04, 2007	Apr	CAHN
@		40MG/ML	A040628	003	Oct 04, 2007	Apr	CAHN
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>							
TABLET;ORAL							
ESTRADIOL AND NORETHINDRONE ACETATE							
AB	MYLAN LABS LTD	0.5MG;0.1MG	A207261	001	Feb 10, 2017	Jan	NEWA
AB		1MG;0.5MG	A207261	002	Feb 10, 2017	Jan	NEWA
<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>							
TABLET;ORAL							
CENESTIN							
+	@ TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Aug	CRLD
+	@	0.45MG	N020992	005	Feb 05, 2004	Aug	CRLD
+	@	0.625MG	N020992	002	Mar 24, 1999	Aug	CRLD
+	@	0.9MG	N020992	003	Mar 24, 1999	Aug	CRLD
+	@	1.25MG	N020992	004	Mar 13, 2000	Aug	CRLD
<u>ESTROGENS, CONJUGATED SYNTHETIC B</u>							
TABLET;ORAL							
ENJUVIA							
@	TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Aug	DISC
		0.3MG	N021443	001	Dec 20, 2004	Apr	CAHN
@		0.45MG	N021443	002	Dec 20, 2004	Aug	DISC
		0.45MG	N021443	002	Dec 20, 2004	Apr	CAHN
@		0.625MG	N021443	003	May 10, 2004	Apr	CAHN
@		0.9MG	N021443	005	Apr 27, 2007	Aug	DISC
		0.9MG	N021443	005	Apr 27, 2007	Apr	CAHN
@		1.25MG	N021443	004	May 10, 2004	Apr	CAHN
<u>ESTROGENS, ESTERIFIED</u>							
TABLET;ORAL							
MENEST							
	MONARCH PHARMS	0.3MG	A084951	001		Jun	CAHN
		0.625MG	A084948	001		Jun	CAHN
		1.25MG	A084950	001		Jun	CAHN
!		2.5MG	A084949	001		Jun	CAHN
<u>ESTRONE</u>							
INJECTABLE;INJECTION							
ESTRONE							
@	WATSON LABS TEVA	5MG/ML	A085239	001		May	CAHN
<u>ESTROPIPATE</u>							
TABLET;ORAL							
ESTROPIPATE							
@	BARR	0.75MG	A040135	001	Nov 27, 1996	May	DISC
@		1.5MG	A040135	002	Nov 27, 1996	May	DISC
@		3MG	A040135	003	Nov 27, 1996	May	DISC
!	WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	May	CHRS
AB		3MG	A081215	001	Sep 23, 1993	Feb	CAHN

TABLET;ORAL

OGEN .625

@ PHARMACIA AND UPJOHN 0.75MG

A083220 001

May DISC

OGEN 1.25

@ PHARMACIA AND UPJOHN 1.5MG

A083220 002

May DISC

OGEN 2.5

@ PHARMACIA AND UPJOHN 3MG

A083220 003

May DISC

ETELCALCETIDE

SOLUTION;INTRAVENOUS

PARSABIV

+! KAI PHARMS INC 2.5MG/0.5ML (2.5MG/0.5ML)

N208325 001

Feb 07, 2017

Feb NEWA

+! 5MG/ML (5MG/ML)

N208325 002

Feb 07, 2017

Feb NEWA

+! 10MG/2ML (5MG/ML)

N208325 003

Feb 07, 2017

Feb NEWA

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

AB PAR PHARM INC 25MG

A208501 001

Jul 21, 2017

Jul NEWA

AB WEST-WARD PHARMS INT 25MG

A207262 001

Feb 23, 2017

Feb NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

ZOVIA 1/35E-21

@ WATSON PHARMS TEVA 0.035MG;1MG

A072720 001

Dec 30, 1991

Mar CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB MYLAN LABS LTD 0.02MG, 0.15MG; 0.025MG,
0.15MG;0.03MG, 0.15MG; 0.01MG, N/A

A206053 001

Oct 02, 2017

Sep NEWA

LO SIMPESSE

AB AUROBINDO PHARMA LTD 0.02MG,0.01MG;0.01MG,N/A

A206852 001

Apr 28, 2017

Apr NEWA

SIMPESSE

AB AUROBINDO PHARMA LTD 0.03MG,0.01MG;0.15MG,N/A

A206851 001

Apr 07, 2017

Mar NEWA

TABLET;ORAL-28

ELIFEMME

AB LABS LEON FARMA 0.03MG,0.04MG,0.03MG;0.05MG,0.075M
G,0.125MG

A202507 001

Dec 04, 2015

Feb CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

NORETHIN 1/35E-21

@ WATSON PHARMS TEVA 0.035MG;1MG

A071480 001

Apr 12, 1988

Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON PHARMS TEVA 0.035MG;1MG

A070685 001

Jan 29, 1987

Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG

A071041 001

Sep 24, 1991

May CAHN

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB ACCORD HLTHCARE 0.035MG;1MG

A206864 001

Apr 28, 2017

Apr NEWA

>D> AB MYLAN LABS LTD 0.035MG,0.035MG,0.035MG;0.5MG,0.75
MG,1MG

A200486 001

Dec 28, 2015

Oct DISC

>A> @ 0.035MG,0.035MG,0.035MG;0.5MG,0.75
MG,1MG

A200486 001

Dec 28, 2015

Oct DISC

@ 0.035MG;0.5MG

A200488 001

Oct 21, 2015

Sep DISC

@ 0.035MG;1MG

A200489 001

Oct 21, 2015

Sep DISC

AB WATSON LABS TEVA 0.035MG;1MG

A070687 001

Jan 29, 1987

May CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG

A071044 001

Apr 01, 1988

May CAHN

TABLET, CHEWABLE;ORAL

NEXESTA FE

AB AUROBINDO PHARMA LTD 0.035MG;0.4MG

A207535 001

Feb 02, 2017

Jan NEWA

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB ACCORD HLTHCARE 0.035MG;0.4MG

A207066 001

Mar 29, 2017

Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

AUROVELA 24 FE

AB AUROBINDO PHARMA LTD 0.02MG;1MG

A207504 001

Jun 15, 2017

Jun NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB MYLAN LABS LTD 0.0025MG;0.5MG

A207260 001

Feb 02, 2017

Jan NEWA

TABLET;ORAL-21

AUROVELA 1.5/30							
AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A207581	001	Jun 26, 2017	Jun	NEWA
AUROVELA 1/20							
AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207506	001	Jun 16, 2017	Jun	NEWA
TABLET;ORAL-28							
AUROVELA FE 1.5/30							
AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A207580	001	Jun 15, 2017	May	NEWA
AUROVELA FE 1/20							
AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207505	001	Jun 16, 2017	Jun	NEWA
LOESTRIN FE 1/20							
AB	+ APIL	0.02MG;1MG	N017354	001		Jul	CRLD
TABLET, CHEWABLE;ORAL							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	AMNEAL PHARMS	0.02MG;1MG	A207514	001	Sep 11, 2017	Aug	NEWA
AB	MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017	Sep	NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28							
NORGESTIMATE AND ETHINYL ESTRADIOL							
AB	AMNEAL PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A203873	001	May 12, 2016	Sep	CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28							
NORGESTREL AND ETHINYL ESTRADIOL							
>D> AB	MYLAN LABS LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Oct	DISC
>A>	@	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Oct	DISC
>D> AB		0.05MG;0.5MG	A202875	001	May 08, 2017	Oct	DISC
>A>	@	0.05MG;0.5MG	A202875	001	May 08, 2017	Oct	DISC
AB		0.05MG;0.5MG	A202875	001	May 08, 2017	Apr	NEWA
OGESTREL 0.5/50-28							
>D> AB	! WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999	Oct	CTEC
>A>	!	0.05MG;0.5MG	A075406	002	Dec 15, 1999	Oct	CTEC
AB	!	0.05MG;0.5MG	A075406	002	Dec 15, 1999	May	CTEC

ETHOSUXIMIDE

SYRUP;ORAL							
ETHOSUXIMIDE							
AA	PHARM ASSOC	250MG/5ML	A040253	001	Nov 22, 2000	May	CAHN
ZARONTIN							
AA	! PARKE-DAVIS	250MG/5ML	A080258	001		Mar	CAHN

ETIDRONATE DISODIUM

TABLET;ORAL							
DIDRONEL							
+ @	APIL	200MG	N017831	001		Jun	DISC
+ @		400MG	N017831	002		Jun	DISC
ETIDRONATE DISODIUM							
	MYLAN	200MG	A075800	001	Jan 24, 2003	Jun	CTEC
!		400MG	A075800	002	Jan 24, 2003	Jun	CHRS

ETODOLAC

CAPSULE;ORAL							
ETODOLAC							
@	CHARTWELL MOLECULES	200MG	A074842	001	Jul 17, 1997	Mar	CAHN
@		300MG	A074842	002	Jul 17, 1997	Mar	CAHN
@	CHARTWELL PHARMS LLC	200MG	A074842	001	Jul 17, 1997	Jan	CAHN
@		300MG	A074842	002	Jul 17, 1997	Jan	CAHN
@	ECI PHARMS LLC	300MG	A074929	001	Jan 30, 1998	Apr	CAHN
LODINE							
+ @	WYETH PHARMS INC	300MG	N018922	003	Jan 31, 1991	Jul	CRLD
TABLET;ORAL							
ETODOLAC							
@	CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997	Jan	CAHN
@	MYLAN PHARMS INC	400MG	A075104	001	Feb 06, 1998	May	DISC
AB		400MG	A075104	001	Feb 06, 1998	Mar	CAHN
@		500MG	A075104	002	Nov 20, 1998	May	DISC
AB		500MG	A075104	002	Nov 20, 1998	Mar	CAHN

ETOMIDATEINJECTABLE; INJECTION
ETOMIDATE

AP	AUROBINDO PHARMA LTD	2MG/ML	A206126	001	Feb 24, 2017	Feb	NEWA
AP	GLAND PHARMA LTD	2MG/ML	A209058	001	Apr 18, 2017	Apr	NEWA
AP	MYLAN LABS LTD	2MG/ML	A201044	001	Feb 07, 2017	Jan	NEWA
AP	WEST-WARD PHARMS INT	2MG/ML	A074593	001	Nov 04, 1996	Jan	CAHN

ETOPOSIDECAPSULE; ORAL
VEPESID

	+ @ DAVA PHARMS INC	50MG	N019557	001	Dec 30, 1986	Sep	CRLD
	+ @	100MG	N019557	002	Dec 30, 1986	Sep	CRLD

INJECTABLE; INJECTION
ETOPOSIDE

>A>	AP	MYLAN LABS LTD	20MG/ML	A204927	001	Oct 31, 2017	Oct	NEWA
-----	----	----------------	---------	---------	-----	--------------	-----	------

EXAMETAZIMEPOWDER; INTRAVENOUS
DRAX EXAMETAZIME

AP	JUBILANT DRAXIMAGE	0.5MG/VIAL	N208870	001	Aug 17, 2017	Aug	NEWA
----	--------------------	------------	---------	-----	--------------	-----	------

EXEMESTANETABLET; ORAL
EXEMESTANE

AB	MYLAN PHARMS INC	25MG	A203315	001	Mar 10, 2017	Feb	NEWA
AB	UPSHER-SMITH LABS	25MG	A209208	001	Jul 26, 2017	Aug	CAHN
AB		25MG	A209208	001	Jul 26, 2017	Jul	NEWA

EXENATIDE

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

>A>		BYDUREON BCISE						
>A>	+	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Oct	NEWA

EZETIMIBETABLET; ORAL
EZETIMIBE

AB	AMNEAL PHARMS CO	10MG	A208803	001	Jun 12, 2017	May	NEWA
AB	APOTEX INC	10MG	A208332	001	Jun 12, 2017	May	NEWA
AB	AUROBINDO PHARMA LTD	10MG	A209838	001	Aug 25, 2017	Aug	NEWA
AB	OHM LABS INC	10MG	A207311	001	Jun 12, 2017	May	NEWA
AB	SANDOZ INC	10MG	A203931	001	Jun 12, 2017	May	NEWA
AB	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	May	NEWA
AB	WATSON LABS INC	10MG	A200831	001	Jun 12, 2017	May	NEWA
AB	ZYDUS PHARMS USA INC	10MG	A204331	001	Jun 12, 2017	May	NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB	DR REDDYS LABS INTL	10MG; 10MG	A200909	001	Apr 26, 2017	Apr	NEWA	
AB		10MG; 20MG	A200909	002	Apr 26, 2017	Apr	NEWA	
AB		10MG; 40MG	A200909	003	Apr 26, 2017	Apr	NEWA	
AB		10MG; 80MG	A200909	004	Apr 26, 2017	Apr	NEWA	
AB	DR REDDYS LABS SA	10MG; 10MG	A200909	001	Apr 26, 2017	May	CAHN	
AB		10MG; 20MG	A200909	002	Apr 26, 2017	May	CAHN	
AB		10MG; 40MG	A200909	003	Apr 26, 2017	May	CAHN	
AB		10MG; 80MG	A200909	004	Apr 26, 2017	May	CAHN	
AB	IMPAX LABS INC	10MG; 10MG	A201890	001	Apr 26, 2017	Apr	NEWA	
AB		10MG; 20MG	A201890	002	Apr 26, 2017	Apr	NEWA	
AB		10MG; 40MG	A201890	003	Apr 26, 2017	Apr	NEWA	
AB		10MG; 80MG	A201890	004	Apr 26, 2017	Apr	NEWA	
AB	WATSON LABS INC	10MG; 10MG	A202968	001	Apr 26, 2017	Apr	NEWA	
AB		10MG; 20MG	A202968	002	Apr 26, 2017	Apr	NEWA	
AB		10MG; 40MG	A202968	003	Apr 26, 2017	Apr	NEWA	
AB		10MG; 80MG	A202968	004	Apr 26, 2017	Apr	NEWA	
	VYTORIN							
AB	+	MSD INTL	10MG; 10MG	N021687	001	Jul 23, 2004	Apr	CFTG
AB	+		10MG; 20MG	N021687	002	Jul 23, 2004	Apr	CFTG
AB	+		10MG; 40MG	N021687	003	Jul 23, 2004	Apr	CFTG
AB	+		10MG; 80MG	N021687	004	Jul 23, 2004	Apr	CFTG

>D>	<u>EZO</u> GABINE									
>D>	TABLET;ORAL									
>D>	POTIGA									
>D>	+	GLAXOSMITHKLINE	50MG			N022345	001	Jun 10, 2011	Oct	DISC
>A>	+	@	50MG			N022345	001	Jun 10, 2011	Oct	DISC
>D>	+		200MG			N022345	002	Jun 10, 2011	Oct	DISC
>A>	+	@	200MG			N022345	002	Jun 10, 2011	Oct	DISC
>D>	+		300MG			N022345	003	Jun 10, 2011	Oct	DISC
>A>	+	@	300MG			N022345	003	Jun 10, 2011	Oct	DISC
>D>	+	!	400MG			N022345	004	Jun 10, 2011	Oct	DISC
>A>	+	@	400MG			N022345	004	Jun 10, 2011	Oct	DISC
<u>FAMCICLOVIR</u>										
TABLET;ORAL										
FAMCICLOVIR										
AB	!	TEVA PHARMS	500MG			A077487	003	Aug 24, 2007	Jan	CHRS
FAMVIR										
	+	@ NOVARTIS	125MG			N020363	003	Dec 11, 1995	Jan	DISC
	+	@	250MG			N020363	001	Apr 26, 1996	Jan	DISC
	+	@	500MG			N020363	002	Jun 29, 1994	Jan	DISC
<u>FAMOTIDINE</u>										
INJECTABLE;INJECTION										
FAMOTIDINE										
AP		ATHENEX INC	10MG/ML			A075651	001	Apr 16, 2001	Mar	CAHN
AP			10MG/ML			A075684	001	Apr 16, 2001	Mar	CAHN
		@ WEST-WARD PHARMS INT	10MG/ML			A075799	001	Apr 30, 2002	Aug	CAHN
FAMOTIDINE PRESERVATIVE FREE										
AP		ATHENEX INC	10MG/ML			A075622	001	Apr 16, 2001	Mar	CAHN
AP			10MG/ML			A075825	001	Apr 17, 2001	Mar	CAHN
		@ WEST-WARD PHARMS INT	10MG/ML			A075789	001	Apr 30, 2002	Aug	CAHN
TABLET;ORAL										
FAMOTIDINE										
AB		PERRIGO R AND D	20MG			A077352	002	Jul 27, 2005	Apr	CAHN
AB			40MG			A077352	001	Jul 27, 2005	Apr	CAHN
<u>FELBAMATE</u>										
SUSPENSION;ORAL										
FELBAMATE										
AB		TARO PHARM	600MG/5ML			A206314	001	Jun 16, 2017	Jun	NEWA
FELBATOL										
AB	+	MYLAN SPECIALITY LP	600MG/5ML			N020189	003	Jul 29, 1993	Mar	CAHN
TABLET;ORAL										
FELBAMATE										
AB		IMPAX LABS INC	400MG			A202284	001	Nov 04, 2015	Feb	CAHN
AB			600MG			A202284	002	Nov 04, 2015	Feb	CAHN
AB		TARO PHARM	400MG			A207093	001	Apr 20, 2017	Apr	NEWA
AB			600MG			A207093	002	Apr 20, 2017	Apr	NEWA
AB		ZYDUS PHARMS USA INC	400MG			A208970	001	May 30, 2017	May	NEWA
AB			600MG			A208970	002	May 30, 2017	May	NEWA
FELBATOL										
AB	+	MYLAN SPECIALITY LP	400MG			N020189	001	Jul 29, 1993	Mar	CAHN
AB	+	!	600MG			N020189	002	Jul 29, 1993	Mar	CAHN
<u>FENOFIBRATE</u>										
CAPSULE;ORAL										
FENOFIBRATE (MICRONIZED)										
AB		GLENMARK PHARMS LTD	67MG			A205566	001	Apr 07, 2017	Mar	NEWA
AB			134MG			A205566	002	Apr 07, 2017	Mar	NEWA
AB			200MG			A205566	003	Apr 07, 2017	Mar	NEWA
AB	!	IMPAX LABS	200MG			A075868	003	Oct 27, 2003	Jun	CHRS
AB		INVAGEN PHARMS	67MG			A207378	001	Mar 28, 2017	Mar	NEWA
AB			134MG			A207378	002	Mar 28, 2017	Mar	NEWA
AB			200MG			A207378	003	Mar 28, 2017	Mar	NEWA
AB		RHODES PHARMS	200MG			A075753	003	Apr 09, 2002	Jun	CHRS
TABLET;ORAL										
FENOFIBRATE										
AB	!	IMPAX LABS	160MG			A076509	002	Mar 26, 2008	Mar	CHRS
AB		RHODES PHARMS	160MG			A076433	002	May 13, 2005	Mar	CHRS
AB		SUN PHARM INDS LTD	48MG			A200884	001	Sep 07, 2017	Aug	NEWA
AB			145MG			A200884	002	Sep 07, 2017	Aug	NEWA

TABLET;ORAL

TRICOR

+ @ ABBVIE INC	54MG	N021203	001	Sep 04, 2001	Aug CAHN
+ @	160MG	N021203	003	Sep 04, 2001	Aug CAHN

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

AP	SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar CAHN
----	------------	-----------------	---------	-----	--------------	----------

FENOPROFEN CALCIUM

CAPSULE;ORAL

NALFON

+! XSPIRE PHARMA	EQ 200MG BASE	N017604	003		Aug CAHN
@	EQ 300MG BASE	N017604	002		Aug CAHN
+	EQ 400MG BASE	N017604	004	Jul 21, 2009	Aug CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

@ WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988	May CAHN
! XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988	Aug CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar CAHN

FENTANYL-12

AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar CAHN
----	------------------	------------	---------	-----	--------------	----------

FENTANYL-25

AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Mar CAHN

FENTANYL-50

AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Mar CAHN

FENTANYL-75

AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Mar CAHN

SPRAY;SUBLINGUAL

SUBSYS

+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012	May CAHN
+		0.2MG	N202788	002	Jan 04, 2012	May CAHN
+!		0.4MG	N202788	003	Jan 04, 2012	May CAHN
+		0.6MG	N202788	004	Jan 04, 2012	May CAHN
+		0.8MG	N202788	005	Jan 04, 2012	May CAHN
+		1.2MG	N202788	006	Aug 30, 2012	May CAHN
+		1.6MG	N202788	007	Aug 30, 2012	May CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb NEWA
AB		8MG	A205007	002	Feb 17, 2017	Feb NEWA
AB	ZYDUS PHARMS USA INC	4MG	A204946	001	Oct 03, 2017	Sep NEWA
AB		8MG	A204946	002	Oct 03, 2017	Sep NEWA

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013	Mar CAHN
AB	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May CAHN

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

>A> AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Nov 03, 2017	Oct NEWA
>A> AB		100MG	A202821	002	Nov 03, 2017	Oct NEWA
>A> AB		150MG	A202821	003	Nov 03, 2017	Oct NEWA

FLUCONAZOLEFOR SUSPENSION; ORAL
FLUCONAZOLE

AB	AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan CAHN
AB		200MG/5ML	A079150	002	Sep 18, 2009	Jan CAHN

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar DISC
+ @		400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+ @	PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar DISC
+ @		400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @	PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar DISC
+ @		400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar DISC

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar CHRS
AP	!		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar CHRS
AP		RENAISSANCE SSA LLC	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Aug CAHN
AP			400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Aug CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		BAXTER HLTHCARE CORP	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Aug CAHN
AP			400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Aug CAHN
		WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan CAHN
AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan CAHN
AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	!	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CHRS
AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CHRS
		RENAISSANCE SSA LLC	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Aug CAHN
AP			200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Aug CAHN
AP			400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Aug CAHN
AP		WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan CAHN
AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan CAHN

TABLET; ORAL

FLUCONAZOLE

AB		UNIQUE PHARM LABS	50MG	A076957	001	Sep 28, 2005	Aug CAHN
AB			100MG	A076957	002	Sep 28, 2005	Aug CAHN
AB			150MG	A076957	004	Feb 27, 2017	Aug CAHN
AB			150MG	A076957	004	Feb 27, 2017	Feb NEWA
AB			200MG	A076957	003	Sep 28, 2005	Aug CAHN
AB		ZYDUS PHARMS USA INC	50MG	A208963	001	Feb 16, 2017	Feb NEWA
AB			100MG	A208963	002	Feb 16, 2017	Feb NEWA
AB			150MG	A208963	003	Feb 16, 2017	Feb NEWA
AB			200MG	A208963	004	Feb 16, 2017	Feb NEWA

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE

AB		NOVEL LABS INC	250MG	A204652	001	Jul 07, 2017	Jun NEWA
AB			500MG	A204652	002	Jul 07, 2017	Jun NEWA
>A>	AB	ROXANE	250MG	A206550	001	Oct 17, 2017	Oct NEWA
>A>	AB		500MG	A206550	002	Oct 17, 2017	Oct NEWA
>A>	AB	WEST-WARD PHARMS INT	250MG	A206550	001	Oct 17, 2017	Oct CAHN
>A>	AB		500MG	A206550	002	Oct 17, 2017	Oct CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP		ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Feb NEWA
>A>	AP	CUSTOPHARM INC	50MG/VIAL	A076349	001	Aug 28, 2003	Oct CAHN
>D>	AP	SAGENT PHARMS	50MG/VIAL	A076349	001	Aug 28, 2003	Oct CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		JUBILANT DRAXIMAGE	20-300mCi/ML	A203920	001	Jun 23, 2015	Sep CAHN
----	--	--------------------	--------------	---------	-----	--------------	----------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

	@	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Aug CAHN
	@		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Aug CAHN
AP		SANDOZ INC	0.5MG/5ML (0.1MG/ML)	A077071	001	May 03, 2005	Apr CAHN
AP			1MG/10ML (0.1MG/ML)	A077071	002	May 03, 2005	Apr CAHN
AP		WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan CAHN
AP			0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan CAHN
AP			1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan CAHN
AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

	+	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Mar CAHN
--	---	---------------------	-------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan CAHN
AT			0.025%	A088169	001	Dec 16, 1982	Jan CAHN
	@	TARO	0.01%	A040035	001	Oct 31, 1994	Apr CAHN
	@		0.025%	A040042	001	Oct 31, 1994	Apr CAHN

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT		PERRIGO ISRAEL	0.01%	A202849	001	Jul 17, 2017	Jul NEWA
----	--	----------------	-------	---------	-----	--------------	----------

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan CAHN
AT		TARO	0.025%	A040041	001	Sep 15, 1994	Apr CAHN

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.01%	A088167	001	Dec 16, 1982	Jan CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1		FOUGERA PHARMS INC	0.05%	A073030	001	Oct 17, 1994	Jan CAHN
AB		PERRIGO ISRAEL	0.1%	A090256	001	Jan 14, 2014	Apr CAHN
AB1		TARO	0.05%	A071500	001	Jun 10, 1987	Mar CMFD

FLUOCINONIDE EMULSIFIED BASE

AB2		G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995	May CMFD
-----	--	------------------	-------	---------	-----	--------------	----------

GEL; TOPICAL

FLUOCINONIDE

>A>	AB	+	CNTY LINE PHARMS	0.05%	N017373	001	Oct CMFD
	AB		FOUGERA PHARMS INC	0.05%	A072933	001	Dec 30, 1994
	AB	!	TARO	0.05%	A074935	001	Jul 29, 1997

LIDEX

>D>		+	@ CNTY LINE PHARMS	0.05%	N017373	001	Oct CMFD
-----	--	---	--------------------	-------	---------	-----	----------

OINTMENT; TOPICAL

FLUOCINONIDE

AB		NOVEL LABS INC	0.05%	A207538	001	Jul 31, 2017	Jul NEWA
AB	!	TARO	0.05%	A075008	001	Jun 30, 1999	Apr CAHN

SOLUTION; TOPICAL

FLUOCINONIDE

AT		NOVEL LABS INC	0.05%	A206003	001	Jul 21, 2017	Jul NEWA
AT	!	TARO	0.05%	A074799	001	Dec 31, 1996	Apr CAHN

LIDEX

AT	+	CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Mar CRLD
----	---	------------------	-------	---------	-----	--------------	----------

FLUOROURACIL

CREAM; TOPICAL

FLUOROURACIL

AB		MYLAN PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Jun CAHN
----	--	------------------	------	---------	-----	--------------	----------

INJECTABLE; INJECTION

FLUOROURACIL

>A>	AP		GLAND PHARMA LTD	500MG/10ML (50MG/ML)	A210123	001	Oct 27, 2017
>A>	AP			1GM/20ML (50MG/ML)	A210123	002	Oct 27, 2017
AP		SAGENT PHARMS	500MG/10ML (50MG/ML)	A203608	001	May 11, 2017	May NEWA

INJECTABLE; INJECTION
FLUOROURACIL

AP		1GM/20ML (50MG/ML)	A203608	002	May 11, 2017	May NEWA
	@ SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011	Jul DISC
	@	5GM/100ML (50MG/ML)	A091299	002	May 02, 2011	Jul DISC
	+ @ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CRLD
	+ @	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016	Aug DISC

SOLUTION; TOPICAL
FLUOROURACIL

AT	TARO PHARM	2%	A076526	001	Nov 05, 2003	Mar CAHN
AT		5%	A076526	002	Nov 05, 2003	Mar CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

@ MYLAN	EQ 10MG BASE	A075207	001	Jan 30, 2002	Jun DISC
@	EQ 20MG BASE	A075207	002	Jan 30, 2002	Jun DISC
@	EQ 40MG BASE	A075207	003	May 25, 2007	Jun DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan CAHN
AA	! PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	May CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A208698	001	Apr 05, 2017	Mar NEWA
AB		EQ 20MG BASE	A208698	002	Apr 05, 2017	Mar NEWA
>D>	+! ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Oct CTEC
>A>	AB +!	EQ 60MG BASE	N202133	001	Oct 06, 2011	Oct CTEC
	+!	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan CAHN
>A>	AB PAR PHARM INC	EQ 60MG BASE	A209419	001	Nov 16, 2017	Oct NEWA

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

!	USL PHARMA	10MG	A088342	001	Oct 21, 1983	Jun CAHN
---	------------	------	---------	-----	--------------	----------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

>A>	AO AUROBINDO PHARMA LTD	25MG/ML	A207739	001	Oct 17, 2017	Oct NEWA
-----	-------------------------	---------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

@ ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991	Jan CAHN
! PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996	May CAHN

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

! PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996	May CAHN
PROLIXIN					
+ @ APOTHECON	2.5MG/5ML	N012145	003		Sep DISC

FLURANDRENOLIDE

CREAM; TOPICAL

FLURANDRENOLIDE

AT	CINTEX SVCS	0.05%	A205342	001	Apr 13, 2016	Jun CAHN
----	-------------	-------	---------	-----	--------------	----------

LOTION; TOPICAL

FLURANDRENOLIDE

AT	CINTEX SVCS	0.05%	A205343	001	Dec 22, 2016	Jun CAHN
----	-------------	-------	---------	-----	--------------	----------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	15MG	A071717	002	Jul 31, 1991	Jan CMS1
-----------------------	------	---------	-----	--------------	----------

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

+ @ SCHERING	125MG	N018554	001	Jan 27, 1989	Sep CRLD
FLUTAMIDE					
@ MYLAN	125MG	A076224	001	May 09, 2003	Jun DISC

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEPOWDER; INHALATION
TRELEGY ELLIPTA

+!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	001	Sep 18, 2017	Sep NEWA
----	-----------------	---	---------	-----	--------------	----------

FLUTICASONE PROPIONATEPOWDER; INHALATION
ARMONAIR RESPICLICK

+	TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017	Jan NEWA
+		0.113MG/INH	N208798	002	Jan 27, 2017	Jan NEWA
+		0.232MG/INH	N208798	003	Jan 27, 2017	Jan NEWA

SPRAY, METERED; NASAL
FLONASE

	+ @	GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jul CRLD
		FLUTICASONE PROPIONATE					
AB	!	WEST-WARD PHARMS INT	0.05MG/SPRAY	A076504	001	Feb 22, 2006	Jul CHRS
		XHANCE					
	+	OPTNOSE US	0.093MG	N209022	001	Sep 18, 2017	Sep NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEPOWDER; INHALATION
AIRDUO RESPICLICK

+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan NEWA
+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan NEWA
+		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jan NEWA

FLUVASTATIN SODIUMCAPSULE; ORAL
FLUVASTATIN SODIUM

AB	!	MYLAN PHARMS INC	EQ 40MG BASE	A090595	002	Apr 11, 2012	May CHRS
		LESCOL					
	+	@ NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	May DISC
	+	@	EQ 40MG BASE	N020261	002	Dec 31, 1993	May DISC

FLUVOXAMINE MALEATECAPSULE, EXTENDED RELEASE; ORAL
FLUVOXAMINE MALEATE

AB	!	ACTAVIS ELIZABETH	150MG	A091482	002	Nov 18, 2013	Apr CHRS
		LUVOX CR					
	+	@ JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Apr DISC
	+	@	150MG	N022033	002	Feb 28, 2008	Apr DISC
		TABLET; ORAL					
		FLUVOXAMINE MALEATE					
	@	ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006	May CAHN
	@		50MG	A075900	002	Feb 23, 2006	May CAHN
	@		100MG	A075900	003	Feb 23, 2006	May CAHN
	@	UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001	Jun CAHN
AB			25MG	A075888	001	Nov 29, 2000	Jun CAHN
	@		50MG	A075887	002	Jan 05, 2001	Jun CAHN
AB			50MG	A075888	002	Nov 29, 2000	Jun CAHN
	@		100MG	A075887	003	Jan 05, 2001	Jun CAHN
AB	!		100MG	A075888	003	Nov 29, 2000	Jun CAHN

FOLIC ACIDTABLET; ORAL
FOLIC ACID

@	CONTRACT PHARMACAL	1MG	A085061	001		Mar DISC
---	--------------------	-----	---------	-----	--	----------

FORMOTEROL FUMARATEPOWDER; INHALATION
FORADIL

+	@	NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb DISC
---	---	----------	-------------	---------	-----	--------------	----------

FORMOTEROL FUMARATE; GLYCOPYRROLATEAEROSOL, METERED; INHALATION
BEVESPI AEROSPHERE

+	!	ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar CAHN
---	---	--------------------	---------------------------	---------	-----	--------------	----------

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

@ HOSPIRA

2.4GM/100ML

A077174 001 May 31, 2005 Sep DISC

FOSCAVIR

+! CLINIGEN HLTHCARE

2.4GM/100ML

N020068 001 Sep 27, 1991 Sep CTEC

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ UPSHER-SMITH LABS

10MG

A076188 001 Oct 08, 2004 Jun CAHN

AB

10MG

A076483 001 Apr 23, 2004 Jun CAHN

@

20MG

A076188 002 Oct 08, 2004 Jun CAHN

AB

20MG

A076483 002 Apr 23, 2004 Jun CAHN

@

40MG

A076188 003 Oct 08, 2004 Jun CAHN

AB

40MG

A076483 003 Apr 23, 2004 Jun CAHN

MONOPRIL

+ @ BRISTOL MYERS SQUIBB

10MG

N019915 002 May 16, 1991 Jan CRLD

+ @

20MG

N019915 003 May 16, 1991 Jan CRLD

+ @

40MG

N019915 004 Mar 28, 1995 Jan CRLD

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP FRESENIUS KABI USA

EQ 50MG PHENYTOIN NA/ML

A078052 001 Aug 06, 2007 Jun CMFD

@ HOSPIRA

EQ 50MG PHENYTOIN NA/ML

A078158 001 Aug 06, 2007 Mar DISC

AP WEST-WARD PHARMS INT

EQ 50MG PHENYTOIN NA/ML

A077481 001 Aug 06, 2007 Jan CAHN

AP

EQ 50MG PHENYTOIN NA/ML

A077989 001 Aug 06, 2007 Jan CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@ ACCORD HLTHCARE

10MG/ML

A070017 001 Dec 15, 1986 Jun CAHN

AP BAXTER HLTHCARE CORP

10MG/ML

A202747 001 Jan 27, 2014 Aug CAHN

TABLET; ORAL

FUROSEMIDE

AB IPCA LABS LTD

20MG

A078010 001 Sep 18, 2006 Aug CTEC

BX

20MG

A078010 001 Sep 18, 2006 Apr CTEC

AB

40MG

A078010 002 Sep 18, 2006 Aug CTEC

BX

40MG

A078010 002 Sep 18, 2006 Apr CTEC

AB

80MG

A078010 003 Sep 18, 2006 Aug CTEC

BX

80MG

A078010 003 Sep 18, 2006 Apr CTEC

>D>

@ MUTUAL PHARM

40MG

N018790 001 Nov 29, 1983 Oct CAHN

AB

PRINSTON INC

20MG

A076796 001 Mar 26, 2004 Feb CAHN

AB

40MG

A076796 002 Mar 26, 2004 Feb CAHN

AB

80MG

A076796 003 Mar 26, 2004 Feb CAHN

@ SUN PHARM INDS INC

20MG

A091258 001 Apr 01, 2014 May DISC

@

40MG

A091258 002 Apr 01, 2014 May DISC

>A>

@

40MG

N018790 001 Nov 29, 1983 Oct CAHN

@

80MG

A091258 003 Apr 01, 2014 May DISC

@ WATSON LABS TEVA

20MG

A070449 001 Nov 22, 1985 May CAHN

@

80MG

A070528 001 Jan 07, 1986 May CAHN

AB WEST-WARD PHARMS INT

20MG

N018823 001 Nov 10, 1983 Jan CAHN

AB

40MG

N018823 002 Nov 10, 1983 Jan CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB AUROBINDO PHARMA LTD

100MG

A078787 001 Jan 31, 2008 Jan CAHN

AB

300MG

A078787 002 Jan 31, 2008 Jan CAHN

AB

400MG

A078787 003 Jan 31, 2008 Jan CAHN

>A>

@ CSPC OUYI PHARM CO

100MG

A075477 001 Mar 23, 2005 Oct CAHN

>A>

@

300MG

A075477 002 Mar 23, 2005 Oct CAHN

>A>

@

400MG

A075477 003 Mar 23, 2005 Oct CAHN

AB EPIC PHARMA LLC

100MG

A207099 001 Mar 24, 2017 Mar NEWA

AB

300MG

A207099 002 Mar 24, 2017 Mar NEWA

AB

400MG

A207099 003 Mar 24, 2017 Mar NEWA

>D>

@ IVAX SUB TEVA PHARMS

100MG

A075477 001 Mar 23, 2005 Oct CAHN

>D>

@

300MG

A075477 002 Mar 23, 2005 Oct CAHN

>D>

@

400MG

A075477 003 Mar 23, 2005 Oct CAHN

>A>

AB

JIANGSU HENGRUI MED

100MG

A091008 001 Oct 26, 2017 Oct NEWA

>A>

AB

300MG

A091008 002 Oct 26, 2017 Oct NEWA

		CAPSULE;ORAL					
		GABAPENTIN					
>A>	AB	400MG		A091008	003	Oct 26, 2017	Oct NEWA
		TABLET;ORAL					
		GABAPENTIN					
>A>	AB	CSPC OUYI PHARM CO	600MG	A207057	001	Oct 26, 2017	Oct NEWA
>A>	AB		800MG	A207057	002	Oct 26, 2017	Oct NEWA
	AB	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	May CAHN
	AB		800MG	A077662	002	Aug 18, 2006	May CAHN
	AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb NEWA
	AB		800MG	A205807	002	Mar 10, 2017	Feb NEWA
<u>GADOTERATE MEGLUMINE</u>							
		SOLUTION;INTRAVENOUS					
		DOTAREM					
	+	GUERBET	1.8845GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Sep CMS1
	+		1.884GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Aug NEWA
<u>GALANTAMINE HYDROBROMIDE</u>							
		TABLET;ORAL					
		GALANTAMINE HYDROBROMIDE					
>D>	AB	MYLAN	EQ 4MG BASE	A077603	001	Aug 28, 2008	Oct DISC
>A>	@		EQ 4MG BASE	A077603	001	Aug 28, 2008	Oct DISC
>D>	AB		EQ 8MG BASE	A077603	002	Aug 28, 2008	Oct DISC
>A>	@		EQ 8MG BASE	A077603	002	Aug 28, 2008	Oct DISC
>D>	AB		EQ 12MG BASE	A077603	003	Aug 28, 2008	Oct DISC
>A>	@		EQ 12MG BASE	A077603	003	Aug 28, 2008	Oct DISC
	AB	YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	Jul CMFD
	AB		EQ 8MG BASE	A077604	002	Feb 06, 2009	Jul CMFD
	AB		EQ 12MG BASE	A077604	003	Feb 06, 2009	Jul CMFD
<u>GANCICLOVIR</u>							
		SOLUTION;IV (INFUSION)					
		GANCICLOVIR					
	+	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb NEWA
<u>GATIFLOXACIN</u>							
		SOLUTION/DROPS;OPHTHALMIC					
		GATIFLOXACIN					
AT		SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb CAHN
<u>GEMCITABINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION					
		GEMCITABINE HYDROCHLORIDE					
>A>	AP	ACTAVIS TOTOWA	EQ 2GM BASE/VIAL	A079160	003	Jul 28, 2016	Oct NEWA
	AP	APOTEX INC	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	May NEWA
	AP		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	May NEWA
	AP		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	May NEWA
		SOLUTION;IV (INFUSION)					
		GEMCITABINE HYDROCHLORIDE					
	+	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017	Aug NEWA
	+		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017	Aug NEWA
	+		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017	Aug NEWA
	+		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017	Aug NEWA
<u>GEMFIBROZIL</u>							
		TABLET;ORAL					
		GEMFIBROZIL					
AB		CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan CAHN
<u>GEMIFLOXACIN MESYLATE</u>							
		TABLET;ORAL					
		FACTIVE					
AB	+	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar CAHN
<u>GENTAMICIN SULFATE</u>							
		CREAM;TOPICAL					
		GENTAMICIN SULFATE					
	@	FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984	Jan DISC
AT	!	PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan CHRS
	@	TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan DISC

OINTMENT;TOPICAL

GENTAMICIN SULFATE

AT	FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan CAHN
----	--------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

GENOPTIC

>D> AT	ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Oct CHRS
--------	----------	--------------	---------	-----	--------------	----------

>A> AT	!	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Oct CHRS
--------	---	--------------	---------	-----	--------------	----------

GENTAMICIN SULFATE

>D> AT	!	BAUSCH AND LOMB	EQ 0.3% BASE	A064048	001	May 11, 1994	Oct DISC
--------	---	-----------------	--------------	---------	-----	--------------	----------

>A>	@		EQ 0.3% BASE	A064048	001	May 11, 1994	Oct DISC
-----	---	--	--------------	---------	-----	--------------	----------

AT	SANDOZ INC	EQ 0.3% BASE	A062196	001		Mar CAHN
----	------------	--------------	---------	-----	--	----------

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Sep CFTG
----	---	-----------------	---------	---------	-----	--------------	----------

GLATIRAMER ACETATE

AP		MYLAN PHARMS INC	20MG/ML	A091646	001	Oct 03, 2017	Sep NEWA
----	--	------------------	---------	---------	-----	--------------	----------

AP			40MG/ML	A206936	001	Oct 03, 2017	Sep NEWA
----	--	--	---------	---------	-----	--------------	----------

GLECAPREVIR; PIBRENTASVIR

TABLET;ORAL

MAVYRET

+	!	ABBVIE INC	100MG;40MG	N209394	001	Aug 03, 2017	Aug NEWA
---	---	------------	------------	---------	-----	--------------	----------

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

@ EPIC PHARMA LLC

1MG

A077274	001	Oct 06, 2005	May CAHN
---------	-----	--------------	----------

@

2MG

A077274	002	Oct 06, 2005	May CAHN
---------	-----	--------------	----------

@

4MG

A077274	003	Oct 06, 2005	May CAHN
---------	-----	--------------	----------

AB		PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb CAHN
----	--	--------------	-----	---------	-----	--------------	----------

AB			2MG	A077370	002	Dec 23, 2005	Feb CAHN
----	--	--	-----	---------	-----	--------------	----------

AB			4MG	A077370	003	Dec 23, 2005	Feb CAHN
----	--	--	-----	---------	-----	--------------	----------

AB			8MG	A077370	004	Dec 23, 2005	Feb CAHN
----	--	--	-----	---------	-----	--------------	----------

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB		WATSON LABS TEVA	5MG	A074223	001	Feb 27, 1995	May CAHN
----	--	------------------	-----	---------	-----	--------------	----------

AB			10MG	A074223	002	Feb 27, 1995	May CAHN
----	--	--	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB		AUROBINDO PHARMA LTD	2.5MG	A206928	001	May 12, 2017	May NEWA
----	--	----------------------	-------	---------	-----	--------------	----------

AB			5MG	A206928	002	May 12, 2017	May NEWA
----	--	--	-----	---------	-----	--------------	----------

AB			10MG	A206928	003	May 12, 2017	May NEWA
----	--	--	------	---------	-----	--------------	----------

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		EPIC PHARMA LLC	2.5MG;250MG	A077507	001	Oct 27, 2005	May CAHN
----	--	-----------------	-------------	---------	-----	--------------	----------

AB			2.5MG;500MG	A077507	002	Oct 27, 2005	May CAHN
----	--	--	-------------	---------	-----	--------------	----------

AB			5MG;500MG	A077507	003	Oct 27, 2005	May CAHN
----	--	--	-----------	---------	-----	--------------	----------

METAGLIP

+	@	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan CRLD
---	---	----------------------	-------------	---------	-----	--------------	----------

+	@		2.5MG;500MG	N021460	002	Oct 21, 2002	Jan CRLD
---	---	--	-------------	---------	-----	--------------	----------

+	@		5MG;500MG	N021460	003	Oct 21, 2002	Jan CRLD
---	---	--	-----------	---------	-----	--------------	----------

GLUTETHIMIDE

TABLET;ORAL

GLUTETHIMIDE

@ UPSHER-SMITH LABS

500MG

A083234	002		Jun CAHN
---------	-----	--	----------

GLYBURIDE

TABLET;ORAL

GLYBURIDE

AB1		EPIC PHARMA LLC	1.25MG	A076257	001	Jun 27, 2002	May CAHN
-----	--	-----------------	--------	---------	-----	--------------	----------

AB1			2.5MG	A076257	002	Jun 27, 2002	May CAHN
-----	--	--	-------	---------	-----	--------------	----------

AB1			5MG	A076257	003	Jun 27, 2002	May CAHN
-----	--	--	-----	---------	-----	--------------	----------

AB2		IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb CAHN
-----	--	----------------	--------	---------	-----	--------------	----------

AB2			2.5MG	A206079	002	Sep 30, 2015	Feb CAHN
-----	--	--	-------	---------	-----	--------------	----------

AB2			5MG	A206079	003	Sep 30, 2015	Feb CAHN
-----	--	--	-----	---------	-----	--------------	----------

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL							
GLUCOVANCE							
	+ @	BRISTOL MYERS SQUIBB	2.5MG; 500MG	N021178	002	Jul 31, 2000	Aug DISC
	+ @		5MG; 500MG	N021178	003	Jul 31, 2000	Aug DISC
GLYBURIDE AND METFORMIN HYDROCHLORIDE							
AB	!	AUROBINDO PHARMA	2.5MG; 500MG	A077870	002	Nov 14, 2007	Aug CHRS
	@	IMPAX LABS INC	1.25MG; 250MG	A076731	001	Nov 19, 2004	Feb CAHN
	@		2.5MG; 500MG	A076731	002	Nov 19, 2004	Feb CAHN
	@		5MG; 500MG	A076731	003	Nov 19, 2004	Feb CAHN

GLYCINE

SOLUTION; IRRIGATION							
GLYCINE 1.5% IN PLASTIC CONTAINER							
AT		ICU MEDICAL INC	1.5GM/100ML	N018315	001		Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION							
GLYCOPYRROLATE							
AP		AMNEAL PHARMS CO	0.2MG/ML	A208973	001	Jun 15, 2017	Jun NEWA
>A> AA		FRESENIUS KABI USA	0.2MG/ML	A209328	001	Oct 27, 2017	Oct NEWA
AP		SOMERSET THERAPS LLC	0.2MG/ML	A207639	001	Jun 23, 2017	Jun NEWA
POWDER; INHALATION							
SEEBRI							
	+!	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Jan CAHN
TABLET; ORAL							
GLYCOPYRROLATE							
	@	EPIC PHARMA LLC	1MG	A040568	001	Dec 22, 2004	May CAHN
	@		2MG	A040568	002	Dec 22, 2004	May CAHN
AA		SANTOS BIOTECH	1MG	A091182	001	Feb 03, 2014	May CAHN
AA			2MG	A091182	002	Feb 03, 2014	May CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION							
UTIBRON							
	+!	SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Jan CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION							
FACTREL							
	@	WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Mar CAHN
	@		EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Mar CAHN
	@		EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Mar CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION							
CHORIONIC GONADOTROPIN							
	+!	FERRING	5,000 UNITS/VIAL	N017016	006		Jan CMFD

GOSERELIN ACETATE

IMPLANT; IMPLANTATION							
ZOLADEX							
	+!	TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726	001	Dec 29, 1989	May CAHN
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996	May CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC							
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN							
AT		AMRING PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Mar CAHN
NEOSPORIN							
AT	!	MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION							
GRANISETRON HYDROCHLORIDE							
	@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Aug CAHN
	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Aug CAHN
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Aug CAHN

INJECTABLE; INJECTION							
GRANISETRON HYDROCHLORIDE							
AP	MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Mar	NEWA
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Mar	NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Jan	NEWA
AP	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078534	001	Apr 30, 2009	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078531	001	Apr 30, 2009	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078531	002	Apr 30, 2009	Mar	CAHN
AP	WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan	CAHN
TABLET; ORAL							
GRANISETRON HYDROCHLORIDE							
	@ EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007	May	CAHN
AB	TARO PHARM	EQ 1MG BASE	A090817	001	May 28, 2010	Mar	CAHN
<u>GRISEOFULVIN, MICROCRYSTALLINE</u>							
TABLET; ORAL							
FULVICIN-U/F							
	@ CHARTWELL RX	250MG	A060569	002		Sep	CAHN
	@	500MG	A060569	001		Sep	CAHN
<u>GRISEOFULVIN, MICROSIZE</u>							
SUSPENSION; ORAL							
GRISEOFULVIN							
AB	CHARTWELL RX	125MG/5ML	A065200	001	Mar 02, 2005	Jun	CAHN
<u>GRISEOFULVIN, ULTRAMICROCRYSTALLINE</u>							
TABLET; ORAL							
FULVICIN P/G							
	@ CHARTWELL RX	125MG	A061996	001		Sep	CAHN
	@	250MG	A061996	002		Sep	CAHN
FULVICIN P/G 165							
	@ CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Sep	CAHN
FULVICIN P/G 330							
	@ CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Sep	CAHN
<u>GRISEOFULVIN, ULTRAMICROSIZE</u>							
TABLET; ORAL							
GRISEOFULVIN, ULTRAMICROSIZE							
AB	IMPAX LABS INC	125MG	A204371	001	Jan 09, 2014	Sep	CAHN
AB		250MG	A204371	002	Jan 09, 2014	Sep	CAHN
<u>GUAIFENESIN; HYDROCODONE BITARTRATE</u>							
SOLUTION; ORAL							
OBREDON							
	+ @ SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML	N205474	001	Nov 14, 2014	Aug	DISC
<u>HALCINONIDE</u>							
CREAM; TOPICAL							
HALOG-E							
	@ SUN PHARM INDS INC	0.1%	N018234	001		Aug	CAHN
OINTMENT; TOPICAL							
HALOG							
	+! SUN PHARM INDS INC	0.1%	N017824	001		Aug	CAHN
SOLUTION; TOPICAL							
HALOG							
	@ SUN PHARM INDS INC	0.1%	N017823	001		Aug	CAHN
<u>HALOBETASOL PROPIONATE</u>							
CREAM; TOPICAL							
HALOBETASOL PROPIONATE							
AB	! G AND W LABS	0.05%	A078162	001	Apr 24, 2007	Apr	CHRS
ULTRAVATE							
AB	+ SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Apr	CHRS
AB	+!	0.05%	N019967	001	Dec 27, 1990	Mar	CAHN

OINTMENT; TOPICAL									
HALOBETASOL PROPIONATE									
AB	!	G AND W LABS	0.05%	A077721	001	Sep 07, 2006	Jun	CHRS	
AB		PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Apr	CAHN	
ULTRAVATE									
AB	+	RANBAXY	0.05%	N019968	001	Dec 17, 1990	Jun	CHRS	
<u>HALOPERIDOL</u>									
TABLET; ORAL									
HALOPERIDOL									
	@	ANDA REPOSITORY	0.5MG	A071156	001	Jan 02, 1987	Sep	CAHN	
	@		1MG	A071157	001	Jan 02, 1987	Sep	CAHN	
	@		2MG	A071172	001	Jan 02, 1987	Sep	CAHN	
	@		5MG	A071212	001	Jan 07, 1988	Sep	CAHN	
	@		10MG	A071173	001	Jan 07, 1988	Sep	CAHN	
	@		20MG	A071177	001	Jan 07, 1988	Sep	CAHN	
	@	FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb	CAHN	
<u>HALOPERIDOL DECANOATE</u>									
INJECTABLE; INJECTION									
HALOPERIDOL DECANOATE									
AO		GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017	May	NEWA	
AO			EQ 100MG BASE/ML	A205241	002	May 12, 2017	May	NEWA	
	@	SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar	CAHN	
	@		EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar	CAHN	
<u>HALOPERIDOL LACTATE</u>									
CONCENTRATE; ORAL									
HALOPERIDOL									
AA		PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May	CAHN	
INJECTABLE; INJECTION									
HALOPERIDOL									
AP		AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug	NEWA	
	@	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Aug	CAHN	
	@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Aug	CAHN	
	@	SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar	CAHN	
<u>HEPARIN SODIUM</u>									
INJECTABLE; INJECTION									
HEPARIN SODIUM									
AP		GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan	NEWA	
	@	WEST-WARD PHARMS INT	1,000 UNITS/ML	N017007	001		Jul	CAHN	
	@		2,500 UNITS/ML	N017007	007		Jul	CAHN	
	@		5,000 UNITS/ML	N017007	002		Jul	CAHN	
	@		5,000 UNITS/0.5ML	N017007	010		Jul	CAHN	
	@		7,500 UNITS/ML	N017007	003		Jul	CAHN	
	@		10,000 UNITS/ML	N017007	004		Jul	CAHN	
	@		15,000 UNITS/ML	N017007	005		Jul	CAHN	
	@		20,000 UNITS/ML	N017007	006		Jul	CAHN	
<u>HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE</u>									
SYRUP; ORAL									
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE									
AA		ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb	NEWA	
AA		BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb	NEWA	
AA		NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan	NEWA	
AA		PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan	NEWA	
TABLET; ORAL									
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE									
AA		AVANTHI INC	1.5MG; 5MG	A207176	001	Aug 07, 2017	Jul	NEWA	
TUSSIGON									
AA	!	KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Feb	CAHN	
<u>HYDRALAZINE HYDROCHLORIDE</u>									
TABLET; ORAL									
HYDRALAZINE HYDROCHLORIDE									
	@	ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986	Sep	CAHN	
	@		25MG	A089258	001	May 05, 1986	Sep	CAHN	
	@		50MG	A089259	001	May 05, 1986	Sep	CAHN	
	@		100MG	A088729	001	Apr 11, 1985	Sep	CAHN	
AA		SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	May	NEWA	
AA			25MG	A205236	002	May 26, 2017	May	NEWA	

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		50MG	A205236	003	May 26, 2017	May NEWA
AA		100MG	A205236	004	May 26, 2017	May NEWA
AA	TECH ORGANIZED	10MG	A205236	001	May 26, 2017	Sep CAHN
AA		25MG	A205236	002	May 26, 2017	Sep CAHN
AA		50MG	A205236	003	May 26, 2017	Sep CAHN
AA		100MG	A205236	004	May 26, 2017	Sep CAHN
	@ UPSHER-SMITH LABS	10MG	A083241	001		Jun CAHN
	@	25MG	A083560	001		Jun CAHN
	@	50MG	A083561	001		Jun CAHN
	@	50MG	A085088	001		Sep CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb CAHN
	TABLET; ORAL					
	HYDROCHLOROTHIAZIDE					
	@ JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Sep DISC
	@	50MG	A040809	002	Sep 04, 2007	Sep DISC
AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb CAHN
AB		50MG	A040412	002	Mar 29, 2002	Feb CAHN
AB	TECH ORGANIZED	25MG	A203018	001	Jul 23, 2014	Sep CAHN
AB		50MG	A203018	002	Jul 23, 2014	Sep CAHN
	@ WATSON LABS TEVA	50MG	A083232	001		May CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ATLAS PHARMS LLC	12.5MG; 150MG	A203036	001	Jan 15, 2016	Mar CAHN
AB		12.5MG; 300MG	A203036	002	Jan 15, 2016	Mar CAHN
AB		25MG; 300MG	A203036	003	Jan 15, 2016	Mar CAHN
AB	UNICHEM LABS LTD	12.5MG; 150MG	A207018	001	Sep 19, 2017	Sep NEWA
AB		12.5MG; 300MG	A207018	002	Sep 19, 2017	Sep NEWA
AB	WEST-WARD PHARMS INT	25MG; 300MG	A090351	003	Jun 08, 2017	May NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG; 10MG	A204058	001	May 23, 2017	May NEWA
AB		12.5MG; 20MG	A204058	002	May 23, 2017	May NEWA
AB		25MG; 20MG	A204058	003	May 23, 2017	May NEWA
	PRINZIDE					
	+ @ MERCK	12.5MG; 10MG	N019778	003	Nov 18, 1993	Jan CRLD
	+ @	12.5MG; 20MG	N019778	001	Feb 16, 1989	Jan CRLD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>A>	AB	PRINSTON INC	12.5MG; 50MG	A204901	001	Nov 06, 2017	Oct NEWA
>A>	AB		12.5MG; 100MG	A204901	002	Nov 06, 2017	Oct NEWA
>A>	AB		25MG; 100MG	A204901	003	Nov 06, 2017	Oct NEWA
	AB	UNICHEM LABS LTD	12.5MG; 50MG	A204832	001	Jul 21, 2017	Jul NEWA
	AB		12.5MG; 100MG	A204832	002	Jul 21, 2017	Jul NEWA
	AB		25MG; 100MG	A204832	003	Jul 21, 2017	Jul NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ CHARTWELL RX	12.5MG; 7.5MG	A090096	001	Sep 25, 2008	Mar CAHN
	@	12.5MG; 15MG	A090096	002	Sep 25, 2008	Mar CAHN
	@	25MG; 15MG	A090096	003	Sep 25, 2008	Mar CAHN
AB	HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
AB		12.5MG; 15MG	A202150	002	Mar 07, 2014	Jan CMS1
AB		25MG; 15MG	A202150	003	Mar 07, 2014	Jan CMS1

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;20MG	A204233	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A204233	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A204233	003	Apr 24, 2017	Apr	NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;20MG	A205391	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A205391	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A205391	003	Apr 24, 2017	Apr	NEWA
AB	PRINSTON INC	12.5MG;20MG	A207804	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A207804	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A207804	003	Apr 24, 2017	Apr	NEWA
AB	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A200532	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A200532	003	Apr 24, 2017	Apr	NEWA
AB	TORRENT PHARMS LTD	12.5MG;20MG	A206515	001	May 03, 2017	Apr	NEWA
AB		12.5MG;40MG	A206515	002	May 03, 2017	Apr	NEWA
AB		25MG;40MG	A206515	003	May 03, 2017	Apr	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Jun	CMS1
AB		12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Jun	CMS1
AB		25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Jun	CMS1

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

@ UPSHER SMITH	25MG;25MG	A087553	001			Jun	CAHN
----------------	-----------	---------	-----	--	--	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

>A> AB	PRINSTON INC	12.5MG;40MG	A209028	001	Nov 06, 2017	Oct	NEWA
>A> AB		12.5MG;80MG	A209028	002	Nov 06, 2017	Oct	NEWA
>A> AB		25MG;80MG	A209028	003	Nov 06, 2017	Oct	NEWA
AB	ZYDUS PHARMS USA INC	12.5MG;40MG	A204221	001	Aug 15, 2017	Jul	NEWA
AB		12.5MG;80MG	A204221	002	Aug 15, 2017	Jul	NEWA
AB		25MG;80MG	A204221	003	Aug 15, 2017	Jul	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	May	CAHN
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	May	CAHN
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	May	CAHN
AB		25MG;160MG	A201662	004	Mar 21, 2013	May	CAHN
AB		25MG;320MG	A201662	005	Mar 21, 2013	May	CAHN
AB	WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013	May	CAHN
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	May	CAHN
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	May	CAHN
AB		25MG;160MG	A091519	004	Mar 21, 2013	May	CAHN
AB		25MG;320MG	A091519	005	Mar 21, 2013	May	CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan	NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan	NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan	NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan	NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	! AMNEAL PHARMS NY	7.5MG;200MG	A076642	001	Oct 12, 2004	Sep	CHRS
	VICOPROFEN						
+	@ ABBVIE	7.5MG;200MG	N020716	001	Sep 23, 1997	Sep	DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ TRIS PHARMA INC

5MG/5ML; 60MG/5ML

A203839 001 Oct 28, 2014 Sep DISC

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT ! FOUGERA PHARMS INC

1%

A080693 003

Jan CAHN

AT ! 2.5%

A089414 001 Dec 16, 1986

Jan CAHN

SYNACORT

@ MEDICIS

1%

A087458 001

Jul DISC

@

2.5%

A087457 001

Jul DISC

LOTION; TOPICAL

STIE-CORT

@ PERRIGO CO

1%

A089066 001 Nov 25, 1985

Apr CAHN

AT 2.5%

A089074 001 Nov 26, 1985

Apr CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT ! FOUGERA PHARMS INC 2.5%

A081203 001 May 28, 1993

Jan CAHN

HYDROCORTISONE IN ABSORBASE

AT CMP PHARMA INC

1%

A088138 001 Sep 06, 1985

Apr CAHN

TABLET; ORAL

HYDROCORTISONE

AB PII

5MG

A207029 001 Apr 27, 2017

Apr NEWA

AB 10MG

A207029 002 Apr 27, 2017

Apr NEWA

AB 20MG

A207029 003 Apr 27, 2017

Apr NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+! MYLAN SPECIALITY LP 10%

N017351 001 Feb 10, 1982 Mar CAHN

CREAM; TOPICAL

HYDROCORTISONE ACETATE

@ FERNDAL LABS

2.5%

A040259 001 Jul 29, 1999 Sep DISC

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+! MONARCH PHARMS 0.5%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050218 001 Aug 09, 1985 Feb CAHN

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX MYLAN SPECIALITY LP 1%; 1%

A086457 001

Mar CAHN

PROCTOFOAM HC

BX MYLAN SPECIALITY LP 1%; 1%

A086195 001

Mar CAHN

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

@ HOSPIRA

EQ 100MG BASE/VIAL

A040666 001 Apr 06, 2006

Sep DISC

SOLU-CORTEF

+! PHARMACIA AND UPJOHN EQ 100MG BASE/VIAL

N009866 001

Sep CTEC

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB ! TARO 0.2%

A075042 001 Aug 25, 1998

Apr CAHN

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

! TARO 0.2%

A075043 001 Aug 25, 1998

Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

AT +! MONARCH PHARMS 1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

N050479 001

Apr CAHN

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE									
AT	AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Mar	CAHN		
AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb	CAHN		

SUSPENSION/DROPS;OPHTHALMIC
CORTISPORIN

	@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001		Apr	CAHN	
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb	CAHN	

SUSPENSION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE									
AT	AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Mar	CAHN		
AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985	Feb	CAHN		

HYDROFLUMETHIAZIDE

TABLET;ORAL

SALURON									
+	SHIRE LLC	50MG	N011949	001		Sep	CTEC		

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID									
AP	+	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009	Jan	CAHN	
AP	+		2MG/ML	N019034	004	Apr 30, 2009	Jan	CAHN	
AP	+		4MG/ML	N019034	005	Apr 30, 2009	Jan	CAHN	

DILAUDID-HP									
AP	+	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Jan	CAHN	
	@		250MG/VIAL	N019034	002	Aug 04, 1994	Jan	CAHN	

HYDROMORPHONE HYDROCHLORIDE

	@	HOSPIRA	10MG/ML	A074598	001	Jun 19, 1997	Sep	DISC	
--	---	---------	---------	---------	-----	--------------	-----	------	--

SOLUTION;ORAL

DILAUDID									
AA	+	RHODES PHARMS	5MG/5ML	N019891	001	Dec 07, 1992	Jun	CAHN	
HYDROMORPHONE HYDROCHLORIDE									
>A> AA		ASCENT PHARMS INC	5MG/5ML	A210176	001	Oct 27, 2017	Oct	NEWA	

TABLET;ORAL

DILAUDID									
AB	+	RHODES PHARMS	2MG	N019892	003	Nov 09, 2007	Jun	CAHN	
AB	+		4MG	N019892	002	Nov 09, 2007	Jun	CAHN	
AB	+		8MG	N019892	001	Dec 07, 1992	Jun	CAHN	

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE									
AB		PADDOCK LLC	32MG	A204278	004	Sep 20, 2017	Sep	NEWA	

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

HYDROXOCOBALAMIN									
!	ACTAVIS LLC	1MG/ML	A085998	001		Feb	CAHN		

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

VISTARIL									
+	@	PFIZER	25MG/ML	N011111	001		Jan	CRLD	
+	@		50MG/ML	N011111	002		Jan	CRLD	

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE									
	@	AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	Jan	CMS1	
	@		25MG	A087871	003	Dec 20, 1982	Jan	CMS1	
AB		BAYSHORE PHARMS LLC	10MG	A207120	001	Mar 29, 2017	Sep	CAHN	
AB			50MG	A207122	001	Mar 29, 2017	Sep	CAHN	
AB		NUVO PHARM INC	10MG	A207120	001	Mar 29, 2017	Mar	NEWA	
AB			25MG	A207121	001	Mar 29, 2017	Mar	NEWA	
AB			50MG	A207122	001	Mar 29, 2017	Mar	NEWA	
AB		PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb	CAHN	
AB			25MG	A040574	001	May 27, 2005	Feb	CAHN	
AB			50MG	A040580	001	May 27, 2005	Feb	CAHN	
	@	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Apr	DISC	

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@ 25MG
@ 50MG

A040899 002 Jun 10, 2008 Apr DISC
A040899 003 Jun 10, 2008 Apr DISC

IBANDRONATE SODIUM

TABLET;ORAL

IBANDRONATE SODIUM

>A> AB MACLEODS PHARMS LTD EQ 150MG BASE
@ MYLAN PHARMS INC EQ 150MG BASE
AB WATSON LABS TEVA EQ 150MG BASE

A206887 001 Oct 31, 2017 Oct NEWA
A078995 001 Mar 19, 2012 May DISC
A079003 001 Mar 20, 2012 May CAHN

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

AB ! ACTAVIS MID ATLANTIC 100MG/5ML
AB TARO 100MG/5ML

A074978 001 Mar 25, 1998 May CAHN
A209204 001 Jun 23, 2017 Jun NEWA

MOTRIN

+ @ MCNEIL CONSUMER 100MG/5ML

N019842 001 Sep 19, 1989 Jan CRLD

TABLET;ORAL

IBUPROFEN

@ MYLAN PHARMS INC 400MG
@ PLIVA 400MG
@ 600MG
@ 800MG

A070045 001 Sep 24, 1985 Mar CAHN
A071666 001 Jun 18, 1987 Aug CAHN
A071667 001 Jun 18, 1987 Aug CAHN
A071668 001 Jun 18, 1987 Aug CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

BX @ WATSON LABS 400MG;5MG
400MG;5MG

A078394 001 Nov 26, 2007 Jun DISC
A078394 001 Nov 26, 2007 Apr CTEC

ICOSAPENT ETHYL

CAPSULE;ORAL

VASCEPA

+ AMARIN PHARMS 500MG

N202057 002 Feb 16, 2017 Mar NEWA

IDOXURIDINE

SOLUTION/DROPS;OPHTHALMIC

DENDRID

+ @ ALCON 0.1%

N014169 001 Jul DISC

IFOSFAMIDE; MESNA

INJECTABLE;INTRAVENOUS

IFOSFAMIDE/MESNA KIT

@ TEVA PHARMS USA 1GM/20ML;1GM/10ML
(50MG/ML;100MG/ML)
@ 3GM/60ML;1GM/10ML
(50MG/ML;100MG/ML)

A075874 001 Feb 26, 2002 Mar DISC
A075874 002 Feb 26, 2002 Mar DISC

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB MYLAN PHARMS INC EQ 100MG BASE
AB EQ 400MG BASE

A204644 001 Jun 21, 2017 Jun NEWA
A204644 002 Jun 21, 2017 Jun NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB MALLINCKRODT INC 10MG
AB 25MG
OXFORD PHARMS 10MG
25MG
@ PAR PHARM 10MG

A087846 002 May 22, 1984 Aug CMS1
A087846 003 May 22, 1984 Aug CMS1
A040751 003 Feb 28, 2008 May CMS1
A040751 002 Feb 28, 2008 May CMS1
A089422 001 Jul 14, 1987 Jul DISC

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

@ MYLAN PHARMS INC EQ 75MG HCL
@ EQ 100MG HCL
@ EQ 125MG HCL
@ EQ 150MG HCL

A202338 001 Jun 28, 2013 Jun DISC
A202338 002 Jun 28, 2013 Jun DISC
A202338 003 Jun 28, 2013 Jun DISC
A202338 004 Jun 28, 2013 Jun DISC

INDACATEROL MALEATEPOWDER; INHALATION
ARCAPTA NEOHALER

+! SUNOVION PHARMS INC EQ 75MCG BASE

N022383 001 Jul 01, 2011 Jan CAHN

INDOMETHACINCAPSULE; ORAL
INDOMETHACIN@ CHARTWELL MOLECULES 25MG
@ 50MG
@ 50MGN018829 002 Aug 06, 1984 Feb CAHN
A070651 001 Mar 05, 1986 Apr CAHN
N018829 001 Aug 06, 1984 Feb CAHNAB JUBILANT GENERICS 25MG
AB 50MGA205215 001 Aug 25, 2017 Aug NEWA
A205215 002 Aug 25, 2017 Aug NEWACAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACINAB CHARTWELL RX 75MG
AB GLENMARK PHARMS LTD 75MG
AB NOVAST LABS LTD 75MG
@ WATSON LABS INC 75MG
AB ZYDUS PHARMS USA INC 75MGA200529 001 Nov 30, 2010 Jun CAHN
A203501 001 Jun 22, 2017 Jun NEWA
A204853 001 May 08, 2017 Apr NEWA
A202572 001 Dec 09, 2013 Feb DISC
A202711 001 Sep 25, 2017 Sep NEWAINDOMETHACIN SODIUMINJECTABLE; INJECTION
INDOMETHACIN SODIUM

AP NAVINTA LLC EQ 1MG BASE/VIAL

A206561 001 Jul 19, 2017 Jul NEWA

INSULIN ASPART RECOMBINANTSOLUTION; IV (INFUSION), SUBCUTANEOUS
FIASP

+! NOVO NORDISK INC 1000 UNITS/10ML (100 UNITS/ML)

N208751 001 Sep 29, 2017 Sep NEWA

SOLUTION; SUBCUTANEOUS
FIASP FLEXTOUCH

+! NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N208751 002 Sep 29, 2017 Sep NEWA

IODIPAMIDE MEGLUMINEINJECTABLE; INJECTION
CHOLOGRAFIN MEGLUMINE

+ @ BRACCO 52%

N009321 003 Aug DISC

IODIXANOLINJECTABLE; INJECTION
VISIPAQUE 270

@ GE HEALTHCARE 55%

N020808 001 Aug 29, 1997 Aug DISC

IOPAMIDOLINJECTABLE; INJECTION
SCANLUX-300

AP MYLAN IRELAND LTD 61%

A090394 001 Jun 18, 2010 Jan CAHN

AP SANOCHEMIA CORP USA 61%

A090394 001 Jun 18, 2010 Feb CAHN

SCANLUX-370

AP MYLAN IRELAND LTD 76%

A090394 002 Jun 18, 2010 Jan CAHN

AP SANOCHEMIA CORP USA 76%

A090394 002 Jun 18, 2010 Feb CAHN

IOPROMIDEINJECTABLE; INJECTION
ULTRAVIST 150

+ @ BAYER HLTHCARE 31.2%

N020220 004 May 10, 1995 Aug DISC

ULTRAVIST 300 IN PLASTIC CONTAINER

+ @ BAYER HLTHCARE 62.3%

N020220 005 Nov 18, 2008 Aug DISC

IPRATROPIUM BROMIDESOLUTION; INHALATION
IPRATROPIUM BROMIDE

@ BAUSCH AND LOMB INC 0.02%

A075835 001 Oct 15, 2001 Jul DISC

IRBESARTANTABLET; ORAL
IRBESARTAN

>D>	AB	AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015	Oct DISC
>A>		@	75MG	A203685	001	Dec 10, 2015	Oct DISC
>D>	AB		150MG	A203685	002	Dec 10, 2015	Oct DISC
>A>		@	150MG	A203685	002	Dec 10, 2015	Oct DISC
>D>	AB		300MG	A203685	003	Dec 10, 2015	Oct DISC
>A>		@	300MG	A203685	003	Dec 10, 2015	Oct DISC

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP		INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May NEWA
AP			100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May NEWA
AP		INTAS PHARMS USA	40MG/2ML (20MG/ML)	A203054	001	Aug 31, 2017	Aug NEWA
AP			100MG/5ML (20MG/ML)	A203054	002	Aug 31, 2017	Aug NEWA
		@ SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jul DISC
		@	100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jul DISC
AP		WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jan CAHN
AP			100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jan CAHN

INJECTABLE, LIPOSOMAL; IV (INFUSION)
ONIVYDE
+! IPSEN INC EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) N207793 001 Oct 22, 2015 Apr CAHN

ISONIAZIDINJECTABLE; INJECTION
ISONIAZID

! SANDOZ INC 100MG/ML A040648 001 Jul 05, 2005 Mar CAHN

SYRUP; ORAL

ISONIAZID

! CMP PHARMA INC 50MG/5ML A088235 001 Nov 10, 1983 Apr CAHN

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

AP		NEXUS PHARMS	0.2MG/ML	A206961	001	Aug 02, 2017	Jul NEWA
AP		ISUPREL					
AP		+! HOSPIRA	0.2MG/ML	N010515	001		Jul CTEC

ISOSORBIDE DINITRATETABLET; SUBLINGUAL
ISOSORBIDE DINITRATE

@ WATSON LABS TEVA 5MG A086031 001 Sep 29, 1987 May CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

@ IMPAX LABS INC 40MG A040723 001 Mar 17, 2008 Feb CAHN

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

>A>	AB	ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017	Oct NEWA
>A>	AB		60MG	A209684	002	Oct 24, 2017	Oct NEWA
>A>	AB		120MG	A209684	003	Oct 24, 2017	Oct NEWA

ISOTRETINOINCAPSULE; ORAL
ABSORICA

BX	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012	Aug CAHN
BX	+		20MG	N021951	002	May 25, 2012	Aug CAHN
	+		25MG	N021951	005	Aug 15, 2014	Aug CAHN
BX	+		30MG	N021951	003	May 25, 2012	Aug CAHN
	+		35MG	N021951	006	Aug 15, 2014	Aug CAHN
BX	+		40MG	N021951	004	May 25, 2012	Aug CAHN

ISOTRETINOIN

AB		AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Sep NEWA
AB			20MG	A207792	002	Sep 29, 2017	Sep NEWA
AB			30MG	A207792	003	Sep 29, 2017	Sep NEWA
AB			40MG	A207792	004	Sep 29, 2017	Sep NEWA

ISRADIPINE

	CAPSULE;ORAL						
	DYNACIRC						
	+ @ SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990	Sep	CRLD
	+ @	5MG	N019546	002	Dec 20, 1990	Sep	CRLD
	ISRADIPINE						
AB	WATSON LABS TEVA	2.5MG	A077317	001	Jan 05, 2006	May	CAHN
AB	!	5MG	A077317	002	Jan 05, 2006	May	CAHN

ITRACONAZOLE

	CAPSULE;ORAL						
	ITRACONAZOLE						
AB	ALKEM LABS LTD	100MG	A208591	001	Jun 12, 2017	May	NEWA
AB	JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	100MG	A204672	001	Sep 19, 2017	Sep	NEWA

KANAMYCIN SULFATE

	INJECTABLE;INJECTION						
	KANAMYCIN						
	@ WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001		Jan	CAHN
	@	EQ 500MG BASE/2ML	A062324	002		Jan	CAHN
	@	EQ 1GM BASE/3ML	A062324	003		Jan	CAHN

KETOCONAZOLE

	AEROSOL, FOAM;TOPICAL						
	EXTINA						
AT	+! MYLAN PHARMS INC	2%	N021738	001	Jun 12, 2007	Jan	CAHN
	CREAM;TOPICAL						
	NIZORAL						
	+ @ JANSSEN PHARMA	2%	N019084	001	Dec 31, 1985	May	CRLD
	TABLET;ORAL						
	NIZORAL						
>D>	@ JANSSEN PHARMS	200MG	N018533	001		Oct	CRLD
>A>	+ @	200MG	N018533	001		Oct	CRLD

KETOPROFEN

	CAPSULE;ORAL						
	KETOPROFEN						
	HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Feb	CAHN
AB		50MG	A074014	002	Jan 29, 1993	Feb	CAHN
AB		75MG	A074014	003	Jan 29, 1993	Feb	CAHN

KETOROLAC TROMETHAMINE

	INJECTABLE;INJECTION						
	KETOROLAC TROMETHAMINE						
	@ BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001	Aug	CAHN
	@	30MG/ML	A075631	001	Jun 29, 2001	Aug	CAHN
AP	CYCLE PHARMS LTD	30MG/ML	A209900	001	Sep 15, 2017	Sep	NEWA
>D> AP	MYLAN LABS LTD	15MG/ML	A078299	001	Jul 16, 2007	Oct	DISC
>A>	@	15MG/ML	A078299	001	Jul 16, 2007	Oct	DISC
>D> AP		15MG/ML	A201155	001	Aug 04, 2014	Oct	DISC
>A>	@	15MG/ML	A201155	001	Aug 04, 2014	Oct	DISC
>D> AP		30MG/ML	A078299	002	Jul 16, 2007	Oct	DISC
>A>	@	30MG/ML	A078299	002	Jul 16, 2007	Oct	DISC
>D> AP		30MG/ML	A201155	002	Aug 04, 2014	Oct	DISC
>A>	@	30MG/ML	A201155	002	Aug 04, 2014	Oct	DISC
	@ SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004	Mar	CAHN
AP		30MG/ML	A076271	002	Oct 06, 2004	Mar	CAHN
	SOLUTION/DROPS;OPHTHALMIC						
	ACUVAIL						
	+! ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Sep	CTEC
	KETOROLAC TROMETHAMINE						
AT	SANDOZ INC	0.5%	A076583	001	Nov 05, 2009	Feb	CAHN

L-GLUTAMINE

	FOR SOLUTION;ORAL						
	ENDARI						
	+ EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jul	NEWA
	NUTRESTORE						
	+! EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jul	CAIN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

	@ BAXTER HLTHCARE CORP	5MG/ML	A 076051	001	Jul 05, 2002	Aug CAHN
AP	SAGENT AGILA LLC	5MG/ML	A 079134	001	Feb 03, 2010	Feb CAHN

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	INNOGENIX	100MG	A 075215	001	Jul 29, 1999	Sep CAHN
AB		200MG	A 075215	002	Jul 29, 1999	Sep CAHN
AB		300MG	A 075215	003	Jul 29, 1999	Sep CAHN
AB	ZYDUS PHARMS USA INC	100MG	A 207743	001	Sep 19, 2017	Sep NEWA
AB		200MG	A 207743	002	Sep 19, 2017	Sep NEWA
AB		300MG	A 207743	003	Sep 19, 2017	Sep NEWA

LACOSAMIDE

SOLUTION; ORAL

VIMPAT

>D> AA	+! UCB INC	10MG/ML	N 022255	001	Apr 20, 2010	Oct CTEC
>A>	+!	10MG/ML	N 022255	001	Apr 20, 2010	Oct CTEC

TABLET; ORAL

VIMPAT

>D> AB	+ UCB INC	50MG	N 022253	001	Oct 28, 2008	Oct CTEC
>A>	+	50MG	N 022253	001	Oct 28, 2008	Oct CTEC
>D> AB	+	100MG	N 022253	002	Oct 28, 2008	Oct CTEC
>A>	+	100MG	N 022253	002	Oct 28, 2008	Oct CTEC
>D> AB	+	150MG	N 022253	003	Oct 28, 2008	Oct CTEC
>A>	+	150MG	N 022253	003	Oct 28, 2008	Oct CTEC
>D> AB	+!	200MG	N 022253	004	Oct 28, 2008	Oct CTEC
>A>	+!	200MG	N 022253	004	Oct 28, 2008	Oct CTEC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	PHARM ASSOC	10GM/15ML	A 074623	001	Jul 30, 1996	May CAHN
----	-------------	-----------	----------	-----	--------------	----------

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

AB	CIPLA LTD	150MG	A 077221	001	Mar 03, 2017	Feb NEWA
AB		300MG	A 077221	002	Mar 03, 2017	Feb NEWA
AB	ECI PHARMS LLC	150MG	A 203586	001	Nov 21, 2016	Aug CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG; 300MG	A 077558	001	May 05, 2017	Apr NEWA
BX	PHARMACARE	150MG; 300MG	N 022018	001	Mar 17, 2017	Mar NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ MYLAN LABS LTD

@

@

@

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	5MG	A 079099	001	Feb 19, 2009	May CAHN
AB		25MG	A 079099	002	Feb 19, 2009	May CAHN
	@ MYLAN	5MG	A 076630	001	Jan 22, 2009	Jun DISC
	@	25MG	A 076630	002	Jan 22, 2009	Jun DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	250MG	A 203733	001	Nov 13, 2013	Apr CAHN
AB	HANDA PHARMS LLC	25MG	A 202887	001	Jun 17, 2013	Jan CAHN
AB		50MG	A 202887	002	Jun 17, 2013	Jan CAHN
AB		100MG	A 202887	003	Jun 17, 2013	Jan CAHN
AB		200MG	A 202887	004	Jun 17, 2013	Jan CAHN

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	INVENTIA HLTHCARE	15MG	A205868	001	Aug 30, 2017	Aug NEWA
AB		30MG	A205868	002	Aug 30, 2017	Aug NEWA
AB	KREMERS URBAN PHARMS	15MG	A207156	001	Sep 28, 2017	Sep NEWA
AB		30MG	A207156	002	Sep 28, 2017	Sep NEWA

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL
PREVACID

AB	+ TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Sep CTEC
AB	+!	30MG	N021428	002	Aug 30, 2002	Sep CTEC

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB	TEVA PHARMS USA	15MG	A208784	001	Sep 21, 2017	Sep NEWA
AB		30MG	A208784	002	Sep 21, 2017	Sep NEWA

LANTHANUM CARBONATETABLET, CHEWABLE;ORAL
FOSRENOL

AB	+ SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul CFTG
AB	+	EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul CFTG
AB	+!	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul CFTG

LANTHANUM CARBONATE

AB	NATCO PHARMA LTD	EQ 500MG BASE	A090978	001	Aug 11, 2017	Jul NEWA
AB		EQ 750MG BASE	A090978	002	Aug 11, 2017	Jul NEWA
AB		EQ 1GM BASE	A090978	003	Aug 11, 2017	Jul NEWA

LATANOPROSTSOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar CAHN
AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb CAHN

LETROZOLETABLET;ORAL
LETROZOLE

	@ KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jun DISC
	@ LANNETT HOLDINGS INC	2.5MG	A202048	001	Oct 29, 2014	Jun DISC
>D> AB	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011	Oct DISC
>A>	@	2.5MG	A091466	001	Jun 03, 2011	Oct DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+!	NOVARTIS PHARMS CORP	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017	May NEWA
----	----------------------	-----------------------------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

>D>	!	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999	Oct CTEC
>A>	!		EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999	Oct CTEC
AP		MYLAN LABS LTD	EQ 100MG BASE/VIAL	A203800	001	May 19, 2017	May NEWA
AP			EQ 200MG BASE/VIAL	A203800	002	May 19, 2017	May NEWA
AP			EQ 350MG BASE/VIAL	A203800	003	May 19, 2017	May NEWA
>A>	AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A209110	001	Oct 26, 2017	Oct NEWA

TABLET;ORAL

LEUCOVORIN CALCIUM

@	EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	May CAHN
@		EQ 25MG BASE	A074544	002	Aug 28, 1997	May CAHN

WELLCOVORIN

+	@	GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983	Jun CRLD
+	@		EQ 25MG BASE	N018342	002	Jul 08, 1983	Jun CRLD

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan NEWA
----	----------------------	---------------	---------	-----	--------------	----------

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jul CAHN
	LEVETIRACETAM IN SODIUM CHLORIDE					
>A> AP	GLAND PHARMA LTD	500MG/100ML (5MG/ML)	A206880	001	Oct 25, 2017	Oct NEWA
>A> AP		1000MG/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Oct NEWA
>A> AP		1500MG/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Oct NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA	ALLIED PHARMA INC	100MG/ML	A078582	001	Jan 15, 2009	Mar CAHN
AA	AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan CAHN

TABLET;ORAL

LEVETIRACETAM

AB	ACI HEALTHCARE LTD	250MG	A078042	001	Jan 15, 2009	Jun CAHN
AB		500MG	A078042	002	Jan 15, 2009	Jun CAHN
AB		750MG	A078042	003	Jan 15, 2009	Jun CAHN
AB		1GM	A078042	004	Jan 15, 2009	Jun CAHN
AB	ACIC PHARMS	250MG	A090767	001	Jul 28, 2010	Sep CAHN
AB		500MG	A090767	002	Jul 28, 2010	Sep CAHN
AB		750MG	A090767	003	Jul 28, 2010	Sep CAHN
AB		1GM	A090767	004	Jul 28, 2010	Sep CAHN
AB	ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Mar CAHN
AB		500MG	A078042	002	Jan 15, 2009	Mar CAHN
AB		750MG	A078042	003	Jan 15, 2009	Mar CAHN
AB		1GM	A078042	004	Jan 15, 2009	Mar CAHN
	ROWEEPPRA					
AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Apr NEWA
AB		500MG	A090906	001	Nov 05, 2010	Apr CTNA
AB		750MG	A090906	003	Oct 31, 2016	Apr NEWA
AB		1GM	A090906	004	Oct 31, 2016	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016	Mar CAHN
AB		750MG	A204754	002	Aug 26, 2016	Mar CAHN
	@ MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr DISC
	@	750MG	A200475	002	Dec 19, 2011	Apr DISC
	@	1GM	A200475	003	Dec 07, 2015	Apr DISC
AB	PHARMTAK INC	500MG	A207175	001	Sep 28, 2017	Sep NEWA
AB		750MG	A207175	002	Sep 28, 2017	Sep NEWA
AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb CAHN
AB		750MG	A202533	002	Jul 20, 2012	Feb CAHN
AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb CAHN
AB		750MG	A091291	002	Sep 12, 2011	Feb CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ BAUSCH AND LOMB	0.25%	A074307	001	Mar 04, 1994	Jul DISC
AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb CAHN

LEVOCARNITINE

INJECTABLE;INJECTION

CARNITOR

AP	+! LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar CAHN
----	------------------------	----------	---------	-----	--------------	----------

SOLUTION;ORAL

CARNITOR

	@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar CAHN
AA	+!	1GM/10ML	N019257	001	Apr 10, 1986	Mar CAHN
	CARNITOR SF					
AA	+ LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar CAHN

TABLET;ORAL

CARNITOR

AB	+! LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar CAHN
	LEVOCARNITINE					
>D> AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Oct CAHN
AB		330MG	A076858	001	Sep 20, 2004	Feb CAHN
>A> AB	RISING PHARMS INC	330MG	A076858	001	Sep 20, 2004	Oct CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE							
AA	SILARX PHARMS INC	2.5MG/ML	A204599	001	May 15, 2017	May	NEWA
XYZAL							
AA	+! SANOFI-AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008	Jul	CAHN
TABLET;ORAL							
LEVOCETIRIZINE DIHYDROCHLORIDE							
AB	ALLIED PHARMA INC	5MG	A202046	001	Sep 17, 2013	Sep	CAHN
AB		5MG	A204323	001	Dec 20, 2016	Apr	CAHN
XYZAL							
AB	+! SANOFI-AVENTIS US	5MG	N022064	001	May 25, 2007	Jul	CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
	+ @ JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan	CRLD
	+ @	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan	CRLD
	+ @	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan	CRLD
LEVOFLOXACIN							
AP	BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Aug	CAHN
AP	SAGENT AGILA LLC	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	CAHN
AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	CAHN
AP	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	May	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	May	NEWA
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	BAXTER HLTHCARE CORP	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Aug	CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Aug	CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Aug	CAHN

SOLUTION;ORAL

LEVAQUIN							
	+ @ JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004	Aug	DISC
LEVOFLOXACIN							
	! HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Aug	CHRS
SOLUTION/DROPS;OPHTHALMIC							
LEVOFLOXACIN							
AT	WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb	CAHN
TABLET;ORAL							
LEVOFLOXACIN							
	@ MYLAN	250MG	A076276	001	Jun 20, 2011	Jul	DISC
	@	500MG	A076276	002	Jun 20, 2011	Jul	DISC
	@	750MG	A077097	001	Jun 20, 2011	Jun	DISC

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM							
AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan	NEWA
	+!	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May	CRLD
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan	NEWA
SOLUTION;IV (INFUSION)							
LEVOLEUCOVORIN CALCIUM							
AP	AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Aug	NEWA

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN							
	@ SEPTODONT INC	0.05MG/ML;2%	A084697	001		May	CAHN
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN							
	@ BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983	Feb	CAHN

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

TIROSINT							
	+ INSTITUT BIOCHIMIQUE	0.175MG	N021924	011	Apr 25, 2017	Sep	NEWA
	+	0.200MG	N021924	012	Apr 25, 2017	Sep	NEWA
SOLUTION;ORAL							
TIROSINT-SOL							
	+ @ INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jun	DISC
	+	25MCG/ML	N206977	002	Dec 15, 2016	Jun	DISC

SOLUTION;ORAL
TIROSINT-SOL

+ @	50MCG/ML	N206977	003	Dec 15, 2016	Jun DISC
+ @	75MCG/ML	N206977	004	Dec 15, 2016	Jun DISC
+ @	88MCG/ML	N206977	005	Dec 15, 2016	Jun DISC
+ @	100MCG/ML	N206977	006	Dec 15, 2016	Jun DISC
+ @	112MCG/ML	N206977	007	Dec 15, 2016	Jun DISC
+ @	125MCG/ML	N206977	008	Dec 15, 2016	Jun DISC
+ @	137MCG/ML	N206977	009	Dec 15, 2016	Jun DISC
+ @	150MCG/ML	N206977	010	Dec 15, 2016	Jun DISC
+ @	175MCG/ML	N206977	011	Dec 15, 2016	Jun DISC
+ @	200MCG/ML	N206977	012	Dec 15, 2016	Jun DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOLET

@ GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003	Sep CAHN
@	0.05MG	N021137	002	Jun 06, 2003	Sep CAHN
@	0.075MG	N021137	003	Jun 06, 2003	Sep CAHN
@	0.088MG	N021137	004	Jun 06, 2003	Sep CAHN
@	0.1MG	N021137	005	Jun 06, 2003	Sep CAHN
@	0.112MG	N021137	006	Jun 06, 2003	Sep CAHN
@	0.125MG	N021137	007	Jun 06, 2003	Sep CAHN
@	0.137MG	N021137	008	Jun 06, 2003	Sep CAHN
@	0.15MG	N021137	009	Jun 06, 2003	Sep CAHN
@	0.175MG	N021137	010	Jun 06, 2003	Sep CAHN
@	0.2MG	N021137	011	Jun 06, 2003	Sep CAHN
@	0.3MG	N021137	012	Jun 06, 2003	Sep CAHN

LEVOXYL

AB1, + KING PHARMS	0.025MG	N021301	001	May 25, 2001	May CAHN
AB3					
AB1, +	0.05MG	N021301	002	May 25, 2001	May CAHN
AB3					
AB1, +	0.075MG	N021301	003	May 25, 2001	May CAHN
AB3					
AB1, +	0.088MG	N021301	004	May 25, 2001	May CAHN
AB3					
AB1, +	0.1MG	N021301	005	May 25, 2001	May CAHN
AB3					
AB1, +	0.112MG	N021301	006	May 25, 2001	May CAHN
AB3					
AB1, +	0.125MG	N021301	007	May 25, 2001	May CAHN
AB3					
AB1, +	0.137MG	N021301	008	May 25, 2001	May CAHN
AB3					
AB1, +	0.15MG	N021301	009	May 25, 2001	May CAHN
AB3					
AB1, +	0.175MG	N021301	010	May 25, 2001	May CAHN
AB3					
AB1, +!	0.2MG	N021301	011	May 25, 2001	May CAHN
AB3					
+ @	0.3MG	N021301	012	May 25, 2001	May CAHN

THYRO-TABS

+ @ LLOYD	0.025MG	N021116	001	Oct 24, 2002	Sep CTNA
+ @	0.05MG	N021116	002	Oct 24, 2002	Sep CTNA
+ @	0.075MG	N021116	003	Oct 24, 2002	Sep CTNA
+ @	0.088MG	N021116	010	Oct 24, 2002	Sep CTNA
+ @	0.1MG	N021116	004	Oct 24, 2002	Sep CTNA
+ @	0.112MG	N021116	011	Oct 24, 2002	Sep CTNA
+ @	0.125MG	N021116	005	Oct 24, 2002	Sep CTNA
+ @	0.137MG	N021116	012	Dec 07, 2004	Sep CTNA
+ @	0.15MG	N021116	006	Oct 24, 2002	Sep CTNA
+ @	0.175MG	N021116	007	Oct 24, 2002	Sep CTNA
+ @	0.2MG	N021116	008	Oct 24, 2002	Sep CTNA
+ @	0.3MG	N021116	009	Oct 24, 2002	Sep CTNA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb NEWA
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan CAHN
AT	RICONPHARMA LLC	5%	A208604	001	Sep 20, 2017	Sep NEWA
AT	VITRUVIAS THERAP	5%	A208822	001	Sep 25, 2017	Sep NEWA

OINTMENT;TOPICAL
XYLOCAINE

+ @ ASTRAZENECA 5% N008048 001 Jan CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

>A> AP AUROBINDO PHARMA LTD 1% A207182 001 Oct 30, 2017 Oct NEWA
>A> AP 2% A207182 002 Oct 30, 2017 Oct NEWA
@ BELMORA LLC 2% A080504 001 Feb CAHN

LIDOCAINE; TETRACAINE

CREAM;TOPICAL
PLIAGLIS

+! TARO PHARMS 7%;7% N021717 001 Jun 29, 2006 May CAHN

LINACLOTIDE

CAPSULE;ORAL
LINZESS

+ FOREST LABS LLC 72MCG N202811 003 Jan 25, 2017 Jan NEWA

LINEZOLID

SOLUTION;IV (INFUSION)
LINEZOLID

AP HQ SPCLT PHARMA 200MG/100ML (2MG/ML) A207001 001 Jul 07, 2017 Jun NEWA
AP 600MG/300ML (2MG/ML) A207001 002 Jul 07, 2017 Jun NEWA
AP SAGENT PHARMS 200MG/100ML (2MG/ML) A204696 001 Mar 02, 2017 Feb NEWA
AP 600MG/300ML (2MG/ML) A204696 002 Mar 02, 2017 Feb NEWA

TABLET;ORAL
LINEZOLID

AB ZYDUS PHARMS USA INC 600MG A206097 001 Feb 22, 2017 Feb NEWA

LIOTHYRONINE SODIUM

TABLET;ORAL
CYTOMEL

AB + KING PHARMS EQ 0.005MG BASE N010379 001 Mar CAHN
AB + EQ 0.025MG BASE N010379 002 Mar CAHN
AB +! EQ 0.05MG BASE N010379 003 Mar CAHN

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE;ORAL
VYVANSE

+ SHIRE DEV LLC 10MG N208510 001 Jan 28, 2017 Jan NEWA
+ 20MG N208510 002 Jan 28, 2017 Jan NEWA
+ 30MG N208510 003 Jan 28, 2017 Jan NEWA
+ 40MG N208510 004 Jan 28, 2017 Jan NEWA
+ 50MG N208510 005 Jan 28, 2017 Jan NEWA
+! 60MG N208510 006 Jan 28, 2017 Apr CHRS
+ 60MG N208510 006 Jan 28, 2017 Jan NEWA

LISINOPRIL

TABLET;ORAL
LISINOPRIL

AB PRINSTON INC 2.5MG A075743 001 Jul 01, 2002 Feb CAHN
AB 5MG A075743 002 Jul 01, 2002 Feb CAHN
AB 10MG A075743 003 Jul 01, 2002 Feb CAHN
AB 20MG A075743 004 Jul 01, 2002 Feb CAHN
AB 30MG A075743 005 Jul 01, 2002 Feb CAHN
AB 40MG A075743 006 Jul 01, 2002 Feb CAHN

LITHIUM CARBONATE

CAPSULE;ORAL
LITHIUM CARBONATE

AB MYLAN PHARMS INC 150MG A076243 002 Feb 24, 2003 Jan CAHN
AB 300MG A076243 001 Jun 27, 2002 Jan CAHN
AB 600MG A078763 001 Apr 15, 2008 Jan CAHN
AB + WEST-WARD PHARMS INT 150MG N017812 002 Jan 28, 1987 Jan CAHN
AB + 300MG N017812 001 Jan CAHN
AB +! 600MG N017812 003 Jan 28, 1987 Jan CAHN

TABLET;ORAL

LITHIUM CARBONATE

AB	+!	WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan CAHN
----	----	----------------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		UNIQUE PHARM LABS	450MG	A205663	001	Jun 05, 2017	May NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	+!	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN
----	----	----------------------	------------------------	---------	-----	--	----------

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

>D>	AA	PADDOCK LLC	2MG/ML	A079244	001	Apr 28, 2009	Oct CAHN
-----	----	-------------	--------	---------	-----	--------------	----------

>A>	AA	SAPTALIS PHARMS	2MG/ML	A079244	001	Apr 28, 2009	Oct CAHN
-----	----	-----------------	--------	---------	-----	--------------	----------

INJECTABLE;INJECTION

LORAZEPAM

AP		SAGENT AGILA LLC	2MG/ML	A200217	001	Apr 04, 2017	Mar NEWA
----	--	------------------	--------	---------	-----	--------------	----------

AP			2MG/ML	A200542	001	Apr 28, 2017	Apr NEWA
----	--	--	--------	---------	-----	--------------	----------

AP			4MG/ML	A200217	002	Apr 04, 2017	Mar NEWA
----	--	--	--------	---------	-----	--------------	----------

AP			4MG/ML	A200542	002	Apr 28, 2017	Apr NEWA
----	--	--	--------	---------	-----	--------------	----------

	@	WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998	Mar CAHN
--	---	----------------------	--------	---------	-----	--------------	----------

	@		4MG/ML	A074496	002	Sep 28, 1998	Mar CAHN
--	---	--	--------	---------	-----	--------------	----------

TABLET;ORAL

LORAZEPAM

	@	ANDA REPOSITORY	0.5MG	A072553	001	Mar 29, 1991	Sep CAHN
--	---	-----------------	-------	---------	-----	--------------	----------

	@		1MG	A072554	001	Mar 29, 1991	Sep CAHN
--	---	--	-----	---------	-----	--------------	----------

	@		2MG	A072555	001	Mar 29, 1991	Sep CAHN
--	---	--	-----	---------	-----	--------------	----------

AB		SANDOZ	0.5	A071141	002	Apr 21, 1987	Apr CMS1
----	--	--------	-----	---------	-----	--------------	----------

AB			1MG	A071141	003	Apr 21, 1987	Apr CMS1
----	--	--	-----	---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB		HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Jul CTEC
----	--	-------------------	------	---------	-----	--------------	----------

AB			50MG	A203835	002	Aug 12, 2015	Jul CTEC
----	--	--	------	---------	-----	--------------	----------

AB			100MG	A203835	003	Aug 12, 2015	Jul CTEC
----	--	--	-------	---------	-----	--------------	----------

AB		UPSHER-SMITH LABS	25MG	A090544	001	Oct 06, 2010	Jun CAHN
----	--	-------------------	------	---------	-----	--------------	----------

AB			50MG	A090544	002	Oct 06, 2010	Jun CAHN
----	--	--	------	---------	-----	--------------	----------

AB			100MG	A090544	003	Oct 06, 2010	Jun CAHN
----	--	--	-------	---------	-----	--------------	----------

AB		VIVA HLTHCARE	25MG	A091541	001	Sep 24, 2012	Sep CAHN
----	--	---------------	------	---------	-----	--------------	----------

AB			50MG	A091541	002	Sep 24, 2012	Sep CAHN
----	--	--	------	---------	-----	--------------	----------

AB			100MG	A091541	003	Sep 24, 2012	Sep CAHN
----	--	--	-------	---------	-----	--------------	----------

AB		VIVIMED GLOBAL	25MG	A090382	001	Oct 06, 2010	Aug CAHN
----	--	----------------	------	---------	-----	--------------	----------

AB			50MG	A090382	002	Oct 06, 2010	Aug CAHN
----	--	--	------	---------	-----	--------------	----------

AB			100MG	A090382	003	Oct 06, 2010	Aug CAHN
----	--	--	-------	---------	-----	--------------	----------

LOVASTATIN

TABLET;ORAL

LOVASTATIN

	@	MYLAN	10MG	A075935	001	Dec 17, 2001	Mar DISC
--	---	-------	------	---------	-----	--------------	----------

	@		20MG	A075935	002	Dec 17, 2001	Mar DISC
--	---	--	------	---------	-----	--------------	----------

	@		40MG	A075935	003	Dec 17, 2001	Mar DISC
--	---	--	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

	@	COVIS PHARMA BV	10MG	N021316	001	Jun 26, 2002	Apr CAHN
--	---	-----------------	------	---------	-----	--------------	----------

+			20MG	N021316	002	Jun 26, 2002	Apr CAHN
---	--	--	------	---------	-----	--------------	----------

+			40MG	N021316	003	Jun 26, 2002	Apr CAHN
---	--	--	------	---------	-----	--------------	----------

+	!		60MG	N021316	004	Jun 26, 2002	Apr CAHN
---	---	--	------	---------	-----	--------------	----------

LOXAPINE

POWDER;INHALATION

ADASUVE

+	!	GALEN UK	10MG	N022549	001	Dec 21, 2012	Sep CAHN
---	---	----------	------	---------	-----	--------------	----------

MAFENIDE ACETATEFOR SOLUTION;TOPICAL
MAFENIDE ACETATE

AT	NOVAST LABS LTD	5%	A206716	001	Jul 31, 2017	Sep CAHN
AT	RICONPHARMA LLC	5%	A206716	001	Jul 31, 2017	Jul NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N017586	001			Feb CAHN
-----------------	---	---------	-----	--	--	----------

SOLUTION;IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N017637	002	Jul 08, 1982		Feb CAHN
-----------------	---	---------	-----	--------------	--	----------

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	Feb NEWA
	SUPREP BOWEL PREP KIT					
AA	+! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	Feb CFTG

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	May CAIN
	SUPREP BOWEL PREP KIT					
AA	+! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	May CAIN

MALATHION

LOTION;TOPICAL

OVIDE

AT	+! TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May CAHN
----	---------------	------	---------	-----	--------------	----------

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 15% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 20% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20GM/100ML	N019603	004	Jan 08, 1990	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 5% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987	Feb CAHN
----	-----------------	-----------	---------	-----	--------------	----------

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001			Feb CAHN
-----------------	-------------------------	---------	-----	--	--	----------

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

@ WATSON LABS TEVA	25MG	A072162	001	Jun 01, 1988	May CAHN
@	50MG	A072163	001	Jun 01, 1988	May CAHN

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

EMVERM

! IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995	Jun CAHN
------------------	-------	---------	-----	--------------	----------

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

MECAMYLAMINE HYDROCHLORIDE

! NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	May CHRS
-----------------	-------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	May CAHN
AA		25MG	A201451	002	Feb 23, 2011	May CAHN
	@	50MG	A201451	003	Feb 23, 2011	May CAHN
	@ PLIVA	25MG	A088734	001	Dec 11, 1985	Aug CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ WATSON LABS TEVA	EQ 100MG BASE	A071469	001	Apr 15, 1987	May CAHN
--------------------	---------------	---------	-----	--------------	----------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@ SANDOZ INC	150MG/ML	A078711	001	May 20, 2009	Jun DISC	
AB	150MG/ML	A078711	001	May 20, 2009	Mar CAHN	
AB	TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	Jan CAHN

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

@ USL PHARMA	10MG	A088484	001	Jul 26, 1984	Jun CAHN
--------------	------	---------	-----	--------------	----------

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	VIVA HLTHCARE	250MG	A090562	001	Nov 19, 2010	Sep CAHN
----	---------------	-------	---------	-----	--------------	----------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

+ @ ROCHE 250MG

N019591	001	May 02, 1989	Sep CRLD
---------	-----	--------------	----------

MEFLOQUINE HYDROCHLORIDE

AB	! BARR	250MG	A076392	001	Dec 29, 2003	Apr CHRS
	@ SANDOZ	250MG	A076175	001	Feb 20, 2002	Apr DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ @ BRISTOL MYERS SQUIBB 40MG/ML

N020264	001	Sep 10, 1993	Feb DISC
---------	-----	--------------	----------

MEGESTROL ACETATE

AB	HI-TECH PHARMACAL	40MG/ML	A203960	001	Jun 09, 2017	May NEWA
AB	! WEST-WARD PHARMS INT	40MG/ML	A075997	001	Feb 15, 2002	Feb CHRS

MELOXICAM

SUSPENSION; ORAL

MOBIC

+ @ BOEHRINGER INGELHEIM 7.5MG/5ML

N021530	001	Jun 01, 2004	Sep DISC
---------	-----	--------------	----------

TABLET; ORAL

MELOXICAM

@ ANDA REPOSITORY 7.5MG

A077935	001	Jul 19, 2006	Sep CAHN
---------	-----	--------------	----------

@ 15MG

A077935	002	Jul 19, 2006	Sep CAHN
---------	-----	--------------	----------

@ SUN PHARM INDS INC 7.5MG

A077937	001	Jul 19, 2006	Apr DISC
---------	-----	--------------	----------

@ 15MG

A077937	002	Jul 19, 2006	Apr DISC
---------	-----	--------------	----------

MELPHALAN

TABLET; ORAL

ALKERAN

AB	+! APOTEX INC	2MG	N014691	002		Mar CFTG
----	---------------	-----	---------	-----	--	----------

MELPHALAN

AB	ALVOGEN MALTA	2MG	A207809	001	Mar 22, 2017	Mar NEWA
----	---------------	-----	---------	-----	--------------	----------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

+ @ APOTEX INC EQ 50MG BASE/VIAL

N020207	001	Nov 18, 1992	May DISC
---------	-----	--------------	----------

MELPHALAN HYDROCHLORIDE

AP	! MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090270	001	Jun 09, 2009	May CHRS
AP	SAGENT PHARMS	EQ 50MG BASE/VIAL	A201379	001	Feb 28, 2017	Feb NEWA

POWDER; IV (INFUSION)							
EVOMELA							
+	!	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Aug CRLD
<u>MEMANTINE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
MEMANTINE HYDROCHLORIDE							
AB		AMNEAL PHARMS	7MG	A205825	001	Oct 12, 2016	May CAHN
AB			14MG	A205825	002	Oct 12, 2016	May CAHN
AB			21MG	A205825	003	Oct 12, 2016	May CAHN
AB			28MG	A205825	004	Oct 12, 2016	May CAHN
AB		ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017	May NEWA
AB			14MG	A205784	002	Jun 09, 2017	May NEWA
AB			21MG	A205784	003	Jun 09, 2017	May NEWA
AB			28MG	A205784	004	Jun 09, 2017	May NEWA
AB		ZYDUS PHARMS USA INC	7MG	A203293	001	Aug 03, 2017	Jul NEWA
AB			14MG	A203293	002	Aug 03, 2017	Jul NEWA
AB			21MG	A203293	003	Aug 03, 2017	Jul NEWA
AB			28MG	A203293	004	Aug 03, 2017	Jul NEWA
TABLET; ORAL							
MEMANTINE HYDROCHLORIDE							
AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	May CAHN
AB			10MG	A090041	002	Apr 10, 2015	May CAHN
AB		STRIDES PHARMA	5MG	A202350	001	May 23, 2017	May NEWA
AB			10MG	A202350	002	May 23, 2017	May NEWA
AB		UPSHER-SMITH LABS	5MG	A090043	001	Jul 31, 2015	Jun CAHN
AB			10MG	A090043	002	Jul 31, 2015	Jun CAHN
AB		ZYDUS PHARMS USA INC	5MG	A090961	001	Jul 10, 2017	Jun NEWA
AB			10MG	A090961	002	Jul 10, 2017	Jun NEWA
<u>MEPENZOLATE BROMIDE</u>							
TABLET; ORAL							
CANTIL							
+	@	SANOFI AVENTIS US	25MG	N010679	003		Aug DISC
<u>MEPERIDINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
MEPERIDINE HYDROCHLORIDE							
AP		WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan CAHN
AP			25MG/ML	A080455	007		Jan CAHN
AP			50MG/ML	A080445	002		Jan CAHN
AP			50MG/ML	A080455	008		Jan CAHN
AP			75MG/ML	A080445	003		Jan CAHN
AP			75MG/ML	A080455	009		Jan CAHN
AP			100MG/ML	A080445	004		Jan CAHN
AP			100MG/ML	A080455	010		Jan CAHN
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	!	ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Apr CAHN
	@	MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997	Mar CAHN
AP		WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993	Apr CAHN
<u>MEPIVACAINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
ISOCAINE HYDROCHLORIDE							
AP	!	SEPTODONT INC	3%	A080925	001		May CAHN
MEPIVACAINE HYDROCHLORIDE							
	@	BELMORA LLC	3%	A083559	001		Feb CAHN
<u>MERCAPTOPURINE</u>							
TABLET; ORAL							
MERCAPTOPURINE							
AB		DR REDDYS LABS SA	50MG	A040461	001	Feb 11, 2004	Jun CAHN
<u>MEROPENEM</u>							
INJECTABLE; INJECTION							
MEROPENEM							
AP		AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar NEWA
AP			1GM/VIAL	A205835	002	Mar 27, 2017	Mar NEWA
MERREM							
AP	+	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Jun CAHN
AP	+		1GM/VIAL	N050706	001	Jun 21, 1996	Jun CAHN

MEROPENEM; VABORBACTAMPOWDER; IV (INFUSION)
VABOMERE

+! REMPEX PHARMS MEDCNS 1GM/VIAL; 1GM/VIAL

N209776 001 Aug 29, 2017 Aug NEWA

MESALAMINEENEMA; RECTAL
ROWASAAB +! MYLAN SPECIALITY LP 4GM/60ML
SFROWASA

N019618 001 Dec 24, 1987 Mar CAHN

AB + MYLAN SPECIALITY LP 4GM/60ML
TABLET, DELAYED RELEASE; ORAL
ASACOL HD

N019618 002 Jun 20, 2008 Mar CAHN

AB +! APIL 800MG
LIALDA

N021830 001 May 29, 2008 Jul CFTG

AB +! SHIRE 1.2GM
MESALAMINE

N022000 001 Jan 16, 2007 May CFTG

AB ZYDUS PHARMS USA INC 800MG

A203286 001 Jul 21, 2017 Jul NEWA

AB 1.2GM

A091640 001 Jun 05, 2017 May NEWA

MESNAINJECTABLE; INTRAVENOUS
MESNA

>D> AP MYLAN LABS LTD 100MG/ML

A203364 001 Jul 18, 2014 Oct DISC

>A> @ 100MG/ML

A203364 001 Jul 18, 2014 Oct DISC

METAXALONETABLET; ORAL
METAXALONEAB ACTAVIS LABS FL INC 800MG
@ EPIC PHARMA LLC 640MG

A203695 001 Jun 15, 2017 Jun NEWA

IMPAX LABS INC 400MG

N022503 001 Jun 01, 2015 May CAHN

AB SCIEGEN PHARMS INC 800MG
SKELAXIN

A040486 001 Feb 27, 2015 Feb CAHN

+ @ KING PHARMS 400MG

A207466 001 Aug 31, 2017 Aug NEWA

AB +! 800MG

N013217 001 May CAHN

N013217 003 Aug 30, 2002 May CAHN

METFORMIN HYDROCHLORIDETABLET; ORAL
METFORMIN HYDROCHLORIDE

>A> AB MACLEODS PHARMS LTD 500MG

A205330 001 Oct 31, 2017 Oct NEWA

>A> AB 850MG

A205330 002 Oct 31, 2017 Oct NEWA

>A> AB 1GM

A205330 003 Oct 31, 2017 Oct NEWA

@ MYLAN PHARMS INC 500MG

A075969 001 Jan 29, 2002 May DISC

@ 850MG

A075969 002 Jan 29, 2002 May DISC

@ 1GM

A075969 003 Jan 29, 2002 May DISC

@ WATSON LABS FLORIDA 500MG

A075961 001 Jan 25, 2002 Mar DISC

@ 850MG

A075961 002 Jan 25, 2002 Mar DISC

@ 1GM

A075961 003 Jan 25, 2002 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1 INTELLIPHARMACEUTICS 500MG

A202306 001 Feb 23, 2017 Feb NEWA

AB 750MG

A202306 002 Feb 23, 2017 Feb NEWA

>D> AB MYLAN 750MG

A077113 001 Sep 08, 2005 Oct DISC

>A> @ 750MG

A077113 001 Sep 08, 2005 Oct DISC

AB1 TORRENT PHARMS LTD 500MG

A090014 001 Dec 30, 2009 Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

>D> PRANDIMET

>D> AB + NOVO NORDISK INC 500MG; 1MG

N022386 001 Jun 23, 2008 Oct DISC

>A> + @ 500MG; 1MG

N022386 001 Jun 23, 2008 Oct DISC

>D> AB +! 500MG; 2MG

N022386 002 Jun 23, 2008 Oct DISC

>A> + @ 500MG; 2MG

N022386 002 Jun 23, 2008 Oct DISC

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

>D> AB LUPIN LTD 500MG; 1MG

A200624 001 Jul 15, 2015 Oct CTEC

>A> 500MG; 1MG

A200624 001 Jul 15, 2015 Oct CTEC

>D> AB 500MG; 2MG

A200624 002 Jul 15, 2015 Oct CHRS

>A> ! 500MG; 2MG

A200624 002 Jul 15, 2015 Oct CHRS

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA

500MG;EQ 1MG BASE

A077337 005 May 19, 2017 May NEWA

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+ @ METHAPHARM

1600MG/VIAL

N019193 002 Aug 29, 2016 Sep DISC

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADOSE

AA +! MALLINCKRODT INC

10MG/ML

N017116 002

Apr CAHN

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

>A>

>A> AP

AKORN

10MG/ML

A208306 001 Oct 27, 2017

Oct NEWA

>D>

+! MYLAN INSTITUTIONAL

10MG/ML

N021624 001

Oct CFTG

>A> AP

+!

10MG/ML

N021624 001

Oct CFTG

>D>

POWDER; FOR RX COMPOUNDING

>D>

METHADONE HYDROCHLORIDE

>D>

MALLINCKRODT INC

50GM/BOT

N006383 002

Oct DISC

>A>

@

50GM/BOT

N006383 002

Oct DISC

50GM/BOT

N006383 002

Apr CAHN

>D>

100GM/BOT

N006383 003

Oct DISC

>A>

@

100GM/BOT

N006383 003

Oct DISC

100GM/BOT

N006383 003

Apr CAHN

>D>

500GM/BOT

N006383 004

Oct DISC

>A>

@

500GM/BOT

N006383 004

Oct DISC

500GM/BOT

N006383 004

Apr CAHN

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT

10MG/30ML

N006134 004

Jan CAHN

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

AA +! WEST-WARD PHARMS INT

5MG

N006134 002

Jan CAHN

AA +!

10MG

N006134 010

Jan CAHN

METHADONE HYDROCHLORIDE

AA EPIC PHARMA LLC

5MG

A090065 001 Aug 18, 2015

May CAHN

AA

10MG

A090065 002 Aug 18, 2015

May CAHN

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA +! WEST-WARD PHARMS INT

40MG

N017058 001

Jan CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB IMPAX LABS INC

1GM

A076411 001 Jun 20, 2003 Feb CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

@ ECI PHARMS LLC

15MG

A040619 003 Jul 12, 2005

May CAHN

TAPAZOLE

AB KING PHARMS LLC

5MG

A040320 001 Mar 31, 2000

Feb CAHN

AB

10MG

A040320 002 Mar 31, 2000

Feb CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP LUITPOLD PHARMS INC

1GM/10ML (100MG/ML)

A207496 001 Jun 22, 2017

Jun NEWA

AP RENAISSANCE PHARMA

1GM/10ML (100MG/ML)

A208116 001 Jan 19, 2017

Jan NEWA

AP RENAISSANCE SSA LLC

1GM/10ML (100MG/ML)

A208116 001 Jan 19, 2017

Mar CAHN

AP SAGENT PHARMS

1GM/10ML (100MG/ML)

A205404 001 Jul 18, 2017

Jul NEWA

AP SOMERSET THERAPS LLC

1GM/10ML (100MG/ML)

A207522 001 Jul 31, 2017

Jul NEWA

TABLET; ORAL

METHOCARBAMOL

AA ATLAS PHARMS LLC

500MG

A203550 001 Feb 08, 2017

Jan NEWA

AA

750MG

A203550 002 Feb 08, 2017

Jan NEWA

AA BEXIMCO PHARMS USA

500MG

A208507 001 Jul 21, 2017

Jul NEWA

TABLET;ORAL
METHOCARBAMOL

AA		750MG	A208507	002	Jul 21, 2017	Jul NEWA
	@ UPSHER SMITH	500MG	A087453	001		Jun CAHN
	@	750MG	A087454	001		Jun CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS
RASUVO

	@ MEDAC PHARMA INC	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Jun DISC
--	--------------------	-------------------------------	---------	-----	--------------	----------

METHOTREXATE SODIUM

INJECTABLE;INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREE

AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040843	002	Jan 11, 2010	Apr CMS1
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Apr CMS1
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040843	004	Jan 11, 2010	Apr CMS1

SOLUTION;ORAL
XATMEP

	+! SILVERGATE PHARMS	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017	Apr NEWA
--	----------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

METHOTREXATE SODIUM

>D>	AB	ORION CORP ORION	EQ 2.5MG BASE	A201749	001	May 21, 2015	Oct CAHN
	AB		EQ 2.5MG BASE	A201749	001	May 21, 2015	Jul CAHN
>A>	AB	SUN PHARMA GLOBAL	EQ 2.5MG BASE	A201749	001	May 21, 2015	Oct CAHN
	AB	ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A207812	001	Jan 13, 2017	Jan NEWA

METHOXSALLEN

CAPSULE;ORAL

>D>		8-MOP					
>D>	+!	VALEANT PHARM INTL	10MG	N009048	001		Oct DISC
>A>	+	@	10MG	N009048	001		Oct DISC

LOTION;TOPICAL

OXSORALEN

>D>	+!	VALEANT PHARM INTL	1%	N009048	002		Oct DISC
>A>	+	@	1%	N009048	002		Oct DISC

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION
METHYLDOPATE HYDROCHLORIDE

!	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Jan CTEC
---	----------	---------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

INJECTABLE;INJECTION
METHYLERGONOVINE MALEATE

AP	BRECKENRIDGE PHARM	0.2MG/ML	A040889	001	Sep 13, 2010	Sep CAHN
----	--------------------	----------	---------	-----	--------------	----------

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017	Jun NEWA
+		17.3MG	N205489	002	Jun 19, 2017	Jun NEWA
+		25.9MG	N205489	003	Jun 19, 2017	Jun NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB2	IMPAX LABS INC	10MG	A205105	001	Jul 28, 2016	Feb CAHN
AB2		20MG	A205105	002	Jul 28, 2016	Feb CAHN
AB2		30MG	A205105	003	Jul 28, 2016	Feb CAHN
AB2		40MG	A205105	004	Jul 28, 2016	Feb CAHN
AB2		50MG	A205105	005	Jul 28, 2016	Feb CAHN
AB2		60MG	A205105	006	Jul 28, 2016	Feb CAHN
!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	Feb CHRS

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	BRECKENRIDGE PHARM	5MG/5ML	A201466	001	Nov 12, 2013	Sep CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Sep CAHN

TABLET;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
AB	ABHAI INC	5MG	A206932	001	May 11, 2017	Apr	NEWA		
AB		10MG	A206932	002	May 11, 2017	Apr	NEWA		
AB		20MG	A206932	003	May 11, 2017	Apr	NEWA		
AB	BRECKENRIDGE PHARM	5MG	A207587	001	Mar 03, 2017	Sep	CAHN		
AB		10MG	A207587	002	Mar 03, 2017	Sep	CAHN		
AB		20MG	A207587	003	Mar 03, 2017	Sep	CAHN		
AB	IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Feb	CAHN		
AB		10MG	A091159	002	Mar 12, 2014	Feb	CAHN		
AB		20MG	A091159	003	Mar 12, 2014	Feb	CAHN		
AB	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Feb	NEWA		
AB		10MG	A207587	002	Mar 03, 2017	Feb	NEWA		
AB		20MG	A207587	003	Mar 03, 2017	Feb	NEWA		
TABLET, CHEWABLE;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
AB	BRECKENRIDGE PHARM	2.5MG	A204954	001	Jan 26, 2017	Sep	CAHN		
AB		5MG	A204954	002	Jan 26, 2017	Sep	CAHN		
AB		10MG	A204954	003	Jan 26, 2017	Sep	CAHN		
AB	NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan	NEWA		
AB		5MG	A204954	002	Jan 26, 2017	Jan	NEWA		
AB		10MG	A204954	003	Jan 26, 2017	Jan	NEWA		
TABLET, EXTENDED RELEASE;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
AB	IMPAX LABS INC	18MG	A208607	001	Jul 14, 2017	Jul	NEWA		
AB		27MG	A208607	002	Jul 14, 2017	Jul	NEWA		
AB		36MG	A208607	003	Jul 14, 2017	Jul	NEWA		
AB		54MG	A208607	004	Jul 14, 2017	Jul	NEWA		
AB	OSMOTICA	18MG	A205327	001	Jul 28, 2017	Jul	NEWA		
AB		27MG	A205327	002	Jul 28, 2017	Jul	NEWA		
AB		36MG	A205327	003	Jul 28, 2017	Jul	NEWA		
AB		54MG	A205327	004	Jul 28, 2017	Jul	NEWA		
		72MG	A205327	005	Jul 28, 2017	Jul	NEWA		
RITALIN-SR									
AB	+ NOVARTIS	20MG	N018029	001	Mar 30, 1982	Feb	CRLD		
<u>METHYLPREDNISOLONE ACETATE</u>									
INJECTABLE;INJECTION									
METHYLPREDNISOLONE ACETATE									
AB	SANDOZ INC	40MG/ML	A040719	001	Jan 29, 2009	Mar	CAHN		
AB		40MG/ML	A040794	001	Mar 05, 2009	Jul	CAHN		
AB		80MG/ML	A040719	002	Jan 29, 2009	Mar	CAHN		
AB		80MG/ML	A040794	002	Mar 05, 2009	Jul	CAHN		
<u>METHYLTESTOSTERONE</u>									
TABLET;ORAL									
ANDROID 10									
	@ VALEANT PHARMS NORTH	10MG	A086450	001		May	CAHN		
<u>METIPRANOLOL HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
METIPRANOLOL									
AT	SANDOZ INC	0.3%	A075720	001	Aug 06, 2001	Feb	CAHN		
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>									
SOLUTION;ORAL									
METOCLOPRAMIDE HYDROCHLORIDE									
AA	PHARM ASSOC	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May	CAHN		
TABLET;ORAL									
METOCLOPRAMIDE HYDROCHLORIDE									
	@ SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997	May	DISC		
<u>METOPROLOL SUCCINATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
TOPROL-XL									
AB	+ ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan	CAHN		
AB	+	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan	CAHN		
AB	+	EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan	CAHN		
AB	+	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan	CAHN		

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

AP	BAXTER HLTHCARE CORP	1MG/ML	A078950	001	Apr 29, 2013	Aug CAHN
AP	SANDOZ INC	1MG/ML	A077360	001	Oct 02, 2007	Mar CAHN
AP	WEST-WARD PHARMS INT	1MG/ML	A076495	001	Jul 07, 2003	Jan CAHN

TABLET;ORAL
LOPRESSOR

AB	+	US PHARMS HOLDINGS I	50MG	N017963	001		Sep CRLD
AB	+		100MG	N017963	002		Sep CRLD
METOPROLOL TARTRATE							
AB		SUN PHARM INDUSTRIES	50MG	A073654	003	Dec 21, 1993	Jul CMS1

METRONIDAZOLE

CAPSULE;ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	375MG	A079065	001	Jun 23, 2009	May CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

GEL;TOPICAL

METRONIDAZOLE

AB		TARO PHARM	1%	A204651	001	Mar 14, 2017	Feb NEWA
----	--	------------	----	---------	-----	--------------	----------

GEL;VAGINAL

NUVESSA

+	!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Aug CAHN
---	---	-------------------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION

METRONIDAZOLE

		@ WEST-WARD PHARMS INT	500MG/100ML	N018907	001	Mar 30, 1984	May CAHN
--	--	------------------------	-------------	---------	-----	--------------	----------

METRONIDAZOLE IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	500MG/100ML	A078084	001	Mar 31, 2008	Aug CAHN
----	--	----------------------	-------------	---------	-----	--------------	----------

AP		MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017	Apr NEWA
----	--	----------------	-------------	---------	-----	--------------	----------

TABLET;ORAL

METRONIDAZOLE

		@ CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983	Jun CAHN
		@	500MG	N018930	001	Aug 18, 1983	Jun CAHN
AB		INNOGENIX	250MG	A070772	001	Jul 16, 1986	Sep CAHN
AB			500MG	A070773	001	Jul 16, 1986	Sep CAHN
AB		LUPIN LTD	250MG	A209096	001	Sep 12, 2017	Sep NEWA
AB			500MG	A209096	002	Sep 12, 2017	Sep NEWA
AB		ORIT LABS LLC	250MG	A208681	001	Jun 20, 2017	Jun NEWA
AB			500MG	A208681	002	Jun 20, 2017	Jun NEWA
AB		VIVIMED GLOBAL	250MG	A070040	001	Jan 29, 1985	Aug CAHN
AB			500MG	A070039	001	Jan 29, 1985	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010	May CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

AB		ACTAVIS PHARMA	200MG	A073508	001	Nov 19, 1993	May CAHN
----	--	----------------	-------	---------	-----	--------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

+	!	MYLAN PHARMS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan CAHN
---	---	------------------	------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

		@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Aug CAHN
		@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Aug CAHN
		FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Mar NEWA
AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075324	001	Jun 20, 2000	Mar CAHN
AP			EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075324	002	Jun 20, 2000	Mar CAHN
AP			EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan CAHN

INJECTABLE; INJECTION		MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE					
AP	SAGENT AGILA LLC	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	May	CAHN
AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	May	CAHN
SYRUP; ORAL							
MIDAZOLAM HYDROCHLORIDE							
	@ SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	May	DISC
<u>MIDODRINE HYDROCHLORIDE</u>							
TABLET; ORAL							
MIDODRINE HYDROCHLORIDE							
BX	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Sep	CTEC
BX		5MG	A077746	002	Sep 12, 2006	Sep	CTEC
BX		10MG	A077746	003	Sep 12, 2006	Sep	CTEC
ORVATEN							
AB	UPSHER-SMITH LABS	2.5MG	A076725	001	Nov 03, 2004	Jun	CAHN
AB		5MG	A076725	002	Nov 03, 2004	Jun	CAHN
AB		10MG	A076725	003	Nov 03, 2004	Jun	CAHN
PROAMATINE							
	+ @ SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Feb	CRLD
	+ @	5MG	N019815	002	Sep 06, 1996	Feb	CRLD
	+ @	10MG	N019815	003	Mar 20, 2002	Feb	CRLD
<u>MIDOSTAURIN</u>							
CAPSULE; ORAL							
RYDAPT							
	+! NOVARTIS PHARMS CORP	25MG	N207997	001	Apr 28, 2017	Apr	NEWA
<u>MILNACIPRAN HYDROCHLORIDE</u>							
TABLET; ORAL							
MILNACIPRAN HYDROCHLORIDE							
	@ WINDLAS HLTHCARE	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN
	@	25MG	A205071	002	Jan 27, 2016	Sep	CAHN
	@	50MG	A205071	003	Jan 27, 2016	Sep	CAHN
	@	100MG	A205071	004	Jan 27, 2016	Sep	CAHN
SAVELLA							
AB	+ ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009	Feb	CAHN
AB	+	25MG	N022256	002	Jan 14, 2009	Feb	CAHN
AB	+!	50MG	N022256	003	Jan 14, 2009	Feb	CAHN
AB	+	100MG	N022256	004	Jan 14, 2009	Feb	CAHN
<u>MILRINONE LACTATE</u>							
INJECTABLE; INJECTION							
MILRINONE LACTATE							
	@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Aug	CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan	CAHN
AP		EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CAHN
	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar	CAHN
MILRINONE LACTATE IN DEXTROSE 5%							
AP	RENAISSANCE SSA LLC	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Aug	CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@ RENAISSANCE SSA LLC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Aug	CAHN
	@ WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar	CAHN
AP		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan	CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan	CAHN
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER							
	+ @ SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan	CRLD
	+ @	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan	CRLD
	+ @	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan	CRLD
	+ @	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan	CRLD

MINOCYCLINE HYDROCHLORIDECAPSULE;ORAL
DYNACIN

AB	CNTY LINE PHARMS	EQ 50MG BASE	A063067	003	Aug 14, 1990	Sep CMFD
----	------------------	--------------	---------	-----	--------------	----------

AB	MINOCYCLINE HYDROCHLORIDE					
AB	WATSON LABS TEVA	EQ 50MG BASE	A063181	001	Dec 30, 1991	May CAHN

CAPSULE, EXTENDED RELEASE;ORAL
XIMINO

	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CMFD
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CMFD
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CMFD

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

	@ BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr DISC
		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr NEWA
	@	EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr DISC
		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr NEWA
	@ MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	May DISC
	@	EQ 80MG BASE	A203443	002	Aug 22, 2014	May DISC
	@	EQ 90MG BASE	A090911	002	Jul 20, 2010	May DISC
	@	EQ 105MG BASE	A203443	003	Aug 22, 2014	May DISC
	@	EQ 135MG BASE	A090911	003	Jul 20, 2010	May DISC
>A> AB	ZYDUS PHARMS USA INC	EQ 45MG BASE	A203553	001	Nov 16, 2017	Oct NEWA
>A> AB		EQ 80MG BASE	A203553	004	Nov 16, 2017	Oct NEWA
>A> AB		EQ 90MG BASE	A203553	005	Nov 16, 2017	Oct NEWA
>A> AB		EQ 105MG BASE	A203553	006	Nov 16, 2017	Oct NEWA
>A> AB		EQ 135MG BASE	A203553	008	Nov 16, 2017	Oct NEWA

MINOLIRA

	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017	May NEWA
		EQ 135MG BASE	N209269	002	May 08, 2017	May NEWA

MIRABEGRONTABLET, EXTENDED RELEASE;ORAL
MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb CHRS
----	-------	------	---------	-----	--------------	----------

MIRTAZAPINETABLET;ORAL
MIRTAZAPINE

	@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Jun CAHN
AB		15MG	A076219	001	Jun 19, 2003	Jun CAHN
	@	30MG	A076189	002	Jun 19, 2003	Jun CAHN
AB		30MG	A076219	002	Jun 19, 2003	Jun CAHN
	@	45MG	A076189	003	Jun 19, 2003	Jun CAHN
AB		45MG	A076219	003	Jun 19, 2003	Jun CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan CAHN
AB	ZYDUS PHARMS USA INC	15MG	A205798	001	Jun 01, 2017	May NEWA
AB		30MG	A205798	002	Jun 01, 2017	May NEWA
AB		45MG	A205798	003	Jun 01, 2017	May NEWA

MITOMYCININJECTABLE;INJECTION
MITOMYCIN

>A> AP	MYLAN LABS LTD	5MG/VIAL	A202670	001	Oct 13, 2017	Oct NEWA
>A> AP		20MG/VIAL	A202670	002	Oct 13, 2017	Oct NEWA
>A> AP		40MG/VIAL	A203386	001	Oct 13, 2017	Oct NEWA
AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MUTAMYCIN

+	@ BRISTOL	5MG/VIAL	N050450	001		Jan CRLD
+	@	20MG/VIAL	N050450	002		Jan CRLD

MODAFINIL

TABLET;ORAL

MODAFINIL

AB	ALEMBIC PHARMS LTD	100MG	A202700	001	Oct 18, 2012	May	CAHN
AB		200MG	A202700	002	Oct 18, 2012	May	CAHN
AB	APPCO PHARMA LLC	100MG	A207196	001	Aug 16, 2017	Aug	NEWA
AB		200MG	A207196	002	Aug 16, 2017	Aug	NEWA
AB	ZYDUS PHARMS USA INC	100MG	A209966	001	Sep 14, 2017	Sep	NEWA
AB		200MG	A209966	002	Sep 14, 2017	Sep	NEWA

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB	CHARTWELL RX	7.5MG	A077536	001	Nov 30, 2006	Apr	CAHN
AB		15MG	A077536	002	Nov 30, 2006	Apr	CAHN

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

	EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015	May	CAHN
		10MG	A090453	002	Mar 20, 2015	May	CAHN
!		25MG	A090453	003	Mar 20, 2015	May	CAHN

MOMETASONE FUROATE

LOTION;TOPICAL

MOMETASONE FUROATE

AB	PERRIGO ISRAEL	0.1%	A077180	001	Apr 06, 2005	Apr	CAHN
----	----------------	------	---------	-----	--------------	-----	------

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar	NEWA
----	---------------	----------------------	---------	-----	--------------	-----	------

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

AB	CSPC OUYI PHARM CO	EQ 10MG BASE	A209012	001	Apr 24, 2017	Apr	NEWA
AB	PERRIGO R AND D	EQ 10MG BASE	A206112	001	Apr 26, 2017	Apr	NEWA

SINGULAIR

>D>	AB	+! MERCK	EQ 10MG BASE	N020829	002	Feb 20, 1998	Oct	CAHN
>A>	AB	+! MSD MERCK CO	EQ 10MG BASE	N020829	002	Feb 20, 1998	Oct	CAHN

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB	CSPC OUYI PHARM CO	EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr	NEWA
AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr	NEWA

SINGULAIR

>D>	AB	+ MERCK	EQ 4MG BASE	N020830	002	Mar 03, 2000	Oct	CAHN
>D>	AB	+!	EQ 5MG BASE	N020830	001	Feb 20, 1998	Oct	CAHN
>A>	AB	+ MSD MERCK CO	EQ 4MG BASE	N020830	002	Mar 03, 2000	Oct	CAHN
>A>	AB	+!	EQ 5MG BASE	N020830	001	Feb 20, 1998	Oct	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Apr	CAHN
		45MG	A079040	002	Jan 16, 2013	Apr	CAHN
		60MG	A079040	003	Jan 16, 2013	Apr	CAHN
		75MG	A079040	004	Jan 16, 2013	Apr	CAHN
		90MG	A079040	005	Jan 16, 2013	Apr	CAHN
!		120MG	A079040	006	Jan 16, 2013	Apr	CAHN
AB	UPSHER-SMITH LABS	10MG	A202104	001	Jun 03, 2013	Jun	CAHN
AB		20MG	A202104	002	Jun 03, 2013	Jun	CAHN
AB		30MG	A202104	003	Jun 03, 2013	Jun	CAHN
AB		50MG	A202104	004	Jun 03, 2013	Jun	CAHN
AB		60MG	A202104	005	Jun 03, 2013	Jun	CAHN
AB		80MG	A202104	006	Jun 03, 2013	Jun	CAHN
AB		100MG	A202104	007	Jun 03, 2013	Jun	CAHN

INJECTABLE;INJECTION

MORPHINE SULFATE

	+ @ HOSPIRA INC	15MG/ML	N202515	005	Nov 14, 2011	Aug	DISC
	@ ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992	Jun	CAHN
AP	+!	1MG/ML	N019916	001	Oct 30, 1992	Apr	CAHN
	+!	5MG/ML	N019916	002	Oct 27, 2006	Apr	CAHN

INJECTABLE; INJECTION

MORPHINE SULFATE

@ MALLINCKRODT INC

1MG/ML

N020631 001 Jul 03, 1996 Apr CAHN

@

2MG/ML

N020631 002 Jul 03, 1996 Apr CAHN

SOLUTION; ORAL

MORPHINE SULFATE

AA HI-TECH PHARMACAL

100MG/5ML

A208809 001 Jul 06, 2017 Jun NEWA

AA RHODES PHARMS

10MG/5ML

A206308 001 Jun 22, 2017 Jun NEWA

AA

100MG/5ML

A206308 002 Jun 22, 2017 Jun NEWA

AA + WEST-WARD PHARMS INT

10MG/5ML

N022195 001 Mar 17, 2008 Jan CAHN

AA +

20MG/5ML

N022195 002 Mar 17, 2008 Jan CAHN

AA +!

100MG/5ML

N022195 003 Jan 25, 2010 Jan CAHN

TABLET; ORAL

MORPHINE SULFATE

+ WEST-WARD PHARMS INT

15MG

N022207 001 Mar 17, 2008 Jan CAHN

+!

30MG

N022207 002 Mar 17, 2008 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

ARYMO ER

+ EGALET

15MG

N208603 001 Jan 09, 2017 Jan NEWA

+

30MG

N208603 002 Jan 09, 2017 Jan NEWA

+

60MG

N208603 003 Jan 09, 2017 Jan NEWA

MORPHABOND ER

+ DAIICHI SANKYO INC

15MG

N206544 001 Oct 02, 2015 Jan CTNA

+

30MG

N206544 002 Oct 02, 2015 Jan CTNA

+

60MG

N206544 003 Oct 02, 2015 Jan CTNA

+!

100MG

N206544 004 Oct 02, 2015 Jan CTNA

MORPHINE SULFATE

AB ACTAVIS ELIZABETH

15MG

A203849 001 Apr 06, 2015 Apr CAHN

AB

30MG

A203849 002 Apr 06, 2015 Apr CAHN

AB

60MG

A203849 003 Apr 06, 2015 Apr CAHN

AB

100MG

A203849 004 Apr 06, 2015 Apr CAHN

AB

200MG

A203849 005 Apr 06, 2015 Apr CAHN

AB EPIC PHARMA LLC

15MG

A091357 001 Jun 23, 2016 May CAHN

AB

30MG

A091357 002 Jun 23, 2016 May CAHN

AB

60MG

A091357 003 Jun 23, 2016 May CAHN

AB

100MG

A091357 004 Jun 23, 2016 May CAHN

AB

200MG

A091357 005 Jun 23, 2016 May CAHN

AB SUN PHARM INDUSTRIES

15MG

A205634 001 Aug 25, 2016 Mar CAHN

AB

30MG

A205634 002 Aug 25, 2016 Mar CAHN

AB

60MG

A205634 003 Aug 25, 2016 Mar CAHN

AB

100MG

A205634 004 Aug 25, 2016 Mar CAHN

AB

200MG

A205634 005 Aug 25, 2016 Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

AP +! BAYER HLTHCARE

400MG/250ML (1.6MG/ML)

N021277 001 Nov 30, 2001 Apr CFTG

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

AP MYLAN LABS LTD

400MG/250ML (1.6MG/ML)

A205833 001 May 05, 2017 Apr NEWA

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

>A> AT1 AKORN

EQ 0.5% BASE

A202916 001 Nov 09, 2017 Oct NEWA

AT1 APOTEX INC

EQ 0.5% BASE

A090080 001 Jun 30, 2017 Jun NEWA

AT1 AUROBINDO PHARMA LTD

EQ 0.5% BASE

A206242 001 Oct 04, 2017 Sep NEWA

TABLET; ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB MSN LABS PVT LTD

EQ 400MG BASE

A208682 001 Sep 22, 2017 Sep NEWA

AB NOVEL LABS INC

EQ 400MG BASE

A207285 001 Feb 13, 2017 Jan NEWA

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB ! PERRIGO NEW YORK

2%

A065123 001 Nov 07, 2003 May CHRS

MUPIROCIN CALCIUM

CREAM; TOPICAL

MUPIROCIN

AB GLENMARK PHARMS INC

EQ 2% BASE

A201587 001 Jan 24, 2013 May CAHN

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

>A> AB	@ JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Sep DISC
	ZHEJIANG HISUN PHARM	250MG	A204077	001	Nov 13, 2017	Oct NEWA

TABLET;ORAL

MYCOPHENOLATE MOFETIL

	@ JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Sep DISC
--	--------------------	-------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP	AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb NEWA
AP	MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar NEWA
AP	ZYDUS PHARMS USA INC	500MG/VIAL	A204473	001	Aug 31, 2017	Aug NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

AB	ACCORD HLTHCARE	180MG	A202555	001	Aug 23, 2017	Aug NEWA
AB		360MG	A202555	002	Aug 23, 2017	Aug NEWA

NABILONE

CAPSULE;ORAL

CESAMET

+!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar CAHN
----	---------------------	-----	---------	-----	--------------	----------

NADOLOL

TABLET;ORAL

NADOLOL

AB	AMNEAL PHARMS CO	20MG	A208832	001	Jun 02, 2017	May NEWA
AB		40MG	A208832	002	Jun 02, 2017	May NEWA
AB		80MG	A208832	003	Jun 02, 2017	May NEWA
AB	LUPIN LTD	20MG	A209309	001	Oct 05, 2017	Sep NEWA
AB		40MG	A209309	002	Oct 05, 2017	Sep NEWA
AB		80MG	A209309	003	Oct 05, 2017	Sep NEWA
AB	ZYDUS PHARMS USA INC	20MG	A207761	001	Jul 28, 2017	Jul NEWA
AB		40MG	A207761	002	Jul 28, 2017	Jul NEWA
AB		80MG	A207761	003	Jul 28, 2017	Jul NEWA

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB	TOLMAR	2%	A206960	001	Apr 10, 2017	Mar NEWA
----	--------	----	---------	-----	--------------	----------

NALDEMEDINE TOSYLATE

TABLET;ORAL

SYMPROIC

+!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar NEWA
----	--------------	---------------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

@ WEST-WARD PHARMS INT 0.4MG/ML

@ 0.4MG/ML

NALOXONE HYDROCHLORIDE

AP	AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb NEWA
AP		0.4MG/ML	A208872	001	Mar 14, 2017	Feb NEWA
AP	SOMERSET THERAPS LLC	0.4MG/ML	A207633	001	Aug 08, 2017	Jul NEWA
AP		0.4MG/ML	A207634	001	Jul 26, 2017	Jul NEWA

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+	@ KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014	Aug DISC
---	-------------	---------------------------	---------	-----	--------------	----------

SPRAY, METERED;NASAL

NARCAN

+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan NEWA
---	-------	-----------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TARGINIQ

>D>	@	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014	Oct	CRLD
>A>	+	@	5MG;10MG	N205777	001	Jul 23, 2014	Oct	CRLD
>D>	@		10MG;20MG	N205777	002	Jul 23, 2014	Oct	CRLD
>A>	+	@	10MG;20MG	N205777	002	Jul 23, 2014	Oct	CRLD
>D>	@		20MG;40MG	N205777	003	Jul 23, 2014	Oct	CRLD
>A>	+	@	20MG;40MG	N205777	003	Jul 23, 2014	Oct	CRLD

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

AB		NALTREXONE HYDROCHLORIDE						
		APOTEX INC	50MG	A207905	001	Jul 21, 2017	Jul	NEWA

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

>D>		TROXYCA ER						
>D>		PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016	Oct	DISC
>A>	@		1.2MG;10MG	N207621	001	Aug 19, 2016	Oct	DISC
>D>			2.4MG;20MG	N207621	002	Aug 19, 2016	Oct	DISC
>A>	@		2.4MG;20MG	N207621	002	Aug 19, 2016	Oct	DISC
>D>			3.6MG;30MG	N207621	003	Aug 19, 2016	Oct	DISC
>A>	@		3.6MG;30MG	N207621	003	Aug 19, 2016	Oct	DISC
>D>			4.8MG;40MG	N207621	004	Aug 19, 2016	Oct	DISC
>A>	@		4.8MG;40MG	N207621	004	Aug 19, 2016	Oct	DISC
>D>			7.2MG;60MG	N207621	005	Aug 19, 2016	Oct	DISC
>A>	@		7.2MG;60MG	N207621	005	Aug 19, 2016	Oct	DISC
>D>			9.6MG;80MG	N207621	006	Aug 19, 2016	Oct	DISC
>A>	@		9.6MG;80MG	N207621	006	Aug 19, 2016	Oct	DISC

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

!		LUITPOLD PHARMS INC	200MG/ML	A091252	001	Aug 30, 2010	Jun	CAHN
---	--	---------------------	----------	---------	-----	--------------	-----	------

NAPROXEN

TABLET; ORAL
NAPROXEN

AB		AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan	CAHN
AB			375MG	A200429	002	Nov 08, 2011	Jan	CAHN
AB			500MG	A200429	003	Nov 08, 2011	Jan	CAHN
	@	CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995	May	CAHN
	@		375MG	A074410	002	Apr 28, 1995	May	CAHN
	@		500MG	A074410	003	Apr 28, 1995	May	CAHN
	@	HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	May	DISC
	@		375MG	A076494	002	Jan 14, 2004	May	DISC
	@		500MG	A076494	003	Jan 14, 2004	May	DISC
	@	WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995	May	CAHN
	@		375MG	A074163	002	Feb 10, 1995	May	CAHN
	@		500MG	A074163	003	Feb 10, 1995	May	CAHN
		TABLET, DELAYED RELEASE; ORAL						
		NAPROXEN						
>D>	AB	MYLAN PHARMS INC	375MG	A075390	001	Apr 19, 2001	Oct	DISC
>A>	@		375MG	A075390	001	Apr 19, 2001	Oct	DISC
>D>	AB		500MG	A075390	002	Apr 19, 2001	Oct	DISC
>A>	@		500MG	A075390	002	Apr 19, 2001	Oct	DISC

NAPROXEN SODIUM

TABLET; ORAL

		NAPROXEN SODIUM						
AB		GLENMARK PHARMS LTD	EQ 250MG BASE	A078314	001	Apr 27, 2007	May	CAHN
AB			EQ 500MG BASE	A078314	002	Apr 27, 2007	May	CAHN

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+	!	NOVARTIS PHARMS CORP	5%	N050514	001		Jan	CAHN
---	---	----------------------	----	---------	-----	--	-----	------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL							
NEBIVOLOL HYDROCHLORIDE							
AB	@	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	May DISC
			EQ 2.5MG BASE	A203821	001	May 25, 2017	May NEWA
AB	@		EQ 5MG BASE	A203821	002	May 25, 2017	May DISC
			EQ 5MG BASE	A203821	002	May 25, 2017	May NEWA
AB	@		EQ 10MG BASE	A203821	003	May 25, 2017	May DISC
			EQ 10MG BASE	A203821	003	May 25, 2017	May NEWA
AB	@		EQ 20MG BASE	A203821	004	May 25, 2017	May DISC
			EQ 20MG BASE	A203821	004	May 25, 2017	May NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL						
BYVALSON						
+!	FOREST LABS LLC	EQ 5MG BASE; 80MG	N206302	001	Jun 03, 2016	May CRLD

NELFINAVIR MESYLATE

POWDER; ORAL						
VIRACEPT						
@	AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997	Jan CAHN
TABLET; ORAL						
VIRACEPT						
+	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997	Jan CAHN
+		EQ 625MG BASE	N021503	001	Apr 30, 2003	Jan CAHN

NEOMYCIN SULFATE

TABLET; ORAL							
NEOMYCIN SULFATE							
AA	BRECKENRIDGE PHARM	500MG	A065468	001	Mar 29, 2010	Sep	CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION						
NEOSPORIN G.U. IRRIGANT						
AT	!	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A060707	001	Apr CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS								
NEOSTIGMINE METHYLSULFATE								
AP	AMPHASTAR PHARMS INC	5MG/10ML (0.5MG/ML)	A209933	001	Sep 25, 2017	Sep	NEWA	
AP		10MG/10ML (1MG/ML)	A209933	002	Sep 25, 2017	Sep	NEWA	
AP	PAR STERILE PRODUCTS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	NEWA	
AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	NEWA	

NERATINIB MALEATE

TABLET; ORAL						
NERLYNX						
+	PUMA BIOTECH	EQ 40MG BASE	N208051	001	Jul 17, 2017	Jul NEWA

NEVIRAPINE

	SUSPENSION;ORAL					
	NEVIRAPINE					
AA	CIPLA LTD	50MG/5ML	A207684	001	Aug 03, 2017	Jul NEWA
	TABLET;ORAL					
	NEVIRAPINE					
AB	TECH ORGANIZED	200MG	A203176	001	May 22, 2012	Sep CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	NEVIRAPINE					
AB	AUROBINDO PHARMA LTD	400MG	A207698	001	Feb 28, 2017	Mar CAHN
AB	AUROBINDO PHARMA USA	400MG	A207698	001	Feb 28, 2017	Feb NEWA
AB	MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Sep NEWA
AB	SCIEGEN PHARMS INC	100MG	A207467	001	Jul 31, 2017	Jul NEWA
AB		400MG	A207467	002	Jul 31, 2017	Jul NEWA
AB	TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017	Sep CAHN
AB		400MG	A207467	002	Jul 31, 2017	Sep CAHN

NIACIN

TABLET; ORAL

NIACOR

>A>	AA	!	AVONDALE PHARMS	500MG	A040378	001	May 03, 2000	Oct	CAHN
>D>	AA	!	UPSHER-SMITH LABS	500MG	A040378	001	May 03, 2000	Oct	CAHN
	AA	!		500MG	A040378	001	May 03, 2000	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB			LANNETT	500MG	A203899	001	Jun 16, 2017	Jun	NEWA
AB				1GM	A203899	002	Jun 16, 2017	Jun	NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP			WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jan	CAHN
----	--	--	----------------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE; INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

			EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Feb	NEWA
				40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Feb	NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

AFEDITAB CR

AB1			WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000	May	CAHN
			NIFEDIPINE						
		@	MYLAN LABS LTD	30MG	A090602	001	Sep 13, 2010	May	DISC
AB2				30MG	A090602	001	Sep 13, 2010	Mar	CAHN
		@		60MG	A090602	002	Sep 13, 2010	May	DISC
AB2				60MG	A090602	002	Sep 13, 2010	Mar	CAHN
		@		90MG	A090602	003	Sep 13, 2010	May	DISC
AB2				90MG	A090602	003	Sep 13, 2010	Mar	CAHN
AB2			OSMOTICA PHARM US	90MG	A077410	001	Oct 03, 2007	Jun	CAHN

NIRAPARIB TOSYLATE

CAPSULE; ORAL

ZEJULA

+	!		TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017	Mar	NEWA
---	---	--	------------	---------------	---------	-----	--------------	-----	------

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

AB	+	!	COVIS PHARMA BV	8.5MG	N020356	008	Jan 02, 2008	May	CAHN
		@		10MG	N020356	001	Feb 02, 1995	May	CAHN
AB	+	!		17MG	N020356	007	Jan 02, 2008	May	CAHN
		@		20MG	N020356	002	Feb 02, 1995	May	CAHN
		@		25.5MG	N020356	006	Jan 02, 2008	May	CAHN
		@		30MG	N020356	003	Feb 02, 1995	May	CAHN
AB	+	!		34MG	N020356	005	Jan 02, 2008	May	CAHN
		@		40MG	N020356	004	Feb 02, 1995	May	CAHN

NITISINONE

CAPSULE; ORAL

ORFADIN

>D>		+	!	SWEDISH ORPHAN	10MG	N021232	003	Jan 18, 2002	Oct	CHRS
>A>			+		10MG	N021232	003	Jan 18, 2002	Oct	CHRS

TABLET; ORAL

NITYR

+			CYCLE PHARMS LTD	2MG	N209449	001	Jul 26, 2017	Jul	NEWA
+				5MG	N209449	002	Jul 26, 2017	Jul	NEWA
+	!			10MG	N209449	003	Jul 26, 2017	Jul	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB			AMNEAL PHARMS	75MG; 25MG	A207372	001	May 15, 2017	May	NEWA
----	--	--	---------------	------------	---------	-----	--------------	-----	------

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL
NITRO-DUR

AB1	+	!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jun	CAHN
AB1	+	!		0.2MG/HR	N020145	002	Apr 04, 1995	Jun	CAHN
		+		0.3MG/HR	N020145	003	Apr 04, 1995	Jun	CAHN
AB1	+	!		0.4MG/HR	N020145	004	Apr 04, 1995	Jun	CAHN
AB1	+	!		0.6MG/HR	N020145	005	Apr 04, 1995	Jun	CAHN
		+		0.8MG/HR	N020145	006	Apr 04, 1995	Jun	CAHN

OINTMENT;TRANSDERMAL
NITROGLYCERIN

!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Jan	CAHN
---	--------------------	----	---------	-----	--------------	-----	------

TABLET;SUBLINGUAL

NITROGLYCERIN

>A>	AB		ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017	Oct	NEWA
>A>	AB			0.4MG	A203693	002	Oct 16, 2017	Oct	NEWA
>A>	AB			0.6MG	A203693	003	Oct 16, 2017	Oct	NEWA
	AB		GLENMARK PHARMS LTD	0.3MG	A206391	001	Sep 19, 2017	Sep	NEWA
	AB			0.4MG	A206391	002	Sep 19, 2017	Sep	NEWA
	AB			0.6MG	A206391	003	Sep 19, 2017	Sep	NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP			BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Aug	CAHN
AP			WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan	CAHN

NORGESTREL

TABLET;ORAL

>A>			OPILL						
>A>		+	@ LABORATOIRE HRA	0.075MG	N017031	001		Oct	CTNA
>D>			OVRETTE						
>D>			@ LABORATOIRE HRA	0.075MG	N017031	001		Oct	CRLD
>A>		+	@	0.075MG	N017031	001		Oct	CRLD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

	@	MYLAN	EQ 10MG BASE	A074234	001	Jul 26, 1993	Jun	DISC
	@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Jun	DISC
	@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Jun	DISC
	@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Jun	DISC
AB		TARO PHARM	EQ 10MG BASE	A075520	004	May 08, 2000	Mar	CAHN
AB			EQ 25MG BASE	A075520	003	May 08, 2000	Mar	CAHN
AB			EQ 50MG BASE	A075520	001	May 08, 2000	Mar	CAHN
AB			EQ 75MG BASE	A075520	002	May 08, 2000	Mar	CAHN

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	May	CAHN
----	---	-------------	------------------	---------	-----	--------------	-----	------

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT			CROWN LABS INC	100,000 UNITS/GM	A207733	001	Sep 26, 2017	Sep	NEWA
----	--	--	----------------	------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

NYSTATIN

AT			G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017	Sep	NEWA
----	--	--	------------------	------------------	---------	-----	--------------	-----	------

PASTILLE;ORAL

MYCOSTATIN

	@	DELCOR ASSET CORP	200,000 UNITS	N050619	001	Apr 09, 1987	Jun	CAHN
--	---	-------------------	---------------	---------	-----	--------------	-----	------

POWDER;TOPICAL

NYSTATIN

AT			LYNE	100,000 UNITS/GM	A208838	001	May 30, 2017	May	NEWA
AT			NESHER PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	May	NEWA
AT			UPSHER-SMITH LABS	100,000 UNITS/GM	A065183	001	May 03, 2005	Jun	CAHN

SUSPENSION;ORAL

NYSTATIN

	@	ALLIED PHARMA INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jul	CAHN
AA		FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan	CAHN
AA		PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	May	CAHN
AA		TARO PHARM	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Apr	CAHN

TABLET;ORAL

NYSTATIN

@ USL PHARMA

500,000 UNITS

A062524 001 Nov 26, 1985 Jun CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYCOLOG-II

@ MYLAN PHARMS INC

100,000 UNITS/GM;0.1%

A062606 001 May 15, 1985 Jan CAHN

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT FOUGERA PHARMS INC

100,000 UNITS/GM;0.1%

A062599 001 Oct 08, 1985 Jan CAHN

AT PERRIGO UK FINCO

100,000 UNITS/GM;0.1%

A208479 001 Aug 14, 2017 Jul NEWA

OINTMENT;TOPICAL

MYCOLOG-II

@ MYLAN PHARMS INC

100,000 UNITS/GM;0.1%

A060572 001 Jun 28, 1985 Jan CAHN

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT AKORN

100,000 UNITS/GM;0.1%

A207217 001 Aug 04, 2017 Jul NEWA

AT DR REDDYS LABS LTD

100,000 UNITS/GM;0.1%

A207741 001 Jan 31, 2017 Jan NEWA

AT FOUGERA PHARMS INC

100,000 UNITS/GM;0.1%

A062602 001 Oct 09, 1985 Jan CAHN

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

@ SUN PHARM INDS

EQ 0.05MG BASE/ML

A077329 001 Mar 04, 2008 Sep DISC

@

EQ 0.1MG BASE/ML

A077329 002 Mar 04, 2008 Sep DISC

>D> AP

@

EQ 0.2MG BASE/ML

A077330 001 Mar 04, 2008 Oct DISC

>A>

@

EQ 0.2MG BASE/ML

A077330 001 Mar 04, 2008 Oct DISC

@

EQ 0.5MG BASE/ML

A077329 003 Mar 04, 2008 Sep DISC

>D> AP

@

EQ 1MG BASE/ML

A077331 001 Mar 04, 2008 Oct DISC

>A>

@

EQ 1MG BASE/ML

A077331 001 Mar 04, 2008 Oct DISC

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT SANDOZ INC

0.3%

A076231 001 May 14, 2004 Feb CAHN

SOLUTION/DROPS;OTIC

OFLOXACIN

AT SANDOZ INC

0.3%

A078222 001 Mar 17, 2008 Feb CAHN

OLANZAPINE

TABLET;ORAL

OLANZAPINE

>D> AB AJANTA PHARMA LTD

2.5MG

A206711 001 Aug 30, 2016 Oct DISC

>A>

@

2.5MG

A206711 001 Aug 30, 2016 Oct DISC

>D> AB

@

5MG

A206711 002 Aug 30, 2016 Oct DISC

>A>

@

5MG

A206711 002 Aug 30, 2016 Oct DISC

>D> AB

@

7.5MG

A206711 003 Aug 30, 2016 Oct DISC

>A>

@

7.5MG

A206711 003 Aug 30, 2016 Oct DISC

>D> AB

@

10MG

A206711 004 Aug 30, 2016 Oct DISC

>A>

@

10MG

A206711 004 Aug 30, 2016 Oct DISC

>D> AB

@

15MG

A206711 005 Aug 30, 2016 Oct DISC

>A>

@

15MG

A206711 005 Aug 30, 2016 Oct DISC

>D> AB

@

20MG

A206711 006 Aug 30, 2016 Oct DISC

>A>

@

20MG

A206711 006 Aug 30, 2016 Oct DISC

AB HIKMA PHARMS

2.5MG

A204866 001 Jun 16, 2017 Jun NEWA

AB

5MG

A204866 002 Jun 16, 2017 Jun NEWA

AB

7.5MG

A204866 003 Jun 16, 2017 Jun NEWA

AB

10MG

A204866 004 Jun 16, 2017 Jun NEWA

AB

15MG

A204866 005 Jun 16, 2017 Jun NEWA

AB

20MG

A204866 006 Jun 16, 2017 Jun NEWA

@ MYLAN PHARMS INC

2.5MG

A076866 001 Apr 23, 2012 Jun DISC

AB

2.5MG

A076866 001 Apr 23, 2012 Mar CAHN

@

5MG

A076866 002 Apr 23, 2012 Jun DISC

AB

5MG

A076866 002 Apr 23, 2012 Mar CAHN

@

7.5MG

A076866 003 Apr 23, 2012 Jun DISC

AB

7.5MG

A076866 003 Apr 23, 2012 Mar CAHN

@

10MG

A076866 004 Apr 23, 2012 Jun DISC

AB

10MG

A076866 004 Apr 23, 2012 Mar CAHN

@

15MG

A076866 005 Apr 23, 2012 Jun DISC

AB

15MG

A076866 005 Apr 23, 2012 Mar CAHN

@

20MG

A076866 006 Apr 23, 2012 Jun DISC

AB

20MG

A076866 006 Apr 23, 2012 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	May NEWA
AB		10MG	A204320	002	May 30, 2017	May NEWA
AB		15MG	A204320	003	May 30, 2017	May NEWA
AB		20MG	A204320	004	May 30, 2017	May NEWA

OLAPARIB

CAPSULE;ORAL

LYNPARZA

+!	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Mar CRLD
TABLET;ORAL						
LYNPARZA						
+	ASTRAZENECA PHARMS	100MG	N208558	001	Aug 17, 2017	Aug NEWA
+	!	150MG	N208558	002	Aug 17, 2017	Aug NEWA

OLIVE OIL; SOYBEAN OIL

INJECTABLE;INJECTION

CLINOLIPID 20%

+	@ BAXTER HLTHCARE CORP	16% (160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jul DISC
---	------------------------	-------------------------------------	---------	-----	--------------	----------

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	ACCORD HLTHCARE	5MG	A207662	001	Apr 24, 2017	Apr NEWA
AB		20MG	A207662	002	Apr 24, 2017	Apr NEWA
AB		40MG	A207662	003	Apr 24, 2017	Apr NEWA
AB	ALEMBIC PHARMS LTD	5MG	A203012	001	Apr 24, 2017	Apr NEWA
AB		20MG	A203012	002	Apr 24, 2017	Apr NEWA
AB		40MG	A203012	003	Apr 24, 2017	Apr NEWA
AB	ALKEM LABS LTD	5MG	A206763	001	Apr 24, 2017	Apr NEWA
AB		20MG	A206763	002	Apr 24, 2017	Apr NEWA
AB		40MG	A206763	003	Apr 24, 2017	Apr NEWA
AB	AUROBINDO PHARMA LTD	5MG	A204798	001	Apr 24, 2017	Apr NEWA
AB		20MG	A204798	002	Apr 24, 2017	Apr NEWA
AB		40MG	A204798	003	Apr 24, 2017	Apr NEWA
AB	GLENMARK PHARMS LTD	5MG	A203281	001	May 25, 2017	May NEWA
AB		20MG	A203281	002	May 25, 2017	May NEWA
AB		40MG	A203281	003	May 25, 2017	May NEWA
AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Apr NEWA
AB		20MG	A205482	002	Apr 24, 2017	Apr NEWA
AB		40MG	A205482	003	Apr 24, 2017	Apr NEWA
AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Apr NEWA
AB		20MG	A206631	002	Apr 27, 2017	Apr NEWA
AB		40MG	A206631	003	Apr 27, 2017	Apr NEWA
AB	MACLEODS PHARMS LTD	5MG	A204814	001	Apr 24, 2017	Apr NEWA
AB		20MG	A204814	002	Apr 24, 2017	Apr NEWA
AB		40MG	A204814	003	Apr 24, 2017	Apr NEWA
AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Apr NEWA
AB		20MG	A091079	002	Apr 24, 2017	Apr NEWA
AB		40MG	A091079	003	Apr 24, 2017	Apr NEWA
AB	TORRENT PHARMS LTD	5MG	A202375	001	Apr 24, 2017	Apr NEWA
AB		20MG	A202375	002	Apr 24, 2017	Apr NEWA
AB		40MG	A202375	003	Apr 24, 2017	Apr NEWA
AB	ZYDUS PHARMS USA INC	5MG	A205192	001	Apr 24, 2017	Apr NEWA
AB		20MG	A205192	002	Apr 24, 2017	Apr NEWA
AB		40MG	A205192	003	Apr 24, 2017	Apr NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	CIPLA LTD	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Jul NEWA
AT	WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jun NEWA
AT	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Sep CAHN
SPRAY, METERED;NASAL						
OLOPATADINE HYDROCHLORIDE						
AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan NEWA

OLSALAZINE SODIUMCAPSULE;ORAL
DIPENTUM

+	!	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Mar CAHN
---	---	---------------------	-------	---------	-----	--------------	----------

OMACETAXINE MEPESUCCINATEPOWDER;SUBCUTANEOUS
SYNRIBO

+	!	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Apr CAHN
---	---	------------------	------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	May CAHN
----	--	---------------	--	---------	-----	--------------	----------

AB		STRIDES PHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A203893	001	Sep 19, 2017	Sep NEWA
----	--	----------------	--	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL

OMTRYG

+	@	OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Sep DISC
---	---	----------	--	---------	-----	--------------	----------

+	!		1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Sep CAHN
---	---	--	--	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB		AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan CAHN
AB			20MG	A203270	002	Aug 19, 2015	Jan CAHN
AB			40MG	A203270	003	Aug 19, 2015	Jan CAHN
AB		BRECKENRIDGE PHARM	10MG	A203481	001	Jul 03, 2017	Jun NEWA
AB			20MG	A203481	002	Jul 03, 2017	Jun NEWA
AB			40MG	A203481	003	Jul 03, 2017	Jun NEWA
AB		TEVA PHARMS USA	20MG	A204661	001	Jun 13, 2017	May NEWA
AB			40MG	A204661	002	Jun 13, 2017	May NEWA

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

+		COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	May CAHN
+	!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	May CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan CTEC
AB			40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan CTEC
AB		PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan CMFD
AB			40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan CMFD
		ZEGERID					
AB	+	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan CTEC
AB	+	!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan CTEC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@ CHARTWELL MOLECULES

@

@

@

@

			4MG	A076506	001	Dec 26, 2006	Mar CAHN
			8MG	A076506	002	Dec 26, 2006	Mar CAHN
			16MG	A077406	001	Dec 26, 2006	Mar CAHN
			24MG	A077406	002	Dec 26, 2006	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CAHN
AP		MYLAN LABS LTD	EQ 2MG BASE/ML	A204906	001	Jul 31, 2017	Jul NEWA
AP		SANDOZ INC	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar CAHN
>D>	AP	SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006	Oct DISC
>A>	@		EQ 2MG BASE/ML	A077172	001	Dec 26, 2006	Oct DISC
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan CAHN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CAHN
AP		SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar CAHN
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan CAHN
AP			EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION
NORFLEX

@ TELIGENT 30MG/ML

N013055 001 Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

NORFLEX

+ @ MEDICIS 100MG

N012157 001 Aug CRLD

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		AMNEAL PHARMS	EQ 30MG BASE	A209093	001	May 17, 2017	May NEWA
AB			EQ 45MG BASE	A209093	002	May 17, 2017	May NEWA
AB			EQ 75MG BASE	A209093	003	May 17, 2017	May NEWA
AB		MACLEODS PHARMS LTD	EQ 30MG BASE	A207211	001	Sep 14, 2017	Sep NEWA
AB			EQ 45MG BASE	A207211	002	Sep 14, 2017	Sep NEWA
AB			EQ 75MG BASE	A207211	003	Sep 14, 2017	Sep NEWA
AB		NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb NEWA
AB			EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb NEWA
AB			EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb NEWA
FOR SUSPENSION;ORAL							
OSELTAMIVIR PHOSPHATE							
>A>	AB	ALVOGEN PINE BROOK	EQ 6MG BASE/ML	A208823	001	Oct 31, 2017	Oct NEWA
	AB	NESHER PHARMS	EQ 6MG BASE/ML	A209113	001	Sep 14, 2017	Sep NEWA
TAMIFLU							
AB	+!	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Sep CFTG

OSPEMIFENE

TABLET;ORAL

OSPHERA

+! DUCHESNAY 60MG

N203505 001 Feb 26, 2013 Mar CAHN

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

>D>	AP	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Oct DISC
>A>	@		EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Oct DISC
>D>	AP		EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Oct DISC
>A>	@		EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Oct DISC
	AP	RENAISSANCE SSA LLC	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Aug NEWA
	AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Aug NEWA
>A>	AP		EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Oct NEWA
	AP	WOCKHARDT BIO AG	EQ 1GM BASE/VIAL	A207147	001	Jul 31, 2017	Jul NEWA
	AP		EQ 2GM BASE/VIAL	A207147	002	Jul 31, 2017	Jul NEWA

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

+ @ SANOFI AVENTIS US 200MG/40ML (5MG/ML)

N021759 003 Nov 17, 2006 Jan CRLD

OXALIPLATIN

AP		ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Mar NEWA
AP			100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Mar NEWA
AP			200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Mar NEWA
AP		CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan NEWA
AP			100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan NEWA
AP		FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan NEWA

INJECTABLE;IV (INFUSION)
OXALIPLATIN

AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan NEWA
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan NEWA
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan NEWA
AP		50MG/VIAL	A207385	001	May 23, 2017	May NEWA
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan NEWA
AP		100MG/VIAL	A207385	002	May 23, 2017	May NEWA
>A>	AP	200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Oct NEWA
AP	LUITPOLD PHARMS INC	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	May NEWA
AP		100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	May NEWA
>A>	AP	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Oct NEWA
AP	! QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan CTEC
AP	SANJA PHARMS CO	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Aug NEWA
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Aug NEWA

OXANDROLONE

TABLET;ORAL
OXANDROLONE

AB	UPSHER-SMITH LABS	2.5MG	A076761	001	Dec 01, 2006	Jun CAHN
AB		10MG	A078033	001	Mar 22, 2007	Jun CAHN

OXAPROZIN

TABLET;ORAL
OXAPROZIN

AB	AMNEAL PHARMS CO	600MG	A208633	001	May 04, 2017	Apr NEWA
----	------------------	-------	---------	-----	--------------	----------

OXAZEPAM

CAPSULE;ORAL
OXAZEPAM

AB	ACTAVIS ELIZABETH	10MG	A072253	002	Apr 14, 1988	May CMS1
AB		15MG	A072253	003	Apr 14, 1988	May CMS1
	@ ANDA REPOSITORY	10MG	A071026	002	Aug 10, 1987	Sep CAHN
	@	15MG	A071026	003	Aug 10, 1987	Sep CAHN
	@	30MG	A071026	001	Aug 10, 1987	Sep CAHN
	@ WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990	May CAHN

TABLET;ORAL
OXAZEPAM

	@ SUN PHARM INDUSTRIES	15MG	A070683	001	Jan 16, 1987	Jan CAHN
--	------------------------	------	---------	-----	--------------	----------

OXCARBAZEPINE

TABLET;ORAL
OXCARBAZEPINE

AB	GLENMARK PHARMS LTD	150MG	A077802	001	Oct 09, 2007	May CAHN
AB		300MG	A077802	002	Oct 09, 2007	May CAHN
AB		600MG	A077802	003	Oct 09, 2007	May CAHN
	@ JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010	Sep DISC
AB		150MG	A090239	001	Jan 25, 2010	Apr CAHN
	@	300MG	A090239	002	Jan 25, 2010	Sep DISC
AB		300MG	A090239	002	Jan 25, 2010	Apr CAHN
	@	600MG	A090239	003	Jan 25, 2010	Sep DISC
AB		600MG	A090239	003	Jan 25, 2010	Apr CAHN

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
CHOLEDYL SA

	@ WARNER CHILCOTT LLC	600MG	A086742	001		Sep DISC
--	-----------------------	-------	---------	-----	--	----------

OXYBUTYNIN CHLORIDE

SYRUP;ORAL
DITROPAN

	+ @ ORTHO MCNEIL JANSSEN	5MG/5ML	N018211	001		Jan CRLD
--	--------------------------	---------	---------	-----	--	----------

AA	PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	May CAHN
----	-------------	---------	---------	-----	--------------	----------

TABLET;ORAL
OXYBUTYNIN CHLORIDE

>A>	AB	NOVITIUM PHARMA	5MG	A209823	001	Oct 23, 2017	Oct NEWA
	AB	UPSHER-SMITH LABS	5MG	A074625	001	Jul 31, 1996	Sep CAHN
	AB	USL PHARMA	5MG	A074625	001	Jul 31, 1996	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
OXYBUTYNIN CHLORIDE

AB	UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	Aug CAHN
----	-------------------	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
OXYBUTYNIN CHLORIDE

AB		10MG	A206121	002	May 27, 2016	Aug CAHN
AB		15MG	A206121	003	May 27, 2016	Aug CAHN
AB	ZYDUS PHARMS USA INC	5MG	A202332	001	Jun 26, 2017	Jun NEWA
AB		10MG	A202332	002	Jun 26, 2017	Jun NEWA
AB		15MG	A202332	003	Jun 26, 2017	Jun NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	ABHAI LLC	5MG/5ML	A208593	001	Jul 21, 2017	Jul NEWA	
AA		100MG/5ML	A208593	002	Jul 21, 2017	Jul NEWA	
AA	ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Aug NEWA	
>A>	AA	ASCENT PHARMS INC	5MG/5ML	A209021	001	Nov 09, 2017	Oct NEWA
>A>	AA		A209021	002	Nov 09, 2017	Oct NEWA	
AA	HI-TECH PHARMACAL	5MG/5ML	A208817	001	Aug 10, 2017	Jul NEWA	
AA		100MG/5ML	A208795	001	Aug 07, 2017	Jul NEWA	
AA	PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017	Jul NEWA	
AA	WES PHARMA INC	100MG/5ML	A209897	001	Sep 06, 2017	Aug NEWA	

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	15MG	A207418	001	Aug 07, 2017	Jul NEWA
AB		30MG	A207418	002	Aug 07, 2017	Jul NEWA
AB	EPIC PHARMA LLC	5MG	A090895	001	Aug 24, 2009	May CAHN
AB		15MG	A090895	002	Aug 24, 2009	May CAHN
AB		30MG	A090895	003	Aug 24, 2009	May CAHN
AB	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	May NEWA
AB		10MG	A204021	002	Jun 12, 2017	May NEWA
AB		15MG	A204021	003	Jun 12, 2017	May NEWA
AB		20MG	A204021	004	Jun 12, 2017	May NEWA
AB		30MG	A204021	005	Jun 12, 2017	May NEWA

ROXYBOND

	DAIICHI SANKYO INC	5MG	N209777	001	Apr 20, 2017	Aug CAHN
		15MG	N209777	002	Apr 20, 2017	Aug CAHN
		30MG	N209777	003	Apr 20, 2017	Aug CAHN
	INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017	Apr NEWA
		15MG	N209777	002	Apr 20, 2017	Apr NEWA
		30MG	N209777	003	Apr 20, 2017	Apr NEWA

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADE

+!	ALLERGAN INC	1%	N208552	001	Jan 18, 2017	Jan NEWA
----	--------------	----	---------	-----	--------------	----------

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+!	MYLAN SPECIALITY LP	50MG	N016848	001		Mar CAHN
----	---------------------	------	---------	-----	--	----------

OXYMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

OPANA

+	@ ENDO PHARMS	1MG/ML	N011707	002		Aug DISC
---	---------------	--------	---------	-----	--	----------

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A201187	001	Dec 15, 2014	May CAHN
AB		10MG	A201187	002	Dec 15, 2014	May CAHN

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

+	@ ENDO PHARMS	5MG	N201655	001	Dec 09, 2011	Aug DISC
+	@	7.5MG	N201655	002	Dec 09, 2011	Aug DISC
+	@	10MG	N201655	003	Dec 09, 2011	Aug DISC
+	@	15MG	N201655	004	Dec 09, 2011	Aug DISC
+	@	20MG	N201655	005	Dec 09, 2011	Aug DISC
+	@	30MG	N201655	006	Dec 09, 2011	Aug DISC
+	@	40MG	N201655	007	Dec 09, 2011	Aug DISC

OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Apr CAHN
AB		7.5MG	A079046	001	Dec 13, 2010	Apr CAHN
AB		10MG	A079046	004	Jul 11, 2013	Apr CAHN
AB		15MG	A079046	002	Dec 13, 2010	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

AB		20MG	A079046	005	Jul 11, 2013	Apr CAHN
AB		30MG	A079046	006	Jul 11, 2013	Apr CAHN
AB		40MG	A079046	007	Jul 11, 2013	Apr CAHN
	@ PAR PHARM	5MG	A200792	001	Oct 24, 2014	May DISC
	@	7.5MG	A200792	002	Oct 24, 2014	May DISC
	@	10MG	A200792	003	Oct 24, 2014	May DISC
	@	15MG	A200792	004	Oct 24, 2014	May DISC
	@	20MG	A200792	005	Oct 24, 2014	May DISC
	@	30MG	A200792	006	Oct 24, 2014	May DISC
	@	40MG	A200792	007	Oct 24, 2014	May DISC

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

!	CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015	001		Jul CAHN
---	-------------------	--------------------------------	---------	-----	--	----------

PALONOSETRON HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	@ DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Sep DISC
	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Sep DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

PERTZYE

+	DIGESTIVE CARE INC	90,750USP UNITS;24,000USP UNITS;86,250USP UNITS	N022175	004	Jul 13, 2017	Sep NEWA
---	--------------------	---	---------	-----	--------------	----------

PANTOPRAZOLE SODIUM

POWDER;IV (INFUSION)

PANTOPRAZOLE SODIUM

EXELA PHARMA SCS LLC EQ 40MG BASE/VIAL

N209463	001	Jun 30, 2017	Jun NEWA
---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

	@ SUN PHARM INDS LTD	EQ 20MG BASE	A077058	001	Sep 10, 2007	Sep DISC
AB		EQ 20MG BASE	A077058	001	Sep 10, 2007	Mar CAHN
	@	EQ 40MG BASE	A077058	002	Sep 10, 2007	Sep DISC
AB		EQ 40MG BASE	A077058	002	Sep 10, 2007	Mar CAHN

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016	May CAHN
AB		2MCG	A204327	002	Jan 13, 2016	May CAHN
AB		4MCG	A204327	003	Jan 13, 2016	May CAHN

ZEMPLAR

>D>	AB	ABBVIE	1MCG	N021606	001	May 26, 2005	Oct CRLD
>A>	AB	+	1MCG	N021606	001	May 26, 2005	Oct CRLD
>D>	AB		2MCG	N021606	002	May 26, 2005	Oct CRLD
>A>	AB	+	2MCG	N021606	002	May 26, 2005	Oct CRLD
>D>		@	4MCG	N021606	003	May 26, 2005	Oct CRLD
>A>		+ @	4MCG	N021606	003	May 26, 2005	Oct CRLD

SOLUTION;INTRAVENOUS

PARICALCITOL

>A>	AP	AKORN	0.005MG/ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Oct NEWA
	AP	AMNEAL PHARMS CO	0.002MG/ML (0.002MG/ML)	A206699	001	Mar 09, 2017	Feb NEWA
	AP		0.005MG/ML (0.005MG/ML)	A206699	002	Mar 09, 2017	Feb NEWA
	AP		0.01MG/2ML (0.005MG/ML)	A206699	003	Mar 09, 2017	Feb NEWA
>A>	AP	MYLAN LABS LTD	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Oct NEWA
>A>	AP		0.005MG/ML (0.005MG/ML)	A203897	002	Nov 02, 2017	Oct NEWA
>A>	AP		0.01MG/2ML (0.005MG/ML)	A203897	003	Nov 02, 2017	Oct NEWA
	AP	SANDOZ INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr CAHN
	AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr CAHN
	AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr CAHN

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAXIL

+! APOTEX TECHNOLOGIES EQ 10MG BASE/5ML

N020710 001 Jun 25, 1997 Sep CTEC

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

@ MYLAN PHARMS INC EQ 10MG BASE

A075716 001 Mar 08, 2004 Apr DISC

@ EQ 20MG BASE

A075716 002 Mar 08, 2004 Apr DISC

@ EQ 30MG BASE

A075716 003 Mar 08, 2004 Apr DISC

@ EQ 40MG BASE

A075716 004 Mar 08, 2004 Apr DISC

@ UPSHER-SMITH LABS EQ 10MG BASE

A075566 001 Mar 08, 2004 Jun CAHN

@ EQ 20MG BASE

A075566 002 Mar 08, 2004 Jun CAHN

@ EQ 30MG BASE

A075566 003 Mar 08, 2004 Jun CAHN

@ EQ 40MG BASE

A075566 004 Mar 08, 2004 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB LUPIN LTD EQ 12.5MG BASE

A204134 001 Jan 20, 2017 Jan NEWA

AB EQ 25MG BASE

A204134 002 Jan 20, 2017 Jan NEWA

AB EQ 37.5MG BASE

A204134 003 Jan 20, 2017 Jan NEWA

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

AB +! SEBELA IRELAND LTD EQ 7.5MG BASE

N204516 001 Jun 28, 2013 Jun CFTG

PAROXETINE MESYLATE

AB ACTAVIS LABS FL INC EQ 7.5MG BASE

A207139 001 Jun 20, 2017 Jun NEWA

AB PRINSTON INC EQ 7.5MG BASE

A207188 001 Aug 18, 2017 Aug NEWA

PENCICLOVIR

CREAM;TOPICAL

DENA VIR

+! MYLAN PHARMS INC 1%

N020629 001 Sep 24, 1996 Jan CAHN

PENICILLAMINE

TABLET;ORAL

DEPEN

+! MYLAN SPECIALITY LP 250MG

N019854 001 Mar CAHN

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

BICILLIN L-A

+! KING PHARMS LLC 300,000 UNITS/ML

N050141 003 May CAHN

BC +! 600,000 UNITS/ML

N050141 001 May CAHN

PERMAPEN

BC CASPER PHARMA LLC 600,000 UNITS/ML

A060014 001 Jul CAHN

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE;INJECTION

BICILLIN C-R

+! KING PHARMS LLC 150,000 UNITS/ML;150,000 UNITS/ML

N050138 002 Apr CAHN

+! 300,000 UNITS/ML;300,000 UNITS/ML

N050138 001 Apr CAHN

BICILLIN C-R 900/300

+! KING PHARMS LLC 900,000 UNITS/2ML;300,000 UNITS/2ML

N050138 003 Apr CAHN

PENICILLIN G PROCAINE

INJECTABLE;INJECTION

PENICILLIN G PROCAINE

! KING PHARMS LLC 300,000 UNITS/ML

A060101 002 Jun CAHN

! 600,000 UNITS/ML

A060101 001 Jun CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION

PENTAM

AP +! FRESENIUS KABI USA 300MG/VIAL

N019264 001 Oct 16, 1984 Sep CTEC

PENTAMIDINE ISETHIONATE

AP SETON PHARMS 300MG/VIAL

A206666 001 Sep 28, 2017 Sep NEWA

PENTOBARBITAL SODIUMINJECTABLE; INJECTION
PENTOBARBITAL SODIUM

>A>	AP	CUSTOPHARM INC	50MG/ML	A203619	001	Nov 13, 2017	Oct NEWA
	AP	SAGENT PHARMS	50MG/ML	A206404	001	May 23, 2016	Apr CAHN

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

		@ PLIVA	400MG	A074874	001	May 25, 1999	Aug CAHN
		PENTOXIL					
AB		UPSHER-SMITH LABS	400MG	A074962	001	Mar 31, 1999	Jun CAHN
		TRENTAL					
		+ @ US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan CRLD

PERINDOPRIL ERBUMINETABLET; ORAL
ACEON

		+ @ SYMPLMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993	May DISC
		+ @	4MG	N020184	002	Dec 30, 1993	May DISC
		+ @	8MG	N020184	003	Dec 30, 1993	May DISC
		PERINDOPRIL ERBUMINE					
AB	!	AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	May CHRS
AB	!		4MG	A079070	002	Nov 10, 2009	May CHRS
AB	!		8MG	A079070	003	Nov 10, 2009	May CHRS

PERMETHRINCREAM; TOPICAL
ELIMITE

AB	+	MYLAN PHARMS INC	5%	N019855	001	Aug 25, 1989	Jan CAHN
		PERMETHRIN					
AB		ACTAVIS LABS	5%	A074806	001	Jan 23, 1998	May CAHN

PERPHENAZINETABLET; ORAL
PERPHENAZINE

AB		MYLAN PHARMS INC	2MG	A206691	001	Apr 14, 2017	Apr NEWA
AB			4MG	A206691	002	Apr 14, 2017	Apr NEWA
AB			8MG	A206691	003	Apr 14, 2017	Apr NEWA
AB			16MG	A206691	004	Apr 14, 2017	Apr NEWA

PHENDIMETRAZINE TARTRATETABLET; ORAL
PHENDIMETRAZINE TARTRATE
@ USL PHARMA

		35MG	A084399	001		Jun CAHN
--	--	------	---------	-----	--	----------

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE; ORAL
PHENOXYBENZAMINE HYDROCHLORIDE

AB		PAR PHARM INC	10MG	A204522	001	Jan 24, 2017	Jan NEWA
----	--	---------------	------	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

		@ ELITE LABS INC	30MG	A040227	001	Jun 18, 1997	May CAHN
		@	30MG	A040448	001	Jan 22, 2003	May CAHN
AA			37.5MG	A040228	001	Jun 19, 1997	May CAHN
		@ UPSHER-SMITH LABS	30MG	A084487	001	Apr 09, 1982	Jun CAHN
		@	30MG	A088430	001	Mar 27, 1984	Jun CAHN

TABLET; ORAL

		PHENTERMINE HYDROCHLORIDE					
AA		ELITE LABS INC	37.5MG	A040190	001	May 30, 1997	May CAHN
AA		KVK TECH INC	8MG	A203436	001	Mar 17, 2017	Mar NEWA
AA		PRINSTON INC	37.5MG	A040377	001	Jan 04, 2002	Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
PHENTERMINE HYDROCHLORIDE

		ZYDUS PHARMS USA INC	15MG	A204663	001	Jun 28, 2017	Jun NEWA
			30MG	A204663	002	Jun 28, 2017	Jun NEWA
			37.5MG	A204663	003	Jun 28, 2017	Jun NEWA

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE

AP		PRECISION DOSE INC	5MG/VIAL	A207686	001	Jul 14, 2017	Jul NEWA
AP	!	WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	Jul CTEC
	!		5MG/VIAL	A040235	001	Mar 11, 1998	May CHRS
		REGITINE					
	+	@ NOVARTIS	5MG/VIAL	N008278	003		May DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)
VAZCULEP

	+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jan CAHN
	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jan CAHN
	+	!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jan CAHN

PHENYTOIN

TABLET, CHEWABLE; ORAL
DILANTIN

AB	!	PFIZER	50MG	A084427	001		Feb CAHN
		PHENYTOIN					
AB		EPIC PHARMA LLC	50MG	A040884	001	Nov 28, 2014	May CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL
DILANTIN

AB	!	PARKE-DAVIS	100MG EXTENDED	A084349	002		Feb CAHN
		INJECTABLE; INJECTION					
		PHENYTOIN SODIUM					
AP		ACELLA PHARMS LLC	50MG/ML	A040573	001	Sep 13, 2006	May CAHN
	@	HOSPIRA	50MG/ML	A089521	001	Mar 17, 1987	Mar DISC

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON

	+	@ TELIGENT	1MG/0.5ML	N012223	002		Apr CAHN
	+	@	10MG/ML	N012223	001		Apr CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC
ISOPTO CARPINE

AT	+	NOVARTIS PHARMS CORP	1%	N200890	001	Jun 22, 2010	Sep CFTG
AT	+		2%	N200890	002	Jun 22, 2010	Sep CFTG
AT	+	!	4%	N200890	003	Jun 22, 2010	Sep CFTG
		PILOCARPINE HYDROCHLORIDE					
AT		AKORN INC	1%	A204398	001	Sep 27, 2017	Sep NEWA
AT			2%	A204398	002	Sep 27, 2017	Sep NEWA
AT			4%	A204398	003	Sep 27, 2017	Sep NEWA

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB		ALLIED PHARMA INC	5MG	A076963	001	Dec 22, 2004	Mar CAHN
AB			7.5MG	A076963	002	Feb 27, 2007	Mar CAHN
AB		INNOGENIX	5MG	A076963	001	Dec 22, 2004	Sep CAHN
AB			7.5MG	A076963	002	Feb 27, 2007	Sep CAHN
AB		PERRIGO PHARMA INTL	5MG	A076746	001	Nov 16, 2004	Apr CAHN

PINDOLOL

TABLET; ORAL
PINDOLOL

AB		IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May CMFD
AB			10MG	A073609	001	Mar 29, 1993	May CMFD
AB		ZYDUS PHARMS USA INC	5MG	A209866	001	Aug 18, 2017	Aug NEWA
AB			10MG	A209866	002	Aug 18, 2017	Aug NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		CIPLA LTD	EQ 15MG BASE	A076798	001	Oct 26, 2012	Jun CAHN
AB			EQ 30MG BASE	A076798	002	Oct 26, 2012	Jun CAHN
AB			EQ 45MG BASE	A076798	003	Oct 26, 2012	Jun CAHN
AB		PURACAP PHARM LLC	EQ 15MG BASE	A206738	001	Oct 06, 2017	Sep NEWA

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		EQ 30MG BASE	A206738	002	Oct 06, 2017	Sep NEWA
AB		EQ 45MG BASE	A206738	003	Oct 06, 2017	Sep NEWA
AB	WATSON LABS TEVA	EQ 15MG BASE	A076798	001	Oct 26, 2012	May CAHN
AB		EQ 30MG BASE	A076798	002	Oct 26, 2012	May CAHN
AB		EQ 45MG BASE	A076798	003	Oct 26, 2012	May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan NEWA
AP	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar NEWA

PIRFENIDONE

TABLET;ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan NEWA
+	@	534MG	N208780	002	Jan 11, 2017	Jan DISC
+	!	801MG	N208780	003	Jan 11, 2017	Jan NEWA

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	HIKMA PHARMS	10MG	A209256	001	Aug 11, 2017	Jul NEWA
AB		20MG	A209256	002	Aug 11, 2017	Jul NEWA
	@ MYLAN	10MG	A074102	001	Jul 31, 1992	Jul DISC
	@	20MG	A074102	002	Jul 31, 1992	Jul DISC
AB	PII	10MG	A206136	001	Jun 20, 2017	Jun NEWA
AB		20MG	A206136	002	Jun 20, 2017	Jun NEWA
>A>	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Oct CMS1
>D>	@	20MG	A073536	001	Mar 12, 1993	Oct CMFD
>A>	AB	20MG	A073536	001	Mar 12, 1993	Oct CMFD
AB	UNICHEM LABS LTD	10MG	A208340	001	Apr 13, 2017	Apr NEWA
AB		20MG	A208340	002	Apr 13, 2017	Apr NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan NEWA
AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan NEWA
AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan NEWA
AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan NEWA
AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan NEWA
AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan NEWA

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

+	ZYDUS PHARMS USA INC	EQ 1MG BASE	N208379	001	Jul 14, 2017	Jul NEWA
+		EQ 2MG BASE	N208379	002	Jul 14, 2017	Jul NEWA
+	!	EQ 4MG BASE	N208379	003	Jul 14, 2017	Jul NEWA

PITAVASTATIN SODIUM

TABLET;ORAL

NIKITA

+	@ LUPIN LTD	EQ 1MG BASE	N209875	001	Aug 04, 2017	Sep DISC
+		EQ 1MG BASE	N209875	001	Aug 04, 2017	Aug NEWA
+	@	EQ 2MG BASE	N209875	002	Aug 04, 2017	Sep DISC
+		EQ 2MG BASE	N209875	002	Aug 04, 2017	Aug NEWA

TABLET;ORAL
NIKITA

+ @	EQ 4MG BASE	N209875	003	Aug 04, 2017	Sep DISC
+!	EQ 4MG BASE	N209875	003	Aug 04, 2017	Aug NEWA

PLECANATIDETABLET;ORAL
TRULANCE

+! SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan NEWA
-------------------	-----	---------	-----	--------------	----------

PODOFILOXSOLUTION;TOPICAL
PODOFILOX

@ BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010	Aug DISC
-----------------------	------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409	001	Apr 02, 2010	Apr DISC
AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A204559	001	Apr 13, 2015	Apr CAHN
		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Mar CAHN
AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Feb NEWA
		TRILYTE				
AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A076491	001	Feb 05, 2004	Mar CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar CAHN
		COLYTE WITH FLAVOR PACKS				
AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar CAHN
		COLYTE-FLAVORED				
	@ MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar CAHN
		PEG 3350 AND ELECTROLYTES				
	@ MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Apr DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	SANDOZ INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb CAHN
----	------------	--------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
KLOR-CON

AB	UPSHER-SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Jun CAHN
AB		10MEQ	A203106	002	Jul 10, 2015	Jun CAHN
		POTASSIUM CHLORIDE				
AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar NEWA
AB		10MEQ	A208864	002	Mar 17, 2017	Mar NEWA

FOR SOLUTION;ORAL
KLOR-CON

>A>	AA	UPSHER-SMITH LABS	20MEQ	A209662	001	Oct 23, 2017	Oct CAHN
>A>	AA		20MEQ	A209662	001	Oct 23, 2017	Oct NEWA
		POTASSIUM CHLORIDE					
>D>	+	PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Oct CFTG
>A>	AA	+	20MEQ	N208019	001	Aug 19, 2015	Oct CFTG
		INJECTABLE;INJECTION					
		POTASSIUM CHLORIDE					
		@ BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr DISC
		POTASSIUM CHLORIDE 10MEQ	IN PLASTIC CONTAINER				
AP	+	ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992	Feb CAHN
AP	+		745MG/100ML	N020161	001	Nov 30, 1992	Feb CAHN
		POTASSIUM CHLORIDE 20MEQ	IN PLASTIC CONTAINER				
AP	+	ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998	Feb CAHN
AP	+		1.49GM/100ML	N020161	002	Nov 30, 1992	Feb CAHN
		POTASSIUM CHLORIDE 30MEQ	IN PLASTIC CONTAINER				
AP	+	ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb CAHN
		POTASSIUM CHLORIDE 40MEQ	IN PLASTIC CONTAINER				
AP	+	ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		KLOR-CON					
AB2	+	UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Jun CAHN
AB2	+		10MEQ	N019123	002	Apr 17, 1986	Jun CAHN
		KLOR-CON M10					
AB1		UPSHER-SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Jun CAHN
		KLOR-CON M15					
		UPSHER-SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Jun CAHN
		KLOR-CON M20					
AB1	!	UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Jun CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

		POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP		ICU MEDICAL INC	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb CAHN
		POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		ICU MEDICAL INC	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb CAHN
		POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		ICU MEDICAL INC	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

		POTASSIUM CITRATE					
AB		IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb CAHN
AB			10MEQ	A077440	002	Jun 09, 2006	Feb CAHN
AB		STRIDES PHARMA	5MEQ	A206813	001	Sep 11, 2017	Aug NEWA
AB			10MEQ	A206813	002	Sep 11, 2017	Aug NEWA
AB			15MEQ	A206813	003	Sep 11, 2017	Aug NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

		PRAMIPEXOLE DIHYDROCHLORIDE					
		@ ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
		@	0.25MG	A091254	002	Nov 30, 2010	Jan DISC
		@	0.5MG	A091254	003	Nov 30, 2010	Jan DISC
		@	0.75MG	A091254	004	Nov 30, 2010	Jan DISC
		@	1MG	A091254	005	Nov 30, 2010	Jan DISC
		@	1.5MG	A091254	006	Nov 30, 2010	Jan DISC
AB		ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010	May CAHN
AB			0.25MG	A078894	002	Oct 08, 2010	May CAHN
AB			0.5MG	A078894	003	Oct 08, 2010	May CAHN
AB			1MG	A078894	004	Oct 08, 2010	May CAHN
AB			1.5MG	A078894	005	Oct 08, 2010	May CAHN

TABLET, EXTENDED RELEASE;ORAL

		PRAMIPEXOLE DIHYDROCHLORIDE					
AB		ACTAVIS ELIZABETH	2.25MG	A203615	001	Oct 14, 2016	Apr CAHN
AB			3.75MG	A203615	002	Jan 03, 2017	Apr CAHN
AB		MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan NEWA

PRASTERONEINSERT;VAGINAL
INTRAROSA

+! AMAG PHARMS INC 6.5MG N208470 001 Nov 16, 2016 May CAHN

PRASUGREL HYDROCHLORIDETABLET;ORAL
EFFIENTAB + ELI LILLY AND CO EQ 5MG BASE N022307 001 Jul 10, 2009 Jun CFTG
AB +! EQ 10MG BASE N022307 002 Jul 10, 2009 Jun CFTG

PRASUGREL

>A>	AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A205888	001	Oct 16, 2017	Oct NEWA
>A>	AB		EQ 10MG BASE	A205888	002	Oct 16, 2017	Oct NEWA
>A>	AB	LIBERTY PHARMA INC	EQ 5MG BASE	A205790	001	Oct 16, 2017	Oct NEWA
>A>	AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Oct NEWA
	AB	MYLAN PHARMS INC	EQ 5MG BASE	A205927	001	Jul 12, 2017	Jun NEWA
	AB		EQ 10MG BASE	A205927	002	Jul 12, 2017	Jun NEWA
>A>	AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A205897	001	Oct 16, 2017	Oct NEWA
>A>	AB		EQ 10MG BASE	A205897	002	Oct 16, 2017	Oct NEWA

PRAVASTATIN SODIUMTABLET;ORAL
PRAVASTATIN SODIUM

AB	AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan NEWA
AB		20MG	A203367	002	Feb 02, 2017	Jan NEWA
AB		40MG	A203367	003	Feb 02, 2017	Jan NEWA
AB		80MG	A203367	004	Feb 02, 2017	Jan NEWA

PRAZOSIN HYDROCHLORIDECAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

	IDT AUSTRALIA LTD	EQ 1MG BASE	A072577	002	May 16, 1989	May CMS1
		EQ 5MG BASE	A072577	003	May 16, 1989	May CMS1

PREDNISOLONESYRUP;ORAL
PREDNISOLONE

AA	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	May CAHN
AA	VISTAPHARM	15MG/5ML	A040323	001	May 13, 1999	Mar CAHN

TABLET;ORAL
PREDNISOLONE

@ CHARTWELL RX 5MG A084542 001 Apr CAHN

PREDNISOLONE SODIUM PHOSPHATESOLUTION;ORAL
PREDNISOLONE SODIUM PHOSPHATE

	@ AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345	001	Mar 10, 2009	May DISC
AA	CHARTWELL RX	EQ 5MG BASE/5ML	A075988	001	May 25, 2004	Jun CAHN
	@ PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUMSOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	! BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb CAHN
AT	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb CAHN

PREDNISONETABLET;ORAL
METICORTEN

	+ @ SCHERING	1MG	N009766	002		Mar CMS1
	+ @	5MG	N009766	001		Mar CMS1

PREDNISONE

	@ CHARTWELL RX	5MG	A083059	001		Apr CAHN
	@ CONTRACT PHARMACAL	5MG	A080209	001		Mar DISC
AB	MYLAN PHARMS INC	5MG	A080292	001		Jan CAHN
AB		10MG	A088832	001	Dec 04, 1985	Jan CAHN
AB		20MG	A083677	001		Jan CAHN
AB	SUN PHARM INDUSTRIES	10MG	A089246	001	Dec 04, 1985	May CAHN
	@ UPSHER SMITH	5MG	A087471	001		Jun CAHN
	@	20MG	A087470	001		Jun CAHN

TABLET, DELAYED RELEASE;ORAL
PREDNISONE

AB	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr NEWA
AB		2MG	A204867	002	Apr 25, 2017	Apr NEWA
AB		5MG	A204867	003	Apr 25, 2017	Apr NEWA
RAYOS						
AB	+ HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Apr CFTG
AB	+	2MG	N202020	002	Jul 26, 2012	Apr CFTG
AB	+	5MG	N202020	003	Jul 26, 2012	Apr CFTG

PREGABALIN

>A> TABLET, EXTENDED RELEASE;ORAL
>A> LYRICA CR

>A>	+	PFIZER INC	82.5MG	N209501	001	Oct 11, 2017	Oct NEWA
>A>	+		165MG	N209501	002	Oct 11, 2017	Oct NEWA
>A>	+		330MG	N209501	003	Oct 11, 2017	Oct NEWA

PRIMIDONE

TABLET;ORAL
PRIMIDONE

AB	ANDA REPOSITORY	50MG	A040626	001	Sep 29, 2005	Sep CAHN
AB		250MG	A040626	002	Sep 29, 2005	Sep CAHN

PROBENECID

TABLET;ORAL
BENEMID

	+	@ MERCK	500MG	N007898	004		Jan CRLD
PROBENECID							
AB	WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	May CAHN	

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL
PROCAINAMIDE HYDROCHLORIDE

@	IDT AUSTRALIA LTD	375MG	A089219	002	Jul 01, 1986	Aug CMS1
@		500MG	A089219	003	Jul 01, 1986	Aug CMS1

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

>A>	AP	NEXUS PHARMS	100MG/ML	A206332	001	Oct 13, 2017	Oct NEWA
>A>	AP		500MG/ML	A206332	002	Oct 13, 2017	Oct NEWA
	@	WEST-WARD PHARMS INT	100MG/ML	A089029	001	Apr 17, 1986	Jan CAHN
	@		500MG/ML	A089030	001	Apr 17, 1986	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

>D>		IDT AUSTRALIA LTD	500MG	A089369	002	Jan 09, 1987	Oct DISC
>A>	@		500MG	A089369	002	Jan 09, 1987	Oct DISC
			500MG	A089369	002	Jan 09, 1987	Aug CMS1
>D>			750MG	A089369	003	Aug 14, 1987	Oct DISC
>A>	@		750MG	A089369	003	Aug 14, 1987	Oct DISC
			750MG	A089369	003	Aug 14, 1987	Aug CMS1

PROCARBAZINE HYDROCHLORIDE

CAPSULE;ORAL
MATULANE

+	!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001		Feb CAHN
---	---	---------------------	--------------	---------	-----	--	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

	@	ATHENEX INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Mar CAHN
	@	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jan CAHN
AP			EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jan CAHN

PROCYCLIDINE HYDROCHLORIDE

TABLET;ORAL

KEMADRIN

@	MONARCH PHARMS	2MG	N009818	005		Apr CAHN
@		5MG	N009818	003		Apr CAHN

PROGESTERONECAPSULE; ORAL
PROGESTERONE

AB	AMNEAL PHARMS NY	100MG	A207724	001	Sep 07, 2017	Aug NEWA
AB		200MG	A207724	002	Sep 07, 2017	Aug NEWA
AB	DR REDDYS LABS INC	100MG	A208801	001	Feb 28, 2017	Feb NEWA
AB		200MG	A208801	002	Feb 28, 2017	Feb NEWA
>A> AB	SANDOZ INC	100MG	A205229	001	Oct 20, 2017	Oct NEWA
>A> AB		200MG	A205229	002	Oct 20, 2017	Oct NEWA

INJECTABLE; INJECTION
PROGESTERONE

AO	+! ACTAVIS LABS UT INC	50MG/ML	N017362	002		Feb CAHN
----	------------------------	---------	---------	-----	--	----------

PROMETHAZINE HYDROCHLORIDESUPPOSITORY; RECTAL
PHENERGAN

	+ @ MYLAN PHARMS INC	50MG	N011689	001		Jan CAHN
--	----------------------	------	---------	-----	--	----------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

	IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008	Aug CMS1
		25MG	A040791	003	Feb 12, 2008	Aug CMS1
AB	PRINSTON INC	12.5MG	A040622	001	Jul 18, 2006	Feb CAHN
AB		25MG	A040622	002	Jul 18, 2006	Feb CAHN
AB		50MG	A040622	003	Jul 18, 2006	Feb CAHN
AB	STRIDES PHARMA	12.5MG	A209177	001	Jun 30, 2017	Jun NEWA
AB		25MG	A209177	002	Jun 30, 2017	Jun NEWA
AB		50MG	A209177	003	Jun 30, 2017	Jun NEWA

PROPAFENONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
PROPAFENONE HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	225MG	A205268	001	Sep 08, 2017	Aug NEWA
AB		325MG	A205268	002	Sep 08, 2017	Aug NEWA
AB		425MG	A205268	003	Sep 08, 2017	Aug NEWA

PROPIOMAZINE HYDROCHLORIDEINJECTABLE; INJECTION
LARGON

	@ WEST-WARD PHARMS INT	20MG/ML	N012382	002		Jan CAHN
--	------------------------	---------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
INNOPRAN XL

BX	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Mar CAHN
BX		120MG	N021438	002	Mar 12, 2003	Mar CAHN

PROPRANOLOL HYDROCHLORIDE

BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Apr CMFD
	@	60MG	A078311	001	Mar 06, 2009	Feb DISC
BX		80MG	A078311	002	Mar 06, 2009	Apr CMFD
	@	80MG	A078311	002	Mar 06, 2009	Feb DISC
BX		120MG	A078311	003	Mar 06, 2009	Apr CMFD
	@	120MG	A078311	003	Mar 06, 2009	Feb DISC
BX		160MG	A078311	004	Mar 06, 2009	Apr CMFD
	@	160MG	A078311	004	Mar 06, 2009	Feb DISC
	@ UPSHER-SMITH LABS	60MG	A078311	001	Mar 06, 2009	Sep DISC
BX		60MG	A078311	001	Mar 06, 2009	Jun CAHN
	@	80MG	A078311	002	Mar 06, 2009	Sep DISC
BX		80MG	A078311	002	Mar 06, 2009	Jun CAHN
	@	120MG	A078311	003	Mar 06, 2009	Sep DISC
BX		120MG	A078311	003	Mar 06, 2009	Jun CAHN
	@	160MG	A078311	004	Mar 06, 2009	Sep DISC
BX		160MG	A078311	004	Mar 06, 2009	Jun CAHN

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Mar CAHN
	@ SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003	Mar CAHN

TABLET; ORAL

INDERAL

	+ @ WYETH PHARMS INC	40MG	N016418	002		Jan CRLD
	PROPRANOLOL HYDROCHLORIDE					
	@ ANDA REPOSITORY	10MG	A070319	001	Oct 22, 1985	Sep CAHN

TABLET;ORAL									
PROPRANOLOL HYDROCHLORIDE									
	@	20MG		A070320	001	Oct 22, 1985	Sep	CAHN	
	@	40MG		A070103	001	Oct 22, 1985	Sep	CAHN	
	@	60MG		A070321	001	Sep 24, 1986	Sep	CAHN	
	@	80MG		A070322	001	Aug 04, 1986	Sep	CAHN	
	@ WATSON LABS TEVA	10MG		A070548	001	Jul 10, 1986	May	CAHN	
	@	20MG		A070549	001	Apr 11, 1986	May	CAHN	
	@	40MG		A070550	001	Apr 11, 1986	May	CAHN	
<u>PROPYLTHIOURACIL</u>									
TABLET;ORAL									
PROPYLTHIOURACIL									
	@ CHARTWELL RX	50MG		A084543	001		Apr	CAHN	
<u>PROTAMINE SULFATE</u>									
INJECTABLE;INJECTION									
PROTAMINE SULFATE									
	@ WEST-WARD PHARMS INT	10MG/ML		A089474	001	Nov 05, 1986	Mar	CAHN	
	@	10MG/ML		A089475	001	Nov 05, 1986	Jan	CAHN	
<u>PYRIDOSTIGMINE BROMIDE</u>									
INJECTABLE;INJECTION									
REGONOL									
AP	SANDOZ INC	5MG/ML		N017398	001		May	CAHN	
TABLET;ORAL									
PYRIDOSTIGMINE BROMIDE									
	@ IMPAX LABS INC	60MG		A040457	001	Dec 26, 2002	Feb	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
PYRIDOSTIGMINE BROMIDE									
AB	KINEDEXE UK	180MG		A205464	001	Aug 15, 2017	Jul	NEWA	
<u>PYRIMETHAMINE</u>									
TABLET;ORAL									
DARAPRIM									
	+! TURING PHARMS LLC	25MG		N008578	001		May	CAHN	
<u>QUETIAPINE FUMARATE</u>									
TABLET;ORAL									
QUETIAPINE FUMARATE									
	@ MYLAN PHARMS INC	EQ 25MG BASE		A090323	001	Mar 27, 2012	May	DISC	
SEROQUEL									
AB	+! ASTRAZENECA PHARMS	EQ 25MG BASE		N020639	001	Sep 26, 1997	Sep	CAHN	
AB	+	EQ 50MG BASE		N020639	007	Oct 04, 2005	Sep	CAHN	
AB	+	EQ 100MG BASE		N020639	002	Sep 26, 1997	Sep	CAHN	
	+ @	EQ 150MG BASE		N020639	004	Dec 20, 1998	Sep	CAHN	
AB	+	EQ 200MG BASE		N020639	003	Sep 26, 1997	Sep	CAHN	
AB	+!	EQ 300MG BASE		N020639	005	Jul 26, 2000	Sep	CAHN	
AB	+	EQ 400MG BASE		N020639	006	Oct 04, 2005	Sep	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
QUETIAPINE FUMARATE									
AB	ACCORD HLTHCARE	EQ 150MG BASE		A090681	001	May 09, 2017	Apr	NEWA	
AB		EQ 200MG BASE		A090681	002	May 09, 2017	Apr	NEWA	
AB		EQ 300MG BASE		A090681	003	May 09, 2017	Apr	NEWA	
AB		EQ 400MG BASE		A090681	004	Nov 01, 2016	Mar	CAHN	
AB	INTELLIPHARMACEUTICS	EQ 50MG BASE		A202939	001	May 09, 2017	Apr	NEWA	
AB		EQ 150MG BASE		A202939	002	May 09, 2017	Apr	NEWA	
AB		EQ 200MG BASE		A202939	003	May 09, 2017	Apr	NEWA	
AB		EQ 300MG BASE		A202939	004	May 09, 2017	Apr	NEWA	
AB		EQ 400MG BASE		A202939	005	May 09, 2017	Apr	NEWA	
AB	LUPIN LTD	EQ 50MG BASE		A204203	001	May 17, 2017	May	NEWA	
AB		EQ 150MG BASE		A204203	002	May 17, 2017	May	NEWA	
AB		EQ 200MG BASE		A204203	003	May 17, 2017	May	NEWA	
AB		EQ 300MG BASE		A204203	004	May 17, 2017	May	NEWA	
AB		EQ 400MG BASE		A204203	005	May 17, 2017	May	NEWA	
AB	PAR PHARM	EQ 50MG BASE		A090482	001	May 09, 2017	Apr	NEWA	
AB		EQ 150MG BASE		A090482	002	May 09, 2017	Apr	NEWA	
AB		EQ 200MG BASE		A090482	003	May 09, 2017	Apr	NEWA	
AB		EQ 300MG BASE		A090482	004	May 09, 2017	Apr	NEWA	
AB		EQ 400MG BASE		A090482	005	May 09, 2017	Apr	NEWA	
AB	PHARMADAX INC	EQ 50MG BASE		A206260	001	May 09, 2017	Apr	NEWA	
AB		EQ 150MG BASE		A206260	002	May 09, 2017	Apr	NEWA	

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

AB		EQ 200MG BASE	A206260	003	May 09, 2017	Apr NEWA
AB		EQ 300MG BASE	A206260	004	May 09, 2017	Apr NEWA
AB		EQ 400MG BASE	A206260	005	May 09, 2017	Apr NEWA
SEROQUEL XR						
AB	+	ASTRAZENECA EQ 50MG BASE	N022047	001	May 17, 2007	Sep CAHN
AB	+	EQ 50MG BASE	N022047	001	May 17, 2007	Apr CTEC
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Sep CAHN
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr CTEC
AB	+	EQ 200MG BASE	N022047	002	May 17, 2007	Sep CAHN
AB	+	EQ 200MG BASE	N022047	002	May 17, 2007	Apr CTEC
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Sep CAHN
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Apr CTEC
AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Sep CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@	SUN PHARM INDS LTD	EQ 5MG BASE	A090800	001	Jun 18, 2009	Sep DISC
@		EQ 10MG BASE	A090800	002	Jun 18, 2009	Sep DISC
@		EQ 20MG BASE	A090800	003	Jun 18, 2009	Sep DISC
@		EQ 40MG BASE	A090800	004	Jun 18, 2009	Sep DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL
ACIPHEX SPRINKLE

+	AVADEL PHARMS	5MG	N204736	001	Mar 26, 2013	Aug CAHN
+	!	10MG	N204736	002	Mar 26, 2013	Aug CAHN

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb NEWA
AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS HD

+	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May NEWA
---	-------------------	---------------	---------	-----	--------------	----------

RAMIPRIL

CAPSULE;ORAL

ALTACE

AB	+	KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul CAHN
AB	+		2.5MG	N019901	002	Jan 28, 1991	Jul CAHN
AB	+		5MG	N019901	003	Jan 28, 1991	Jul CAHN
AB	+	!	10MG	N019901	004	Jan 28, 1991	Jul CAHN

RAMIPRIL

AB	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	Mar CAHN
AB		2.5MG	A202392	002	Apr 15, 2014	Mar CAHN
AB		5MG	A202392	003	Apr 15, 2014	Mar CAHN
AB		10MG	A202392	004	Apr 15, 2014	Mar CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

AP	+	TELIGENT	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr CAHN
AP	+	TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN

ZANTAC IN PLASTIC CONTAINER

@	TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	May CAHN
@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	May CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan CAHN
AA	PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	May CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB	GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	May CAHN
AB		EQ 300MG BASE	A078542	002	Nov 19, 2008	May CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

+	GILEAD	500MG	N021526	002	Jan 27, 2006	Feb CTEC
+	!	1GM	N021526	001	Feb 12, 2007	Feb CTEC
	RANOLAZINE					
@	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb DISC
@		1GM	A201046	002	Jul 29, 2013	Feb DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>A>	AB	ALKEM LABS LTD	EQ 0.5MG BASE	A201889	001	Oct 30, 2017	Oct NEWA
>A>	AB		EQ 1MG BASE	A201889	002	Oct 30, 2017	Oct NEWA
	AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A201971	001	May 15, 2017	Jul CMFD
		@	EQ 0.5MG BASE	A201971	001	May 15, 2017	Jun DISC
	AB		EQ 0.5MG BASE	A201971	001	May 15, 2017	May NEWA
	AB		EQ 1MG BASE	A201971	002	May 15, 2017	Jul CMFD
		@	EQ 1MG BASE	A201971	002	May 15, 2017	Jun DISC
	AB		EQ 1MG BASE	A201971	002	May 15, 2017	May NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

AB	+	GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Feb CAHN
AB	+		1MG	N020741	002	Dec 22, 1997	Feb CAHN
AB	+	!	2MG	N020741	003	Dec 22, 1997	Feb CAHN
		REPAGLINIDE					
AB		BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Jun CAHN
AB			1MG	A091517	002	Apr 24, 2015	Jun CAHN
AB			2MG	A091517	003	Apr 24, 2015	Jun CAHN

RESERPINE

TABLET;ORAL

RESERPINE

+	@	SANDOZ	0.1MG	N009838	001		Apr DISC
+	@		0.25MG	N009838	002		Apr DISC

RIBAVIRIN

CAPSULE;ORAL

RIBASPHERE

AB		KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan CAHN
		TABLET;ORAL					
		RIBAVIRIN					
AB		KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan CAHN
AB			400MG	A077456	002	Dec 05, 2005	Jan CAHN
AB	!		600MG	A077456	003	Dec 05, 2005	Jan CAHN

RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI

+	!	NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017	Mar NEWA
---	---	----------------------	---------------	---------	-----	--------------	----------

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

AP		WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb CAHN
AP		WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan CAHN

RILUZOLE

TABLET;ORAL

RILUTEK

AB	+	COVIS PHARMA BV	50MG	N020599	001	Dec 12, 1995	Aug CAHN
		RILUZOLE					
AB		GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013	May CAHN

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

>D>	AB	+	!	CARACO	100MG	N019649	001	Sep 17, 1993	Oct CAHN
>A>	AB	+	!	SUN PHARM INDS INC	100MG	N019649	001	Sep 17, 1993	Oct CAHN
				RIMANTADINE HYDROCHLORIDE					
				@ IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb CAHN

RISPERIDONE

TABLET; ORAL

RISPERIDONE

				@ JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009	Apr CAHN
				@	0.5MG	A078828	002	Mar 23, 2009	Apr CAHN
				@	1MG	A078828	003	Mar 23, 2009	Apr CAHN
				@	2MG	A078828	004	Mar 23, 2009	Apr CAHN
				@	3MG	A078828	005	Mar 23, 2009	Apr CAHN
				@	4MG	A078828	006	Mar 23, 2009	Apr CAHN
AB				PRINSTON INC	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
AB					0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
AB					1MG	A078707	003	Dec 29, 2008	Feb CAHN
AB					2MG	A078707	004	Dec 29, 2008	Feb CAHN
AB					3MG	A078707	005	Dec 29, 2008	Feb CAHN
AB					4MG	A078707	006	Dec 29, 2008	Feb CAHN

RITONAVIR

POWDER; ORAL

NORVIR

				+	!	ABBVIE INC	100MG/PACKET	N209512	001	Jun 07, 2017	Jun NEWA
--	--	--	--	---	---	------------	--------------	---------	-----	--------------	----------

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB				AJANTA PHARMA LTD	EQ 1.5MG BASE	A207797	001	Sep 28, 2017	Sep NEWA
AB					EQ 3MG BASE	A207797	002	Sep 28, 2017	Sep NEWA
AB					EQ 4.5MG BASE	A207797	003	Sep 28, 2017	Sep NEWA
AB					EQ 6MG BASE	A207797	004	Sep 28, 2017	Sep NEWA
AB				CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan NEWA
AB					EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan NEWA
AB					EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan NEWA
AB					EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan NEWA
AB				SUN PHARM INDS LTD	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Mar CAHN
AB					EQ 3MG BASE	A077131	002	Oct 22, 2007	Mar CAHN
AB					EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Mar CAHN
AB					EQ 6MG BASE	A077131	004	Oct 22, 2007	Mar CAHN

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

AB				ECI PHARMS LLC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Mar CAHN
AB					EQ 10MG BASE	A202047	002	Dec 31, 2012	Mar CAHN
AB				UNICHEM LABS LTD	EQ 5MG BASE	A207836	001	Mar 07, 2017	Feb NEWA
AB					EQ 10MG BASE	A207836	002	Mar 07, 2017	Feb NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RIZATRIPTAN BENZOATE

AB				GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	May CAHN
AB					EQ 10MG BASE	A201914	002	Jul 01, 2013	May CAHN
AB				PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan NEWA
AB					EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan NEWA
AB				UNICHEM LABS LTD	EQ 5MG BASE	A207835	001	Mar 07, 2017	Feb NEWA
AB					EQ 10MG BASE	A207835	002	Mar 07, 2017	Feb NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP				AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar NEWA
AP					100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar NEWA
AP	!			SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar CAHN
AP	!				100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar CAHN
AP				WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb NEWA
AP					100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb NEWA

ROLAPITANT HYDROCHLORIDE

>A> EMULSION; IV (INFUSION)

>A> VARUBI

>A> +! TESARO INC EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML) N208399 001 Oct 25, 2017 Oct NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Apr CAHN
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Apr CAHN
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Apr CAHN
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Apr CAHN
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Apr CAHN
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Apr CAHN
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Apr CAHN
AB	ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb NEWA
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb NEWA
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb NEWA
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb NEWA
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb NEWA
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb NEWA
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb NEWA
	@ EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008	May CAHN
	@	EQ 0.5MG BASE	A078230	002	May 20, 2008	May CAHN
	@	EQ 1MG BASE	A078230	003	May 20, 2008	May CAHN
	@	EQ 2MG BASE	A078230	004	May 20, 2008	May CAHN
	@	EQ 3MG BASE	A078230	005	May 20, 2008	May CAHN
	@	EQ 4MG BASE	A078230	006	May 20, 2008	May CAHN
	@	EQ 5MG BASE	A078230	007	May 20, 2008	May CAHN

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	May CAHN
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	May CAHN
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	May CAHN
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	May CAHN
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	May CAHN
	@ MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	150MG/30ML (5MG/ML)	A203955	001	Apr 11, 2016	Jun CDFR
----	-----------	---------------------	---------	-----	--------------	----------

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar CAHN
AB		10MG	A206434	002	Oct 31, 2016	Mar CAHN
AB		20MG	A206434	003	Oct 31, 2016	Mar CAHN
AB		40MG	A206434	004	Oct 31, 2016	Mar CAHN
AB	ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar NEWA
AB		10MG	A206465	002	Mar 21, 2017	Mar NEWA
AB		20MG	A206465	003	Mar 21, 2017	Mar NEWA
AB		40MG	A206465	004	Mar 21, 2017	Mar NEWA
AB	LUPIN LTD	5MG	A205587	001	Jul 31, 2017	Jul NEWA
AB		10MG	A205587	002	Jul 31, 2017	Jul NEWA
AB		20MG	A205587	003	Jul 31, 2017	Jul NEWA
AB		40MG	A205587	004	Jul 31, 2017	Jul NEWA
AB	TORRENT PHARMS LTD	5MG	A201619	001	Oct 31, 2016	Apr CAHN
AB		10MG	A201619	002	Oct 31, 2016	Apr CAHN
AB		20MG	A201619	003	Oct 31, 2016	Apr CAHN
AB		40MG	A201619	004	Oct 31, 2016	Apr CAHN

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 250MG BASE	N209115	003	May 01, 2017	May NEWA
---	---------------------	---------------	---------	-----	--------------	----------

SAFINAMIDE MESYLATE

TABLET; ORAL

XADAGO

+	NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Mar	NEWA
+	!	100MG	N207145	002	Mar 21, 2017	Mar	NEWA
+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Apr	CAHN
+	!	100MG	N207145	002	Mar 21, 2017	Apr	CAHN

SECNIDAZOLE

GRANULE; ORAL

SOLOSEC

>A>	+	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017	Oct	CAHN
>D>	+	SYMBIOMIX THERAP	2GM/PACKET	N209363	001	Sep 15, 2017	Oct	CAHN
	+	!	2GM/PACKET	N209363	001	Sep 15, 2017	Sep	NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB		BOSCOGEN	5MG	A074912	001	Apr 30, 1998	May	CAHN
	@	CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan	CAHN
	@		5MG	A074641	001	Aug 02, 1996	Jan	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@	ALLIED PHARMA INC	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	CAHN
---	-------------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jun	CAHN
	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Jun	CAHN
	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Jun	CAHN
	@	ALLIED PHARMA INC	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	CAHN
	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	CAHN
	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	CAHN
	@	ANDA REPOSITORY	EQ 25MG BASE	A077818	001	Feb 06, 2007	Sep	CAHN
	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Sep	CAHN
	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Sep	CAHN
	@	MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar	DISC
	@		EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar	DISC
	@		EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar	DISC
>D> AB		SUN PHARM INDS (IN)	EQ 25MG BASE	A078108	001	Feb 06, 2007	Oct	DISC
>A>	@		EQ 25MG BASE	A078108	001	Feb 06, 2007	Oct	DISC
>D> AB			EQ 50MG BASE	A078108	002	Feb 06, 2007	Oct	DISC
>A>	@		EQ 50MG BASE	A078108	002	Feb 06, 2007	Oct	DISC
>D> AB			EQ 100MG BASE	A078108	003	Feb 06, 2007	Oct	DISC
>A>	@		EQ 100MG BASE	A078108	003	Feb 06, 2007	Oct	DISC
	@	WATSON LABS TEVA	EQ 25MG BASE	A077663	001	Feb 06, 2007	May	CAHN
	@		EQ 50MG BASE	A077663	002	Feb 06, 2007	May	CAHN
	@		EQ 100MG BASE	A077663	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

RENVELA

AB	+	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	May	CFTG
AB	+	!	2.4GM/PACKET	N022318	002	Feb 18, 2009	May	CFTG

SEVELAMER CARBONATE

AB		AUROBINDO PHARMA LTD	800MG/PACKET	A207624	001	Jun 13, 2017	May	NEWA
AB			2.4GM/PACKET	A207624	002	Jun 13, 2017	May	NEWA

TABLET; ORAL

RENVELA

AB	+	GENZYME	800MG	N022127	001	Oct 19, 2007	Jul	CFTG
		SEVELAMER CARBONATE						
AB		AUROBINDO PHARMA LTD	800MG	A207179	001	Jul 17, 2017	Jul	NEWA
AB		DR REDDYS LABS LTD	800MG	A206094	001	Sep 29, 2017	Sep	NEWA
>A> AB		IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017	Oct	NEWA
>A> AB		INVAGEN PHARMS	800MG	A203860	001	Oct 26, 2017	Oct	NEWA

SILDENAFIL CITRATETABLET;ORAL
VIAGRA

+	PFIZER INC	EQ 25MG BASE	N020895	001	Mar 27, 1998	May CAHN
+		EQ 50MG BASE	N020895	002	Mar 27, 1998	May CAHN
+	!	EQ 100MG BASE	N020895	003	Mar 27, 1998	May CAHN

SILODOSINCAPSULE;ORAL
RAPAFLO

AB	+	!	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Mar CFTG
AB	+			8MG	N022206	002	Oct 08, 2008	Mar CFTG
SILODOSIN								
AB			SANDOZ INC	4MG	A204726	001	Mar 31, 2017	Mar NEWA
AB				8MG	A204726	002	Mar 31, 2017	Mar NEWA

SILVER SULFADIAZINECREAM;TOPICAL
SILVADENE

AB	+	!	KING PHARMS LLC	1%	N017381	001		Aug CAHN
----	---	---	-----------------	----	---------	-----	--	----------

SIMVASTATINSUSPENSION;ORAL
FLOLIPID

>A>								
>A>	+		TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Oct CTNA
>A>	+	!		40MG/5ML	N206679	002	Apr 21, 2016	Oct CTNA
>D>			SIMVASTATIN					
>D>	+		TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Oct CTNA
>D>	+	!		40MG/5ML	N206679	002	Apr 21, 2016	Oct CTNA

TABLET;ORAL
SIMVASTATIN

>A>	AB		HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Oct NEWA
>A>	AB			20MG	A206557	002	Nov 13, 2017	Oct NEWA
>A>	AB			40MG	A206557	003	Nov 13, 2017	Oct NEWA
>A>	AB			80MG	A206557	004	Nov 13, 2017	Oct NEWA
		@	MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010	May DISC
		@		10MG	A090868	002	Jun 08, 2010	May DISC
		@		20MG	A090868	003	Jun 08, 2010	May DISC
		@		40MG	A090868	004	Jun 08, 2010	May DISC
		@		80MG	A090868	005	Jun 08, 2010	May DISC
	AB		VIVA HLTHCARE	5MG	A090383	001	Sep 16, 2011	Sep CAHN
	AB			10MG	A090383	002	Sep 16, 2011	Sep CAHN
	AB			20MG	A090383	003	Sep 16, 2011	Sep CAHN
	AB			40MG	A090383	004	Sep 16, 2011	Sep CAHN
	AB			80MG	A090383	005	Sep 16, 2011	Sep CAHN
	AB		WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006	May CAHN
	AB			10MG	A076685	002	Dec 20, 2006	May CAHN
	AB			20MG	A076685	003	Dec 20, 2006	May CAHN
	AB			40MG	A076685	004	Dec 20, 2006	May CAHN
	AB			80MG	A076685	005	Dec 20, 2006	May CAHN

ZOCOR

>D>	AB	+	MERCK	5MG	N019766	001	Dec 23, 1991	Oct CAHN
>D>	AB	+		10MG	N019766	002	Dec 23, 1991	Oct CAHN
>D>	AB	+		20MG	N019766	003	Dec 23, 1991	Oct CAHN
>D>	AB	+		40MG	N019766	004	Dec 23, 1991	Oct CAHN
>D>	AB	+	!	80MG	N019766	005	Jul 10, 1998	Oct CAHN
>A>	AB	+	MSD MERCK CO	5MG	N019766	001	Dec 23, 1991	Oct CAHN
>A>	AB	+		10MG	N019766	002	Dec 23, 1991	Oct CAHN
>A>	AB	+		20MG	N019766	003	Dec 23, 1991	Oct CAHN
>A>	AB	+		40MG	N019766	004	Dec 23, 1991	Oct CAHN
>A>	AB	+	!	80MG	N019766	005	Jul 10, 1998	Oct CAHN

SODIUM ACETATEINJECTABLE;INJECTION
SODIUM ACETATE

>A>			FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017	Oct NEWA
-----	--	--	--------------------	---------	---------	-----	--------------	----------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)

SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul CAHN
----	------------------	-----------------------------	---------	-----	--------------	----------

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb NEWA
AP			1MEQ/ML	A202432	001	Sep 26, 2017	Sep NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb NEWA
AP		INTL MEDICATION SYS	1MEQ/ML	A203449	001	Sep 19, 2017	Sep NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	450MG/100ML	N018090	001		Feb CAHN
		SODIUM CHLORIDE 0.9%					
AP		SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jul NEWA
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan CAHN
		SODIUM CHLORIDE 0.9%					
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		FRESENIUS KABI USA	900MG/100ML	A207310	001	Sep 19, 2017	Sep NEWA
AP	+	ICU MEDICAL INC	900MG/100ML	N016366	001		Feb CAHN
AP		LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017	May NEWA
AP	!	TARO	9MG/ML	A077407	001	Aug 11, 2006	Apr CAHN
		SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER					
	+	@ ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan CRLD
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
AP		B BRAUN	3GM/100ML	N019635	003	Mar 09, 1988	Jul CMFD
AP	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Jul CTEC
		SODIUM CHLORIDE 5% IN PLASTIC CONTAINER					
AP		B BRAUN	5GM/100ML	N019635	004	Mar 09, 1988	Jul CMFD
AP	+	BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983	Jul CTEC
		SODIUM CHLORIDE IN PLASTIC CONTAINER					
	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar CRLD
		SOLUTION;IRRIGATION					
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AT		ICU MEDICAL INC	900MG/100ML	N017514	001		Feb CAHN
AT			900MG/100ML	N018314	001		Feb CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		JUBILANT DRAXIMAGE	10-200mCi/ML	A203968	001	Oct 23, 2015	Sep CAHN
----	--	--------------------	--------------	---------	-----	--------------	----------

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

AP		AKORN	25MG/ML	A208635	001	May 04, 2017	Apr NEWA
>A> AP		AMNEAL PHARMS CO	25MG/ML	A209493	001	Nov 07, 2017	Oct NEWA
AP		NEXUS PHARMS	25MG/ML	A207499	001	May 25, 2017	May NEWA
		SOLUTION;IV (INFUSION)					
		NIPRIDE RTU IN SODIUM CHLORIDE 0.9%					
	+	EXELA PHARMA SCS LLC	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar NEWA

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

AA		WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan NEWA
----	--	----------------------	----------	---------	-----	--------------	----------

SODIUM PHENYLBUTYRATE

TABLET; ORAL

SODIUM PHENYLBUTYRATE

AB	ALVOGEN MALTA	500MG	A090910	001	Nov 18, 2011	Apr CAHN
----	---------------	-------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXALATE

AA	! KVK TECH	454GM/BOT	A040905	001	Mar 30, 2009	Sep CHRS
----	------------	-----------	---------	-----	--------------	----------

KAYEXALATE

	+ @ CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Sep DISC
--	--------------------------	-------------	---------	-----	--	----------

SODIUM POLYSTYRENE SULFONATE

AA	AILEX PHARMS LLC	454GM/BOT	A206815	001	Feb 18, 2016	Sep CAHN
----	------------------	-----------	---------	-----	--------------	----------

AA	CMP PHARMA INC	454GM/BOT	A089910	001	Jan 19, 1989	Apr CAHN
----	----------------	-----------	---------	-----	--------------	----------

AA	ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar CAHN
----	----------------	-------------	---------	-----	--------------	----------

SUSPENSION; ORAL, RECTAL

SPS

AA	! CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Apr CAHN
----	------------------	-----------	---------	-----	--------------	----------

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET; ORAL

VOSEVI

	+! GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017	Jul NEWA
--	------------------------	-------------------	---------	-----	--------------	----------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

VALTROPIN

BX	LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007	Jun CAHN
----	-------------	----------	---------	-----	--------------	----------

SONIDEGIB PHOSPHATE

CAPSULE; ORAL

ODOMZO

	+! SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar CAHN
--	-----------------------	---------------	---------	-----	--------------	----------

	+! SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015	May CAHN
--	----------------------	---------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

AB1	+ COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May CAHN
-----	-------------------	------	---------	-----	--------------	----------

AB1	+	120MG	N019865	005	Apr 20, 1994	May CAHN
-----	---	-------	---------	-----	--------------	----------

AB1	+!	160MG	N019865	002	Oct 30, 1992	May CAHN
-----	----	-------	---------	-----	--------------	----------

AB1	+	240MG	N019865	003	Oct 30, 1992	May CAHN
-----	---	-------	---------	-----	--------------	----------

@

		320MG	N019865	004	Oct 30, 1992	May CAHN
--	--	-------	---------	-----	--------------	----------

BETAPACE AF

	@ COVIS PHARMA BV	40MG	N021151	006	Apr 02, 2003	May CAHN
--	-------------------	------	---------	-----	--------------	----------

	@	60MG	N021151	007	Apr 02, 2003	May CAHN
--	---	------	---------	-----	--------------	----------

AB2	+	80MG	N021151	001	Feb 22, 2000	May CAHN
-----	---	------	---------	-----	--------------	----------

	@	100MG	N021151	005	Mar 14, 2003	May CAHN
--	---	-------	---------	-----	--------------	----------

AB2	+	120MG	N021151	002	Feb 22, 2000	May CAHN
-----	---	-------	---------	-----	--------------	----------

AB2	+!	160MG	N021151	003	Feb 22, 2000	May CAHN
-----	----	-------	---------	-----	--------------	----------

SORINE

AB1	UPSHER-SMITH LABS	80MG	A075500	001	Apr 27, 2001	Jun CAHN
-----	-------------------	------	---------	-----	--------------	----------

AB1		120MG	A075500	004	Apr 27, 2001	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

AB1		160MG	A075500	002	Apr 27, 2001	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

AB1		240MG	A075500	003	Apr 27, 2001	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

	@ MYLAN	80MG	A075237	001	May 01, 2000	Jun DISC
--	---------	------	---------	-----	--------------	----------

	@	80MG	A075725	001	Dec 19, 2000	Jun DISC
--	---	------	---------	-----	--------------	----------

	@	120MG	A075237	002	May 01, 2000	Jun DISC
--	---	-------	---------	-----	--------------	----------

	@	120MG	A075725	002	Dec 19, 2000	Jun DISC
--	---	-------	---------	-----	--------------	----------

	@	160MG	A075237	003	May 01, 2000	Jun DISC
--	---	-------	---------	-----	--------------	----------

	@	160MG	A075725	003	Dec 19, 2000	Jun DISC
--	---	-------	---------	-----	--------------	----------

	@	240MG	A075237	004	May 01, 2000	Jun DISC
--	---	-------	---------	-----	--------------	----------

	@	240MG	A075725	004	Dec 19, 2000	Jun DISC
--	---	-------	---------	-----	--------------	----------

	@ TEVA	80MG	A076883	001	Jul 26, 2004	Apr DISC
--	--------	------	---------	-----	--------------	----------

	@	120MG	A076883	002	Jul 26, 2004	Apr DISC
--	---	-------	---------	-----	--------------	----------

	@	160MG	A076883	003	Jul 26, 2004	Apr DISC
--	---	-------	---------	-----	--------------	----------

AB1	UPSHER-SMITH LABS	80MG	A075366	001	May 01, 2000	Jun CAHN
-----	-------------------	------	---------	-----	--------------	----------

AB1		120MG	A075366	002	May 01, 2000	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

AB1		160MG	A075366	003	May 01, 2000	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

AB1		240MG	A075366	004	May 01, 2000	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

SOYBEAN OILINJECTABLE;INJECTION
INTRALIPID 30%

+	!	FRESENIUS	30%	N019942	001	Dec 30, 1993	Sep CTEC
---	---	-----------	-----	---------	-----	--------------	----------

SPIRONOLACTONESUSPENSION;ORAL
CAROSPIR

+	!	CMP DEV LLC	25MG/5ML	N209478	001	Aug 04, 2017	Sep CAHN
+	!	CMP PHARMA INC	25MG/5ML	N209478	001	Aug 04, 2017	Aug NEWA

TABLET;ORAL
SPIRONOLACTONE

AB		ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016	Mar CAHN
AB			50MG	A203512	002	Sep 19, 2016	Mar CAHN
AB			100MG	A203512	003	Sep 19, 2016	Mar CAHN
AB		AMNEAL PHARMS	25MG	A091426	001	Jul 02, 2010	May CAHN
AB			25MG	A091426	001	Jul 02, 2010	May CMS1
AB			50MG	A091426	002	Jul 02, 2010	May CAHN
AB			50MG	A091426	002	Jul 02, 2010	May CMS1
AB			100MG	A091426	003	Jul 02, 2010	May CAHN
AB			100MG	A091426	003	Jul 02, 2010	May CMS1
	@	UPSHER SMITH	25MG	A087554	001		Jun CAHN

STAVUDINECAPSULE;ORAL
STAVUDINE

	@	MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009	May DISC
AB			30MG	A078775	001	Jan 05, 2009	Mar CAHN
	@		40MG	A078775	002	Jan 05, 2009	May DISC
AB			40MG	A078775	002	Jan 05, 2009	Mar CAHN

FOR SOLUTION;ORAL
STAVUDINE

@	AUROBINDO PHARMA	1MG/ML	A077774	001	Dec 29, 2008	Jul DISC
---	------------------	--------	---------	-----	--------------	----------

STERILE WATER FOR INJECTION

LIQUID;N/A

AP		WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan CAHN
		STERILE WATER FOR INJECTION IN PLASTIC CONTAINER					
AP	+	!	ICU MEDICAL INC	100%	N018233	001	Feb CAHN
AP	+			100%	N019869	001	Dec 26, 1989
AP			TARO	100%	A077393	001	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

		STERILE WATER IN PLASTIC CONTAINER					
AT		ICU MEDICAL INC	100%	N017513	001		Feb CAHN
AT			100%	N018313	001		Feb CAHN

SUCCINYLCHOLINE CHLORIDEINJECTABLE;INJECTION
ANECTINE

AP	+	!	SANDOZ INC	20MG/ML	N008453	002	May CAHN
	@		50MG/ML	N008453	003		May CAHN
	@		500MG/VIAL	N008453	001		May CAHN
	@		1GM/VIAL	N008453	004		May CAHN

SULCONAZOLE NITRATECREAM;TOPICAL
EXELDERM

+	!	SUN PHARM INDS INC	1%	N018737	001	Feb 28, 1989	Aug CAHN
---	---	--------------------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL
EXELDERM

+	!	SUN PHARM INDS INC	1%	N018738	001	Aug 30, 1985	Aug CAHN
---	---	--------------------	----	---------	-----	--------------	----------

SULFACETAMIDE SODIUMSOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM

AT	SANDOZ INC	10%	A089560	001	Oct 18, 1988	Feb CAHN
----	------------	-----	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIMINJECTABLE;INJECTION
BACTRIM

>D>	+ @ MUTUAL PHARM	80MG/ML;16MG/ML	N018374	001		Oct CAHN
	+ @	80MG/ML;16MG/ML	N018374	001		Sep CRLD
>A>	+ @ SUN PHARM INDS INC	80MG/ML;16MG/ML	N018374	001		Oct CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	MYLAN LABS LTD	80MG/ML;16MG/ML	A206607	001	Aug 30, 2017	Aug NEWA
AP	! TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Aug CTEC

TABLET;ORAL

SEPTRA

AB	MONARCH PHARMS	400MG;80MG	N017376	001		May CAHN
	SEPTRA DS					

AB	MONARCH PHARMS	800MG;160MG	N017376	002		May CAHN
	SULFAMETHOXAZOLE AND TRIMETHOPRIM					

AB	CHARTWELL MOLECULES	400MG;80MG	A078060	002	Jan 25, 2007	Mar CAHN
AB		800MG;160MG	A078060	001	Jan 25, 2007	Mar CAHN
AB	CHARTWELL PHARMS LLC	400MG;80MG	A078060	002	Jan 25, 2007	Jan CAHN
AB		800MG;160MG	A078060	001	Jan 25, 2007	Jan CAHN
>A>	SUN PHARM INDUSTRIES	400MG;80MG	A071017	002	Aug 25, 1986	Oct CMS1

SULFANILAMIDECREAM;VAGINAL
AVC

+	! MYLAN SPECIALITY LP	15%	N006530	003	Jan 27, 1987	Mar CAHN
---	-----------------------	-----	---------	-----	--------------	----------

SUPPOSITORY;VAGINAL
AVC

@	MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987	Mar CAHN
---	---------------------	--------	---------	-----	--------------	----------

SULINDACTABLET;ORAL
SULINDAC

AB	EPIC PHARMA LLC	150MG	A073262	002	Sep 06, 1991	Aug CAHN
AB		200MG	A073262	001	Sep 06, 1991	Aug CAHN

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

@	SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009	Mar CAHN
@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009	Mar CAHN
AP	WEST-WARD PHARMS INT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jan CAHN

SYSTEM;IONTOPHORESIS
ZECUITY

+	@ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan DISC
---	----------------------	-------------------	---------	-----	--------------	----------

SUNITINIB MALATECAPSULE;ORAL
SUTENT

+	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Mar CTEC
+		EQ 25MG BASE	N021938	002	Jan 26, 2006	Mar CTEC
+		EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Mar CTEC
+	!	EQ 50MG BASE	N021938	003	Jan 26, 2006	Mar CTEC

TACROLIMUSINJECTABLE;INJECTION
PROGRAF

AP	! ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Aug CFTG
	TACROLIMUS					
AP	HOSPIRA INC	EQ 5MG BASE/ML	A203900	001	Aug 25, 2017	Aug NEWA

TALCPOWDER; INTRAPLEURAL
STERITALC

+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017	Apr	NEWA
+		3GM/VIAL	N205555	002	May 01, 2017	Apr	NEWA
+	!	4GM/VIAL	N205555	003	May 01, 2017	Apr	NEWA

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

AB	!	MAYNE PHARMA	EQ 20MG BASE	A075797	002	Feb 20, 2003	Sep	CMS1
>A>	AB	ZYDUS PHARMS USA INC	EQ 10MG BASE	A206694	001	Oct 27, 2017	Oct	NEWA
>A>	AB		EQ 20MG BASE	A206694	002	Oct 27, 2017	Oct	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan	NEWA
		TAMSULOSIN HYDROCHLORIDE						
AB		ALKEM LABS LTD	0.4MG	A207405	001	Aug 11, 2017	Jul	NEWA

TAZAROTENEAEROSOL, FOAM; TOPICAL
FABIOR

	+	!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan	CAHN
			CREAM; TOPICAL						
			AVAGE						
AB	+	!	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Mar	CFTG
			TAZAROTENE						
AB			TARO	0.1%	A208258	001	Apr 03, 2017	Mar	NEWA
			TAZORAC						
AB	+	!	ALLERGAN	0.1%	N021184	002	Sep 29, 2000	Mar	CFTG

TECHNETIUM TC-99M EXAMETAZIME KITPOWDER; INTRAVENOUS
DRAX EXAMETAZIME

JUBILANT DRAXIMAGE N/A

N208870	001	Aug 17, 2017	Aug	NEWA
---------	-----	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION
MDP-BRACCO

AP		CARDINAL HEALTH 414	N/A	N018107	001		Apr	CAHN
----	--	---------------------	-----	---------	-----	--	-----	------

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION
AN-DTPA

@ JUBILANT DRAXIMAGE N/A

DTPA

DRAXIMAGE N/A

N017714	001		Aug	DISC
---------	-----	--	-----	------

N018511	001	Dec 29, 1989	Aug	CTEC
---------	-----	--------------	-----	------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP		CARDINAL HEALTH 414	N/A	A078809	001	Apr 28, 2009	Sep	CAHN
AP		JUBILANT DRAXIMAGE	N/A	A078806	001	Apr 29, 2009	Jun	CAHN

TECHNETIUM TC-99M TETROFOSMIN KITINJECTABLE; INJECTION
MYOVUE

+ @ GE HEALTHCARE N/A

MYOVUE 30ML

+! GE HEALTHCARE N/A

+ @ N/A

N020372	001	Feb 09, 1996	Jul	DISC
---------	-----	--------------	-----	------

N020372	002	Jul 07, 2005	Aug	CMFD
---------	-----	--------------	-----	------

N020372	002	Jul 07, 2005	Jul	DISC
---------	-----	--------------	-----	------

TECHNETIUM TC-99M TILMANOCEPTINJECTABLE; INJECTION
LYMPHOSEEK KIT

+! CARDINAL HEALTH 414 N/A

+! CARDINAL HLTH 414 N/A

N202207	001	Mar 13, 2013	Sep	CAHN
---------	-----	--------------	-----	------

N202207	001	Mar 13, 2013	Mar	CAHN
---------	-----	--------------	-----	------

TELAVANCIN HYDROCHLORIDEPOWDER;IV (INFUSION)
VIBATIV

+ @ THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Aug DISC
+	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	May CAHN
+	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	May CAHN

TELMISARTANTABLET;ORAL
TELMISARTAN

AB	CADILA PHARMS LTD	20MG	A208605	001	Jul 25, 2017	Jul NEWA
AB		40MG	A208605	002	Jul 25, 2017	Jul NEWA
AB		80MG	A208605	003	Jul 25, 2017	Jul NEWA
AB	GLENMARK PHARMS LTD	20MG	A090032	001	Jul 07, 2014	May CAHN
AB		40MG	A090032	002	Jul 07, 2014	May CAHN
AB		80MG	A090032	003	Jul 07, 2014	May CAHN
AB	MICRO LABS	20MG	A207016	001	Oct 03, 2017	Sep NEWA
AB		40MG	A207016	002	Oct 03, 2017	Sep NEWA
AB		80MG	A207016	003	Oct 03, 2017	Sep NEWA
AB	PRINSTON INC	20MG	A207882	001	May 03, 2017	Apr NEWA
AB		40MG	A207882	002	May 03, 2017	Apr NEWA
AB		80MG	A207882	003	May 03, 2017	Apr NEWA

TELOTTRISTAT ETIPRATETABLET;ORAL
XERMELO

+! LEXICON PHARMS INC	EQ 250MG BASE	N208794	001	Feb 28, 2017	Feb NEWA
-----------------------	---------------	---------	-----	--------------	----------

TEMAZEPAMCAPSULE;ORAL
TEMAZEPAM

AB	ACTAVIS ELIZABETH	15MG	A071620	002	Aug 07, 1987	May CMS1
AB	PRINSTON INC	7.5MG	A201781	001	Jun 04, 2015	Feb CAHN
AB		15MG	A201781	002	Jun 04, 2015	Feb CAHN
AB		22.5MG	A201781	003	Jun 04, 2015	Feb CAHN
AB		30MG	A201781	004	Jun 04, 2015	Feb CAHN

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

AB	ACCORD HLTHCARE	5MG	A201528	001	Feb 27, 2017	Feb NEWA
AB		20MG	A201528	002	Feb 27, 2017	Feb NEWA
AB		100MG	A201528	003	Feb 27, 2017	Feb NEWA
AB		140MG	A201528	004	Feb 27, 2017	Feb NEWA
AB		180MG	A201528	005	Feb 27, 2017	Feb NEWA
AB		250MG	A201528	006	Feb 27, 2017	Feb NEWA
AB	DEVA HOLDING AS	5MG	A207658	001	Apr 26, 2017	Apr NEWA
AB		20MG	A207658	002	Apr 26, 2017	Apr NEWA
AB		100MG	A207658	003	Apr 26, 2017	Apr NEWA
AB		140MG	A207658	004	Apr 26, 2017	Apr NEWA
AB		180MG	A207658	005	Apr 26, 2017	Apr NEWA
AB		250MG	A207658	006	Apr 26, 2017	Apr NEWA
AB	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Apr NEWA
AB		20MG	A203959	002	Apr 18, 2017	Apr NEWA
AB		100MG	A203959	003	Apr 18, 2017	Apr NEWA
AB		140MG	A203959	004	Apr 18, 2017	Apr NEWA
AB		250MG	A203959	005	Apr 18, 2017	Apr NEWA
AB	ZYDUS PHARMS USA INC	5MG	A206750	001	Jul 31, 2017	Jul NEWA
AB		20MG	A206750	002	Jul 31, 2017	Jul NEWA
AB		100MG	A206750	003	Jul 31, 2017	Jul NEWA
AB		140MG	A206750	004	Jul 31, 2017	Jul NEWA
AB		180MG	A206750	005	Jul 31, 2017	Jul NEWA
AB		250MG	A206750	006	Jul 31, 2017	Jul NEWA

TENIPOSIDEINJECTABLE;INJECTION
VUMON

+ @ HQ SPECILT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Aug DISC
-----------------------	---------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE	A075140	002	Feb 11, 2000	Mar CAHN
AB		EQ 2MG BASE	A075140	003	Feb 11, 2000	Mar CAHN
AB		EQ 5MG BASE	A075140	001	Feb 11, 2000	Mar CAHN
AB		EQ 10MG BASE	A075140	004	Feb 11, 2000	Mar CAHN

TERBINAFINE HYDROCHLORIDE

GRANULE;ORAL

LAMISIL

+	@ NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007	Aug DISC
+	@	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007	Aug DISC

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

@	MYLAN	EQ 250MG BASE	A077195	001	Jul 02, 2007	Aug DISC
---	-------	---------------	---------	-----	--------------	----------

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP	!	ATHENEX INC	1MG/ML	A076770	001	Apr 23, 2004	Mar CAHN
		TABLET;ORAL					
		BRETHINE					
	+	@ ANI PHARMS INC	2.5MG	N017849	001		Feb CAHN
	+	@	5MG	N017849	002		Feb CAHN
		TERBUTALINE SULFATE					
	!	LANNETT	5MG	A077152	002	Mar 25, 2005	Jan CHRS

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

AB2	+	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jun CFTG
AB2	+	!	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jun CFTG
		TESTIM					
AB2	+	!	AUXILIUM PHARMS LLC	50MG/5GM PACKET	N021454	001	Oct 31, 2002
		TESTOSTERONE					
AB2		ACTAVIS LABS UT INC	50MG/5GM PACKET	A091073	001	Sep 18, 2017	Sep NEWA
AB2		PERRIGO UK FINCO	1.62% (20.25MG/1.25GM PACKET)	A205781	001	Jul 12, 2017	Jun NEWA
AB2			1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jun NEWA

VOGELXO

AB2		UPSHER-SMITH LABS	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun CAHN
-----	--	-------------------	-----------------	---------	-----	--------------	----------

GEL, METERED;TRANSDERMAL

TESTOSTERONE

AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Mar CAHN
		VOGELXO					

BX		UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun CAHN
----	--	-------------------	-------------------------	---------	-----	--------------	----------

SOLUTION, METERED;TRANSDERMAL

AXIRON

	+	@ ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Sep DISC
AT	+	!	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Feb CFTG

TESTOSTERONE

AT		ACTAVIS LABS UT INC	30MG/1.5ML ACTUATION	A205328	001	Aug 07, 2017	Jul NEWA
>A> AT		LUPIN LTD	30MG/1.5ML ACTUATION	A208061	001	Oct 23, 2017	Oct NEWA
AT	!	PERRIGO ISRAEL	30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Sep CHRS
AT			30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Feb NEWA

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

+	!	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	May CAHN
---	---	---------------------	------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

AO		LUITPOLD PHARMS INC	200MG/ML	A207742	001	Jun 16, 2017	Jun NEWA
AO		SANDOZ INC	100MG/ML	A040615	001	Aug 10, 2006	Mar CAHN
AO			200MG/ML	A040615	002	Aug 10, 2006	Mar CAHN
AO		WATSON PHARMS INC	200MG/ML	A086030	001		Feb CAHN
AO		WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan CAHN
AO			200MG/ML	A090387	002	Jul 15, 2010	Jan CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

AO	WATSON PHARMS INC	200MG/ML	A085598	001		Feb	CAHN
----	-------------------	----------	---------	-----	--	-----	------

TETRABENAZINE

TABLET; ORAL
TETRABENAZINE

AB	ACTAVIS LABS FL INC	25MG	A206686	001	Jul 07, 2017	Jun	NEWA
AB	APICORE US	12.5MG	A207682	001	Jan 31, 2017	Jan	NEWA
AB		25MG	A207682	002	Jan 31, 2017	Jan	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

AB	+ HERITAGE PHARMA	250MG	N050278	003		Jan	CAHN
AB	+!	500MG	N050278	001		Jan	CAHN

TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL TETRA	250MG	A062752	001	Aug 12, 1988	Apr	CAHN
AB		500MG	A062752	002	Aug 12, 1988	Apr	CAHN
	@ IMPAX LABS	100MG	A060469	002		Jul	DISC
	@	250MG	A060469	001		Jul	DISC
	@	500MG	A060469	003		Jul	DISC

THEOPHYLLINE

ELIXIR; ORAL
THEOPHYLLINE

@ CHARTWELL RX 80MG/15ML
@ PHARM ASSOC 80MG/15ML

A085952	001	Apr	CAHN
A086720	001	May	CAHN

TABLET, EXTENDED RELEASE; ORAL
THEOCHRON

AB	NOSTRUM PHARMS LLC	100MG	A088320	001	Feb 21, 1985	May	CAHN
AB		200MG	A088321	001	Feb 21, 1985	May	CAHN
	@	300MG	A087400	002	Jan 11, 1983	May	CAHN
	THEOPHYLLINE						
!	ALEMBIC LTD	450MG	A090430	002	Oct 27, 2010	Apr	CHRS
AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May	CAHN
!		450MG	A090430	002	Oct 27, 2010	May	CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT 100MG/ML

A080575	001	Jan	CAHN
---------	-----	-----	------

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC 30MG/ML
@ PHARM ASSOC 30MG/ML
@ 100MG/ML

A089602	001	Nov 09, 1987	Jan	CAHN
A040187	001	Aug 28, 1997	May	CAHN
A040213	001	May 29, 1998	May	CAHN

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@ WATSON LABS TEVA 15MG
@ 25MG
@ 200MG

A088477	001	Nov 08, 1983	May	CAHN
A088567	001	May 11, 1984	May	CAHN
A088872	001	Apr 26, 1985	May	CAHN

THIOTEPA

POWDER; IV (INFUSION)
TEPADINA

+! ADIENNE SA 15MG/VIAL
+! 100MG/VIAL

N208264	001	Jan 26, 2017	Jan	NEWA
N208264	002	Jan 26, 2017	Jan	NEWA

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL

>D>	+	CEPHALON	12MG	N020646	002	Sep 30, 1997	Oct	CFTG
>A>	AB	+	12MG	N020646	002	Sep 30, 1997	Oct	CFTG
>D>	+		16MG	N020646	003	Sep 30, 1997	Oct	CFTG
>A>	AB	+	16MG	N020646	003	Sep 30, 1997	Oct	CFTG

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

>A>	AB	WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Oct NEWA
>A>	AB		4MG	A206857	002	Oct 13, 2017	Oct NEWA
>A>	AB		12MG	A206857	003	Oct 13, 2017	Oct NEWA
>A>	AB		16MG	A206857	004	Oct 13, 2017	Oct NEWA

TICAGRELOL

TABLET;ORAL

BRILINTA

+	ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jan CAHN
+	!	90MG	N022433	001	Jul 20, 2011	Jan CAHN

TIGECYCLINE

POWDER;IV (INFUSION)

TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Feb CDFR
		TYGACIL					
AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Feb CDFR

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB		SANDOZ INC	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Feb CAHN
AB			EQ 0.5% BASE	N020963	002	Oct 21, 1998	Feb CAHN

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT	!	SANDOZ INC	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Feb CAHN
AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Feb CAHN

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

AB		UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan CTEC
AB			500MG	A202489	002	Oct 09, 2013	Jan CTEC

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		JUBILANT GENERICS	EQ 2MG BASE	A209605	001	Aug 04, 2017	Jul NEWA
AB			EQ 4MG BASE	A209605	002	Aug 04, 2017	Jul NEWA
AB			EQ 6MG BASE	A209605	003	Aug 04, 2017	Jul NEWA
AB		PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb NEWA
AB			EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb NEWA
AB			EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb NEWA
AB		ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb NEWA
AB			EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb NEWA
AB			EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	EQ 2MG BASE	A076347	001	Oct 11, 2002	May CAHN
AB			EQ 4MG BASE	A076347	002	Oct 11, 2002	May CAHN
AB		PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan NEWA
AB			EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan NEWA

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN		AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	May CAHN
AN		LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar NEWA
>A>	AN	MYLAN PHARMS INC	300MG/5ML	A209554	001	Oct 13, 2017	Oct NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT		SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Jun NEWA
		TOBREX					
AT		SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb CAHN

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Aug CAHN
----	----------------------	-----------------	---------	-----	--------------	----------

TOLMETIN SODIUMTABLET; ORAL
TOLMETIN SODIUM

	@ SUN PHARM INDUSTRIES	EQ 200MG BASE	A073310	001	Nov 27, 1991	Apr DISC
--	------------------------	---------------	---------	-----	--------------	----------

TOPIRAMATECAPSULE, EXTENDED RELEASE; ORAL
QUDEXY XR

+	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jun CAHN
+		50MG	N205122	002	Mar 11, 2014	Jun CAHN
+		100MG	N205122	003	Mar 11, 2014	Jun CAHN
+		150MG	N205122	004	Mar 11, 2014	Jun CAHN
+		200MG	N205122	005	Mar 11, 2014	Jun CAHN

TABLET; ORAL
TOPIRAMATE

	@ MYLAN	25MG	A076314	001	Mar 27, 2009	May DISC
	@	50MG	A076314	002	Mar 27, 2009	May DISC
	@	100MG	A076314	003	Mar 27, 2009	May DISC
	@	200MG	A076314	004	Mar 27, 2009	May DISC
AB	UPSHER-SMITH LABS	25MG	A078499	001	Jan 07, 2010	Jun CAHN
AB		50MG	A078499	002	Jan 07, 2010	Jun CAHN
AB		100MG	A078499	003	Jan 07, 2010	Jun CAHN
AB		200MG	A078499	004	Jan 07, 2010	Jun CAHN

TOPOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

AP	HONG KONG	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Sep CAHN
AP	NOVAST LABS LTD	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Sep CAHN
	@ SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013	Sep DISC

SOLUTION; INTRAVENOUS
TOPOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017	Jun NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204406	002	Jul 06, 2017	Jun NEWA

TOREMIFENE CITRATETABLET; ORAL
FARESTON

+	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan CAHN
---	-------------	--------------	---------	-----	--------------	----------

TORSEMIDETABLET; ORAL
DEMADEX

AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar CAHN
AB	+		10MG	N020136	002	Aug 23, 1993	Mar CAHN
AB	+		20MG	N020136	003	Aug 23, 1993	Mar CAHN
AB	+		100MG	N020136	004	Aug 23, 1993	Mar CAHN

TORSEMIDE

	@ SUN PHARM INDS	5MG	A078478	001	Feb 26, 2008	Sep DISC
	@	10MG	A078478	002	Feb 26, 2008	Sep DISC
	@	20MG	A078478	003	Feb 26, 2008	Sep DISC
	@	100MG	A078478	004	Feb 26, 2008	Sep DISC

TRAMADOL HYDROCHLORIDETABLET; ORAL
TRAMADOL HYDROCHLORIDE

>D>	AB	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013	Oct DISC
>A>		@	50MG	A202390	001	May 16, 2013	Oct DISC
	AB		50MG	A202390	001	May 16, 2013	Mar CAHN
	AB	AMNEAL PHARMS	50MG	A076003	001	Jun 20, 2002	May CAHN

TABLET, EXTENDED RELEASE; ORAL
ULTRAM ER

+	@ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar CRLD
+	@	200MG	N021692	002	Sep 08, 2005	Mar CRLD
+	@	300MG	N021692	003	Sep 08, 2005	Mar CRLD

TRAMETINIB DIMETHYL SULFOXIDETABLET;ORAL
MEKINIST

+ @ NOVARTIS PHARMS CORP EQ 1MG

N204114 002 May 29, 2013 Jul DISC

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

	@ EPIC PHARMA LLC	1MG	A 077256	001	Jun 12, 2007	May CAHN
	@	2MG	A 077256	002	Jun 12, 2007	May CAHN
	@	4MG	A 077256	003	Jun 12, 2007	May CAHN
	@ INVAGEN PHARMS	1MG	A 078320	001	Jun 12, 2007	Jun DISC
BX		1MG	A 078320	001	Jun 12, 2007	Apr CTEC
	@	2MG	A 078320	002	Jun 12, 2007	Jun DISC
BX		2MG	A 078320	002	Jun 12, 2007	Apr CTEC
	@	4MG	A 078320	003	Jun 12, 2007	Jun DISC
BX		4MG	A 078320	003	Jun 12, 2007	Apr CTEC
	@ MYLAN	1MG	A 078346	001	Apr 28, 2008	May DISC
	@	2MG	A 078346	002	Apr 28, 2008	May DISC
	@	4MG	A 078346	003	Apr 28, 2008	May DISC

TRANEXAMIC ACIDINJECTABLE;INJECTION
TRANEXAMIC ACID

AP	AKORN	100MG/ML	A 206594	001	Sep 28, 2017	Sep NEWA
AP	AMNEAL PHARMS CO	100MG/ML	A 208840	001	Feb 28, 2017	Feb NEWA
AP	GLAND PHARMA LTD	100MG/ML	A 207239	001	Feb 13, 2017	Jan NEWA
AP	MICRO LABS	100MG/ML	A 206713	001	Jun 27, 2017	Jun NEWA
AP	VIRTUS PHARMS	100MG/ML	A 202755	001	Feb 25, 2016	Sep CAHN
AP	VIVA HLTHCARE	100MG/ML	A 206713	001	Jun 27, 2017	Sep CAHN
AP	ZYDUS PHARMS USA INC	100MG/ML	A 205228	001	Jul 17, 2017	Jul NEWA

TRAVOPROSTSOLUTION/DROPS;OPHTHALMIC
TRAVOPROST

AT	MYLAN PHARMS INC	0.004%	A 205050	001	Jul 07, 2017	Jun NEWA
----	------------------	--------	----------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A 206923	001	Sep 08, 2017	Aug NEWA
AB		100MG	A 206923	002	Sep 08, 2017	Aug NEWA
AB		150MG	A 206923	003	Sep 08, 2017	Aug NEWA
AB		300MG	A 206923	004	Sep 08, 2017	Aug NEWA
	@ MYLAN PHARMS INC	50MG	A 090514	001	Jun 02, 2009	May DISC
	@	100MG	A 090514	002	Jun 02, 2009	May DISC
	@	150MG	A 090514	003	Jun 02, 2009	May DISC
	@	300MG	A 090514	004	Jun 02, 2009	May DISC
AB	ZYDUS PHARMS USA INC	50MG	A 205253	001	Oct 10, 2017	Sep NEWA
AB		100MG	A 205253	002	Oct 10, 2017	Sep NEWA
AB		150MG	A 205253	003	Oct 10, 2017	Sep NEWA
AB		300MG	A 205253	004	Oct 10, 2017	Sep NEWA

TRETINOIN

CAPSULE;ORAL

TRETINOIN

AB	GLENMARK PHARMS LTD	10MG	A 208279	001	Dec 23, 2016	Jun CAHN
----	---------------------	------	----------	-----	--------------	----------

VESANOID

+ @ CHEPLAPHARM 10MG

N 020438 001 Nov 22, 1995 May CAHN

CREAM;TOPICAL

TRETINOIN

AB2	ZO SKIN HEALTH	0.05%	A 076498	001	Sep 15, 2005	Feb CAHN
-----	----------------	-------	----------	-----	--------------	----------

GEL;TOPICAL

RETIN-A-MICRO

>A> +! VALEANT INTL 0.06%

N 020475 004 Oct 23, 2017 Oct NEWA

TRETINOIN

AB	MYLAN PHARMS INC	0.04%	A 202567	001	Jul 17, 2013	Jun CAHN
AB		0.05%	A 207955	001	Aug 13, 2015	Jun CAHN
AB		0.1%	A 202026	001	Jul 17, 2013	Jun CAHN

SOLUTION;TOPICAL									
RETIN-A									
>D>	+!	VALEANT INTL	0.05%	N016921	001			Oct	DISC
>A>	+	@	0.05%	N016921	001			Oct	DISC
<u>TRIAMCINOLONE ACETONIDE</u>									
CREAM;TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017		Jan	NEWA
AT			0.1%	A208763	002	Feb 01, 2017		Jan	NEWA
AT			0.5%	A208763	003	Feb 01, 2017		Jan	NEWA
AT	+	MYLAN PHARMS INC	0.025%	N011601	003			Jan	CAHN
AT	+		0.1%	N011601	006			Jan	CAHN
	@	TARO	0.025%	A040038	001	Oct 26, 1994		Apr	CAHN
AT			0.1%	A040039	001	Nov 26, 1997		Apr	CAHN
AT			0.1%	A040039	001	Nov 26, 1997		Mar	CAHN
AT		TELIGENT PHARMA INC	0.1%	A208848	001	Sep 18, 2017		Sep	NEWA
>A>	FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR								
>A>	ZILRETTA								
>A>	+!	FLEXION THERAPS INC	32MG/VIAL	N208845	001	Oct 06, 2017		Oct	NEWA
INJECTABLE;INJECTION									
KENALOG-10									
	+	APOTHECON	10MG/ML	N012041	001			Jun	CRLD
TRIAMCINOLONE ACETONIDE									
	@	SANDOZ INC	10MG/ML	A090166	001	May 27, 2009		Apr	CAHN
	@		40MG/ML	A090164	001	Jun 01, 2009		Apr	CAHN
OINTMENT;TOPICAL									
KENALOG									
	+	@ MYLAN PHARMS INC	0.025%	N011600	003			Sep	CRLD
	@		0.025%	N011600	003			Aug	DISC
AT			0.025%	N011600	003			Jan	CAHN
	+	@	0.1%	N011600	001			Sep	CRLD
	@		0.1%	N011600	001			Aug	DISC
AT			0.1%	N011600	001			Jan	CAHN
TRIAMCINOLONE ACETONIDE									
AT		G AND W LABS INC	0.5%	A208925	001	Oct 06, 2017		Sep	NEWA
AT		GLENMARK PHARMS	0.1%	A208320	001	Aug 22, 2017		Aug	NEWA
	@	TARO	0.025%	A040040	001	Sep 30, 1994		Apr	CAHN
AT			0.1%	A040037	001	Sep 30, 1994		Apr	CAHN
AT		TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017		Feb	NEWA
TRIAMCINOLONE ACETONIDE IN ABSORBASE									
	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995		Apr	CAHN
PASTE;DENTAL									
TRIAMCINOLONE ACETONIDE									
AT		G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017		Jan	NEWA
SPRAY;TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		RICONPHARMA LLC	0.147MG/GM	A206786	001	Sep 08, 2017		Aug	NEWA
SPRAY, METERED;NASAL									
TRIAMCINOLONE ACETONIDE									
	@	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009		Jan	CAHN
<u>TRIAMCINOLONE DIACETATE</u>									
INJECTABLE;INJECTION									
ARISTOCORT									
	@	SANDOZ INC	25MG/ML	N011685	003			Jun	CAHN
	+	@	40MG/ML	N012802	001			Jun	CAHN
<u>TRIAMCINOLONE HEXACETONIDE</u>									
INJECTABLE;INJECTION									
ARISTOSPAN									
	+!	SANDOZ INC	5MG/ML	N016466	001			Jun	CAHN
	+!		20MG/ML	N016466	002			Jun	CAHN
<u>TRIFLURIDINE</u>									
SOLUTION/DROPS;OPHTHALMIC									
TRIFLURIDINE									
AT		HI-TECH PHARMACAL	1%	A205438	001	Jul 28, 2017		Jul	NEWA
AT		SANDOZ INC	1%	A074311	001	Oct 06, 1995		Feb	CAHN
VIROPTIC									
AT	+!	MONARCH PHARMS	1%	N018299	001			Feb	CAHN

TRIHEXYPHENIDYL HYDROCHLORIDE

	ELIXIR;ORAL						
	TRIHEXYPHENIDYL HYDROCHLORIDE						
AA	! PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997	May	CAHN
	TABLET;ORAL						
	TRIHEXYPHENIDYL HYDROCHLORIDE						
AA	VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar	CAHN
AA		5MG	A040254	002	Dec 24, 1998	Mar	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

	CAPSULE;ORAL						
	TIGAN						
AB	+! KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	May	CAHN

TRIMETHOPRIM HYDROCHLORIDE

	SOLUTION;ORAL						
	PRIMSOL						
>A>	+! ALLEGIS	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Oct	CAHN
>D>	+! AYU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Oct	CAHN

TRIMIPRAMINE MALEATE

	CAPSULE;ORAL						
	TRIMIPRAMINE MALEATE						
AB	ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006	May	CAHN
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	May	CAHN
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	May	CAHN

TRIPTORELIN PAMOATE

	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR						
	TRIPTODUR KIT						
	+! ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun	NEWA

TROPICAMIDE

	SOLUTION/DROPS;OPHTHALMIC						
	MYDRIACYL						
AT	! SANDOZ INC	0.5%	A084305	001		Feb	CAHN

TROSPIMUM CHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	TROSPIMUM CHLORIDE						
	@ UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015	Jun	CAHN

ULIPRISTAL ACETATE

	TABLET;ORAL						
	ELLA						
AB	+! LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan	CFTG
	LOGILIA						
AB	TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan	NEWA

URSODIOL

	CAPSULE;ORAL						
	URSODIOL						
	@ IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	May	DISC
BX		300MG	A077895	001	Jul 27, 2006	Apr	CTEC
AB		300MG	A077895	001	Jul 27, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

	TABLET;ORAL						
	VALACYCLOVIR HYDROCHLORIDE						
	@ MYLAN	EQ 500MG BASE	A078070	001	May 24, 2010	Jun	DISC
	@	EQ 1GM BASE	A078070	002	May 24, 2010	Jun	DISC

VALBENAZINE TOSYLATE

	CAPSULE;ORAL						
	INGREZZA						
>A>	+! NEUROCRINE	40MG	N209241	001	Apr 11, 2017	Apr	NEWA
	+	80MG	N209241	002	Oct 04, 2017	Oct	NEWA

VALPROATE SODIUMINJECTABLE; INJECTION
VALPROATE SODIUM

AP	ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Mar CAHN
----	-------------	------------------	---------	-----	--------------	----------

VALPROIC ACIDCAPSULE; ORAL
VALPROIC ACID

@ USL PHARMA

250MG

A070631	001	Jun 11, 1987	Jun CAHN
---------	-----	--------------	----------

SYRUP; ORAL

VALPROIC ACID

AA	ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
AA	PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000	May CAHN
AA	VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000	Feb CAHN

VALSARTANTABLET; ORAL
VALSARTAN

AB	AMNEAL PHARMS	40MG	A204011	001	Jan 11, 2016	May CAHN
AB		80MG	A204011	002	Jan 11, 2016	May CAHN
AB		160MG	A204011	003	Jan 11, 2016	May CAHN
AB		320MG	A204011	004	Jan 11, 2016	May CAHN
AB	MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb CAHN
AB		80MG	A090866	002	Jan 05, 2015	Feb CAHN
AB		160MG	A090866	003	Jan 05, 2015	Feb CAHN
AB		320MG	A090866	004	Jan 05, 2015	Feb CAHN

VANCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

AP	MUSTAFA NEVZAT ILAC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Aug CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Aug CAHN
>D> AP	TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015	Oct DISC
>A>	@	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015	Oct DISC
>D> AP		EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015	Oct DISC
>A>	@	EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015	Oct DISC
>D> AP		EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015	Oct DISC
>A>	@	EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015	Oct DISC
>D> AP		EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015	Oct DISC
>A>	@	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015	Oct DISC

VARDENAFIL HYDROCHLORIDETABLET; ORAL
VARDENAFIL HYDROCHLORIDE

@ TEVA PHARMS

2.5MG

A091347	001	May 03, 2012	Sep DISC
---------	-----	--------------	----------

@

5MG

A091347	002	May 03, 2012	Sep DISC
---------	-----	--------------	----------

@

10MG

A091347	003	May 03, 2012	Sep DISC
---------	-----	--------------	----------

@

20MG

A091347	004	May 03, 2012	Sep DISC
---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING; ORAL
STAXYN

+!	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Jun CTEC
----	----------------	------	---------	-----	--------------	----------

VASOPRESSINSOLUTION; IV (INFUSION)
VASOSTRICT

+!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	May CMFD
+	@	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr DISC
+!		20UNITS/ML (20UNITS/ML)	N204485	002	Mar 18, 2016	Apr NEWA
+!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	May NEWA

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

@ WEST-WARD PHARMS INT

10MG/VIAL

A075218	001	Aug 23, 1999	Mar CAHN
---------	-----	--------------	----------

AP		10MG/VIAL	A075549	001	Jun 13, 2000	Jan CAHN
----	--	-----------	---------	-----	--------------	----------

@

20MG/VIAL

A075218	002	Aug 23, 1999	Mar CAHN
---------	-----	--------------	----------

AP		20MG/VIAL	A075549	002	Jun 13, 2000	Jan CAHN
----	--	-----------	---------	-----	--------------	----------

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 37.5MG BASE	A204889	001	Oct 05, 2017	Sep NEWA
AB		EQ 75MG BASE	A204889	002	Oct 05, 2017	Sep NEWA
AB		EQ 150MG BASE	A204889	003	Oct 05, 2017	Sep NEWA
	@ MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011	Aug DISC
	@	EQ 75MG BASE	A078789	002	Jun 01, 2011	Aug DISC
	@	EQ 150MG BASE	A078789	003	Jun 01, 2011	Aug DISC

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb CAHN
AB		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb CAHN
AB		EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb CAHN
AB		EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb CAHN
AB		EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar NEWA
AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar NEWA
AB	+ OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008	Mar CFTG

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

	+ @ PFIZER	180MG	N019152	002	Dec 15, 1989	Jan CRLD
	COVERA-HS					
	@ GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan DISC
	@	240MG	N020552	002	Feb 26, 1996	Jan DISC

VERAPAMIL HYDROCHLORIDE

AB	CADILA PHARMS LTD	180MG	A206173	001	May 05, 2017	Apr NEWA
AB		240MG	A206173	002	May 05, 2017	Apr NEWA

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	+! LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr CFTG
	+!	500MG/PACKET	N022006	001	Aug 21, 2009	Jan CAHN

VIGABATRIN

AA	PAR PHARM INC	500MG/PACKET	A208218	001	Apr 27, 2017	Apr NEWA
----	---------------	--------------	---------	-----	--------------	----------

TABLET;ORAL

SABRIL

	+! LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009	Jan CAHN
--	------------------------	-------	---------	-----	--------------	----------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

>D>	AP	MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Oct DISC
>A>		@	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Oct DISC
	AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Mar CAHN
	AP		EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan CAHN

VORICONAZOLE

POWDER;IV (INFUSION)

VORICONAZOLE

	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar NEWA
--	-------------------	------------	---------	-----	--------------	----------

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

	+ @ TAKEDA PHARMS USA	EQ 15MG BASE	N204447	003	Sep 30, 2013	Mar DISC
--	-----------------------	--------------	---------	-----	--------------	----------

WARFARIN SODIUM

TABLET;ORAL

JANTOVEN

AB	USL PHARMA	1MG	A040416	001	Oct 02, 2003	Jun CAHN
AB		2MG	A040416	002	Oct 02, 2003	Jun CAHN
AB		2.5MG	A040416	003	Oct 02, 2003	Jun CAHN
AB		3MG	A040416	004	Oct 02, 2003	Jun CAHN
AB		4MG	A040416	005	Oct 02, 2003	Jun CAHN
AB		5MG	A040416	006	Oct 02, 2003	Jun CAHN

TABLET; ORAL

JANTOVEN

AB		6MG	A040416	007	Oct 02, 2003	Jun CAHN
AB		7.5MG	A040416	008	Oct 02, 2003	Jun CAHN
AB		10MG	A040416	009	Oct 02, 2003	Jun CAHN

WARFARIN SODIUM

	@ MYLAN	1MG	A040415	001	Sep 27, 2004	Apr DISC
	@	2MG	A040415	002	Sep 27, 2004	Apr DISC
	@	2.5MG	A040415	003	Sep 29, 2004	Apr DISC
	@	3MG	A040415	004	Sep 27, 2004	Apr DISC
	@	4MG	A040415	005	Sep 27, 2004	Apr DISC
	@	5MG	A040415	006	Sep 27, 2004	Apr DISC
	@	6MG	A040415	007	Sep 27, 2004	Apr DISC
	@	7.5MG	A040415	008	Sep 27, 2004	Apr DISC
	@	10MG	A040415	009	Sep 27, 2004	Apr DISC
AB	TARO PHARM	1MG	A040301	002	Jul 15, 1999	Mar CAHN
AB		2MG	A040301	003	Jul 15, 1999	Mar CAHN
AB		2.5MG	A040301	004	Jul 15, 1999	Mar CAHN
AB		3MG	A040301	005	Jul 15, 1999	Mar CAHN
AB		4MG	A040301	006	Jul 15, 1999	Mar CAHN
AB		5MG	A040301	007	Jul 15, 1999	Mar CAHN
AB		6MG	A040301	008	Jul 15, 1999	Mar CAHN
AB		7.5MG	A040301	009	Jul 15, 1999	Mar CAHN
AB		10MG	A040301	001	Jul 15, 1999	Mar CAHN

ZALEPLON

CAPSULE; ORAL

ZALEPLON

	@ MYLAN	5MG	A077238	001	Jun 06, 2008	Jul DISC
	@	10MG	A077238	002	Jun 06, 2008	Jul DISC
	@ UPSHER-SMITH LABS	5MG	A078095	001	Jun 06, 2008	Jun CAHN
	@	10MG	A078095	002	Jun 06, 2008	Jun CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

	@ HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	May CAHN
--	---------------------	-------	---------	-----	--------------	----------

ZILEUTON

TABLET, EXTENDED RELEASE; ORAL

ZILEUTON

AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar NEWA
AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar CAHN
	ZYFLO CR					
AB	+! CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb NEWA
AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb NEWA
AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A208988	001	Aug 22, 2017	Aug NEWA
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Aug NEWA
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Aug NEWA
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Aug NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOLEDRONIC ACID

AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Sep CAHN
AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Sep CAHN
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Sep CAHN
>A> AP	CIPLA LTD	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Oct NEWA
AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan NEWA
>A> AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Oct NEWA
AP	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May CAHN
>D> AP	SUN PHARMA GLOBAL	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Oct DISC
>A>	@	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Oct DISC

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	APPCO PHARMA LLC	2.5MG	A206973	001	Jun 30, 2017	Jun NEWA
AB		5MG	A206973	002	Jun 30, 2017	Jun NEWA
AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb NEWA
AB		5MG	A207867	002	Feb 27, 2017	Feb NEWA
>D> AB	SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014	Oct DISC
>A>	@	2.5MG	A203476	001	Nov 13, 2014	Oct DISC
>D> AB		5MG	A203476	002	Nov 13, 2014	Oct DISC
>A>	@	5MG	A203476	002	Nov 13, 2014	Oct DISC

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+!	MAGNA PHARMS	5MG/SPRAY	N022196	001	Dec 19, 2008	Aug CAHN
----	--------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

ZOLPIDEM TARTRATE

AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Mar CAHN
AB		10MG	A077214	002	Apr 23, 2007	Mar CAHN
	@ VIVIMED GLOBAL	5MG	A076062	001	Apr 23, 2007	Aug CAHN
	@	10MG	A076062	002	Apr 23, 2007	Aug CAHN

TABLET;SUBLINGUAL

EDLUAR

AB	+ MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar CAHN
AB	+!	10MG	N021997	002	Mar 13, 2009	Mar CAHN

ZOLPIDEM TARTRATE

AB	PAR PHARM INC	1.75MG	A204229	001	Sep 11, 2017	Aug NEWA
AB		3.5MG	A204229	002	Sep 11, 2017	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan NEWA
	@ SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr DISC
	@	12.5MG	A078483	002	Jun 06, 2011	Apr DISC

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

@	EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007	May CAHN
@		50MG	A077876	002	Feb 21, 2007	May CAHN
@		100MG	A077876	003	Feb 21, 2007	May CAHN
@	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005	Jun DISC
@		50MG	A077647	002	Dec 22, 2005	Jun DISC
@		100MG	A077647	003	Dec 22, 2005	Jun DISC
@	UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Jun CAHN
@		50MG	A077644	002	Dec 22, 2005	Jun CAHN
@		100MG	A077644	003	Dec 22, 2005	Jun CAHN

ACETAMINOPHENSUPPOSITORY;RECTAL
ACETAMINOPHEN

>A>	@ ACINO PRODS	120MG	A 071010	001	May 12, 1987	Oct CAHN
>A>	@	650MG	A 071011	001	May 12, 1987	Oct CAHN
>D>	@ ROXANE	120MG	A 071010	001	May 12, 1987	Oct CAHN
>D>	@	650MG	A 071011	001	May 12, 1987	Oct CAHN

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATETABLET, CHEWABLE;ORAL
FOAMCOAT

@ GUARDIAN DRUG	80MG;20MG	A 071793	001	Sep 04, 1987	Sep DISC
-----------------	-----------	----------	-----	--------------	----------

AVOBENZONE; OCTINOXATE; OXYBENZONELOTION;TOPICAL
SHADE UVAGUARD

+ @ BAYER HEALTHCARE LLC	3%;7.5%;3%	N 020045	001	Dec 07, 1992	Jun DISC
--------------------------	------------	----------	-----	--------------	----------

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

>A>	BUTENAFINE HYDROCHLORIDE					
>A>	TARO	1%	A 205181	001	Nov 16, 2017	Oct NEWA

BUTOCONAZOLE NITRATECREAM;VAGINAL
FEMSTAT 3

+ @ BAYER	2%	N 020421	001	Dec 21, 1995	Aug DISC
-----------	----	----------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY
STRIDES PHARMA 10MG

A 205291	001	Jul 21, 2017	Jul NEWA
----------	-----	--------------	----------

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
ALLIED PHARMA INC 5MG/5ML

A 091327	001	Oct 17, 2011	Apr CAHN
----------	-----	--------------	----------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
ALLIED PHARMA INC 5MG/5ML

A 091327	002	Oct 17, 2011	Apr CAHN
----------	-----	--------------	----------

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY
JUBILANT CADISTA 5MG

A 078933	001	Jun 15, 2010	Apr CAHN
----------	-----	--------------	----------

JUBILANT CADISTA 10MG

A 078933	002	Jun 15, 2010	Apr CAHN
----------	-----	--------------	----------

UNIQUE PHARM LABS 5MG

A 077829	001	Aug 26, 2009	Aug CAHN
----------	-----	--------------	----------

UNIQUE PHARM LABS 10MG

A 077829	004	Aug 26, 2009	Aug CAHN
----------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES

JUBILANT CADISTA 5MG

A 078933	003	Jun 15, 2010	Apr CAHN
----------	-----	--------------	----------

JUBILANT CADISTA 10MG

A 078933	004	Jun 15, 2010	Apr CAHN
----------	-----	--------------	----------

UNIQUE PHARM LABS 5MG

A 077829	003	Aug 26, 2009	Aug CAHN
----------	-----	--------------	----------

UNIQUE PHARM LABS 10MG

A 077829	002	Aug 26, 2009	Aug CAHN
----------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY
PERRIGO R AND D 10MG

A 205490	001	Sep 02, 2015	Aug CAHN
----------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL MULTI-SYMPTOM COLD & FLU

+! PFIZER	4MG;200MG;10MG	N 022113	002	Apr 28, 2017	Apr NEWA
-----------	----------------	----------	-----	--------------	----------

CIMETIDINE

TABLET;ORAL

CIMETIDINE

>D>	CONTRACT PHARMACAL	200MG	A 074961	001	Jun 19, 1998	Oct DISC
>A>	@	200MG	A 074961	001	Jun 19, 1998	Oct DISC
>D>		200MG	A 074963	001	Jun 19, 1998	Oct DISC
>A>	@	200MG	A 074963	001	Jun 19, 1998	Oct DISC
	L PERRIGO CO	200MG	A 075285	001	Oct 29, 1998	Apr CAHN
	@ SANDOZ INC	100MG	A 075122	001	Jun 19, 1998	Mar CAHN
	@	200MG	A 075122	002	Jun 19, 1998	Mar CAHN
	@ WATSON LABS TEVA	200MG	A 075425	001	Jul 29, 1999	May CAHN

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

L PERRIGO CO

1.34MG

A074512 001 Nov 22, 1995 Apr CAHN

TAVIST-1

+! GLAXOSMITHKLINE CONS 1.34MG

N020925 001 Aug 21, 1992 Apr CAHN

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE

! ACTAVIS MID ATLANTIC 1%

A074165 001 Jul 16, 1993 Jun CHRS

TARO 1%

A072641 001 Dec 04, 1995 Apr CAHN

GYNE-LOTTRIMIN

+ @ BAYER HEALTHCARE LLC 1%

N018052 002 Nov 30, 1990 Jun DISC

GYNE-LOTTRIMIN 3

+ @ BAYER HEALTHCARE LLC 2%

N020574 001 Nov 24, 1998 Jun DISC

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTTRIMIN 3 COMBINATION PACK

+ @ BAYER HEALTHCARE LLC 1%, 200MG

N020526 002 Jul 29, 1996 Jun DISC

GYNE-LOTTRIMIN COMBINATION PACK

+ @ BAYER HEALTHCARE LLC 1%, 100MG

N020289 002 Apr 26, 1993 Jun DISC

TABLET; VAGINAL

GYNE-LOTTRIMIN

+ @ BAYER HEALTHCARE LLC 100MG

N017717 002 Nov 30, 1990 Jun DISC

GYNE-LOTTRIMIN 3

+ @ BAYER HEALTHCARE LLC 200MG

N020525 001 Jul 29, 1996 Jun DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL 30MG; 600MG

A091070 001 Aug 31, 2015 Mar CAHN

60MG; 1.2GM

A091070 002 Aug 31, 2015 Mar CAHN

AUROBINDO PHARMA LTD 30MG; 600MG

A206941 001 Mar 17, 2017 Mar NEWA

60MG; 1.2GM

A206941 002 Mar 17, 2017 Mar NEWA

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

AMNEAL PHARMS LLC EQ 30MG HBR/5ML

A203133 001 Jul 28, 2017 Jul NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

>A> AUROBINDO PHARMA LTD EQ 20MG BASE

A209339 001 Oct 16, 2017 Oct NEWA

PERRIGO R AND D EQ 20MG BASE

A207193 001 Aug 18, 2017 Aug NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

PERRIGO R AND D 20MG

A077351 001 Sep 25, 2006 Apr CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

>A> TARO PHARM 30MG/5ML

A208123 001 Nov 09, 2017 Oct NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

>A> TARO PHARM 30MG/5ML

A208123 002 Nov 09, 2017 Oct NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> AUROBINDO PHARMA LTD 60MG; 120MG

A209116 001 Oct 30, 2017 Oct NEWA

FLUTICASONE FUROATE

SPRAY, METERED; NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+! GLAXOSMITHKLINE CONS 0.0275MG/SPRAY

N022051 002 Aug 02, 2016 Jun CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN

ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015	Mar CAHN
GUARDIAN PHARMS	600MG	A209215	001	Sep 06, 2017	Aug NEWA
	1.2GM	A209215	002	Sep 06, 2017	Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015	Mar CAHN
	1.2GM;120MG	A091071	002	May 27, 2015	Mar CAHN

IBUPROFEN

CAPSULE;ORAL
IBUPROFEN

AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011	May CAHN
>D> ! CONTRACT PHARMACAL	200MG	A074782	001	Jul 06, 1998	Oct DISC
>A> @	200MG	A074782	001	Jul 06, 1998	Oct DISC

SUSPENSION;ORAL
IBUPROFEN

AMNEAL PHARMS	100MG/5ML	A200457	001	Aug 18, 2011	Oct CAHN
>A> ARISE PHARMS	100MG/5ML	A200457	001	Aug 18, 2011	Oct CAHN
TARO	100MG/5ML	A209207	001	Jun 27, 2017	Jun NEWA

SUSPENSION/DROPS;ORAL
IBUPROFEN

L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998	Apr CAHN
--------------	---------	---------	-----	--------------	----------

TABLET;ORAL
IBUPROFEN

AIPING PHARM INC	200MG	A207095	001	May 05, 2017	Apr NEWA
AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Apr CAHN
>A> AUROBINDO PHARMA LTD	200MG	A208865	001	Nov 08, 2017	Oct NEWA
>D> CONTRACT PHARMACAL	200MG	A071735	001	Sep 10, 1987	Oct DISC
>A> @	200MG	A071735	001	Sep 10, 1987	Oct DISC
>D>	200MG	A074931	001	Jul 20, 1998	Oct DISC
>A> @	200MG	A074931	001	Jul 20, 1998	Oct DISC
STRIDES PHARMA	200MG	A207052	001	May 30, 2017	Jun CMS2
	200MG	A207052	001	May 30, 2017	May NEWA

JUNIOR STRENGTH IBUPROFEN

L PERRIGO CO	100MG	A075367	001	Apr 22, 1999	Apr CAHN
--------------	-------	---------	-----	--------------	----------

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D> CONTRACT PHARMACAL	200MG;30MG	A075588	001	Apr 08, 2002	Oct DISC
>A> @	200MG;30MG	A075588	001	Apr 08, 2002	Oct DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

KREMERS URBAN PHARMS	15MG	A207157	001	Sep 29, 2017	Sep NEWA
----------------------	------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL
XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Feb CAHN
+ UCB INC	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Jan NEWA

TABLET;ORAL
XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US	5MG	N209089	001	Jan 31, 2017	Feb CAHN
+ UCB INC	5MG	N209089	001	Jan 31, 2017	Jan NEWA

LEVONORGESTREL

TABLET;ORAL
LEVONORGESTREL

RECKITT BENCKISER	1.5MG	A202246	001	Jun 05, 2015	Apr CAHN
-------------------	-------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

ALLIED PHARMA INC 1MG/5ML

A073079 001 Apr 30, 1992 Mar CAHN

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

>D> CONTRACT PHARMACAL 2MG

A073254 001 Jul 30, 1993 Oct DISC

>A> @ 2MG

A073254 001 Jul 30, 1993 Oct DISC

L PERRIGO CO 2MG

A075232 001 Jan 06, 2000 Apr CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO 2MG;125MG

A076029 001 Aug 30, 2002 Jan CHRS

LORATADINE

SYRUP;ORAL

LORATADINE

TARO PHARM 1MG/ML

A201865 001 Jul 31, 2015 Mar CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

TARO 2%

A074444 001 Jan 13, 1997 Apr CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC 2%,200MG

A074926 001 Apr 16, 1999 Jun CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACTAVIS PHARMA 100MG

A073507 001 Nov 19, 1993 May CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

WATSON LABS INC 5%

A208092 001 Feb 17, 2017 Feb NEWA

MINOXIDIL (FOR WOMEN)

WATSON LABS INC 5%

A208092 002 Jul 27, 2017 Jul NEWA

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

L PERRIGO CO 2%

A075357 001 Jul 30, 1999 Apr CAHN

MINOXIDIL (FOR WOMEN)

L PERRIGO CO 2%

A075357 002 Jul 30, 1999 Apr CAHN

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

>D> CONTRACT PHARMACAL EQ 200MG BASE

A074789 001 Feb 27, 1997 Oct DISC

>A> @ EQ 200MG BASE

A074789 001 Feb 27, 1997 Oct DISC

LNK INTL INC EQ 200MG BASE

A204872 001 Jan 23, 2017 Jan NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+ DR REDDYS LABS SA 7MG/24HR

N020076 004 Nov 12, 1999 Jun CAHN

+ 14MG/24HR

N020076 005 Nov 12, 1999 Jun CAHN

+! 21MG/24HR

N020076 006 Nov 12, 1999 Jun CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

L PERRIGO CO EQ 2MG BASE

A076775 001 Sep 16, 2004 Apr CAHN

EQ 2MG BASE

A076776 001 Sep 16, 2004 Apr CAHN

EQ 2MG BASE

A076777 001 Sep 16, 2004 Apr CAHN

EQ 4MG BASE

A076778 001 Sep 16, 2004 Apr CAHN

EQ 4MG BASE

A076779 001 Sep 16, 2004 Apr CAHN

EQ 4MG BASE

A076789 001 Sep 16, 2004 Apr CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
OMEPRAZOLE

+ DEXCEL PHARMA 20MG N209400 001 Jul 05, 2017 Jul NEWA

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR

@ BAYER HEALTHCARE LLC 0.025% N018471 001 May 30, 1986 May DISC

PERMETHRIN

LOTION;TOPICAL
PERMETHRIN

ACTAVIS MID ATLANTIC 1% A075014 001 Mar 28, 2000 May CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350

AILEX PHARMS LLC 17GM/SCOOPFUL A202071 001 Dec 28, 2012 Sep CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 120MG A209008 001 Jun 09, 2017 May NEWA
L PERRIGO CO 120MG A075153 001 Feb 26, 1999 Apr CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>A> AUROBINDO PHARMA LTD EQ 75MG BASE A207579 001 Nov 13, 2017 Oct NEWA
>A> EQ 150MG BASE A207578 001 Nov 13, 2017 Oct NEWA
>D> CONTRACT PHARMACAL EQ 75MG BASE A075094 001 Jun 21, 1999 Oct DISC
>A> @ EQ 75MG BASE A075094 001 Jun 21, 1999 Oct DISC
STRIDES PHARMA EQ 150MG BASE A200536 001 Jun 28, 2011 Jan CAHN
ZANTAC 150
+! SANOFI US EQ 150MG BASE N021698 001 Aug 31, 2004 Mar CAHN
+ EQ 150MG BASE N021698 002 Mar 13, 2007 Mar CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL
LAMISIL

+! GLAXOSMITHKLINE 1% N020980 001 Mar 09, 1999 Jul CAHN

TIOCONAZOLE

OINTMENT;VAGINAL
VAGISTAT-1

+! COMBE 6.5% N020676 001 Feb 11, 1997 Jul CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL
TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL 0.055MG/SPRAY A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2017

NO OCTOBER 2017 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A 201107 001					PC	Mar 14, 2018
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	>A> 7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	>A> 7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	>A> 7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	>A> 7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579			
	8822438	Aug 24, 2027	U-1580			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001					>A> NCE	Oct 31, 2022
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9610265	Nov 13, 2028	U-2000		M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	9561204	May 08, 2032	U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	9561204	May 08, 2032	U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Sep 05, 2020	DS DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE</u>						
A 203790 001					PC	Jan 23, 2018
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Oct 16, 2030	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURNIA</u>						
N 021985 001	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTURNIA</u>						
N 021985 002	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029				U-2104
	8283369	Nov 26, 2028				U-2104
	8357713	Nov 26, 2028	DP			U-2104
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029				U-2104
	9216179	Aug 01, 2031				U-2104
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029				U-2104
	8283369	Nov 26, 2028				U-2104
	8357713	Nov 26, 2028	DP			U-2104
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029				U-2104
	9216179	Aug 01, 2031				U-2104
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025				U-1338
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025				U-1338
	8697125	Jun 16, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	>A> 8112290	Jul 31, 2030	U-1443	Y		
	>A> 8645160	Jun 18, 2029	U-1485	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	8741343	Dec 02, 2030	U-2106		>A> ODE	Aug 24, 2024
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	8741343	Dec 02, 2030	U-2106		>A> ODE	Aug 24, 2024
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630 001					ODE	Jun 06, 2024
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325 001	8709491	Jun 28, 2032	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147 001	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003					I-746	Jul 27, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033	U-1902			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001					NCE	Aug 27, 2017
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001					M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002					M-204	Jun 23, 2020
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 001	8791140	Dec 14, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Dec 14, 2030	DS			
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 001					PC	Mar 26, 2018
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 002					PC	Mar 26, 2018
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2018	DS DP U-594		NCE	Oct 13, 2018
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 001					NCE	Aug 29, 2022
				>A>	ODE	Aug 29, 2024
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 002					NCE	Aug 29, 2022
				>A>	ODE	Aug 29, 2024
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9655907	Aug 31, 2030	DP U-1858			
	>A> 9775851	Aug 31, 2030	DP U-1858			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 001	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	6376515	Sep 15, 2020	DS DP U-1502			
	6376515	Sep 15, 2020	DS DP U-2029			
	6376515	Sep 15, 2020	DS DP U-2030			
	6835739	Sep 15, 2020	DS DP			
	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8518977	Sep 15, 2020	DS			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8691847	Sep 15, 2020	DS DP U-2029			
	8691847	Sep 15, 2020	DS DP U-2035			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
	9629831	Sep 15, 2020	U-1167			
	9629831	Sep 15, 2020	U-1502			
	9629831	Sep 15, 2020	U-2030			
	9629831	Sep 15, 2020	U-2035			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	6376515	Sep 15, 2020	DS DP U-1502			
	6376515	Sep 15, 2020	DS DP U-2029			
	6376515	Sep 15, 2020	DS DP U-2030			
	6835739	Sep 15, 2020	DS DP			
	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8518977	Sep 15, 2020	DS			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8691847	Sep 15, 2020	DS DP U-2029			
	8691847	Sep 15, 2020	DS DP U-2035			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
	9629831	Sep 15, 2020	U-1167			
	9629831	Sep 15, 2020	U-1502			
	9629831	Sep 15, 2020	U-2030			
	9629831	Sep 15, 2020	U-2035			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9579270	Jan 31, 2021	U-1975			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSENTAN - TRACLEER</u>						
N 021290 001					>A> NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 021290 002					>A> NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 209279 001	7959945	Dec 28, 2027	DP		>A> NP	Sep 05, 2020
	8309126	May 15, 2026	DP			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	>A> 6002008	Mar 27, 2018	DS DP U-1284		>A> ODE	Sep 04, 2019
	>A> 7417148	Jan 23, 2026	U-1283			
	>A> 7767678	Nov 23, 2026	DS DP			
	>A> 7919625	Dec 11, 2025	DP			
	>A> RE42376	Apr 13, 2024	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	>A> 9012462	Feb 06, 2031	DS		>A> NCE	Apr 28, 2022
	>A> 9273077	May 21, 2029	U-1927		>A> ODE	Apr 28, 2024
	>A> 9611283	Apr 10, 2034	U-1927			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	>A> 9770453	Apr 19, 2022	DP U-2131			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	>A> 6784197	Feb 21, 2021	DS DP U-1815			
	>A> 6784197	Feb 21, 2021	DS DP U-2130			
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 6911461	Feb 21, 2021	DS DP U-2130			
	>A> 8492416	Feb 21, 2021	U-1815			
	>A> 8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	>A> 6784197	Feb 21, 2021	DS DP U-1815			
	>A> 6784197	Feb 21, 2021	DS DP U-2130			
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 6911461	Feb 21, 2021	DS DP U-2130			
	>A> 8492416	Feb 21, 2021	U-1815			
	>A> 8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	>A> 6784197	Feb 21, 2021	DS DP U-1815			
	>A> 6784197	Feb 21, 2021	DS DP U-2130			
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 6911461	Feb 21, 2021	DS DP U-2130			
	>A> 8492416	Feb 21, 2021	U-1815			
	>A> 8492416	Feb 21, 2021	U-2130			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	>A> 6784197	Feb 21, 2021	DS DP U-1815			
	>A> 6784197	Feb 21, 2021	DS DP U-2130			
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 6911461	Feb 21, 2021	DS DP U-2130			
	>A> 8492416	Feb 21, 2021	U-1815			
	>A> 8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	>A> 6784197	Feb 21, 2021	DS DP U-1815			
	>A> 6784197	Feb 21, 2021	DS DP U-2130			
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 6911461	Feb 21, 2021	DS DP U-2130			
	>A> 8492416	Feb 21, 2021	U-1815			
	>A> 8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			
	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP		NPP	Jan 27, 2020
	7367333*PED	May 11, 2019			PED	Jul 27, 2020
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP		M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-2002			
	7897646	Sep 09, 2018	U-2122			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-2002			
	8461211	Sep 09, 2018	U-2122			
	8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	9642850	Sep 29, 2017	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	9655843	Jul 23, 2027	DP U-2017			
<u>CABAZITAXEL - JEV TANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			M-209	Sep 14, 2020
	7241907	Dec 10, 2025	DS		PED	Nov 17, 2020
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	9724342	Jul 09, 2033	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	9724342	Jul 09, 2033	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	9724342	Jul 09, 2033	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					M-197	Feb 01, 2020
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9700575	Jul 10, 2035	DP			
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001	>A> 6239180	Jun 04, 2021	DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	9493582	Feb 27, 2033	DP			
	9629797	Nov 10, 2028		U-2004		
	9629797	Nov 10, 2028		U-2005		
	9629797	Nov 10, 2028		U-2006		
	>A> 9750822	Mar 13, 2029	DP			
	9770407	Nov 10, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9533046	Dec 26, 2028	DP U-219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	9522191	Jun 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	9493582	Feb 27, 2033	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	9493582	Feb 27, 2033	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 001	9636407	Dec 21, 2032	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 002	9636407	Dec 21, 2032	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	9629861	Sep 21, 2030	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	9629861	Sep 21, 2030	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	8188276	Jan 31, 2023	DS DP		M-199	May 26, 2020
	8399450	Nov 20, 2027	DS DP		ODE	May 26, 2024
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	8829005	Mar 15, 2030	U-1680		NDF	May 30, 2020
	8829005*PED	Sep 15, 2030			PED	Nov 30, 2020
	9254286	Jul 09, 2032	DP			
	9254286*PED	Jan 09, 2033				
	9750684	Mar 15, 2030	DP			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001					NP	Sep 26, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					M-200	May 23, 2020
<u>CLOFARABINE - CLOFARABINE</u>						
A 204029 001					PC	Nov 05, 2017
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NCE	Aug 27, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001					NCE	Aug 27, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7176220	Aug 27, 2026	DS DP U-257		NCE NPP	Aug 27, 2017 Sep 25, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
	9744181	Jan 13, 2024	DP U-257		NPP	Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
	>A> 9789108	Aug 22, 2033	U-1020			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	7511041	May 13, 2024	DS DP		NCE	Sep 14, 2022
	8466283	Oct 22, 2029	DS DP U-2124		>A> ODE	Sep 14, 2024
	9636344	Mar 29, 2032	U-2124			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
	9682092	Feb 16, 2027	U-1932			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	9585868	Oct 31, 2031	DS U-1319			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	7850990	Jan 23, 2027	DP U-2090		NP	Aug 03, 2020
	8022279	Sep 14, 2027	DP U-2090			
	8092828	Apr 01, 2029	U-2090			
	8431806	Apr 22, 2025	DP U-2090			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	>A> 6414126	Oct 04, 2020	DS DP U-493		>A> M-212	Oct 20, 2020
	>A> 6414126	Oct 04, 2020	DS DP U-2139			
	>A> 6479065	Aug 10, 2020	DP			
	>A> 6495164	May 25, 2020	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	>A> 6515117	Oct 04, 2020	DS DP U-493			
	>A> 6515117	Oct 04, 2020	DS DP U-2139			
	>A> 6667061	May 25, 2020	DP			
	>A> 6824822	Oct 09, 2022	DP			
	>A> 6872700	Jan 14, 2020	U-654			
	>A> 6956026	Jan 07, 2018	U-687			
	>A> 7223440	Aug 31, 2021	DP			
	>A> 7456254	Jun 30, 2025	DP U-1223			
	>A> 7563871	Apr 15, 2024	DP			
	>A> 7612176	Apr 13, 2025	DP U-1223			
	>A> 7741269	Jan 07, 2018	U-1224			
	>A> 8216180	Jan 11, 2028	DP			
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8329648	Aug 18, 2026	U-2153			
	>A> 8329648	Aug 18, 2026	U-2155			
	>A> 8329648	Aug 18, 2026	U-2156			
	>A> 8361972	Mar 21, 2028	U-493			
	>A> 8361972	Mar 21, 2028	U-2139			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8439864	Mar 25, 2028	DP			
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8690837	May 19, 2029	DP			
	>A> 8712615	Jan 18, 2030	DP			
	>A> 8758292	Nov 12, 2027	DP			
	>A> 8827963	Feb 04, 2029	DP			
	>A> 8906851	Aug 18, 2026	U-1313			
	>A> 8998876	Jan 07, 2030	DP			
	>A> 9198925	Oct 04, 2020	U-493			
	>A> 9198925	Oct 04, 2020	U-2139			
	>A> 9238076	Apr 15, 2024	DP U-412			
	>A> 9320853	Mar 25, 2028	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	>A> 6414126	Oct 04, 2020	DS DP U-493		>A> M-212	Oct 20, 2020
	>A> 6414126	Oct 04, 2020	DS DP U-2139			
	>A> 6479065	Aug 10, 2020	DP			
	>A> 6495164	May 25, 2020	DP			
	>A> 6515117	Oct 04, 2020	DS DP U-493			
	>A> 6515117	Oct 04, 2020	DS DP U-2139			
	>A> 6667061	May 25, 2020	DP			
	>A> 6824822	Oct 09, 2022	DP			
	>A> 6872700	Jan 14, 2020	U-654			
	>A> 6956026	Jan 07, 2018	U-687			
	>A> 7223440	Aug 31, 2021	DP			
	>A> 7456254	Jun 30, 2025	DP U-1223			
	>A> 7563871	Apr 15, 2024	DP			
	>A> 7612176	Apr 13, 2025	DP U-1223			
	>A> 7741269	Jan 07, 2018	U-1224			
	>A> 8216180	Jan 11, 2028	DP			
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8329648	Aug 18, 2026	U-2153			
	>A> 8329648	Aug 18, 2026	U-2155			
	>A> 8329648	Aug 18, 2026	U-2156			
	>A> 8361972	Mar 21, 2028	U-493			
	>A> 8361972	Mar 21, 2028	U-2139			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8439864	Mar 25, 2028	DP			
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8690837	May 19, 2029	DP			
	>A> 8712615	Jan 18, 2030	DP			
	>A> 8758292	Nov 12, 2027	DP			
	>A> 8827963	Feb 04, 2029	DP			
	>A> 8906851	Aug 18, 2026	U-1313			
	>A> 8998876	Jan 07, 2030	DP			
	>A> 9198925	Oct 04, 2020	U-493			
	>A> 9198925	Oct 04, 2020	U-2139			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	>A> 9238076	Apr 15, 2024	DP U-412			
	>A> 9320853	Mar 25, 2028	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002					M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003					M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	9629841	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	9744170	Jan 02, 2035	DP U-1889			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001	6465504	Apr 05, 2019	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003	6465504	Apr 05, 2019	DS DP			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9579359	Feb 10, 2029	U-1978			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			
	9539250	Oct 07, 2025	DS DP U-2028			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	9539250	Oct 07, 2025	DS DP U-2028			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	9539302	Jun 15, 2030	DP			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 001					PC	Jan 25, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 003					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 002					PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	9296739	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9592242	Oct 20, 2020	U-1989			
	9592242	Oct 20, 2020	U-1990			
	>A> 9775849	Oct 20, 2020	U-1989			
	>A> 9775849	Oct 20, 2020	U-1990			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9539335	Oct 17, 2027	U-1614			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	7560122	Jan 25, 2019	DP			
	9089489	Feb 18, 2033	DP U-1382			
	9375404	Feb 18, 2033	DP U-1382			
	9526703	Feb 18, 2033	DP U-1382			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 001	6933310	Nov 13, 2020	U-2013		NCE ODE	May 05, 2022 May 05, 2024
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8598185	Apr 28, 2029	DP			
	9545414	Jun 13, 2026	DP U-750			
	9545414	Jun 13, 2026	DP U-1170			
	9744181	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 24, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
>A>	9789125	Jul 07, 2028	DP U-1709			
>A>	9789125	Jul 07, 2028	DP U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
>A>	9789125	Jul 07, 2028	DP U-1709			
>A>	9789125	Jul 07, 2028	DP U-2152			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	8673927	May 04, 2027	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	8673927	May 04, 2027	U-1652			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001					M-206	Aug 21, 2020
					M-207	Aug 21, 2020
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP	Sep 25, 2020
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245*PED	May 04, 2021				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	9669008	Mar 25, 2036	DP			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026		U-1281		
	8183274	Aug 24, 2026		U-1588		
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 003	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 004	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9295657	Mar 13, 2035		U-1829		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESTRADIOL - ESTRADIOL</u>						
A 205256 001					PC	Apr 15, 2017
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	9724310	Jul 10, 2028	DS DP			
	9730900	Jul 10, 2028	DP U-2086			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	8486907	Jun 28, 2025	U-1904	Y		
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	8486907	Jun 28, 2025	U-1904	Y		
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287 001					PC	Sep 11, 2017
<u>ETONOGESTREL - IMPLANON</u>						
N 021529 001	9757552	Jul 28, 2030	DP U-1			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	9757552	Jul 28, 2030	DP U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004					ODE	Feb 26, 2023
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	>A> 6479065	Aug 10, 2020	DP		>A> NP	Oct 20, 2020
	>A> 6667061	May 25, 2020	DP			
	>A> 6824822	Oct 09, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	>A> 6872700	Jan 14, 2020	U-654			
	>A> 6956026	Jan 07, 2018	U-687			
	>A> 7223440	Aug 31, 2021	DP			
	>A> 7456254	Jun 30, 2025	DP U-1223			
	>A> 7563871	Apr 15, 2024	DP			
	>A> 7612176	Apr 13, 2025	DP U-1223			
	>A> 7741269	Jan 07, 2018	U-1224			
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8329648	Aug 18, 2026	U-2154			
	>A> 8329648	Aug 18, 2026	U-2155			
	>A> 8329648	Aug 18, 2026	U-2156			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8895033	Oct 04, 2030	DP U-1313			
	>A> 8895033	Oct 04, 2030	DP U-2157			
	>A> 8895033	Oct 04, 2030	DP U-2158			
	>A> 8906851	Aug 18, 2026	U-1313			
	>A> 9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001				>A> M-212		Oct 20, 2020
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	>A> 6414126	Oct 04, 2020	DS DP U-493			
	>A> 6414126	Oct 04, 2020	DS DP U-2139			
	>A> 6515117	Oct 04, 2020	DS DP U-493			
	>A> 6515117	Oct 04, 2020	DS DP U-2139			
	>A> 6936590	Oct 04, 2020	U-493			
	>A> 7851502	Aug 19, 2028	DP			
	>A> 7919598	Dec 16, 2029	DS			
	>A> 8221786	Mar 21, 2028	DP			
	>A> 8361972	Mar 21, 2028	U-493			
	>A> 8361972	Mar 21, 2028	U-2139			
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8685934	May 26, 2030	U-1522			
	>A> 8690837	May 19, 2029	DP			
	>A> 8712615	Jan 18, 2030	DP			
	>A> 8716251	Mar 21, 2028	DP			
	>A> 8758292	Nov 12, 2027	DP			
	>A> 8827963	Feb 04, 2029	DP			
	>A> 8998876	Jan 07, 2030	DP			
	>A> 9198925	Oct 04, 2020	U-493			
	>A> 9198925	Oct 04, 2020	U-2139			
	>A> 9320853	Mar 25, 2028	DP			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001					M-205	Aug 15, 2020
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002					M-205	Aug 15, 2020
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9731869	Jan 26, 2032	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9731121	Oct 17, 2031	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9757416	Feb 18, 2024	DS DP U-1577			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					NCE	Jul 13, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	003				NCE	Jul 13, 2021
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054	001	Nov 09, 2018	DS			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482	001	>A> 6537983	Aug 03, 2021	DP U-2125	NCE	May 10, 2018
		>A> 6759398	Aug 03, 2021	DP U-2125	NCE	Dec 18, 2018
		>A> 6878698	Aug 03, 2021	U-2134		
		>A> 7101866	Aug 03, 2021	DS DP U-2126		
		>A> 7439393	May 21, 2025	DS DP U-2127		
		>A> 7488827	Dec 18, 2027	DS DP		
		>A> 7498440	Apr 27, 2025	DS DP		
		>A> 7629335	Aug 03, 2021	DP		
		>A> 7776895	Sep 11, 2022	DP		
		>A> 8113199	Oct 23, 2027	DP		
		>A> 8161968	Feb 05, 2028	DP		
		>A> 8183257	Jul 27, 2025	U-2128		
		>A> 8309572	Apr 27, 2025	U-2129		
		>A> 8511304	Jun 14, 2027	DP		
		>A> 8534281	Aug 10, 2029	DP		
		>A> 8746242	Oct 11, 2030	DP		
		>A> 9333310	Oct 02, 2027	DP		
		>A> 9750762	Nov 29, 2030	DP		
		>A> RE44874	Mar 23, 2023	DS DP U-2127		
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	001	7439393	May 21, 2025	DS DP U-1401	M-202	May 15, 2020
		7439393	May 21, 2025	DS DP U-1691	NCE	May 10, 2018
		7439393	May 21, 2025	DS DP U-2099		
		7439393	May 21, 2025	DS DP U-2100		
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	002	7439393	May 21, 2025	DS DP U-1691	M-202	May 15, 2020
		7439393	May 21, 2025	DS DP U-2099	NCE	May 10, 2018
		7439393	May 21, 2025	DS DP U-2100		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	001	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
		9731087	May 18, 2031	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	002	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	>A> 6715485	Mar 03, 2020	DP		NP	Sep 18, 2020
	>A> 7975690	Dec 29, 2025	U-2133			
	>A> 8327844	Oct 08, 2023	U-2133			
	>A> 8522778	May 11, 2022	DP			
	>A> 8550073	Oct 22, 2029	DP			
	>A> 8555878	Mar 20, 2020	DP			
	>A> 8978647	Aug 06, 2030	DP			
	>A> 9072857	Apr 10, 2021	DP			
	>A> 9468727	Jul 30, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	>A> 6774122	Jan 09, 2021	U-596		I-749	Aug 25, 2020
	>A> 6774122	Jan 09, 2021	U-1826			
	>A> 6774122	Jan 09, 2021	U-2108			
	>A> 6774122*PED	Jul 09, 2021				
	>A> 7456160	Jan 09, 2021	U-596			
	>A> 7456160	Jan 09, 2021	U-1826			
	>A> 7456160	Jan 09, 2021	U-2108			
	>A> 7456160*PED	Jul 09, 2021				
	>A> 8329680	Jan 09, 2021	U-596			
	>A> 8329680	Jan 09, 2021	U-1826			
	>A> 8329680	Jan 09, 2021	U-2108			
	>A> 8329680*PED	Jul 09, 2021				
	>A> 8466139	Jan 09, 2021	U-596			
	>A> 8466139	Jan 09, 2021	U-1826			
	>A> 8466139	Jan 09, 2021	U-2108			
	>A> 8466139*PED	Jul 09, 2021				
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 005					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001					NCE	Aug 03, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9561197	Sep 22, 2030	U-1383		NPP	Apr 28, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474 001	9549907	Nov 13, 2035	DS DP U-2023			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA PRESERVATIVE FREE</u>						
N 021945 002					ODE	Feb 03, 2018
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	8476284	Dec 28, 2026	U-1650		I-753	Aug 02, 2020
	8476284	Dec 28, 2026	U-1946		ODE	Jan 18, 2024
	8476284	Dec 28, 2026	U-1947		ODE	Aug 02, 2024
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
>A>	9795604	Oct 24, 2034	U-2150			
>A>	9801881	Jun 03, 2031	U-1491			
>A>	9801883	Jun 03, 2031	U-2159			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9649284	Sep 30, 2029	U-2018			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617594	Apr 29, 2030	U-1287			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8623406	Apr 29, 2030	U-1287			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001 >A>	9789078	May 15, 2033	U-2138			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - FIASP</u>						
N 208751 001 >A>	8324157	Jun 25, 2030	DP		NP	Sep 29, 2020
<u>INSULIN ASPART RECOMBINANT - FIASP FLEXTOUCH</u>						
N 208751 002 >A>	6899699	Jan 02, 2022	DP		NP	Sep 29, 2020
	>A> 7686786	Aug 03, 2026	DP			
	>A> 8324157	Jun 25, 2030	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
	>A> 9457154	Jan 20, 2026	DP			
	>A> 9486588	Jan 02, 2022	DP			
	>A> 9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9707176	Nov 11, 2030	DP			
	9775954	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
>A>	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	>A> 6444226	Jun 29, 2020	DP U-1534			
	>A> 6652885	Jun 29, 2020	U-1535			
	>A> 7648960	Jun 29, 2020	U-1535			
	>A> 7943178	Jun 29, 2020	DP U-1535			
	>A> 7943572	Aug 10, 2026	U-1539			
	>A> 8119593	Aug 11, 2029	U-1537			
	>A> 8258095	Aug 11, 2029	U-1537			
	>A> 8389470	Jun 29, 2020	DP U-1621			
	>A> 8623817	Sep 18, 2029	U-1537			
	>A> 8778403	Jun 11, 2030	DP U-1538			
	>A> 8889099	Jun 29, 2020	DP U-1621			
	>A> 8912193	Jun 12, 2029	DP U-1538			
	>A> 9192675	Jun 12, 2029	DP U-1788			
	>A> 9358352	Feb 15, 2031	DP U-1861			
	>A> 9446133	Jun 12, 2029	DP U-1861			
	>A> 9597374	Oct 08, 2031	U-1987			
	>A> 9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	>A> 6444226	Jun 29, 2020	DP U-1534			
	>A> 6652885	Jun 29, 2020	U-1535			
	>A> 7648960	Jun 29, 2020	U-1535			
	>A> 7943178	Jun 29, 2020	DP U-1535			
	>A> 7943572	Aug 10, 2026	U-1539			
	>A> 8119593	Aug 11, 2029	U-1537			
	>A> 8258095	Aug 11, 2029	U-1537			
	>A> 8389470	Jun 29, 2020	DP U-1621			
	>A> 8623817	Sep 18, 2029	U-1537			
	>A> 8778403	Jun 11, 2030	DP U-1538			
	>A> 8889099	Jun 29, 2020	DP U-1621			
	>A> 8912193	Jun 12, 2029	DP U-1538			
	>A> 9192675	Jun 12, 2029	DP U-1788			
	>A> 9358352	Feb 15, 2031	DP U-1861			
	>A> 9446133	Jun 12, 2029	DP U-1861			
	>A> 9597374	Oct 08, 2031	U-1987			
	>A> 9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	>A> 6444226	Jun 29, 2020	DP U-1534			
	>A> 6652885	Jun 29, 2020	U-1535			
	>A> 7648960	Jun 29, 2020	U-1535			
	>A> 7943178	Jun 29, 2020	DP U-1535			
	>A> 7943572	Aug 10, 2026	U-1539			
	>A> 8119593	Aug 11, 2029	U-1537			
	>A> 8258095	Aug 11, 2029	U-1537			
	>A> 8389470	Jun 29, 2020	DP U-1621			
	>A> 8623817	Sep 18, 2029	U-1537			
	>A> 8778403	Jun 11, 2030	DP U-1538			
	>A> 8889099	Jun 29, 2020	DP U-1621			
	>A> 8912193	Jun 12, 2029	DP U-1538			
	>A> 9192675	Jun 12, 2029	DP U-1788			
	>A> 9358352	Feb 15, 2031	DP U-1861			
	>A> 9446133	Jun 12, 2029	DP U-1861			
	>A> 9597374	Oct 08, 2031	U-1987			
	>A> 9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020351 002					I-752	Apr 05, 2020
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020808 002					I-752	Apr 05, 2020
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9717724	Jun 12, 2033	U-1848			
	9717724	Jun 12, 2033	U-2091			
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025	U-1848			
	>A> 9782349	May 02, 2025	DS DP			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	9670163	Dec 28, 2026	DP U-1311		>A> NPP	Jul 31, 2020
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	9670163	Dec 28, 2026	DP U-1311		>A> NPP	Jul 31, 2020
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	9670163	Dec 28, 2026	DP U-1311		>A> NPP	Jul 31, 2020
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>L-GLUTAMINE - ENDARI</u>						
N 208587 001					I-748 ODE	Jul 07, 2020 Jul 07, 2024
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-1663			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-1663			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-1663			
	7754731*PED	Sep 11, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-1663			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-1663			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-1663			
	7754731*PED	Sep 11, 2029				
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001					I-754 >A> ODE	Sep 15, 2020 Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002					I-754 >A> ODE	Sep 15, 2020 Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003					I-754 >A> ODE	Sep 15, 2020 Sep 15, 2024
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	9708371	Aug 16, 2033	DP U-1515			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	9708371	Aug 16, 2033	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001					I-750	Aug 25, 2020
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-8			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9707176	Nov 11, 2030	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9707176	Nov 11, 2030	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	9770455	Aug 31, 2031	U-2110			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	9770455	Aug 31, 2031	U-2110			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9687487	Oct 26, 2021	DS DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jan 18, 2020	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP PED	Jan 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	9649318	Mar 31, 2035	DP			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002	9649318	Mar 31, 2035	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	8680136	Aug 17, 2031	DS DP			
	9694025	Aug 08, 2031	U-2120			
<u>MESALAMINE - MESALAMINE</u>						
A 091640 001					>A> PC	Jan 14, 2018
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9259427	Jan 02, 2033	DP		ODE	Apr 25, 2024
					ODE	Apr 25, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	9492445	Sep 30, 2029	DP U-1185			
	9724343	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE	Apr 28, 2024
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
	9775838	Mar 16, 2035	U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
	9707226	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	>A> 9693978	Mar 03, 2026	DP			
	>A> 9693979	Mar 03, 2026	DP			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	9662398	Dec 01, 2030	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	6288082	Sep 24, 2019	DS DP U-2043		NCE	Jul 17, 2022
	7399865	Dec 29, 2025	DS DP			
	7982043	Oct 08, 2025	U-2043			
	8518446	Nov 20, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-2043			
	9139558	Oct 15, 2028	U-2043			
	9211291	Mar 24, 2030	U-2043			
	9630946	Oct 15, 2028	U-2043			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE	Mar 27, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	003				M-167	Oct 09, 2018
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531	001	6166197	DS		ODE	Dec 23, 2023
		6210892		U-1942		
		7101993	DS			
		7838657	DS			
		8110560		U-1942		
		8110560		U-1943		
		8110560		U-1944		
		8361977	DS DP			
		8980853		U-1941		
		9717750		U-1942		
		9717750		U-1943		
		9717750		U-2093		
		9717750		U-2094		
<u>OLAPARIB - LYNPARZA</u>						
N 208558	001	7151102	DS DP		NCE	Dec 19, 2019
		7449464	DS DP		NP	Aug 17, 2020
		7981889	DS DP		ODE	Dec 19, 2021
		8143241		U-2101		
		8143241		U-2102		
		8143241		U-2103		
		8475842	DP			
		8859562		U-2101		
		8859562		U-2102		
		8912187		U-2101		
		8912187		U-2102		
<u>OLAPARIB - LYNPARZA</u>						
N 208558	002	7151102	DS DP		NCE	Dec 19, 2019
		7449464	DS DP		NP	Aug 17, 2020
		7981889	DS DP		ODE	Dec 19, 2021
		8143241		U-2101		
		8143241		U-2102		
		8143241		U-2103		
		8475842	DP			
		8859562		U-2101		
		8859562		U-2102		
		8912187		U-2101		
		8912187		U-2102		
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108	001	8733341	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001	6149054	DP			
		6149054*PED				
		6846413	DP			
		6846413*PED				
		6977042	DP			
		6977042*PED				
		6988496	DP			
		6988496*PED				
		7284474	DP			
		7284474*PED				
		7396341	DP			
		7396341*PED				
		7802568	DP			
		7802568*PED				
		7837235	DP			
		7837235*PED				
		8733341	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6149054	Dec 19, 2016	DP			
	6149054*PED	Jun 19, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			
<u>OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE</u>						
A 090848 001					PC	Dec 05, 2017
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2018	DP			
	5948818	May 13, 2018	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	9649352	Jul 16, 2035	DP			
	9682061	Apr 26, 2030	U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1370			
	9566252	Jul 21, 2020	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	7812049	May 02, 2028		U-1959	NP	Jan 18, 2020
	8420688	Aug 02, 2024		U-1959		
	8883838	Dec 01, 2031	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Mar 04, 2032		U-1290		
	9511046	Jan 12, 2034		U-1434		
	9597409	Mar 04, 2032		U-1290		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023		U-1998		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023		U-1998		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023		U-1998		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 001	>A> 7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 002	>A> 7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 003	>A> 7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 001	>A> 7473761	Dec 14, 2026	DS DP			
	>A> 9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 002	>A> 7473761	Dec 14, 2026	DS DP			
	>A> 9351923	May 23, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 003	>A> 7473761	Dec 14, 2026	DS DP			
	>A> 9351923	May 23, 2028	DP			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001					NPP	Sep 20, 2020
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
	>A> 9789210	Mar 16, 2037	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
	9765053	Jul 27, 2022	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7566729	Apr 22, 2029	U-2077		NCE	Oct 16, 2019
	7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE	Oct 16, 2019
					ODE	Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	7566729	Apr 22, 2029	U-2077		NCE	Oct 16, 2019
	7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022	U-1964			
	9610321	Sep 11, 2031	U-1999			
	9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 001					PC	Feb 11, 2018
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 002					PC	Feb 11, 2018
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 001	>A> 6197819	Dec 30, 2018	DS DP		>A> NP	Oct 11, 2020
	>A> 8945620	Nov 02, 2026	DP U-2136			
	>A> 8945620	Nov 02, 2026	DP U-2137			
	>A> 9144559	Nov 02, 2026	DP			
	>A> RE41920	Dec 30, 2018	U-2136			
	>A> RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 002	>A> 6197819	Dec 30, 2018	DS DP		>A> NP	Oct 11, 2020
	>A> 8945620	Nov 02, 2026	DP U-2136			
	>A> 8945620	Nov 02, 2026	DP U-2137			
	>A> 9144559	Nov 02, 2026	DP			
	>A> RE41920	Dec 30, 2018	U-2136			
	>A> RE41920	Dec 30, 2018	U-2137			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA CR</u>						
N 209501 002	>A> 6197819	Dec 30, 2018	DS DP		>A> NP	Oct 11, 2020
	>A> 8945620	Nov 02, 2026	DP U-2136			
	>A> 8945620	Nov 02, 2026	DP U-2137			
	>A> 9144559	Nov 02, 2026	DP			
	>A> RE41920	Dec 30, 2018	U-2136			
	>A> RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 003	>A> 6197819	Dec 30, 2018	DS DP		>A> NP	Oct 11, 2020
	>A> 8945620	Nov 02, 2026	DP U-2136			
	>A> 8945620	Nov 02, 2026	DP U-2137			
	>A> 9144559	Nov 02, 2026	DP			
	>A> RE41920	Dec 30, 2018	U-2136			
	>A> RE41920	Dec 30, 2018	U-2137			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
	7169780*PED	Apr 03, 2024			PED	Nov 26, 2020
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	7169780	Oct 03, 2023	DS DP		NS	May 26, 2020
	7169780*PED	Apr 03, 2024			PED	Nov 26, 2020
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030	DP			
	9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 002					PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001					M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jun 28, 2022	DS		I-744 ODE	Apr 27, 2020 Apr 27, 2024
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9629828	Jul 24, 2029	U-1994			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-1953		>A> D-168	Oct 27, 2020
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					M-208	Aug 31, 2020
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	8404702	Apr 04, 2027	U-1741			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001					>A> NCE	Sep 01, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 001					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 002					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 003					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 004					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006					M-203	Mar 23, 2020
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	6495541	Jan 10, 2020	DS DP		>A> NCE	Dec 19, 2021
	7351701	Jul 23, 2024	U-2012		>A> ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	9045487	Feb 10, 2031	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9662335	Dec 12, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001					NCE GAIN	Sep 15, 2022 Sep 15, 2027
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002	9597289	Feb 23, 2030	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	>A> 9770406	Jul 12, 2025	DP U-172			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	9757406	Jan 30, 2034	DP		NPP	Aug 01, 2020
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039		NCE	Dec 06, 2018
	7964580	Mar 26, 2029	DS DP U-2040		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-2039		NCE	Jul 18, 2022
	8334270	Mar 21, 2028	DS DP U-2040			
	8575135	Nov 05, 2033	DS DP U-2039			
	8575135	Nov 05, 2033	DS DP U-2040			
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			
	9585906	Mar 21, 2028	DS DP U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 001	6017927	Nov 19, 2018	DS DP			
	6017927*PED	May 19, 2019				
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 002	6017927	Nov 19, 2018	DS DP			
	6017927*PED	May 19, 2019				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	9724297	Aug 31, 2035	DP U-2096			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	9757394	Oct 28, 2036	DP U-2109			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	>A> 6174442	Dec 19, 2018	DS U-1468			
	9561251	Jan 23, 2030	DP U-1468			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	5686060	Nov 11, 2019	DS DP			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	9549918	May 30, 2028	DP			
<u>TALC - STERITALC</u>						
N 205555 001					ODE	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 002					ODE	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003					ODE	May 01, 2024
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	>A> 5856529	Dec 09, 2018	DS DP U-2149			
	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-2016			
	9549938	Feb 16, 2026	U-1951			
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026	U-1970			
	9572823	Feb 16, 2026	U-1970			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	9572867	Nov 01, 2025	U-1320			
	9592273	Nov 01, 2025	U-1320			
	9592274	Nov 01, 2025	U-1320			
<u>TELOTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028	U-1979			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9662340	Feb 11, 2034	DP U-1531			
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9694078	Mar 13, 2026	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	6149054	Dec 16, 2016	DP		PED	Aug 15, 2020
	6149054*PED	Jun 16, 2017				
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	RE41783	Dec 08, 2025	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRIAMCINOLONE ACETONIDE - ZILRETTA</u>						
N 208845 001	>A> 8828440	Aug 04, 2031	DP		>A> NP	Oct 06, 2020
	>A> 9555048	Aug 04, 2031		U-2151		
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001					NP	Jun 29, 2020
					ODE	Jun 29, 2024
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	7439393	May 21, 2025	DS DP	U-1476	NCE	May 10, 2018
	7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
	9750726	Nov 29, 2030	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027		U-1995		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	>A> 8039627	Oct 06, 2029	DS DP		>A> NCE	Apr 11, 2022
	>A> 8357697	Nov 08, 2027		U-1995		
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	>A> 8889109	Dec 11, 2027	DP			
	9642911	Dec 11, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001 >A>	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002 >A>	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003 >A>	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004 >A>	7144884	Oct 02, 2022	DS DP U-1439			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	9707270	Oct 01, 2024	U-2084			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm